Marksans Pharma Ltd.

Date: August 04, 2026

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub: Submission of Annual Report for the Financial Year 2025-26 and Notice of the Annual General Meeting

Dear Sir/Madam,

Pursuant to Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable regulations, kindly find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26 along with the Notice convening the 34th Annual General Meeting to be held on Thursday, August 27, 2026 at 11:00 a.m. through electronic mode (video conference or other audio visual means) being sent to the members through electronic mode.

Further, the aforesaid Annual Report along with Notice has also been uploaded on the website of the Company at https://www.marksanspharma.com/pdf/marksans-annual-report-2025-26.pdf

The Company is providing e-voting facility to its shareholders, in respect of all shareholders resolutions, to be passed at the AGM. The e-voting period will start on Monday, August 24, 2026 at 09:00 A.M. and will end on Wednesday, August 26, 2026 at 05:00 P.M.

The facility for voting through e-voting system will also be made available during the AGM. Members attending the AGM through VC / OAVM facility who have not cast their vote by remote e-voting will be able to vote during the AGM.

We request you to take the aforesaid on records.

Thanking You.
For **Marksans Pharma Limited**

H PANIGRAHI
Digitally signed by H PANIGRAHI
Date: 2026.08.04 11:08:00 +05'30'

Harshavardhan Panigrahi
Company Secretary
Encl.: As Above

CIN : L24110MH1992PLC066364

Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000
E-mail: companysecretary@marksanspharma.com
www.marksanspharma.com

Marksans Pharma Ltd.

Marksans Pharma Limited
Annual Report 2025-26

Relentless.
Resilient.
Rising.

Contents

01-38
Company Overview

39-125
Statutory Reports

126-238
Financial Statements

239-255

To see the online version of this report please log on to www.marksanspharma.com

Forward Looking Statement

Some information in this report may contain forward-looking statements. We have based these forward looking statements on our current beliefs, expectations and intentions as to facts, actions and events that will or may occur in the future. Such statements generally are identified by forward-looking words such as "believe," "plan," "anticipate," "continue," "estimate," "expect," "may," "will" or other similar words. A forward-looking statement may include a statement of the assumptions or basis underlying the forward-looking statement. We have chosen these assumptions or basis in good faith, and we believe that they are reasonable in all material respects. However, we caution you that forward looking statements and assumed facts or bases almost always vary from actual results, and the differences between the results implied by the forward-looking statements and assumed facts or bases and actual results can be material, depending on the circumstances.

Theme introduction

Resilient. Relentless. Rising.

Our mission to advance global well-being has shaped our journey and defines the way we move forward. Built on a robust manufacturing base, a diversified product portfolio and a strategic focus on expanding our presence across regulated markets, we have established a platform for sustainable growth. Our forward integration capabilities, complemented by continuous innovation, reinforce our competitive advantage and enable us to maintain a differentiated product pipeline.

These core competencies have enabled us to navigate an evolving pharmaceutical landscape while upholding uncompromising standards of quality, compliance and operational excellence. A robust R&D ecosystem, supported by advanced manufacturing capabilities, allows us to meet increasingly rigorous regulatory requirements across global markets. Together with our presence across regulated and emerging geographies, these capabilities have earned Marksans the trust of customers and partners worldwide.

This resilience is matched by a relentless pursuit of progress. As healthcare expectations rise, technologies advance and regulatory frameworks evolve, we remain focused on anticipating change rather than responding to it. Through close collaboration with partners and regulatory authorities, we continue to develop high-quality products that address changing patient needs and create lasting value.

Today, Marksans is rising alongside a nation that is strengthening its position in global healthcare. Our strategy is centred on deepening our presence across key markets, broadening our global reach and pursuing opportunities that support sustainable, long-term growth. As we look ahead, we remain committed to delivering accessible healthcare solutions, advancing scientific excellence and building a stronger, more resilient future for patients, partners and stakeholders alike.

About Us

Delivering everyday healthcare solutions

Marksans Pharma is a globally trusted pharmaceutical company, distinguished by our customer-centric approach and strong presence in regulated markets. We develop, manufacture and distribute a wide range of over-the-counter (OTC) and prescription (Rx) drugs, aligning our portfolio with the evolving needs of patients and healthcare providers worldwide.

Backed by robust R&D capabilities and advanced manufacturing facilities across domestic and international locations, we have established a strong presence in the United Kingdom, where we rank among the top five Indian companies and continue to expand our footprint in the United States and other regulated markets. Headquartered in Mumbai, we operate in over 60 countries, supported by an integrated business model and a capable workforce, enabling us to pursue sustained growth and long-term value creation.

Vision

To become a respected, profitable, and integrated global pharmaceutical company

Our Strengths

- Robust QC and QA processes
- Adherence to cGMP norms
- Continuous improvement across products, processes and skills
- Alignment with evolving client requirements
- Manufacturing facilities approved by US FDA, UK MHRA and Australian TGA

Core Values

- **Customer Centric Approach**

  We are committed to delivering drugs that cater to the specific needs of our consumers

- **Commitment to Excellence**

  Our quality-focused approach extends from research and development to manufacturing and customer service

- **Global Responsibility**

  We are committed to sustainable practices and ethical business conduct

- **Empowering People**

  We empower our employees through a culture of collaboration and innovation

Key Highlights

₹ 3,033 cr
Revenue

₹ 601 cr
EBITDA

20.4%
EBITDA Margin

₹ 420 cr
PAT

4
Manufacturing Units

4
R&D Centres

350+
Products

2,000+
SKUs

2000+
Total Employees

$175 mn in US
Amongst the top Indian Companies in OTC segment

Amongst Top 5
Indian Pharma companies in UK

Accreditations

- USFDA
- UK MHRA
- Australian TGA
- EU and Health Canada

Journey

From Foundations to scale

2001
Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.

2003
Spun off into a separate entity - Glenmark Laboratories Ltd. Changed its name to 'Marksans Pharma Ltd

2005
Acquired Nova Pharmaceuticals Australasia Pty Ltd

2007
Acquired Bell, Sons & Co. (Druggists) Ltd. UK

2008
Acquired Relonchem Ltd. UK

2015
Acquired Time-Cap Laboratories Inc. USA

2017
Increased focus on OTC segment in US market

2022
Acquired Access Healthcare Dubai

2023
Raised **₹ 372.40 cr** in equity via conversion of warrants issued to OrbiMed and Promoters. Acquired a manufacturing facility from Tevapharm India

2024
Marksans crossed **₹ 2,000 cr revenue**

2025
OTC Segment crossed **₹ 2,000 cr revenue**

2026
Entered Germany, Canada and Ireland markets and launched Nova Pharma's branded prescription business in Australia and New Zealand.

Geographic Presence

Building a global healthcare platform

Our geographic presence spans regulated and emerging markets, supported by a growing global footprint. We have expanded our presence through strategic tie-ups and acquisitions across key markets, while collaborating with established partners to ensure the timely delivery of high-quality pharmaceutical solutions.

Global Mission

- Strengthen presence in the US generics market through organic growth and strategic acquisitions
- Focus on building Intellectual Property assets, particularly in specialised dosage forms
- Pursue in-licensing of Intellectual Property to support growth and scalability
- Develop and launch generic products for niche market segments
- Expand OTC presence in regulated markets to broaden portfolio and reach

01 India
02 Sri Lanka
03 Myanmar
04 Combodia
05 Philippines
06 Iraq
07 Ukraine
08 Greece
09 Germany
10 UK & Europe
11 Iceland
12 Canada
13 USA
14 The Caribben
15 Latin America

Resilient Foundation. Relentless Execution. Rising Stronger.

"Simultaneously, we continued to augment our manufacturing capabilities to support future demand. The Goa facility ramped up steadily during the year and performed in line with expectations. With utilisation levels approaching 50% and significant capacity available for future expansion, the facility provides a strong foundation to support our next chapter.

Dear Shareholders,

I am pleased to present the Annual Report for FY 2025-26, a year that marks an important milestone in our journey. Over the years, we have built a diversified global healthcare company with a balanced portfolio and multiple growth drivers across regulated markets. Through sustained investments in manufacturing, product development, market expansion and strategic business initiatives, we have created a stronger and more resilient organisation. These efforts translated into tangible outcomes during the year as we surpassed the ₹3,000 crore revenue mark for the first time and delivered our highest-ever profitability.

Our culture is anchored in an unwavering commitment to global standards and operational excellence. As the healthcare industry enters a new phase, with the traditional model of high-volume, low-cost generics giving way to more specialised, innovation-driven opportunities, we are uniquely positioned at the intersection of quality, capability and scale.

Resilient Amid Challenges

The global operating environment during FY 2025-26 was characterised by evolving geopolitical turmoil, supply chain bottlenecks and periodic cost pressures across the pharmaceutical value chain. In such a dynamic environment, success relied on agility, operational resilience and disciplined execution.

Amid these challenges, we remained focused on broadening our footprint across regulated markets, including our entry into Germany, Canada and Ireland, while continuing to strengthen our presence across existing markets.

North America remained our largest and fastest-growing market, supported by new product launches, market share gains and strong customer relationships. In the United Kingdom, business performance improved significantly during the second half of the year, culminating in record quarterly revenue in the fourth quarter.

Simultaneously, we continued to augment our manufacturing capabilities to support future demand. The Goa facility ramped up steadily during the year and performed in line with expectations. With utilisation levels approaching 50% and significant capacity available for future expansion, the facility provides a strong foundation to support our next chapter.

Relentless in Pursuit of Innovation

Our continued success in R&D has enhanced our ability to develop differentiated offerings and address evolving healthcare needs across regulated markets. During FY 2025-26, we invested ₹89 crore in R&D, reinforcing our commitment to shaping the future of healthcare.

In North America, we launched 112 SKUs and advanced our development pipeline with 51 additional products, reinforcing our position in one of our most important markets. Simultaneously, we have made significant progress in our regulatory programme in the UK through product approvals, filings and ongoing reviews. Looking ahead, we intend to file more than 200 products in the UK market over the next four years, creating a substantial platform for future commercialisation.

Expanding Our Horizons

While we recorded strong performance of our established businesses, we made meaningful progress in creating new avenues of value creation. A notable milestone during the year was our advancement in Australia through Nova Pharma, where we entered the prescription segment for the first time and launched 11 branded generic products. Building on more than two decades of expertise in the OTC market, this strategic expansion broadens our addressable opportunities in the Australian market and adds a complementary platform to support our long-term ambitions.

Europe represents the next important phase of our strategic roadmap to success. As we scale our presence across the region, our focus remains on enhancing portfolio diversity, expanding our commercial reach and creating a more balanced business mix. Together, these initiatives reinforce our strategic position and strengthen our ability to deliver sustainable value over the years ahead.

For People, Communities and a Better Tomorrow

We recognise that long-term value creation extends beyond financial performance. Guided by this belief, we remained committed to initiatives that positively impact communities and contribute to inclusion.

Our efforts spanned healthcare, education, community welfare and environmental stewardship. We improved healthcare access through medical camps, medicine distribution programmes, assistance for patients with critical illnesses and support for robust healthcare infrastructure. In education, we helped expand learning opportunities for underprivileged students and supported initiatives aimed at improving access to knowledge and digital resources. Additionally, our community programmes focused on nutrition, sanitation, livelihood support and child development, helping create lasting social impact and improving quality of life across the communities we serve. The impact we create is made possible by the dedication, expertise and shared sense of purpose of our people. We remain committed to fostering a collaborative and inclusive workplace where individuals are encouraged to learn, grow and contribute meaningfully. Through ongoing learning initiatives, we equip our teams with the skills and knowledge required to navigate an evolving industry landscape while supporting their professional aspirations and personal growth.

Rising to Unlock New Possibilities

FY 2025-26 has been a defining year in our journey, marked by strong execution, expanding capabilities and meaningful progress across our strategic priorities. The foundations we have built over the years position us well to capitalise on favourable industry trends. Building on our established positions across North America, the United Kingdom and Australia, we remain focused on selectively pursuing opportunities that complement our long-term strategic priorities.

Supported by a debt-free balance sheet, healthy cash generation and a scalable operating platform, we stride ahead with confidence. Our focus remains on delivering sustainable value through disciplined execution, prudent capital allocation and an unwavering commitment to excellence.

I would like to conclude by expressing my sincere gratitude to all our stakeholders for their continued trust and support. Your confidence inspires us to remain resilient in the face of challenges, relentless in our pursuit of excellence and focused on rising to new possibilities.

Regards,

Mark Saldanha
Chairman and Managing Director

Q&A with the CFO

Creating Enduring Value through Financial Discipline

"This preparedness is complemented by a well-established operating model and a broad revenue base, which help mitigate concentration risks and reduce exposure to disruptions in any single market or product category.

Q. Marksans Pharma achieved several financial milestones during FY 2025-26. What were the defining highlights of the Company's performance, and what do they reveal about its underlying financial health?

FY 2025-26 marked a significant year for Marksans Pharma, with the total revenue crossing the ₹3,000 crore mark for the first time at ₹3,033 crores, along with its highest-ever profitability. The year was defined by improved business quality, supported by margin expansion, disciplined execution and robust cash generation.

Our operating revenue stood at ₹2,951 crores, representing a growth of 12.5% year-on-year. Gross profit increased by 13.2% to ₹1,674 crores, with gross margin improving to 56.7%. EBITDA for the year stood at ₹601 crores, translating into a margin of 20.4%, while profit after tax reached ₹420 crores. In addition, we generated operating cash flows of ₹458 crores and free cash flows of ₹328 crores, ending the year with cash and cash equivalents of approximately ₹990 crores as well as maintaining a debt-free balance sheet.

Q. What were the principal drivers of Marksans' revenue growth in FY 2025-26, and how did key markets contribute to this performance?

Our performance in FY 2025-26 was underpinned by sustained demand across key markets, a broader product offering and consistent commercial execution. These factors enabled us to deliver growth across multiple geographies while maintaining healthy profitability.

North America remained one of the most important markets for us, with revenue increasing 24% year-on-year to ₹1,533 crores. This performance was driven by a combination of new product introductions, market share expansion and proper customer engagement. During the year, we launched 112 SKUs which strengthened our market position and reinforced our development pipeline.

Building on this momentum, the United Kingdom business delivered a significantly improved performance during the second half of the year. Following a challenging start, market conditions stabilised and business momentum improved steadily, resulting in record quarterly revenue during the fourth quarter.

We also recorded encouraging progress in Australia and New Zealand, supported by sustained demand across our OTC portfolio. In addition, our entry into the branded prescription generics segment through Nova Pharma established a new revenue stream and expanded our participation in the market.

Collectively, these factors led to a more balanced revenue mix, improved geographic diversification and another year of healthy financial performance.

Q. How did profitability evolve during the year and what were the key factors behind the improvement in margins?

FY 2025-26 saw a notable improvement across our key earnings metrics. Gross margin expanded to 56.7%, while EBITDA margin improved to 20.4%. The momentum was particularly encouraging during the fourth quarter, when EBITDA margin reached 22.8%, reflecting the cumulative benefits of several operational and commercial initiatives.

This performance was supported by a favourable product mix across key geographies and improved operating leverage as revenues increased during the year. At the same time, we remained focused on enhancing efficiency across our operations, which contributed to better cost absorption and overall earnings quality. Raw material costs also moderated during the second half of the year, providing an additional tailwind.

This financial strength provides considerable flexibility in how we deploy capital. Over the years, we have balanced investments in the business with a prudent approach to liquidity management, ensuring that we remain well positioned to fund strategic requirements while preserving balance sheet stability.

The Board has recommended a final dividend of ₹0.90 per equity share for FY 2025-26, reflecting our commitment to rewarding shareholders while maintaining adequate resources for future requirements. In an industry characterised by long investment cycles and ongoing regulatory commitments, financial discipline remains essential. Our healthy cash reserves, strong liquidity profile and debt-free status provide the foundation to pursue our priorities with confidence while maintaining the flexibility to respond to changing business conditions.

Q. The pharmaceutical industry continues to face periodic supply-chain disruptions and cost volatility. What measures has Marksans Pharma put in place to mitigate these risks and maintain business continuity?

The pharmaceutical industry continues to operate in an environment characterised by geopolitical developments, supply-chain bottlenecks and periodic cost pressures. During the latter part of FY 2025-26, we witnessed inflationary trends across several raw materials, especially those linked directly or indirectly to petroleum-based intermediates.

In response, we have remained focused on proactive planning and prudent risk management. We maintain prudent inventory levels for critical raw materials and actively monitor developments across the supply chain to safeguard business continuity. Our sourcing strategy, supported by long-standing supplier relationships, provides the flexibility required to manage fluctuations in availability, lead times and pricing.

This preparedness is complemented by a well-established operating model and a broad revenue base, which help mitigate concentration risks and reduce exposure to disruptions in any single market or product category. We have also managed periodic volatility in freight and logistics costs through careful planning and ongoing monitoring of procurement and distribution activities.

While external factors may create short-term fluctuations, we remain confident in our ability to navigate these challenges and maintain our long-term growth trajectory.

Q. What steps is Marksans Pharma taking to enhance its capabilities and create a scalable platform for the future?

Over the past several years, we have focused on building the capabilities required to support the Company's long-term aspirations. This has involved targeted investments across research and development, manufacturing infrastructure and regulatory programmes, creating a scalable platform for the years ahead.

During the year, we invested ₹89 crores in R&D, representing approximately 3% of consolidated revenue. We continue to advance our product pipeline across key markets through ongoing development, filings and approvals. In the United States, we currently have 51 products under development, while in the United Kingdom we plan to submit more than 200 products over the next four years.

On the manufacturing front, the Goa facility continued to ramp up in line with expectations, with utilisation levels approaching 50% during the year. Importantly, significant capacity remains available within the existing infrastructure, providing the ability to accommodate higher volumes without the need for substantial near-term capital expenditure.

With much of the major investment cycle now behind us, our focus is increasingly on optimising asset utilisation and enhancing returns from the capabilities we have established. This positions us well to support future demand while improving the efficiency and scalability of our operating model.

Q. As Marksans enters FY 2026-27, what are your key priorities for the year ahead?

We are entering FY 2026-27 with a strong financial foundation, healthy liquidity and a well-established operating platform. Over the past several years, we have made significant investments across manufacturing, research and development, and commercial capabilities. As many of these investments mature, our focus is increasingly shifting towards enhancing utilisation, improving productivity and translating these investments into sustained financial performance.

From an operational perspective, we remain focused on driving profitable revenue growth and maintaining healthy margin profile and cash flows. At the same time, we will continue to allocate capital prudently, balancing investment requirements with financial discipline and shareholder returns.

The business is supported by a robust product development programme, expanding manufacturing capacity and a strong financial foundation that provides the flexibility to respond to evolving market dynamics. Our debt-free balance sheet and cash reserves of approximately ₹990 crores further strengthen our ability to pursue value-accretive opportunities while maintaining financial discipline. Backed by a scalable operating platform and a prudent approach to capital allocation, we remain confident in our ability to deliver consistent performance and create sustainable long-term value for our stakeholders.

Performance Highlights

Numbers that define our progress

Revenue from Operations

(₹ in million)



Revenue by Delivering System

OTC (₹ in million)



RX (₹ in million)



Geographical-Wise Revenue

Europe and UK (₹ in million)



The US and North America (₹ in million)



Australia and New Zealand (₹ in million)



Rest of the World (₹ in million)



Revenue by Therapeutic Segment

Pain Management (₹ in million)



Anti-Diabetic (₹ in million)



Upper Respiratory (₹ in million)



Gastrointestinal (₹ in million)



Central Nervous System (CNS) (₹ in million)



Cardiovascular System (₹ in million)



Anti-Infective (₹ in million)



Anti-Allergic (₹ in million)



Anti-Cancer (₹ in million)



Anti- Hairfall (₹ in million)



Vitamin & Minerals Supplement (VMS) (₹ in million)



Financial Measurements and Key Financial Ratios

EBITDA (₹ in million)



PAT (₹ in million)



EPS (in ₹)



Debt-Equity Ratio



ROCE (in %)



ROE (in %)



Cash from Operations (₹ in million)



Overview of Our Key Market Areas

Where we operate and grow

Our geographic presence spans regulated and emerging markets, supported by a growing global footprint. We have expanded our presence through strategic tie-ups and acquisitions across key markets, while collaborating with established partners to ensure the timely delivery of high-quality pharmaceutical solutions.

India

We operate state-of-the-art manufacturing facilities in Goa, India, spanning 43,325 sq. m, equipped with advanced infrastructure, automated manufacturing and packaging lines, and product innovation and formulation development capabilities, in compliance with global regulatory standards.

Product Development and Pipeline

Our Company has established a strong R&D infrastructure with dedicated centres in Goa and Navi Mumbai, supporting a broad portfolio across key therapeutic areas, including pain management, upper respiratory conditions, cardiovascular and central nervous system disorders, anti-diabetic medications and gastrointestinal drugs. As of March 31, 2026, our R&D capabilities have enabled us to secure more than 350 approved ANDAs and Market Authorisations (MAs), with over 30 filings awaiting approval and a pipeline of more than 200 products under development.

Outlook

With a robust manufacturing base, a diversified product portfolio and a strategic focus on expanding our presence in regulated markets, we are positioned for consistent growth. Our forward integration capabilities, supported by a continued focus on innovation, strengthen our competitive advantage and support a sustained product pipeline.

Europe and UK

In the UK, we operate through our subsidiaries Bell, Sons & Co. (Druggists) Limited and Relonchem Limited. These acquisitions have enabled us establish ourselves among the top five Indian pharmaceutical companies in the UK.

Our Subsidiaries

Bell's Healthcare focuses on OTC medications, supplying own-label products to supermarkets, high street retailers, pharmacy chains and wholesalers, with a portfolio spanning analgesics, upper respiratory remedies, gastrointestinal treatments, ear care and skincare solutions.

Relonchem caters to Rx requirements, holding over 175 market authorizations and distributing own-label pharmaceutical products across therapeutic categories, including anti-diabetic, CNS, anti-cancer, anti-ulcerative, anti-allergy, antiviral and pain relief treatments.

Market Presence

We maintain strong partnerships with key UK retailers, including AAH, Lloyds, NHS, TESCO, ASDA, Morrisons, Coop, Boots-Almus and others. Our products have presence across supermarkets, pharmacy chains, high street outlets and wholesale channels.

Product Development and Outlook

During the year, 18 products were approved and 30 filings were completed, with 24 products awaiting approval. The Group also plans to file more than 200 products over the next four years. Through portfolio diversification, strategic retail partnerships and a continued focus on innovation, we aim to further strengthen our presence in the European and UK pharmaceutical markets.

₹ 1,015 cr

Revenue

↓ 1.4

Yoy (%)

United States

In the United States, our operations are anchored by our subsidiary, Time Cap Laboratories Inc. (TCL), which focuses on the manufacturing of solid oral generic formulations. The company has capabilities in delayed and sustained-release dosage forms and offers a range of products including tablets and hard gelatin capsules. Its portfolio also includes OTC formulations such as analgesics, dietary supplements and upper respiratory treatments, along with select prescription drugs.

Manufacturing Excellence

TCL's facility is Good Manufacturing Practices (GMP) certified, ensuring compliance with regulatory requirements and global quality standards, and supports the production of products across OTC and Rx segments in multiple therapeutic areas.

Market Presence

TCL distributes its products through major wholesalers and pharmacies across the United States. Key retail clients include Walmart, Walgreens, CVS, Dollar General, Target and Kroger, reflecting strong market integration and brand recognition.

Product Pipeline and Outlook

In FY26, TCL launched 112 new SKUs and maintained a pipeline of 51 products, comprising oral solids, hard capsules, as well as ointments, creams and liquid formulations. With an expanding pipeline, a continued focus on quality and ongoing investments in R&D, Time Cap Laboratories Inc. is positioned to strengthen its market presence and drive growth.

₹ 1,533 cr

Revenue

↑ 24

Yoy (%)

Australia and New Zealand

We have established a strong presence in the pharmaceutical markets of Australia and New Zealand, which together represent the third-largest contribution to our overall revenues.

Partnership and Distribution

The Australia and New Zealand segment contributes approximately 10.3% to our total revenue, highlighting the importance of these markets to our business.

Product Pipeline and Outlook

During the year, Marksans launched 20 SKUs and established Nova Pharma, its branded prescription division, launching 11 Rx brands in FY 2025-26. We have 18 SKUs planned for FY 2026-27 and remains focused on strengthening its position in these markets through ongoing product development and an expanded distribution reach.

₹ 303 cr

Revenue

↑ 20

Yoy (%)

Rest of the World (RoW)

We have expanded our presence across Southeast Asia, the Middle East, Africa and the CIS countries. The Rest of the World segment now covers 13 countries across the CIS and MENA regions.

Market Presence

In FY26, these markets continued to form an important part of our global operations, with 230+ licensed products across UAE and other RoW geographies and 230 products awaiting regulatory approval, as we pursued deeper market penetration and portfolio expansion.

₹ 99 cr

Revenue

↑ 4

Yoy (%)

Business Model

Capital	Inputs
Financial Capital Maximising shareholder value through sustainable growth, strong balance sheet, and prudent financial management.	Net Worth - ₹30,526.80 mn Total capital employed – ₹29,253.26 mn Net Capital Expenditure - ₹ 131 cr
Manufactured Capital Enhancing capacity utilisation and operational efficiency to deliver consistent, high-quality products and services.	Manufacturing Units - 4 Formulation Capacity - 26 bn
Intellectual Capital Driving innovation to improve product efficacy, process efficiency, and long-term competitive advantage.	Scientists – 50+ R&D Expenditure – ₹890.38 mn R&D Centres - 4
Human Capital Empowering employees through development opportunities, inclusive culture, and a safe, performance-driven work environment.	Total Employees - 2000+
Social and Relationship Capital Engaging communities, patients, and partners to strengthen trust and deliver broader societal impact.	CSR Spend - ₹35.28 mn
Natural Capital Minimising environmental footprint through responsible resource use, waste reduction, and sustainable operational practices.	Energy Consumed – 264,246,687 MJ Water Withdrawal – 178,034 KL

Our Ecosystem



Value Creation Process
- Energy and Waste Management
- Talent Management
- Strategy and Planning
- Risk Management
- Finance and Cost Management

Stakeholders Impacted
- Customers
- Shareholders and Investors
- Suppliers and Business Partners
- Government and Regulatory Bodies
- Communities
- Employees

Delivery Forms
- Soft Gels
- Sachets
- Hard Gelatin Capsules
- Extended Release
- Liquid Bottles
- Otc Products
- Ointments
- Tablets

Outputs	SDGs Covered
Revenue - ₹30,334.71 mn EBITDA - ₹6,007.79 mn PAT - ₹4,200mn Dividend payout ratio – 12.06% ROE – 15.20% Market Capitalisation - ₹115,462 mn	8, 9
India 2.4 bn soft gel and hard gelatin capsules produced per annum 14 bn oral solid tablets produced per annum **UK** 1 bn tubes produced per annum 1 bn sachets produced per annum 2 bn bottles produced per annum **US** 6 bn tablets and hard capsules produced per annum	3, 8, 9, 12
Products Under Development – 200+ Approved ANDAs/MAs – 350+ ANDAs/MAs Awaiting Approval – 30+	3, 12
Diversity Ratio – 1:9 Attrition Rate – 16.85% Complaints on Discrimination – Nil POSH complaints – Nil Fatalities and Accidents – Nil	3, 5, 8, 10
Number of CSR Projects Conducted – 34	3, 4, 10, 11
Waste Recycled – 322.84 Mt	12

Risk Management

Championing challenges to drive growth

Our enterprise-wide risk management framework is integrated across all areas of our operations, enabling us to proactively identify, assess and monitor potential risks while implementing robust mitigation strategies to safeguard business continuity and create sustained value for our stakeholders. Continuously evolving in response to changing market dynamics and emerging challenges, our approach enhances organisational resilience, minimises disruptions, unlocks new opportunities and supports our long-term growth ambitions.

Identified Risk	Risk Description	Mitigation Measure	Material Issues Impacted
Strategic Risk			
Economic Risk	Macroeconomic volatility, geopolitical developments and regional uncertainties may affect operating conditions, influencing business performance and growth prospects.	• Diversified operations across multiple geographies reduce dependence on individual markets. • Revenue streams spanning different regions provide stability during economic fluctuations. • Continuous market assessment enables timely strategic responses.	• Governance • Ethics • People Retention • Data Privacy & Technology Environment
Competition Risk	Intensifying competition and changing market dynamics may impact market positioning and profitability.	• Focused investments in research and development strengthen product differentiation. • Ongoing monitoring of market trends supports informed decision-making. • Close collaboration between commercial and innovation teams drives portfolio expansion.	

Identified Risk	Risk Description	Mitigation Measure	Material issues impacted
Financial risk			
Liquidity Risk	Variations in input costs and working capital requirements may influence financial flexibility and earnings performance.	• Prudent financial management supports operational stability. • Long-term supplier partnerships improve cost visibility and planning. • Efficient cash-flow management strengthens the balance sheet.	• Governance • Ethics • People Retention • Data Privacy & Technology Environment
Operational risk			
Human Resource Risk	Challenges in attracting, developing and retaining talent may affect organisational capabilities and long-term performance.	• Employee-centric policies promote engagement and retention. • Learning and capability-building initiatives strengthen workforce readiness. • Well-being programmes contribute to a positive work environment.	
Supply Chain Risk	Disruptions across procurement and logistics networks may affect production schedules and customer commitments.	• A geographically distributed manufacturing footprint enhances resilience. • Supplier diversification reduces dependence on individual vendors. • Robust sourcing practices support business continuity.	
Environmental, Health and Safety Risk	Evolving environmental standards and workplace safety requirements may influence operational efficiency and compliance obligations.	• Manufacturing facilities adhere to stringent environmental and safety protocols. • Ongoing sustainability initiatives reduce resource intensity and emissions. • Periodic reviews strengthen health and safety practices.	
Technology Risk	Rapid technological advancements may affect competitiveness, innovation capabilities and operational effectiveness.	• Modern manufacturing infrastructure enables technology adoption. • Investments in R&D capabilities support continuous innovation. • Regular evaluation of emerging technologies sustains market relevance.	
Operational Risk			
Compliance Risk	Failure to comply with applicable regulations and industry standards may result in legal, financial and reputational consequences.	• Robust governance and quality systems reinforce regulatory compliance. • Facilities operate in accordance with relevant certifications and standards. • Continuous monitoring helps address evolving regulatory requirements.	

Stakeholder Engagement

Forging enduring bonds of trust

Our long-term success is closely linked to the strength of our relationships with stakeholders. We maintain continuous engagement through multiple channels to understand their expectations, perspectives and emerging priorities. The insights gathered through these interactions inform our strategic priorities and operational decisions, enabling us to strengthen trust, enhance collaboration and deliver solutions that create sustainable value for all stakeholders



Stakeholder	Why We Engage	How We Engage	Expectations/ Concerns	Frequency Of Engagement
Customers	To understand evolving healthcare needs and strengthen patient-centric solutions.	• Digital platforms • Customer interactions and feedback channels • Corporate website	• Effective and dependable products • Affordable healthcare solutions • Transparent product communication • Consistent quality standards	Continuous
Channel Partners	To enhance market reach and ensure seamless product availability across geographies.	• Distributor meetings • Field visits and market reviews	• Efficient logistics and supply management • Timely fulfilment of orders • Strong business partnerships • Sales and marketing support	Periodic and need-based

Stakeholder	Why We Engage	How We Engage	Expectations/ Concerns	Frequency of Engagement
Suppliers	To build a resilient procurement ecosystem and maintain uninterrupted operations.	• Supplier assessments • Site visits • Compliance and quality reviews • Grievance resolution mechanisms	• Long-term collaboration • Predictable business demand • Prompt settlements • Adherence to quality and regulatory standards	Quarterly and throughout the project cycle
Government and Regulatory Authorities	To uphold regulatory compliance and contribute to the advancement of the healthcare sector.	• Regulatory submissions • Consultations and meetings	• Compliance with applicable laws and standards • Ethical business practices • Transparent disclosures • Support for public health priorities	As and when required
Healthcare Professionals	To gain clinical insights and address emerging patient-care requirements.	Engagement through field teams	• Accurate scientific information • Access to knowledge-sharing initiatives • Collaborative engagement focused on patient outcomes	Regular interactions throughout the year
Communities	To create meaningful social impact and contribute to the well-being of society.	Community development and CSR programmes	• Healthcare and wellness initiatives • Environmental stewardship • Inclusive development programmes • Responsible corporate citizenship	Based on programme schedules and community requirements
Shareholders and Investors	To communicate business performance and reinforce confidence in the Company's long-term vision.	• Annual reports • Investor presentations • Earnings announcements • Annual General Meeting • Investor calls	• Sustainable growth and profitability • Effective governance practices • Timely and transparent disclosures • Long-term value creation	Quarterly and annual engagements
Employees	To nurture talent, strengthen organisational capabilities and foster a high-performance culture	• Leadership interactions • Town halls • Employee feedback forums • Grievance mechanisms	• Professional growth opportunities • Inclusive and safe workplace • Recognition and rewards • Competitive compensation and benefits	Ongoing through formal and informal engagement platforms

Research and Development

Powering growth through innovation

We invest in research and development to support a consistent pipeline of products aligned with market and patient needs. Our portfolio spans both over-the-counter (OTC) and prescription segments, with plans to introduce around 15 new products annually. Our R&D teams work in collaboration with partners and regulatory authorities to ensure that products meet established standards of safety, efficacy and quality.

4
R&D Centres

50+
Scientists

200+
Products in pipeline

350+
ANDAs/MAs Approved

25+
ANDAs/MAs Filed

R&D
(₹ in cr)



R&D to Sales
(in %)



Our Strengths

- Global R&D footprint across four locations
- Regulatory-accredited facilities approved by US FDA, MHRA (UK), TGA (Australia), European Medicines Agency and Health Canada
- Experienced scientific team of over 50 professionals with strong formulation and regulatory expertise
- Accelerated development and commercialisation capabilities
- Enhanced competitiveness in global markets

Our Focus

- Development of specialised dosage forms, including soft gels, extended-release formulations, liquids, ointments and other delivery systems
- OTC product development across therapeutic categories such as pain management, upper respiratory, digestive health, vitamins, supplements and anti-allergic treatments
- Prescription formulations addressing cardiovascular conditions, central nervous system disorders and diabetes

Contract Research and Collaboration

Our R&D function collaborates with academic institutions, hospitals and research organisations to support development activities. These partnerships leverage scientific expertise, trained personnel and infrastructure, helping us align our development processes with established industry standards.

Strategy

Executing with discipline

Our strategy is anchored in strengthening our presence in core markets while building capabilities that support long-term, scalable growth. We are focused on expanding our OTC portfolio, advancing our product pipeline through sustained R&D, and enhancing manufacturing capacity to improve operating leverage. At the same time, we continue to pursue selective acquisitions and front-end expansion to deepen market access. Behind these efforts is a commitment to quality, regulatory compliance and responsible business practices, allowing us to deliver consistent performance and create enduring value.

Core Strategies for Future Growth

Focus on Store Brand OTC Segment

- Expanding within proven OTC demand areas, expanding market share with customers and key regions. Aim to capture a significant part of the multi-billion-dollar OTC opportunity. According to IQVIA, Global OTC Size in 2026 is expected to be ~$ 215bn.
- Our OTC segment grew at CAGR of 21% (from FY17-FY25)
- Marksans is the most preferred and growing low-cost store brand manufacturing partner

Innovation & Pipeline Power

- Continued focus on R&D leading to a strong product pipeline and successful launches
- Strong pipeline of more than 200 products

Scale capacity and operating leverage

- Aim to expanding capacity, scale the acquired unit in Goa, capacity to 8bn units p.a. Plan to manufacture tablets, hard capsules, ointments, liquids, and creams

Sustainable & Responsible Growth

- Commit to environmentally sustainable, socially responsible practices across the Consumer Healthcare value chain
- Promote access to safe, effective, and affordable OTC healthcare solutions
- Uphold quality, regulatory, and ESG standards to build enduring value

Strategic Acquisitions & Front-End Expansion

- We will follow calibrated inorganic growth approach
- Expansion in growing markets and EU through acquiring front-end marketing and distribution companies
- Strong balance sheet to support the growth

Focus Areas: Key Markets and Portfolio Expansion

- Focus on strengthening presence across Europe, the US and emerging markets
- Leverage manufacturing and infrastructure capabilities to enhance position as a manufacturing and distribution partner in regulated markets
- Build a strong presence in the US generics market
- Focus on developing Intellectual Property assets, particularly in niche dosage forms
- Explore out-licensing of IP to support growth and scalability
- Develop and launch generic products in niche and technology-driven segments, while exploring new markets
- Expand OTC presence across regulated markets



ESG

Our commitment to Environmental, Social and Governance (ESG) principles is integral to our strategy and long-term growth. By embedding ESG across our operations, we enhance value, manage risks and align with the evolving expectations of our stakeholders.



Social

Support our people and communities through respect for human rights and a focus on diversity and inclusion.

S



E

Environment

Promote sustainability across our operations and projects while minimising our impact on the natural environment.

G

Governance

Uphold ethical practices and strengthen trust through transparency and accountability.

Environment

Balancing Growth with Responsibility

We are committed to building a sustainable future by translating our environmental priorities into measurable actions. Our approach focuses on improving energy efficiency, reducing waste and strengthening responsible practices across our operations and supply chain.

We continue to adopt energy-efficient technologies, recycling initiatives and packaging optimisation to minimise our environmental impact, while aligning our efforts with the United Nations Sustainable Development Goals (UN SDGs), including responsible consumption and resource conservation. We also work closely with our suppliers to support progress towards shared sustainability objectives.

Sustainability Goals and Progress

Goal	Initial Milestone	Status
Reducing Annual Virgin Plastic Usage in Packaging Through Supplier and Customer Collaboration	Use of **100%** recyclable HDPE/ PET bottles/ LDPE Shrink wrapping Use of **70-80%** recyclable labels	In Progress
Reducing Carbon Footprint Through Packaging Optimisation	Initial evaluation of the use of paperboard with **20%** recycled content Size & configuration optimization of the package size Use of Forest Stewardship Council (FSC) certified packaging	In Progress
Focus Areas: Preventive Healthcare, Education, Nutrition, Women & Child Welfare, and Rural Development	Mobile health care units to support the grievances of communities in around **20-25** villages	2% of the net profit is spent for overall development of the communities

Implementing Sustainability Standards Across All Customers	**100%** Compliance with Target Chemical Policy SMETA 4 Pillar compliance as per prevailing laws including gender equity policies Whistleblower mechanism- different channels of communication for grievances Continuous skill enhancement is in place	Establishing policies on incidence reporting Continuous skill enhancement of all employees
Targeting Sustainable Waste Disposal by 2028	Waste disposal with co-processing – Recycled and Reused **100%** Waste water utilization after reprocessing	In Progress Use of renewable/ recyclable sources of energy
Focus on Reducing Greenhouse Gas Emissions	**Scope 1 -** Reduction in steam consumption by **2%** **Scope 2 -** Reduction in electrical energy by **3%**, reduction in raw water consumption by **2%**	Policies and monitoring are in place for environment and biodiversity Commitment to preserve nature and environment

Social

Strengthening communities around us

At Marksans, we seek to contribute meaningfully to society through our CSR initiatives, focusing on healthcare, education, environmental sustainability and social welfare.

Our efforts are directed towards improving quality of life, supporting underserved communities and promoting inclusive socio-economic development. Through targeted interventions and partnerships, we aim to address essential community needs while creating meaningful and measurable impact across the regions we serve.

₹ 3.52 cr

Total CSR Expenditure

34

Number of CSR Projects Undertaken

Healthcare

- Organized free health check-up camps and distributed free medicines and other medical supplies to under privileged people in the state of Goa
- Medical treatment to underprivileged patients of cancer and bone marrow transplantation

Education & Training

- Contribution towards education of underprivileged students
- Sponsored disaster management training workshops

Environment

- Building and upkeep of public gardens/parks and tree plantation in Verna Industrial Estate, Goa

Food Distribution

- Distribution of free food items to daily wage labourers, people below poverty line and other economically backward people who do not have regular income

Overall Wellbeing of Women and Children

- Women and child development, professionalizing Anganwadis and national nutrition mission in Goa

Governance

Built on accountability

Our corporate governance framework is aligned with the objective of long-term value creation and sustainable growth. The Board of Directors provides oversight on strategy, risk and performance, while upholding transparency, accountability and ethical conduct across the organisation.

At Marksans, we have established internal controls, defined processes and codes of conduct to guide business operations and decision-making. These are complemented by practices focused on responsible resource management, ethical employment standards and regulatory compliance. Through ongoing review and refinement of governance processes, we aim to maintain an effective framework that supports operational stability and long-term resilience.

Corporate Governance Principles

- Business continues to create value for customers and consumers responsibly
- Application of Best management practices
- Tracing Emission/ Waste and maintain them below permissible levels
- Maintain a strong track record of withholding & promotion of Human rights
- Effective management and distribution of wealth
- Adherence to ethical working standards to ensure the wellbeing of all employee
- Producing goods which have a sustainable life cycle
- Conducting Business in Ethical, Transparent and Accountable manner

Policies and Codes

In line with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have adopted the requisite policies and codes applicable to listed entities. These are reviewed and updated periodically to ensure continued alignment with regulatory requirements.

- **Code of conduct for directors and employees**
- **Code of conduct to regulate, monitor and report trading in securities**
- **Policy on related party transactions**
- **Corporate social responsibility policy**
- **Whistle blower policy**
- **Policy for determination of materiality of events or information and disclosures**
- **Code of practice and procedure for fair disclosure of unpublished price-sensitive information**
- **Policy for determining material subsidiaries**
- **Dividend distribution policy**
- **Nomination and remuneration policy**

Our Committees

We have constituted various Board committees to support effective governance and oversight across key areas. Each committee operates under a defined charter and comprises members of the Board, enabling focused supervision of specific functions in line with regulatory requirements and organisational objectives.

- Audit Committee
- Corporate Social Responsibility Committee
- Nomination and Remuneration Committee
- Risk Management Committee
- Stakeholders' Relationship Committee

Awards/Recognition

Our focus on operational excellence, quality and continuous improvement was recognised through prestigious industry acknowledgements during the year. These recognitions highlight the strength of our manufacturing practices, supply chain capabilities and continued focus on delivering high-quality pharmaceutical products to patients across global markets.

ISCM Supply Chain Ranking 2026

Marksans Pharma was recognised by the Institute of Supply Chain Management (ISCM) for excellence in inventory management. The recognition acknowledges our disciplined inventory management practices that support reliable pharmaceutical supply across domestic and international markets.

USP Certificate of Appreciation

Marksans Pharma received a Certificate of Appreciation from the U.S. Pharmacopeial Convention (USP) in recognition of our participation in USP's standards-setting activities.

Board of Directors

Mr. Mark Saldanha

(Chairman & Managing Director)

Executive, Non Independent & Promoter

Business, Marketing, Production and Finance

Mrs. Sandra Saldanha

Executive, Non-Independent & Promoter

Human Resource Management, Business Development, Projects and Supply Chain Management

Mr. Varddhman Vikramaditya Jain

Executive, Non Independent

Manufacturing, quality R&D, compliance & regulatory affairs both for API and finished dosages

Mr. Digant Mahesh Parikh

Non-Executive & Independent

Corporate Finance, Strategic Planning and Business Set-up & Scale up

Mr. Abhinna Sundar Mohanty

Non-Executive & Independent

Sales and Marketing, Business Development and Business Strategy

Dr. Sunny Sharma

Non-Executive & Non-Independent

Corporate Finance and Investment Banking

Mrs. Shailaja Vardhan

Non-Executive & Independent

Corporate communication, public communication, Building brand architecture and CSR

Mr. Srinivas Mishra

Non-Executive & Independent

Corporate Finance, Wholesale Banking, Business & Administration and Risk Management

CSRC C M | RMC C M | SRC C M | NRC C M | AC C M

Chairman C | Member M

Corporate Information

Board of Directors

Mr. Mark Saldanha
Chairman & Managing Director
(DIN: 00020983)

Mrs. Sandra Saldanha
Whole-time Director
(DIN: 00021023)

Mr. Varddhman V. Jain
Whole-time Director
(DIN: 08338573)

Mr. Digant Mahesh Parikh
Independent Director
(DIN: 00212589)

Mr. Abhinna Sundar Mohanty
Independent Director
(DIN: 00007995)

Dr. Sunny Sharma
Non-executive Director
(DIN: 02267273)

Mrs. Shailaja Vardhan
Independent Director
(DIN: 10172764)

Mr. Srinivas Mishra
Independent Director
(DIN: 1005205)

Key Management Personnel

Mr. Mark Saldanha
Chairman & Managing Director

Mrs. Sandra Saldanha
Whole-time Director

Mr. Varddhman V. Jain
Whole-time Director

Mr. David Mohammed
Managing Director - Australia Operations

Mr. Sathish Kumar
Managing Director - UK Operations

Mr. Anjani Kumar
COO - US Operations

Mr. Jitendra Sharma
Group Chief Financial Officer

Mr. Harshavardhan Panigrahi
Company Secretary

Registered Office

11th Floor, Grandeur,
Veera Desai Extension Road,
Oshiwara, Andheri (West),
Mumbai – 400053.

CIN

L24110MH1992PLC066364

Registrar & Share Transfer Agent

Bigshare Services Private Limited
Office No S6-2, 6th floor
Pinnacle Business Park,
Next to Ahura Centre,
Mahakali Caves Road,
Andheri (East)
Mumbai - 400093.

Bankers

State Bank of India
Bank of Baroda

Works

1 L-82 & L-83, Verna Industrial Estate, Verna, Goa – 403722.

2 Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa - 403722

3 Bell, Sons & Co. (Druggists) Ltd. Gifford House, Slaidburn Crescent, Southport, PR9 9AL.

4 Time-Cap Laboratories Inc. 7, Michael Avenue, Farmingdale, New York- 11735, USA.

34th Annual General Meeting

Day & Date: Thursday, 27 August 2026

Time: 11:00 A.M.

The 34th Annual General Meeting will be held through Video Conferencing / Other Audio Visual Means.

Statutory Auditors

M/s. M S K A & Associates LLP

Secretarial Auditor

M/s. Jinesh Dedhia & Associates

Management Discussion and Analysis

Economic Overview

Global Economy

In CY 2025, the global economy demonstrated resilience, with GDP grew by 3.4% despite policy uncertainty and rising trade tensions. Technology-related investment, accommodative financial conditions, and supportive fiscal & monetary policies drove economic activity.

Inflation moderated across major economies, settling at approximately 4.1%. This moderation was largely driven by improved supply chains, better inventory management and a gradual softening of labor markets. This easing of price pressure allowed major central banks to transition to a more accommodative stance, lowering interest rates to sustain growth and financial stability further.

Global trade volume expanded by 5.1% during the year. Merchandise trade remained strong, driven by front-loaded shipments. Services trade also expanded, particularly in medicines and pharmaceuticals.

Global Growth Projections (%)



Source: World Economic Outlook April 2026

Outlook[2]

Global economic growth is projected at 3.1% in CY 2026. The outlook remains uncertain due to shifting trade policies and fiscal pressures. However, policy support and resilient domestic demand, aided by monetary easing, are expected to sustain growth.

Rising conflict in West Asia continues to disrupt global energy supply chains, fueling inflationary pressures. If the crisis persists, it could weigh on global economic growth and weaken investor confidence over the medium term. Consequently, inflation is projected to edge up to 4.4% in CY 2026 before declining to 3.7% in CY 2027, due to easing labor market conditions and subdued demand for tradable goods.

This situation, along with tariff-related uncertainties and elevated energy prices, is expected to moderate global trade growth. However, expanding bilateral partnerships may help economies diversify trade flows and reduce dependence on a limited number of markets.

Us Economy[3]

The US economy recorded steady expansion in CY 2025, with GDP growing by 2.1%. Growth was backed by robust investment in equipment and technology, along with a notable contribution from net international trade. Federal government spending also rebounded despite global uncertainties. Improved economic activity supported labor market conditions, with the unemployment rate easing to 4.3%, resulting in increased labor participation[4].

Inflation eased during the year to 2.7%, despite the implementation of new tariffs, tighter immigration policy and elevated uncertainty, which led to price fluctuations[5]. This moderation, combined with rising household wealth, supported stronger consumer spending. Service-sector spending also increased, driven primarily by healthcare services, recreation and transportation.

Outlook[6]

Economic growth in the United States is forecasted at 2.3% in CY 2026. Growth is likely to be supported by easing tariff pressures, tax reductions under the One Big Beautiful Bill Act, and stronger consumer spending driven by real wage gains, rising wealth, and improved business investment conditions.

The labor market is expected to remain in a 'low hiring, low firing' phase, where companies remain cautious in recruitment but avoid significant job cuts. As a result, unemployment is expected to rise modestly to around the 4.4% range in CY 2026[7].

[1] https://www.imf.org/-/media/files/publications/weo/2026/april/english/text.pdf
[2] https://www.imf.org/-/media/files/publications/weo/2026/april/english/text.pdf
[3] https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026
[4] https://www.imf.org/external/datamapper/LUR@WEO/OEMDC/ADVEC/WEOWORLD/AUS/USA
[5] https://www.imf.org/external/datamapper/PCPIPCH@WEO/OEMDC/ADVEC/WEOWORLD/USA
[6] https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026
[7] https://www.imf.org/external/datamapper/LUR@WEO/OEMDC/ADVEC/WEOWORLD/USA

Tariffs have so far contributed to gradual price increases and are largely viewed as a one-time adjustment that may reduce consumers' purchasing power without significantly affecting overall economic growth. Inflation is projected at 3.2% in CY 2026 and will likely remain above the 2% target. However, it is expected to moderate gradually to 2.1% in CY 2027, as tariff effects wane and housing costs stabilize[8].

UK Economy[9]

The United Kingdom (UK) economy grew modestly by 1.3% in CY 2025, driven by rising consumer spending despite challenges such as global uncertainty and higher taxes. Total trade also remains strong, supported by healthcare exports, especially medicines and pharmaceutical products, reflecting the resilience of the economy.

Consumer price inflation averaged at 3.4%, largely due to declining energy costs and slower price increases across different sectors[10]. In response to easing inflationary pressure, the Bank of England reduced the Bank Rate by 25 basis points to 3.75%[11].

However, the unemployment rate edged up to 4.9%, indicating some softening in the labor market as employers responded to slower economic growth and cost pressures[12]. Immigration continues to support workforce availability, particularly in critical sectors such as healthcare. The National Health Service (NHS) benefited from targeted recruitment of overseas healthcare professionals through the Skilled Worker visa scheme, helping to address staffing gaps across key services.

Outlook

Economic growth in the UK is projected to ease to 0.8% in CY 2026 due to planned fiscal tightening and higher energy prices before recovering slightly to 1.3% in CY 2027, supported by business investment and exports, as financial conditions and global trade may improve.

Inflation is expected to continue moderating as a weakening labor market continues to exert downward pressure on wage growth. With inflation easing, the Bank of England is expected to continue its cautious rate-cutting cycle, potentially reducing the policy rate to 3.25%. This may help support consumer spending and ease pressure on real income.

The proposed India-UK Free Trade Agreement, if successfully ratified, is expected to lower tariff and non-tariff barriers between the two countries. Over the long term, this agreement could increase the UK's real GDP by approximately 0.13% by 2040[13].

Russia Economy

The Russian economy remained resilient in CY 2025, with GDP expanding by 1.0%. However, declining oil revenues and Western sanctions weighed on broader economic activity. Higher military spending contributed to inflationary pressures. Inflation moderated but remained above the Central Bank of Russia's 4% target. As inflation eased, the central bank reduced the policy rate from 21% to 16%[14] .

On the demand side, consumption eased as high borrowing costs curtailed consumer lending. Investment activity declined due to weaker corporate lending and lower fiscal spending. The labor market remained tight, with unemployment at 2.2%, increasing real wages[15].

Trade with Asian economies has expanded steadily, strengthening Russia's economic integration with regional markets, including China, India and Central Asia. China remains Russia's largest trading partner, particularly in energy and raw materials. India expanded its role through higher pharmaceutical and engineering exports alongside energy imports.

Outlook

The Russian economy is expected to remain uncertain. GDP is projected to grow by 1.1% in CY 2026. Structural challenges, including labor shortages, weak consumer demand and import dependence, are expected to persist. Geopolitical tensions may further constrain economic activity. Growth is likely to be supported by defence-related production and stable oil and gas revenues.

Inflation is expected to decline over the medium term. However, external pressures may slow the pace of disinflation in 2026. Inflation is estimated to reach the central bank's target of 4% in 2028 as external factors phase out, and tight domestic demand conditions persist.

Economic reforms are expected to strengthen public finances and improve long-term growth prospects. These measures include enhanced tax collection and productivity-focused initiatives. The government has also launched National Projects 2.2 to improve economic efficiency and increase social spending. These initiatives aim to enhance overall quality of life.

Australia Economy

Australia's economy grew at its fastest pace in nearly three years, with GDP rising by 2.0% in 2025[16]. Growth was primarily driven by strong domestic demand, particularly private investment and household consumption. However, economic activity faced headwinds as businesses reduced inventories and the trade deficit widened due to imports growing faster than exports. Wage growth remains robust across industries, with healthcare and social assistance being the most significant contributor to wage growth in both the private and public sectors.

---

[8]https://www.imf.org/external/datamapper/PCPIPCH@WEO/OEMDC/ADVEC/WEOWORLD/USA
[9]https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026
[10]https://www.imf.org/external/datamapper/PCPIPCH@WEO/OEMDC/ADVEC/WEOWORLD/GBR
[11]https://www.bankofengland.co.uk/monetary-policy/the-interest-rate-bank-rate
[12]https://www.imf.org/external/datamapper/LUR@WEO/OEMDC/ADVEC/WEOWORLD/GBR
[13]https://obr.uk/docs/dlm_uploads/OBR_Economic_and_fiscal_outlook_November_2025.pdf
[14]https://thedocs.worldbank.org/en/doc/d5f32ef28464d01f195827b7e020a3e8-0500022021/related/mpo-rus.pdf
[15]https://www.imf.org/external/datamapper/LUR@WEO/OEMDC/ADVEC/WEOWORLD/GBR/RUS
[16]https://www.imf.org/external/datamapper/NGDP_RPCH@WEO/OEMDC/ADVEC/WEOWORLD/AUS

On top of that, national non-defense spending supported economic growth, particularly through social benefits programs such as Medicare and the Pharmaceutical Benefits Scheme, highlighting strong demand for essential goods and healthcare services.

Inflation stood at 2.9%, with healthcare and housing costs contributing significantly to price pressures and keeping inflation above the Reserve Bank of Australia (RBA)'s target range[17]. In response, the Reserve Bank of Australia (RBA) increased its policy rate by 25 basis points to 3.85%, signaling its commitment to maintaining price stability.[18]

Outlook

Australia's growth rate is projected to remain at 2% in CY 2026, supported by firm private demand. However, the recent conflict and elevated energy prices may slow household consumption growth in the near term. This impact is expected to be partly offset by lower import growth.

Inflation is expected to edge up to 4% in CY 2026, driven by services inflation and persistently strong wage growth. This may present a policy challenge for the Reserve Bank of Australia in determining the pace of further interest rate cuts.

Emerging markets and developing economies

Economic growth in Emerging Market and Developing Economies (EMDEs) was faster than expected during CY 2025. Despite elevated macroeconomic and policy uncertainty, capital flows to major developing economies remained robust, strengthening external balances. Overall, EMDEs recorded growth of 4.4% in CY 2025[19].

Among developing economies, China continued to lead export growth, supported by strong shipments of manufactured and industrial goods. India continued to demonstrate strong economic momentum driven by robust domestic demand. Growth also improved across regions such as the Middle East, Central Asia and sub-Saharan Africa, supported by higher commodity production, economic reforms and macroeconomic stabilization. Other regions experienced mixed but gradually improving performance as trade-related pressures ease.

Outlook[20]

Growth in EMDEs is expected to moderate slightly in CY 2026 as the temporary boost from earlier trade activity fades. However, improving financial conditions are expected to help offset the impact of ongoing trade restrictions and weaker business confidence.

Several major developing economies, including China, India and Indonesia, are expected to maintain solid growth. Resilient domestic demand and targeted policy measures will continue to support economic activity. However, growth prospects for many low-income and vulnerable economies remain constrained.

To sustain long-term growth, EMDEs are going to need to implement structural reforms that diversify trade, strengthen economic policies and address domestic economic constraints. Without stronger and more dynamic growth, many EMDEs may face challenges in generating sufficient employment opportunities for their expanding working-age populations.

Indian Economy[21]

India's economy grew by 7.7% in FY 2025–26, retaining its position as the world's fastest-growing major economy for the fourth consecutive year[22]. Stable macroeconomic fundamentals and continued policy support sustained growth despite a challenging global environment.

Inflation remained moderate during the year, with the Consumer Price Index (CPI) at around 3.48%[23]. Improved supply chains and lower input costs helped contain price pressures[24]. In response, the Reserve Bank of India reduced the policy repo rate by a cumulative 125-basis-points. The measure aimed to support growth while maintaining price stability.

Strong domestic demand continued to drive economic activity. Lower income tax rates and GST rationalization improved consumer spending and purchasing power. On the supply side, industrial activity gained momentum across key sectors. Manufacturing remained a significant contributor, with pharmaceuticals and chemicals among the leading performers.

India, now the world's fourth-biggest economy, also recorded a strong trade performance. Export growth varied across sectors, with drugs and pharmaceuticals emerging as key contributors to merchandise exports.

Government initiatives strengthened healthcare access and infrastructure. Expanded health insurance coverage, digital health programs and improved access to affordable medicines supported more inclusive healthcare developments.

Outlook[20]

India's growth outlook remains positive despite global uncertainty and trade-related challenges. Strong domestic demand and sustained investment activity are expected to support economic growth. As a result, India is projected to remain the fastest-growing major economy among advanced and emerging markets in FY 2026-27.

[17] https://www.imf.org/external/datamapper/PCPIPCH@WEO/OEMDC/ADVEC/WEOWORLD/AUS

[18] Statement by the Monetary Policy Board: Monetary Policy Decision | Media Releases | RBA

[19] https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026

[20] https://openknowledge.worldbank.org/server/api/core/bitstreams/a9e24256-baf8-45bb-9075-75e437e1d6f7/content

[21] https://rbidocs.rbi.org.in/rdocs/Bulletin/PDFs/0BULT23042026FL5A726E38FAF84453B435F18A3709DD11.PDF

[22] https://www.mospi.gov.in/uploads/latestReleases/latest_release_1780655857536_5ac01869-ca4a-422d-b7a7-57b81da60932_Press_Note_on_GDP_Estimates_for_Q4_2025-26_and_PE_FY_2025-26_F.pdf

[23] https://www.mospi.gov.in/uploads/PressRelease/CPI%20Press%20Release%20of%20April%202026.pdf

[24] https://www.pib.gov.in/PressReleasePage.aspx?PRID=2251519&reg=3&lang=1

Supply-chain disruptions arising from the West Asia conflict may increase commodity prices and constrain the availability of key inputs for downstream industries, including chemicals. However, measures to secure critical inputs from alternative sources are expected to mitigate the impact.

The Union Budget 2026–27 significantly increased the allocation to the Ministry of Health and Family Welfare. The allocation rose to ₹1,06,530.42 crore, representing an increase of approximately 10% over the previous year. This record allocation emphasizes strengthening healthcare infrastructure, expanding medical education and advancing digital health initiatives [25].

Forecast[26]

GDP growth is forecasted at 6.6% for FY 2026-27. The government has introduced direct tax reforms to enhance the ease of doing business. Key measures include streamlined Tax Deducted at Source (TDS) workflows, reduced pre-deposits for legal disputes and longer deadlines to file revised returns. These updates aim to minimize compliance bottlenecks and free up business cash flow.

CPI inflation for 2026-27 is projected at 5.1%, bolstered by favorable supply conditions and the ongoing benefits of GST rate rationalization[27]. To support consumer demand in this environment, the MPC has kept the repo rate at 5.25% and maintained its neutral stance.

Additionally, the recently concluded Free Trade Agreement (FTA) with the European Union is expected to strengthen India's trade balance by approximately USD 16 billion through increased exports and deeper market integration, creating wider trade opportunities for Indian manufacturers[28].

GDP Growth Trend in India (%)



FRE- First Revised Estimate; PE- Provisional Estimate; P- Projected

Source: MOSPI Provisional Estimate; RBI Press Release

Industry Overview

Global Pharmaceutical Industry

US Pharma[29]

The U.S. healthcare system is transforming due to shifting medicine use patterns, evolving patient cost burdens, changing benefit designs and innovation-driven spending. Concurrently, structural barriers in access and affordability present persistent challenges, preventing patients who need medicines most from receiving them. These factors increase market complexity while creating opportunities for system-level improvements.

Empirically, total prescription medicine use increased 1.5% to reach 210 billion days of therapy in 2025. Additionally, the U.S. market at net prices grew 10.6% in 2025, maintaining an average annual growth rate of 9.3% over the last five years.

The market is driven by increasing demand for personalized and regenerative therapies to treat chronic diseases, while technologies such as Artificial Intelligence (AI) and Machine Learning (ML) are accelerating research and transforming drug discovery. During the year, the U.S. Food and Drug Administration (FDA) approved 46 novel drugs alongside several other significant drugs[30]. This reflects sustained innovation across therapeutic areas, particularly oncology, immunology and rare diseases.

Moreover, demand for medicines continues to rise as populations age. Companies developing therapies for chronic diseases and affordable generic medicines are expected to benefit from this trend. In addition, the growing demand for weight-loss treatment is likely to provide further momentum to market growth.

U.S. medicine spending at net prices is projected to grow by 4.5% to 7.5% through 2030. At list prices, spending is expected to increase by 6% to 9%. Pricing pressures and patent expiries are likely to moderate growth over the period. However, continued adoption of innovative therapies is expected to offset much of this impact.

UK and Eurozone Pharma

Europe is emerging as a key growth region for the pharmaceutical industry, driven by high healthcare expenditure and robust Research and Development (R&D) activity. Germany leads the region with advanced pharmaceutical technologies and a strong demand for treatments addressing chronic illness. Meanwhile, the UK's zero-tariff export agreement with the U.S. has strengthened exporter confidence, while commitments to reduce medicine prices aim to enhance affordability.

[25] https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221616&reg=3&lang=2#:~:text=The%20Union%20Budget%202026%E2%80%9327%20marks%20a%20significant,to%20the%20health%20budget%20of%20FY%202014%E2%80%9315.

[26] https://rbidocs.rbi.org.in/rdocs/Bulletin/PDFs/0BULT23042026FL5A726E38FAF84453B435F18A3709DD11.PDF

[27] https://www.rbi.org.in/Scripts/BS_PressReleaseDisplay.aspx?prid=62863

[28] https://www.pib.gov.in/PressReleasePage.aspx?PRID=2219146&reg=3&lang=2#:~:text=Accelerating%20Exports%20through%20Engineering%20Excellence,industrial%20modernisation%20and%20global%20competitiveness.

[29] https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026

[30] https://www.fda.gov/media/190705/download?attachment

The pharmaceutical industry invests €55 billion in research each year and exports medicines valued at around €320 billion annually. Its trade surplus is nearly 30% larger than that of all other sectors combined, emphasizing the industry's strategic importance to Europe's innovation ecosystem, trade and long-term economic resilience[31].

Despite its strong manufacturing infrastructure, reliable supply chain and high production standards, Europe is gradually losing competitiveness in pharmaceutical innovation. This is largely due to slower clinical trial initiation and a comparatively less supportive regulatory and funding environment than in the U.S. and China, making the early-stage development and commercialization of new medicines more challenging.

Pharmaceutical production in the Eurozone increased sharply by 21.6% in 2025, primarily due to front-loading in response to potential US tariff threats, with Ireland benefiting the most from this surge. However, this increase is expected to be temporary, with production projected to contract by 3.7% in 2026 as demand normalizes[32].

Russia Pharma

Russia's retail pharmaceutical market reached RUB 1.89 trillion, representing a year-on-year growth of 15.8%. However, the number of drug packages sold increased by only 1.8%, indicating that market expansion was largely driven by higher prices rather than volume growth[33]. Both retail sales and public procurement of medicines remain the key drivers.

Following Western trade restrictions and the exit of several multinational pharmaceutical companies, Russia's pharmaceutical sector experienced a shortage of Active Pharmaceutical Ingredients (APIs) and reduced research funding. To mitigate supply disruptions and control price increases, the government introduced emergency support measures under its Pharma-2030 strategy, including subsidies, tax incentives, research grants and accelerated drug approval processes. These Initiatives aim to strengthen domestic manufacturing capabilities, reduce import dependence and achieve 80% local production of essential medicines by 2030.

Moreover, the pharmaceutical market in Russia will show a moderation due to several systemic challenges, including a high level of tax burden and competitive pressure from federal pharmacy chains and marketplaces. Consolidation, improving operational efficiency, and developing a customer-centric approach are major strategies for survival in 2026.

Australia and New Zealand Pharma

The Australian pharmaceutical market plays a critical role in the country's healthcare system. Valued at $25.3 billion in 2025, the market is supported by an ageing population, a rising prevalence of chronic diseases, increasing healthcare expenditure and ongoing investments in R&D. The market is projected to reach $31.9 billion by 2034, reflecting a CAGR of 2.57% from 2026 to 2034[34].

In New Zealand, the pharmaceutical market growth is driven by increased government funding for medicines and greater adoption of innovation and specialty therapies. Government healthcare programs, including national reimbursement schemes that subsidise essential medicines, along with healthcare reforms aimed at improving access and affordability, are expected to further support the expansion.

The healthcare and pharmaceutical markets in Australia and New Zealand remain attractive due to strong spending across both over the counter (OTC) and prescription (Rx) segments, supported by advanced healthcare systems and continued innovation. In addition, digitalization is playing an increasingly important role in healthcare delivery, with data systems such as real-world evidence (RWE) supporting improved patient outcomes and more cost-effective care.

Australian Pharmaceutical Market Size ($ billion)



Source: IMARC

Global Biologics Industry

Global Generic Industry[35]

Generic medicines remain a key driver of growth in the global pharmaceutical market. Rising healthcare costs have increased demand for affordable treatment options, and generic drugs provide a cost-effective alternative to branded medications.

The global generic drugs market is valued at $468.08 billion in 2025. North America accounts for the largest revenue share at 39%, supported by strong regulatory frameworks and widespread adoption of generic medicines. Meanwhile, the Asia-Pacific region is expected to experience faster growth, driven by expanding pharmaceutical manufacturing capacity and rising healthcare demand.

However, generic drug manufacturers often face regulatory challenges and lengthy approval timelines before products reach the market. Compliance with stringent regulatory requirements set by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increases development costs and can slow the approval process for generic medicines.

[31] European pharmaceuticals key to strengthening EU competitiveness

[32] https://atradius.us/dam/jcr:59079c5d-af53-4382-a069-81e43e2bb033/Industry-trends-pharmaceuticals-January-2026.pdf

[33] https://pharmprom.net/change-of-leader-rating-of-pharmaceutical-companies-in-the-russian-market-for-2025/

[34] https://www.imarcgroup.com/australia-pharmaceutical-market

[35] Generic Drugs Market Size to Hit Nearly USD 762.48 Billion by 2035

The market is expected to grow from $491.67 billion in 2026 to approximately $762.48 billion by 2035, representing a CAGR of around 5% over the forecast period. Growth will be supported by a significant number of patent expirations, an increasing prevalence of chronic diseases and government initiatives promoting the use of affordable therapies. The factors enable manufacturers to expand market reach while maintaining high-quality and cost-efficient production.

Generic Drugs Market Size 2025-2035 ($ Billion)



Source: Precedence Research

Global OTC Industry

The over-the-counter (OTC) pharmaceutical market is evolving rapidly as rising consumer expectations, regulatory flexibility and digital integration reshape the industry. North America remains the largest region in the OTC market, while the Asia-Pacific is expected to record the fastest growth. Ageing populations in developed markets and China are also contributing to higher demand for OTC medicines, generics and treatments for chronic conditions.

However, U.S. tariffs introduced in 2025 created challenges for the OTC drug market by increasing costs and disrupting supply chains. In response, manufacturers are diversifying supplier networks, strengthening domestic manufacturing capabilities and adjusting pricing strategies to maintain consumer access.

The OTC drugs market is projected to grow from $ 56.75 billion in 2025 to $ 61.50 billion in 2026 and is expected to reach $ 103.96 billion by 2032, reflecting a CAGR of 9.03%[36]. This growth is driven by product innovation and evolving retail and distribution channels, creating significant opportunities for pharmaceutical manufacturers and investors.

Over-the-Counter Drug Market



Source: Research and Markets

Trends

The OTC drug market is being reshaped by rising demand for self-care solutions, the increasing prevalence of chronic diseases and growing healthcare costs. Consumers are becoming more health-conscious and are increasingly opting for affordable OTC options, driven by the growth of e-commerce and digital marketing channels.

At the same time, demand for natural remedies, personalized healthcare solutions and improved product packaging is influencing product innovation and shaping new product development across the industry.

Indian Pharma

As India enters 2026, its pharmaceutical industry remains strong, resilient and strategically positioned for sustained growth. The sector continues to be a trusted and competitive contributor to global healthcare, reinforcing confidence among both domestic and international stakeholders.

During the year, India's pharma industry continued its transition from a model primarily driven by low-cost generics toward one increasingly focused on quality, innovation and adherence to global standards. This is helping establish a stronger, more sustainable and differentiated growth trajectory for the sector.

The domestic market is also undergoing structural changes, driven by rising demand for high-quality pharmaceuticals. In addition, India's expanding middle class and the growing penetration of health insurance are improving access to medicines, which is expected to further stimulate domestic demand.

India's recent trade engagements with the European Union and the United States are expected to create new export opportunities for the pharmaceutical sector. Access to the 572.3 billion EU pharmaceuticals and medical devices market, along with improved trade arrangements with the US, could significantly enhance market access and price competitiveness for Indian pharma companies[37].

Encouraging Trends

Recent government measures, including GST 2.0 exemptions and rate rationalization, are aimed at improving the affordability and accessibility of medicines while supporting the supply of high-quality pharmaceuticals. The National Pharmaceutical Policy (NPP) is also focused on reducing production costs and lowering dependence on Chinese API imports.

In addition, the Union Budget 2026 reinforces the government's commitment to strengthening the pharmaceutical and healthcare ecosystem by promoting innovation in drug development and encouraging research in quality Ayurveda and traditional medicine. These initiatives support India's broader vision of becoming a Viksit Bharat.

[36]https://www.researchandmarkets.com/report/otc?srsltid=AfmBOorP97QbehU7sCAk6lYp25hyZH_SReQd_EwyNX2I7kyf7e1QxLpB

[37]https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2231234&reg=3&lang=2#:~:text=India's%20pharmaceutical%20export%20performance%20continues,USD%20130%20billion%20by%202030.

Further strengthening healthcare delivery, the Union Budget 2026–27 allocated ₹39,390 crore to the National Health Mission (NHM) to enhance primary healthcare services, maternal and child health programs, and disease control initiatives across the country[38].

Looking ahead, India's pharmaceutical industry is expected to grow at a rate of 7–9%, supported by robust domestic demand, stable export growth and increasing focus on generics, biosimilars and specialty products[39].

Company Overview

Geography-wise Overview

US and North America

The US and North America represent major growth markets for Marksans Pharma Limited, operating in this region through its wholly owned subsidiary, Time Cap Labs Inc., USA. The operations in the region are primarily focused on the consumer healthcare and OTC segments, supplying store-brand products to leading US retailers.

This region stands as Marksans' largest market, contributing approximately 52% of FY 2025-26 revenue, anchored by the Consumer Healthcare and OTC store brand opportunity. The market achieved FY 2025-26 growth of 24% YoY, which was driven by new launches, market share gains and strong order book execution through the year.

100+
Products Manufactured & Distributed

112
New SKUs Launched in FY 2025-26

51
Products in Pipeline

UK and Europe

The UK is the Company's second-largest market, contributing approximately 34% to FY 2025-26 revenue. The Company serves this region through its wholly owned subsidiary, Marksans Pharma (UK) Ltd, which includes two step-down subsidiaries: Bells, Sons & Co., managing an OTC portfolio with 450+ products / SKUs, and Relonchem, managing a high-end Rx portfolio with 175+ Market Authorizations. Together, these entities offer a broad portfolio of OTC and prescription medicines across the UK market, ranking Marksans among the top five Indian pharmaceutical companies in the UK in terms of revenue.

18
Products Approved during the Year

30
Filings Completed in FY 2025-26

24
Products Filed and Awaiting Approval during the Year

200+
Products Planned for Filing over the Next 4-5 Years

Australia and New Zealand

Marksans established its presence in Australia in 2005 through the acquisition of a 60% stake in Nova, which provides an established base in the region. Nova is engaged in the R&D and marketing of generic OTC products, acting as a leading supplier of branded generic and private label products in Australasia. The Company currently holds 100+ market authorizations across Australia and New Zealand, strengthening its presence in the region's consumer healthcare market.

Australia and New Zealand delivered strong growth of 20% YoY, reaching ₹303 crore in FY 2025-26. Historically an OTC-only company in this region, Marksans executed a strategic portfolio expansion in FY 2025-26 by diversifying into Rx and launching its branded prescription division, Nova Pharma.

11
Rx Brands Launched in FY 2025-26

20
SKUs Launched in FY 2025-26

18
SKUs Planned for FY 2026-27

Rest of the World

The Rest of the World (RoW) segment includes 10 countries across the CIS and MENA regions, contributing approximately 3.4% of FY 2025-26 consolidated revenue. Marksans has strengthened its presence in the Middle East and Africa through the acquisition of a 100% stake in Access Healthcare in Dubai. The Company continues to expand its presence in these markets through multiple product approvals and regulatory filings while steadily broadening its product portfolio.

FY26 revenue moderated 4% YoY to ₹99 crore, reflecting a deliberate and disciplined approach to RoW markets. This moderation was due to ongoing geopolitical tensions in key MENA and CIS regions, as well as macroeconomic volatility and elevated payment risks in select regions with credits availed.

230+
Licensed Products across UAE & Other RoW Geographies

---

[38]https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221616&reg=3&lang=2#:~:text=The%20Union%20Budget%202026%E2%80%9327%20marks%20a%20significant,to%20the%20health%20budget%20of%20FY%202014%E2%80%9315.

[39]India Pharma's 2026 Reset: Reforms, Innovation and the Road to the Future | IPA India

Key Strengths

Strong Focus on the OTC Segment

Marksans maintains a strong focus on the OTC segment by strengthening its presence in the large, rapidly growing global store-brand market. The Company aims to increase market share with leading retailers and expand its footprint across key international markets. Concurrently, Marksans is transitioning from generic pharma to consumer healthcare as its OTC product mix rises.

Strong Product Pipeline

Marksans maintains a pipeline of over 200 products with a target of 20 to 25 new launches annually. Concurrently, the Company is strengthening its pipeline to achieve complete coverage in key therapeutic segments.

Continuous Investment in R&D

The Company maintains a strong focus on R&D investments to expand its product portfolio and strengthen its pipeline. Marksans Pharma currently has 4 R&D centers, more than 50 scientists and over 200 products in its pipeline. Furthermore, the Company has more than 350 ANDAs/MAs approved and over 30 ANDAs/MAs filed that are awaiting approval.

Global Manufacturing Footprint

Marksans operates four regulatory-approved facilities in India, the USA, and the UK with an annual capacity of approximately 26 billion units. These plants hold USFDA, UK MHRA, Australian TGA, EU, and Health Canada accreditations to supply international markets.

Strong Balance Sheet

Marksans maintains a strong balance sheet supported by consistent cash generation and prudent financial management. Furthermore, it provides the flexibility to drive inorganic growth by evaluating acquisitions in the Europe region for front-end presence, backed by a strong credit rating of CARE AA-; Stable for the long term and CARE A1+ for the short term.

Risk & Mitigation Strategies

Risk	Impact	Mitigation Strategy
Regulatory Risk	The pharmaceutical industry is highly regulated, and every product must meet stringent quality and regulatory standards before it can be commercialised. Any regulatory action against the Company could adversely impact its reputation and business.	The Company mitigates regulatory risk by maintaining strong quality management systems and ensuring strict compliance with global regulatory standards. All products undergo rigorous R&D processes, regulatory approvals and quality checks, while manufacturing facilities operate in accordance with guidelines set by leading regulatory authorities.
Macroeconomic Risk	Global economic uncertainties, including European stagflation, geopolitical tensions, economic slowdowns and increasing geoeconomic fragmentation, may impact global demand and limit the Company's ability to expand its business.	The Company mitigates these risks by closely monitoring macroeconomic and geopolitical developments while maintaining a diversified presence across markets and product segments. It also focuses on product cost optimization, efficient working capital management and lean operational practices.
Technology Risk	As a research-driven industry, pharmaceuticals require continuous technological advancement and sustained investment in R&D. Failure to keep pace with technological developments could affect competitiveness.	The Company addresses this risk by continuously investing in technological advancement and strengthening its R&D capabilities. It also collaborates with reputed international organizations to remain aligned with emerging pharmaceutical developments and industry best practices.

Risk	Impact	Mitigation Strategy
Environmental Risk	Increasing global focus on climate change, environmental protection and sustainable manufacturing has led to stricter regulatory standards and higher stakeholder expectations. Non-compliance with environmental norms or ineffective waste and emission management could result in regulatory penalties, operational disruptions and reputational damage.	The Company mitigates this risk by adhering to strict environmental compliance and responsible manufacturing practices. It implements proper waste disposal and effluent treatment protocols while investing in green chemistry, energy-efficient systems and tree plantation initiatives to reduce its environmental footprint.
Competition Risk	Expansion into new geographic markets may expose the Company to competition from established players, which could impact its market position and profitability.	The Company mitigates this risk through continuous investment in R&D to strengthen its product portfolio and maintain its competitive edge. Its experienced marketing and business development teams closely monitor market trends and provide strategic insights to support informed decision-making.

Outlook

Marksans Pharma remains focused on strengthening its growth trajectory through capacity expansion, enhancement of its product portfolio and deeper penetration across key therapeutic segments.

The Company's growth roadmap for FY 2026-27 and beyond rests upon 4 pillars-

Broaden	Expand	Deepen	Scale
To add adjacent OTC categories, select Rx-to-OTC switches, and increase its retailer base in key regions.	Focuses on organic entry into new geographies and selective front-end acquisitions.	To increase SKUs per existing retailer and expand its share in core OTC categories.	To ramp up utilisation of expanded manufacturing capacity and improve operating leverage.

Under its Strategic Vision FY 2029-30, Marksans Pharma aims to become a top global consumer healthcare company and establish a multi-continent front-end direct presence. The Company also targets generating strong FCF to support shareholder returns. Additionally, its vision includes maintaining ESG-embedded, compliant, sustainable operations.

Financial Review [Consolidated]

Profit & Loss Review

(₹ in Million)

Particulars	FY 2025-26	FY 2024-25	YoY Change (%)
Revenue	29,509.38	26,228.45	12.51%
Cost of Goods Sold	12,772.79	11,437.42	11.68%
Employee Benefits Expense	4,209.34	3,502.99	20.16%
Depreciation and Amortisation Expense	986.32	833.86	18.28%
Finance Cost	241.25	116.60	106.90%
Profit After Tax	4,200.60	3,826.19	9.79%

Balance Sheet Review

Equity & Liabilities

(₹ in Million)

Particulars	FY 2025-26	FY 2024-25	YoY Change (%)
Reserves & Surplus	29,778.40	24,215.96	22.97%
Trade Payables	3,369.09	3,057.00	10.21%
Non-current Liabilities	2,811.32	2,729.11	3.01%
Other Financial Liabilities	301.30	236.49	27.40%
Provisions - Current Liabilities	3.18	14.47	(78.02%)
Lease Liabilities (Current)	436.58	354.92	23.01%
Other Current Liabilities	449.01	580.26	(22.62%)
Borrowings	295.91	230.85	28.18%

Assets

(₹ in Million)

Particulars	FY 2025-26	FY 2024-25	YoY Change (%)
Property, Plant & Equipment (including ROU Assets)	9,258.76	8,864.09	4.45%
Other Financial Assets (Non-current)	38.72	35.71	8.43%
Other Current Financial Assets	49.26	35.57	38.49%
Inventories	9,722.81	8,455.16	14.99%
Trade Receivables	6,445.66	5,400.43	19.35%
Other Current Assets	1,004.62	977.94	2.73%
Other Non-current Assets	175.54	217.60	(19.33%)
Cash & Cash Equivalents	6,341.37	4,957.86	27.91%
Bank Balances Other than Cash & Cash Equivalents	3,555.14	2,084.23	70.57%

Key Financial Ratios [Consolidated]

Particulars	FY 2025-26	FY 2024-25	YoY growth	Details of significant changes
Debtors' turnover ratio (days)	73	69	5.80	-
Inventory Turnover (days)	260	234	11.11	-
Interest Coverage ratio (times)	24.90	45.68	-45.49	Due to higher profit margin
Operating profit margin (%)	19.81	19.66	0.76	-
Return on net worth (%)	13.76	15.37	-10.47	-
Net Profit (%)	14.23	14.59	-2.47	-
Current ratio (times)	5.17	4.62	11.90	-
Debt-equity ratio (times)	0.11	0.13	-15.38	-

Key Financial Ratios [Standalone]

Particulars	FY 2025-26	FY 2024-25	YoY growth	Details of significant changes
Debtors' turnover ratio (days)	160	143	11.89	-
Inventory Turnover (days)	106	113	-6.19	-
Interest Coverage ratio (times)	243.83	177.26	37.56	-
Operating profit margin (%)	29.29	20.81	40.75	Due to increase in revenue and profit after tax
Return on net worth (%)	18.20	13.61	33.73	Due to increase in profit after tax
Net Profit (%)	22.42	16.03	39.86	Due to increase in profit after tax
Current ratio (times)	4.22	3.13	34.82	Due to increase in cash and bank balance
Debt-equity ratio (times)	0.01	0.01	-	-

Human Resource

Marksans is committed to upholding and promoting human rights across its operations. With a workforce of over 2,000 employees, the Company places strong emphasis on employee empowerment, teamwork and continuous skill development.

Through comprehensive talent development programs, Marksans focuses on strengthening employee capabilities and fostering a culture of teamwork and innovation. These initiatives help build a highly skilled and motivated workforce that supports the Company's long-term growth and operational excellence.

Internal Control System and Their Adequacy

The Company has established a comprehensive internal control and risk management framework to ensure operational efficiency, effectiveness, and compliance with applicable laws and regulations. It integrates various personnel who coordinate their responsibilities to maintain robust oversight and risk management processes. The Board of Directors provides strategic oversight and guidance to the management, supported by specialized committees that monitor control and risk management processes. The internal audit function operates under the supervision of the Board and in coordination with the Board-appointed Statutory Auditors. Regular reviews by senior management, including the Chairman, Managing Director, COO, and CFO, enable timely identification and resolution of any discrepancies, thereby ensuring the adequacy and reliability of the internal control system.

Cautionary Statement

In accordance with applicable securities laws and regulatory requirements, certain statements in this section relating to the Company's objectives, expectations, projections, and estimates may constitute "forward-looking statements". These statements are based on current assumptions and expectations regarding future events. The Company does not, however, guarantee that these forecasts and assumptions are true or that they will come to pass. Several external factors outside the control of the Company may cause actual results to differ materially from those stated or implied in these statements. The Company disclaims any obligation to update, change, or modify forward-looking statements in response to future developments.

Directors' Report

Dear Shareholders,

The Directors take pleasure in presenting the thirty fourth (34th) Annual Report along with the financial statements for the year ended March 31, 2026.

FINANCIAL HIGHLIGHTS

(₹ in Million)

Particulars	Standalone		Consolidated	
	2025-26	2024-25	2025-26	2024-25
Turnover	13,414.76	11,743.74	29,509.38	26,228.45
Profit before Tax expenses	3,915.43	2,432.59	5,605.55	5,039.67
Less: Tax expenses	908.45	549.87	1,404.91	1,213.48
Profit after Tax	**3,006.98**	**1,882.72**	**4,200.64**	**3,826.19**

OPERATIONS/STATE OF AFFAIRS OF THE COMPANY

During the year 2025-26, your Company achieved turnover of Rs 13,414.76 Million with net profit of Rs 3,006.98 Million as compared to turnover of Rs. 11,743.74 Million with net profit of Rs. 1,882.72 Million in the previous year.

On consolidated basis, your Company achieved turnover of Rs. 29,509.38 Million with net profit of Rs. 4,200.64 Million as compared to turnover of Rs. 26,228.45 Million with net profit of Rs. 3,826.19 Million in the previous year. During the year, US and North America formulation business reported growth of 24% and Australia and New Zealand formulation business reported growth of 20%. Europe and UK formulation business reported moderated revenue due to a seasonally weak Q1 and high single-digit price erosion in select UK products. Rest of world business performance impacted by ongoing geopolitical disruptions leading to order fulfilment constrained by logistics challenges and deliveries deferred to subsequent quarters.

In compliance with the IND AS on Consolidated Financial Statements, this Annual Report also includes Consolidated Financial Statements for the financial year under review.

DIVIDEND

The Board of Directors at its meeting held on May 26, 2026 recommended a final dividend of Rs. 0.90/- (90%) per equity share of Re. 1/- each for the financial year ended March 31, 2026 subject to approval of the Members at the ensuing Annual General Meeting ("AGM"). Total cash outflow on account of dividend payment will be Rs. 407.85 Million. The Dividend will be paid in compliance with applicable laws and in accordance with Company's Dividend Distribution Policy. The Dividend Distribution Policy is available on the Company's website https://www.marksanspharma.com/pdf/dividend-distribution-policy.pdf.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

i. Marksans Pharma (UK) Limited, through step down subsidiaries Bell, Sons & Co. (Druggists) Limited and Relonchem Limited which operates in the European markets, has achieved sales of Rs 10,140.65 Million as compared to sales of Rs. 10,193.51 Million during previous year.

ii. Marksans Pharma Inc., through step down subsidiary Time-Cap Laboratories Inc. which operates mainly in US and North America, has achieved sales of Rs. 14,950.25 Million as compared to sales of Rs. 12,081.76 Million during previous year.

iii. Nova Pharmaceuticals Australasia Pty Ltd. (your company holds 60% of the share capital) which operates mainly in Australia and New Zealand has achieved sales of Rs. 2,897.62 Million as compared to sales of Rs. 2,351.69 Million during previous year.

iv. Access Healthcare for Medical Products LLC, a wholly owned subsidiary which operates mainly in UAE and neighbouring countries has achieved sales of Rs. 179.20 Million as compared to sales of Rs. 157.06 Million during previous year.

Pursuant to a Central Government's Circular dated February 08, 2011, the audited accounts together with Directors' Report and Auditors' Report of the subsidiaries namely Marksans Pharma (U.K.) Limited, Marksans Pharma Inc., Nova Pharmaceuticals Australasia Pty Ltd and Access Healthcare for Medical Products LLC are not being appended to the Annual Report. However, a statement giving information in aggregate for each subsidiary including step down subsidiaries are attached to the Consolidated Balance Sheet. Further, statement containing the salient features of financial statements of subsidiary companies and their contribution to the overall performance of the company are given in **Form AOC-1** forming part of this report as **Annexure - H**.

During the year, your company has incorporated two wholly owned subsidiaries viz., Marksans (Canada) Inc. in Canada and Marksans Pharma (Europe) Limited in Ireland. These companies are yet to commence operations.

Your company has no joint ventures and associate companies.

MANAGEMENT DISCUSSION AND ANALYSIS

A report on Management Discussion and Analysis covering industry structure and developments, financial and operational performance of the Company, risks, threats and outlook forms a part of this Report.

RESERVES

Your Company has not transferred any amount out of the profit of the year to the General Reserve.

SHARE CAPITAL

During the year under review, there was no change in the capital structure of the Company.

Your Company has neither issued any equity shares with differential rights as to dividend, voting or otherwise nor issued sweat equity shares to Directors or employees, under any Scheme.

MARKSANS EMPLOYEE STOCK OPTION SCHEME 2024

At the Annual General Meeting (AGM) of the Company held on 24 September 2024, the Members had approved the Marksans Employees Stock Option Scheme 2024 (the Scheme) as amended at the AGM held on 08 August 2025 for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 2,300,000 equity shares of face value of ₹ 1/- each. Under the said Scheme, the Company has granted 400,000 equity stock options on 24 September 2025 to certain eligible employees of the Company and its Subsidiary Companies.

DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP)

As on March 31, 2026, the composition of the Board of Directors is in accordance with the provisions of Section 149 of the Companies Act, 2013 and Regulation 17 of SEBI Listing Regulations, with an appropriate mix of executive, non-executive and independent directors. The Board comprises of 8 (eight) directors, of which 5 (five) directors are non-executive of which 4 (four) directors are independent, and 3 (three) directors are executive. The list of directors of the Company has been disclosed as part of the Corporate Governance Report.

a. Appointment/ Resignation/ Retirement of Directors:

i. Mr. Seetharama Raju Buddharaju (DIN: 03630668) retired as an independent director of the Company on completion of his tenure on 31 March 2025.

Mr. Srinivas Mishra (DIN: 1005205) has been appointed as an independent director with effect from 01 April 2025. In the opinion of the Board, Mr. Srinivas Mishra is best suited to the integrity, expertise and experience required by the Company. He has also passed proficiency test conducted by the Indian Institute of Corporate Affairs.

ii. In terms of Section 152 of the Companies Act, 2013, Dr. Sunny Sharma (DIN: 02267273) will retire by rotation at the ensuing Annual General Meeting and being eligible for re-appointment, offers himself for re-appointment.

b. Appointment/ Resignation/ Retirement of Key Managerial Personnels:

During the year under review, there was no change in the Key Managerial Personnel of the Company.

NUMBER OF MEETINGS OF THE BOARD

During the financial year 2025-26, the Board met 6 (six) times on 19.05.2025, 11.07.2025, 25.07.2025, 12.08.2025, 13.11.2025 and 05.02.2026.

POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION

Your Company has in place a policy relating to nomination and remuneration of directors as well as key managerial personnel formulated by the Nomination and Remuneration Committee. The Nomination and Remuneration Policy, inter alia, provides for the following:

1. The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director in terms of Diversity Policy of the Board and recommend to the Board his/ her appointment.
2. For the appointment of KMP (other than Managing Director/ Whole-time Director) or Senior Management, a person should possess adequate qualification, expertise and experience for the position he/ she is considered for the appointment. For administrative convenience, the Managing Director is authorised to identify and appoint a suitable person for the position of KMP (other than Managing Director/ Whole-time Director) and Senior Management.
3. The remuneration/ compensation/ commission, etc., as the case may be, to the Managing/ Whole-time Director is determined by the Nomination and Remuneration Committee and recommended to the Board for approval. Such remuneration/ compensation/ commission, etc., as the case may be, is subject to approval of the shareholders of the Company and is in accordance with the provisions of the Companies Act, 2013 and Rules made there under. Remuneration of KMP (other than Managing Director/ Whole-time Director) and Senior Management is decided by the Managing Director based on the standard market practice and prevailing HR policies of the Company.
4. The remuneration/ commission/ sitting fee, as the case may be, to the Non-executive Director/ Independent Director, is in accordance with the provisions of the Companies Act, 2013 and the Rules made there under for the time being in force or as may be decided by the Committee/ Board/ shareholders.
5. Promoter directors and independent directors are not entitled to stock option of the Company.

DISCLOSURE UNDER SECTION 197(14) OF THE COMPANIES ACT, 2013

During the Financial Year 2025-26, Mr. Mark Saldanha, Managing Director of the Company has also received remuneration of Rs. 1,27,25,280.00 from the Company's wholly owned subsidiary, Time-Cap Laboratories Inc.

EVALUATION OF PERFORMANCE OF BOARD, COMMITTEE AND DIRECTORS

Performance evaluation of the Board as a whole, the Committees of Directors and all individual Directors including Independent Directors has been carried out for the year under review in accordance with the criteria framed pursuant to the provisions of the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Guidance Notes issued by SEBI.

Performance evaluation of each individual director including independent director:

A questionnaire containing performance evaluation criteria was circulated to each Director including Independent Directors. The Directors filled up the questionnaire pertaining to other Directors (except for himself/herself) and submitted the same to the Chairman of the Board for review.

The Nomination and Remuneration Committee also carried out performance evaluation of each director of the Company for the year 2025-26. Evaluation of each director was done by all the other Directors (other than the director being evaluated) in accordance with the performance criteria suggested by the Committee and applicable SEBI Guidance Note.

Performance Evaluation of the Board and Committees of Directors:

The Board reviewed a questionnaire containing performance criteria for the Board and the Committees of Directors. For the evaluation, the Board took into consideration composition of the Board and Committees of Directors, frequency of the meetings, attendance of each director at the Board and respective Committee Meetings, discharge of key functions and responsibilities prescribed under law, effectiveness of corporate governance practices in the Company, integrity of the Company's accounting/auditing and financial reporting/control systems, etc.

All the Independent Directors of your Company had a separate meeting without the attendance of executive directors and management personnel and reviewed the performance of the Board of Directors as a whole, the Chairman of the Board and the executive non-independent directors during the year 2025-26. The Independent Directors have also reviewed the quality, quantity and timeliness of flow of information between the Company management and the directors that was necessary for the directors to effectively and reasonably perform their duties.

The results of the above performance evaluations are satisfactory and adequate and meet the requirement of the Company.

DECLARATION FROM INDEPENDENT DIRECTORS

The Company has received necessary declaration from all the Independent Directors confirming that they meet the criteria of independence as laid down in Section 149(6) of the Companies Act, 2013 read with Schedule IV of the Act and rules made there under, as well as Regulations 16(1)(b) of the SEBI Listing Regulations and they have registered themselves with the Independent Director's Database maintained by the Indian Institute of Corporate Affairs. The Independent Directors also confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties. In the opinion of the Board, the independent directors fulfilled the conditions specified in the above Act and Regulations and are independent of the management.

FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Company conducts familiarization programme for Independent Directors to enable them to understand their roles, rights and responsibilities and proactively keeps them informed of the activities of the Company, its management and operations and provides an overall industry perspective as well as issues being faced by the industry. Company's policy on the familiarization program for the independent directors as well as details of familiarization programme imparted during the year is available on the Company's web link at https://www.marksanspharma.com/pdf/familiarisation-programme-for-independent-directors-2025-26.pdf.

COMMITTEES OF THE COMPANY

Currently the Company has five committees: Audit Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee, Corporate Social Responsibility Committee and Risk Management Committee. Details of the composition of these committees are given in the Corporate Governance Report section of this Annual Report.

POLICIES AND CODES

Your Company always strives to promote and follow the highest level of ethical standards in all its business transactions. SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated formulation of certain policies and codes for all listed companies. All the policies and codes adopted by your Company are available on the web link at http://marksanspharma.com/codes-policies.html. These policies and codes are reviewed periodically by the Board and updated based on need and new compliance requirement. Key policies and codes that have been adopted by the Company are as follows:

Name of the Policy and Code with weblink	Brief Description
Code of Conduct for Directors & Employees http://marksanspharma.com/pdf/Code-of-Conduct.pdf	The Code envisages directors and employees of the Company to observe in day-to-day operations of the Company
Code of Conduct to Regulate, Monitor and Report Trading in securities http://marksanspharma.com/pdf/Code-Of-Conduct-Insider-Trading.pdf	The Code provides framework for dealing with securities of the Company by directors and employees of the Company

Name of the Policy and Code with weblink	Brief Description
Policy on Related Party Transactions https://marksanspharma.com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf	The Policy regulates all transactions between the Company and its related parties
Corporate Social Responsibility (CSR) Policy http://marksanspharma.com/pdf/CSR-Poilcy.pdf	The Policy outlines Company's strategy to bring about a positive impact on society
Whistle Blower Policy (Vigil Mechanism) http://marksanspharma.com/pdf/whistle-blower-policy.pdf	The Policy provides for directors and employees to report concerns about unethical behaviour, actual or suspected fraud or violation of the Company's codes of conduct and ethics
Policy for determination of materiality of events or information and disclosures https://www.marksanspharma.com/pdf/policy-for-determination-of-materiality-of-events-or-information-and-disclosures.pdf	The policy provides for determination of materiality of events or information and disclosures of the same to stock exchanges
Code of Practice and Procedure for Fair Disclosure of Unpublished Price Sensitive Information http://marksanspharma.com/pdf/code-of-fair-disclosure.pdf	The Code envisages fair disclosure of events and occurrences that could impact price discovery in the market for the Company's securities.
Policy for determining Material Subsidiary http://marksanspharma.com/pdf/policy-on-material-subsidiary.pdf	The Policy provides criteria when a subsidiary becomes a material subsidiary
Dividend Distribution Policy http://marksanspharma.com/pdf/dividend-distribution-policy.pdf	The Policy envisages criteria for distribution of dividend.
Nomination and Remuneration Policy http://marksanspharma.com/pdf/nomination-and-remuneration-policy.pdf	The Policy provides for criteria for appointment and remuneration of directors and employees of the Company.

DEPOSITS

During the year under review, the Company has not accepted any deposit within the meaning of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 and therefore, there are no deposits which are outstanding as on the date of the Balance Sheet.

LOANS, GUARANTEES OR INVESTMENTS

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, are given in Note No. 5 of the notes to the Standalone Financial Statements of the Company.

RESEARCH AND DEVELOPMENT (R&D)

Your Company is committed to continuously fund its R&D capabilities. One of the Company's biggest strength lies in vibrant and productive R&D function that has continuously placed your Company ahead through consistent development of niche technology, processes and products. Your Company will continue to invest in R&D to keep pace with the changing global scenario.

Your Company has a Research & Development Centre at Verna, Goa and at Navi Mumbai, Maharashtra to foray into new segments, respond to globally unmet therapeutic needs, enhance the Company's opportunity responsiveness and file a larger number of ANDAs.

REGULATORY COMPLIANCES

Your Company's facilities in UK and USA are approved by UK MHRA and US FDA respectively. The Goa main facility and A-1 facility have also gone through successful GMP audit by US FDA, UK MHRA & Australian TGA and US FDA respectively.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo as required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed to this report as **Annexure - A.**

INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY

Your Company has in place adequate system of internal control and management information systems which covers all financial and operating functions. These systems are designed in a manner which provides assurance with regard to maintenance of strict accounting control, optimum efficiency in operations and utilization of resources as well as financial reporting, protection of Company's tangible and intangible assets and compliance with policies, applicable laws, rules and regulations. Your Company has in place a mechanism to identify, assess, monitor and mitigate various risks to key business objectives. The Audit Committee has a process for timely check for compliance with the operating systems, accounting procedures and policies. Major risks identified by the Company are systematically addressed through mitigating action on continuing basis.

INFORMATION TECHNOLOGY

Your Company continues to make required investments in the Information Technology area to cope up with the growing information technological needs necessary to manage operations efficiently. Your Company has implemented state-of-the-art IT applications in automating the processes in Quality, Manufacturing and R&D. Your Company has also invested significant amount of resources to build IT platform to de-risk manufacturing process and to adopt best practices in the industry. The implementations spread across Lab automation, instrument integration and manufacturing execution systems. Virtually every aspect of your Company's operations is carried out through SAP (Systems Applications and Products in Data Processing) Enterprise Resource Planning.

HEALTH, SAFETY & ENVIRONMENT

Your Company is committed to ensure safety and sound health of the employees at the workplaces. Your Company is also committed to strengthen pollution prevention and waste management practices for a safe and healthy environment. The Company's Plants are in compliance with environmental regulations.

RELATED PARTY TRANSACTIONS

Your Company has not entered into any transaction during the year with any related parties which are not at arm's length basis.

All Related Party Transactions (with the subsidiaries) that were entered into during the financial year were in the ordinary course of business at arm's length basis and repetitive in nature. These transactions were placed before the Audit Committee for review and entered in the Register maintained under Section 189 of the Companies Act, 2013. The Audit Committee has granted omnibus (ad hoc) approval for Related Party Transactions as per the provisions and restrictions contained in the policy framed under Regulation 23 of the SEBI (LODR) Regulations, 2015.

Company's Policy on Related Party Transactions is available on the Company's web link at https://marksanspharma.com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf. Particulars of related party transactions entered into during the FY 2025-26 have been disclosed under Note No. 38(c) of the Notes to the Standalone Financial Statements. Details of material transactions with the related parties entered into during the year are disclosed in **Form AOC – 2** annexed to this report as **Annexure - B.**

WHISTLE BLOWER POLICY/VIGIL MECHANISM

Your Company has in place a Whistle Blower Policy to deal with instance of fraud and mismanagement, if any. Under the policy, an effective vigil mechanism for directors and employees has been established to report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct. The details of establishment of the Whistle-Blower Policy have been disclosed on the Company's web link at http://marksanspharma.com/pdf/whistle-blower-policy.pdf.

The said mechanism also provides for adequate safeguards against victimisation of the persons who use such mechanism and makes provision for direct access to the chairperson of the Audit Committee. During the financial year 2025-26, no employee of the Company was denied access to the Audit Committee and there were no instances of any unethical behaviour, actual or suspicious fraud or violation in the Company's operational policies.

RISK MANAGEMENT SYSTEM

Your directors are aware of the risks associated with the Company's business. Your Company makes timely and regular analysis of various risks associated with the Company's business and takes corrective actions for managing/mitigating the same. Your Company has institutionalized the policy/process for identifying, minimizing and mitigating risks under the supervision of the Risk Management Committee of the Company. The key risks and mitigation measures are also reviewed by the Audit Committee. There is no element of risk which in the opinion of the Board may threaten the existence of the Company.

CORPORATE SOCIAL RESPONSIBILITY

Your company understands its responsibility towards the society, community and environment and is committed to spend sensibly to meet its CSR objectives. The report on the CSR activities undertaken by the Company in the format prescribed under the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021 is given in **Annexure – C** annexed to this Report.

DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMAN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Company is fully committed to uphold and maintain dignity of women working in the Company and has zero tolerance towards any actions which may fall under the ambit of sexual harassment at workplace. The Company has in place a Prevention of Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaints Committees have been set up in compliance with provisions relating to the constitution of Internal Complaints Committee under the said Act to redress complaints regarding sexual harassment at Mumbai office, Goa plants and R&D Centre at Navi Mumbai. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

Details of complaints received, disposed and pending, during FY 2025-26 are as follows:

Particulars	No. of complaints
Number of complaints received during the financial year	Nil
Number of complaints resolved during the financial year	NA
Number of complaints pending as on March 31, 2026	Nil

COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961

The Company is compliant with the applicable provisions of the Maternity Benefit Act, 1961 and has policies, systems and processes in place to ensure ongoing compliance.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There are no orders passed by the Regulators/Courts/Tribunals which would impact the going concern status of the Company and its future operations. During the year under review, securities of the Company were not suspended from trading on the stock exchanges on which they are listed.

CHANGE IN THE NATURE OF BUSINESS

During the year under review, there was no change in the nature of business of the Company.

MATERIAL CHANGES & COMMITMENT AFFECTING FINANCIAL POSITION OF THE COMPANY

There have been no material changes and commitments, affecting the financial position of the Company between the end of the financial year of the Company to which the financial statements relate and the date of this Report.

CORPORATE GOVERNANCE

Corporate Governance is an ethical business process to create and enhance value of stakeholders and reputation of an organization. Your directors function as trustees of the shareholders and ensure long term economic value for its stakeholders. Pursuant to Schedule V of SEBI (LODR) Regulations, 2015, a detailed report on Corporate Governance and a certificate from the Auditors regarding compliance with the conditions of Corporate Governance is annexed to this report as **Annexure - D**.

ANNUAL RETURN

In accordance with the requirements of Section 92(3) of the Companies Act, 2013 and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return in the prescribed Format proposed to be submitted to the Registrar of Companies for the financial year ended March 31, 2026 is available on the Company's website at http://marksanspharma.com/annual-reports.html

INSOLVENCY AND BANKRUPTCY CODE 2016

There is no application made nor any proceeding pending under the Insolvency and Bankruptcy Code 2016.

EMPLOYEES

The ratio of the remuneration of each director to the median employee's remuneration and other details in terms of Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is annexed to this report as **Annexure - E**.

The statement showing particulars of employees as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of the Report. Any member interested in obtaining a copy thereof, may write an email to companysecretary@marksanspharma.com.

HUMAN RESOURCES DEVELOPMENT AND INDUSTRIAL RELATIONS

The guiding principle of HR Policy at your Company is that the "Intellectual Capital" and dedication of employees will help the Company emerge as a successful player in this highly competitive scenario.

The recruitment procedure ensures that people with talent and the right skill sets are selected. Nurturing of talent and a Performance Management System (PMS) is in place to ensure that the coordinated efforts of our people lead to achievement of the Business Goals of the company.

Empowerment and a motivational package ensure that employees keep performing at peak levels. The HR Policy is directed towards creating "Ownership of Goals" at each level and synchronizing the efforts of all employees to achieve the company's quality and business goals.

Development of skills through mentoring and training by our seasoned professionals ensures that the talent pool keeps expanding. The Leadership Role played by our senior professionals helps to keep the next rung of leadership ready to take up the challenges thrown up by the global market.

The management helps the process of decision making by decentralizing and empowering professionals to execute tasks in a speedy manner. The management fosters information sharing and free exchange of ideas. Above all, the sense of ownership and empowerment to take decisions helps the Company to adapt and be ahead of the competition in this rapidly changing global environment.

The industrial relation at all the plant sites of your Company is cordial.

As on March 31, 2026, the Company's permanent employee strength was 1,685 (1,840 on March 31, 2025).

DIRECTORS RESPONSIBILITY STATEMENT

In terms of provisions of Section 134(3)(c) of the Companies Act, 2013, your Directors confirm that:

- in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures.
- they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended March 31, 2026 and Profit of the Company for the period ended March 31, 2026.

- proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- the annual accounts have been prepared on a going concern basis.
- proper internal finance controls were in place and that the financial controls were adequate and were operating effectively.
- they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT

The Business Responsibility and Sustainability Report for the financial year 2025-26 forms part of this Annual Report as required under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as **Annexure – F**.

AUDIT & AUDITORS

Statutory Audit:

MSKA & Associates LLP, the Statutory Auditors of the Company have issued an unmodified opinion on the Financial Statements, both standalone and consolidated for the financial year ended March 31, 2026. The Statutory Auditor's reports do not contain any qualification, reservation or adverse remark.

Secretarial Audit:

Secretarial audit report for the financial year ended March 31, 2026 issued by Jinesh Dedhia & Associates, the Secretarial Auditors of the Company is annexed to this report as **Annexure - G**. There are no qualification, reservation or adverse remark made by the Secretarial Auditors in their report.

Cost Audit:

The Company has maintained cost accounts and cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013. However, your Company is a 100% export-oriented unit and therefore, it is exempted from audit of its cost accounting records.

Reporting of Frauds:

There was no instance of any fraud during the year under review which required the Statutory Auditors to report to the Audit Committee or the Board under Section 143(12) of Act and Rules framed there under.

SECRETARIAL STANDARDS

The Company has complied with the applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively.

APPRECIATION

The Directors place on record their appreciation for the contribution made by the employees at all levels enabling the Company to achieve the performance during the year under review.

The Directors also appreciate the valuable co-operation and continued support extended by Company's Bankers, Medical Professionals, Business Associates and Investors who have put their faith in the Company.

For and on behalf of the Board of Directors of
Marksans Pharma Limited

Mark Saldanha
Chairman & Managing Director
DIN: 00020983

Place: Mumbai
Dated: May 26, 2026

Annexure - A

Annexure to the Report of the Board of Directors

Particulars of Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo required under the Companies (Accounts) Rules, 2014.

A. CONSERVATION OF ENERGY

a) The steps taken or impact on conservation of energy:

The Company continues with its policy of giving priority to energy conservation measures including regular review of energy generation and consumption and effective control on utilization of energy.

The following energy conservation methods were implemented during the year.

a) Intensified internal audit aimed at detecting wastage and leakage of utility Circuits.

b) We schedule production batches such as to run optimum utility.

c) Optimization of Agro Waste Fired Boilers.

d) Optimization in use of cooling water pumps.

e) Use of energy efficient pumps and motors.

f) Chemical dosing of cooling/chilling water system.

g) Installed energy efficient motors for chilling plant compressors.

h) Cold insulation ducting and HVAC system are regularly checked and sections redone.

i) Conducted compressed air audit.

j) Optimized air compressor pressure such that air compressors switch ON/OFF automatically based on set pressure.

k) AHU condensate water recovery through cooling tower top up water to increase air conditioning efficiency.

Additional investments:

a) Continuously install electronic devices to improve quality of power and reduction of energy consumption.

b) Condensate heat recovery system enhancement.

c) Harmonics and power factor improvements.

d) Install energy saving lamps.

e) Install VFD for air compressor motors.

f) Motion sensors for lighting systems.

g) UPS for critical processes to reduce rejection waste.

Impact of above measures:

The adoption of energy conservation measures has resulted in considerable savings and increased level of awareness amongst the employees. The energy conservation measures have also resulted in improvement of power factor and consequential tariff benefits. These measures have also resulted into better quality of power, reduction in fossil fuel combustion, optimal utilization of resources resulting in overall efficiency improvement and reduced consumption of fuel, water and power resulted in lowering overall costs.

b) The steps taken by the Company for utilising alternate source of energy:

a) Company has started using electric operated vehicles for some part of internal logistic operation to reduce dependency on petroleum products.

b) Facility is using agro waste as boiler fuel for steam generation for drying process.

c) The capital investment on energy conservation equipment:

a) Facility has incorporated various highly automatic high-speed coating and compression machines which are giving higher efficiencies compared to earlier machines, additionally producing more output in same time.

b) Capital investment approximately INR 20 Cr.

B. TECHNOLOGY ABSORPTION

Research and Development (R&D)

1. Specific areas in which R&D is carried out by the Company

Foray into Generic business and identification of few niche areas for product development, mainly in dossier development, post patent filing for regulated and emerging markets. The company is building future by strengthening its research formulation through consistent investments in every aspect of its R&D programs, be its Generics Research or Advanced Drugs Delivery Systems (ADDS). The Generics R&D programs continues to create meaningful product pipelines for the US, European and other advanced and emerging markets.

2. Benefits derived as a result of above R&D

The year was a strong year for the company's R&D as the Company continued to benefit from its consistent investments in research through increase in number of products exported to US, Europe and other regulated and emerging markets.

3. Future plan of action

Development of new and innovative products will lead to evolution of comprehensive range of generics leading to Abbreviated New Drug Applications / Dossiers for filing.

4. Expenditure on R&D

The Company continues to benefit from the extensive Research and Development (R&D) activity carried on. The

Company has set-up a New Research & Development centre at Navi Mumbai, Maharashtra with a view to foray into new segments, respond to globally unmet therapeutic needs, enhance the Company's opportunity responsiveness and to file a larger number of ANDAs.

During the year, the Company has incurred expenses of R & D nature for new product development and ANDA / Dossiers filing for regulated and emerging markets.

Expenditure on R&D	Rs. in Million
a. Capital expenditure	2.23
b. Revenue expenditure	258.82
c. Total	261.05

d. Total R&D expenditure as percentage of total standalone revenue – 1.95%

5. Technology absorption, adaptation and innovation

i. Efforts, in brief, made towards technology absorption, adaptation and innovation

Improvements in process parameters, up-gradation of plant and systems facility, working systems, documentation and practices to international regulatory standards for European and U.S. Market.

ii. Benefits derived as a result of the above efforts

Biofuel being substantially cheaper to Furnace Oil, its usage will generate savings in fuel cost. Also, it will save time on steam generation and add to operator safety. Access to highly regulated markets, thereby increasing the sales volumes. Installation of new testing equipment has substantially reduced dependency on external testing, thereby reducing the overall operational time cycles. The same has also resulted in reduction in manpower. Improvements in process parameters have reduced the percentage rejection in the process thereby reducing the wastage of costly raw material.

iii. Imported Technology

The Company has not imported technology during the last three years.

C. FOREIGN EXCHANGE EARNINGS & OUTGO

During the financial year 2025-26, the Company used foreign exchange amounting to Rs. 2,213.70 million (Previous year Rs. 1,635.02 million) and earned foreign exchange amounting to Rs. 13,266.86 million (Previous Year Rs. 11,628.00 million).

For and on behalf of the Board of Directors of
Marksans Pharma Limited

Mark Saldanha
Chairman & Managing Director
DIN: 00020983

Place: Mumbai
Dated: May 26, 2026

Annexure - B

Annexure to the Report of the Board of Directors

Form No. AOC -2

(Pursuant to Clause (h) of sub-section (3) of Section 134 of the Companies Act, 2013 and
Rule 8(2) of the Companies (Accounts) Rules, 2014)

Disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis: Nil

2. Details of material contracts or arrangements or transactions at arm's length basis:

    a) Corporate identity number (CIN) or foreign company registration number (FCRN) or Limited Liability Partnership number (LLPIN) or Foreign Limited Liability Partnership number (FLLPIN) or Permanent Account Number (PAN)/Passport for individuals or any other registration: 587358 (New York, USA)

    b) Name of the related party: Time-Cap Laboratories Inc.

    c) Nature of relationship: Wholly owned subsidiary.

    d) Nature of contracts/ arrangements/ transactions: Sale & purchase of finished goods & fixed assets.

    e) Duration of the contracts/ arrangements/ transactions: FY 2025-26

    f) Salient terms of the contracts or arrangements or transactions including the value, if any: Rs. 8,83,45,71,434.00 (Rs. 8,834.57 Million) (includes both sale and purchase of finished goods and fixed assets).

    g) Date(s) of approval by the Board, if any: Not applicable, since the contracts were entered in the ordinary course of business and are at arm's length basis.

    h) Amount paid as advances: Nil

For and on behalf of the Board of Directors of
Marksans Pharma Limited

Mark Saldanha
Chairman & Managing Director
DIN: 00020983

Place: Mumbai
Dated: May 26, 2026

Annexure - C

Annexure to the Report of the Board of Directors

Annual Report on Corporate Social Responsibility (CSR) Activities for FY 2025-26

[Pursuant to Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014]

1. Brief outline on CSR Policy of the Company:

Marksans Pharma Limited ('Marksans') actively contributes to the social and economic development of the communities and builds a better sustainable way of life for weaker sections of society. The Company's CSR activities are spread across Maharashtra & Goa states, largely addressing in the areas of preventive healthcare, eradicating hunger and malnutrition, welfare of women and children and other activities as the Company may choose in fulfilling its CSR objectives.

2. The Composition of the CSR Committee:

As on March 31, 2026, CSR Committee of the Company consists of three (3) Directors which include one (1) Independent Director. The Composition of the CSR Committee is set out below:

Sr. No	Name	Designation - Category
1.	Mr. Varddhman Vikramaditya Jain	Chairman – Whole-time Director
2.	Mrs. Sandra Saldanha	Member – Whole-time Director
3.	Mr. Abhinna Sundar Mohanty	Member - Independent Director

3. Web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the Board are disclosed on the website of the company.

The composition of the CSR Committee is available on the Company's web-link at https://marksanspharma.com/composition-of-board-and-committees.html

The Company's CSR Policy is available on the Company's web-link at https://www.marksanspharma.com/pdf/CSR-Poilcy.pdf

The Company's CSR Projects is available on the Company's web-link at https://marksanspharma.com/csr-activities.html

4. Details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report):

Not Applicable

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

Sl. No.	Financial Year	Amount available for set-off from preceding financial years (in Rs.)	Amount required to be set off for the financial year, if any (in Rs.)
1	2024-25	19,25,841.48	19,25,841.48

6. Average Net Profits of the Company as per section 135(5):

The average net profit of the Company made during the three immediately preceding financial years calculated as specified by the Companies Act, 2013 was Rs. 1,85,91,55,433.00.

7. (a) Two percent of average net profit of the company as per section 135(5)

The prescribed CSR expenditure requirement was Rs. 3,71,83,108.66.

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years

Not Applicable

(c) **Amount required to be set off for the financial year, if any**

The amount available for set off for the FY 2025-26 is Rs. 19,25,841.48.

(d) **Total CSR obligation for the financial year (7a+7b-7c)**

Total CSR obligation for the financial year is Rs. 3,52,57,267.18.

8. (a) **CSR amount spent or unspent for the financial year:**

Total Amount Spent for the Financial Year (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
3,52,79,715.00	Not Applicable				

(b) **Details of CSR amount spent against ongoing projects for the financial year:**

(1) Sl. No	(2) Name of the Project	(3) Item from the list of activities in Schedule VII to the Act	(4) Local area (Yes/No)	(5) Location of the project	(6) Project duration
Not Applicable					

(7) Amount allocated for the project (in Rs.)	(8) Amount spent in the current financial Year (in Rs.)	(9) Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.)	(10) Mode of Implementation - Direct (Yes/No)	(11) Mode of Implementation - Through Implementing Agency	
				Name	CSR Registration Number
Not Applicable					

(c) **Details of CSR amount spent against other than ongoing projects for the financial year:**

(1) Sl. No.	(2) Name of the Project	(3) Item from the list of activities in Schedule VII to the Act	(4) Local area (Yes/No)	(5) Location of the project	
				State	District
1.	Organized free health check-up camps and distributed free medicines and other medical supplies to under privileged people in the state of Goa.	Promotion of Health Care including preventive health care	Yes	Goa	North Goa
2.	Distribution of free food items to daily wage labourers, people below poverty line and other economically backward people who do not have regular income.	Eradicating hunger and malnutrition	Yes	Goa	North Goa
3.	Building and upkeep of public garden/park and tree plantation in Verna Industrial area, Goa.	Environmental sustainability and ecological balance	Yes	Goa	North Goa
4.	Contributions towards women and child development, professionalizing Anganwadis and national nutrition mission in Goa.	Promoting education especially among children and women and eradicating malnutrition	Yes	Goa	North Goa
5.	Various projects undertaken from time to time as per CSR policy of the Company in the areas of education, healthcare and disaster management.	Promoting education, healthcare and disaster management	Yes	Goa/ Maharashtra	North Goa/ Mumbai
	Total				

(6)	(7)	(8)	
Amount spent for the project (in Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
		Name	CSR Registration Number
1,76,89,509.00	Yes	-	-
71,60,525.00	Yes	-	-
45,03,759.00	Yes	-	-
4,00,000.00	Yes	-	-
55,25,922.00	Yes	-	-
3,52,79,715.00			

(d) Amount spent in Administrative Overheads

Rs. 16,14,008.00 (included in the above amount)

(e) Amount spent on Impact Assessment, if applicable

Not Applicable

(f) Total amount spent for the Financial Year (8b+8c+8d+8e)

Rs. 3,52,79,715.00

(g) Excess amount for set off, if any

Rs. 22,447.51

Sr. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the Company as per section 135(5)	3,71,83,108.66
(ii)	Total amount spent for the Financial Year	3,72,05,556.17*
(iii)	Excess amount spent for the financial year [(ii)-(i)]	22,447.51
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	NIL
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	22,447.51

*It includes Rs. 19,25,841.48 brought forward from previous financial year.

9. (a) Details of Unspent CSR amount for the preceding three financial years:

Preceding Financial Year	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Amount spent in the reporting Financial Year (in Rs.)	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in Rs.)
			Name of the Fund	Amount (in Rs.)	Date of transfer	
Not Applicable						

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

(1)	(2)	(3)	(4)	(5)
Sr. No.	Project ID	Name of the Project	Financial Year in which the project was commenced	Project duration
Not Applicable				

(6)	(7)	(8)	(9)
Total amount allocated for the project (in Rs.)	Amount spent on the project in the reporting Financial Year (in Rs.)	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project - Completed /Ongoing
Not Applicable			

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year

Not Applicable

a) Date of creation or acquisition of the capital asset(s): None

b) Amount of CSR spent for creation or acquisition of capital asset: Nil

c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc: Not Applicable

d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset): Not Applicable

11. Reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5).

Not Applicable. The Company has spent the entire estimated CSR expenditure during the financial year 2025-26.

For and on behalf of the CSR Committee

Mr. Varddhman V. Jain
Chairman- CSR Committee
DIN: 08338573

Mr. Mark Saldanha
Managing Director
DIN: 00020983

Place: Mumbai
Date: 26 May 2026

Annexure - D

Annexure to the Report of the Board of directors

CORPORATE GOVERNANCE REPORT 2025-26

A. Company's Philosophy of Code of Governance

The Company is committed to the principles of good corporate governance to achieve long-term corporate goals and to enhance shareholder value by managing its operations at all levels with the highest degree of transparency, responsibility and delegation with equity in all facets of its operations leading to sharp focus and operationally efficient growth. The spirit of Corporate Governance has prevailed in the Company and has influenced its decisions and policies. The strong internal control system and procedures and code of conduct for observance by the Company's directors and employees are conducive in achieving good corporate governance practices in the Company. The compliance report is prepared and given below in conformity to the mandatory requirements of Regulation 34(3) read with Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

B. Board of Directors

i. Composition of the Board:

The Company has an appropriate mix of Executive, Non-Executive and Independent Directors. As on March 31, 2026, the Board comprised of eight (8) Directors; of which, three (3) including the Chairman are executive and five (5) are non-executive, of which, four (4) are independent directors. Two (2) are women directors; of which one (1) is Independent. The composition of the Board is in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Companies Act, 2013. All the Directors have confirmed that they are not debarred from holding the office of Director by virtue of any Order passed by SEBI or any other regulatory authority.

ii. Meetings of the Board:

During the financial year under review, six (6) Board Meetings were held on 19.05.2025, 11.07.2025, 25.07.2025, 12.08.2025, 13.11.2025 and 05.02.2026. The necessary quorum was present at all the meetings. The time gap between any two consecutive meetings was not more than 120 days.

None of the Directors are members of more than 10 Committees nor are the Chairman of more than 5 Committees across all the Companies in which they are Directors. The details regarding Composition, shareholding in the Company, attendance at the Board Meetings and the last Annual General Meeting, details of Directorships and Board committee memberships/ chairmanships in other Companies held by them as on March 31, 2026 are set out below:

Name of the Director (DIN)	Category (Executive/ Non-executive/ Independent/ Non-Independent/ Promoter)	No. of Shares held in the Company	Board Meetings held / conducted during the year	No. of Board Meetings attended	No. of Directorship in other Companies(1)	No. of Committee Memberships / Chairmanships (including the Company)(2)		Whether attended last AGM held on 08.08.2025
						Member	Chairman	
Mr. Mark Saldanha (DIN: 00020983)	Executive, Non-Independent & Promoter	198491553	6	5	-	-	-	Yes
Mrs. Sandra Saldanha (DIN: 00021023)	Executive, Non-Independent & Promoter	330456	6	5	-	-	-	Yes
Mr. Varddhman Vikramaditya Jain (DIN: 08338573)	Executive & Non-Independent	Nil	6	6	-	1	-	Yes
Mr. Digant Mahesh Parikh (DIN: 00212589)	Non-Executive & Independent	Nil	6	6	1	1	1	Yes
Mr. Abhinna Sundar Mohanty (DIN: 00007995)	Non-Executive & Independent	Nil	6	6	1	2	-	Yes

Name of the Director (DIN)	Category (Executive/ Non-executive/ Independent/ Non-Independent/ Promoter)	No. of Shares held in the Company	Board Meetings held / conducted during the year	No. of Board Meetings attended	No. of Directorship in other Companies(1)	No. of Committee Memberships / Chairmanships (including the Company)(2)		Whether attended last AGM held on 08.08.2025
						Member	Chairman	
Dr. Sunny Sharma (DIN: 02267273)	Non-Executive & Non-Independent	Nil	6	5	1	1	-	Yes
Mrs. Shailaja Vardhan (DIN: 10172764)	Non-Executive & Independent	Nil	6	6	-	-	-	Yes
Mr. Srinivas Mishra (DIN: 10052055)	Non-Executive & Independent	Nil	6	5	-	-	-	Yes

(1) This excludes directorship held in private companies, foreign companies and companies formed under Section 8 of the Companies Act, 2013.

(2) Memberships include Chairmanships. Only membership of Audit Committee and Stakeholders Relationship Committee are considered. This includes memberships in deemed public company and excludes memberships in high value debt listed entities.

iii. The details pertaining to the directorships held by a director in listed companies other than the Company and Disclosure of relationships between directors inter-se:

Name of the Director	Name of the listed entity(1)	Category of Directorship	Relationship between Directors inter se
Mr. Mark Saldanha	Nil	-	Relative of Mrs. Sandra Saldanha
Mrs. Sandra Saldanha	Nil	-	Relative of Mr. Mark Saldanha
Mr. Varddhman Vikramaditya Jain	Nil	-	None
Mr. Digant Mahesh Parikh	Nil	-	None
Mr. Abhinna Sundar Mohanty	Nil	-	None
Dr. Sunny Sharma	Advanced Enzyme Technologies Limited	Non-executive & Non-Independent	None
Mrs. Shailaja Vardhan	Nil	-	None
Mr. Srinivas Mishra	Nil	-	None

(1) Only equity listed companies are considered.

iv. Details of core skills/expertise/competencies identified by the Board of Directors required in the context of its business and sector for it to function effectively and those actually available with the Board:

Skills/expertise/ competencies identified by the Board which are required in the context of its business and sector	The Board of Directors shall comprise directors who have the right skills/expertise/competencies that allow them to make effective contributions to the Board and its Committees. Such skills/expertise/competencies as identified by the Board are: 1. All Board members shall be financially literate and at least one member shall have accounting or related financial management expertise. 2. Members of the Board shall be capable of risk assessment and suggest risk mitigation measures in general and particularly with respect to risk associated with the pharma sector. 3. The right qualifications and expertise necessary to understand and navigate the Pharma industry. 4. Expertise in corporate strategy, budgets and business plans and setting performance objectives. 5. Best corporate governance practice. 6. Oversight into the general management and affairs of the Company. 7. Board members should act in good faith and with due diligence and care and in the best interest of the Company and shareholders. 8. Board members should be capable of exercising independent judgment. 9. Board members should be able to commit themselves effectively to their responsibilities.

Skills/expertise/ competencies actually available with the Board	All the Directors of the Company are financially literate wherein one of the Directors holds an MBA in Finance. All Directors are well versed with pharmaceutical business, general management and administration, risk identification and management, good corporate governance practices, etc. The Directors possess strong working experience in the above fields. The Company's Board is comprised of perfect blend of the above skills/ expertise/ competencies.

The Core Skills identified of each of the Directors of the Company are as follows:

Name of the Directors	Skills / Expertise / Competence of the Board of Directors are required in the context of business of the Company
Mr. Mark Saldanha	Business Marketing, Production and Finance
Mrs. Sandra Saldanha	Human Resource Management, Business Development, Projects and Supply Chain Management
Mr. Varddhman Vikramaditya Jain	Manufacturing, quality R&D, compliance & regulatory affairs both for API and finished dosages
Mr. Digant Mahesh Parikh	Corporate Finance, Strategic Planning and Business Set-up & Scale up
Mr. Abhinna Sundar Mohanty	Sales and Marketing, Business Development and Business Strategy.
Dr. Sunny Sharma	Corporate Finance and Investment Banking
Mrs. Shailaja Vardhan	Corporate Communication, Public Communication, Building Branch Architecture and CSR Activities.
Mr. Srinivas Mishra	Corporate Finance & Wholesale Banking, Corporate Governance, Business & Administration, Legal Abilities, Risk Management, Financial Administration.

v. Independent Directors:

The Company has received the necessary declaration from all the independent directors confirming that they meet the criteria of independence. The maximum tenure of Independent Directors is in accordance with the Companies Act, 2013. In the opinion of the Board of Directors of the Company, the independent directors fulfill the conditions specified in the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and are independent of the management.

During the financial year under review, the Independent Directors held a meeting on February 05, 2026, without the attendance of non-independent directors and the management. The Independent Directors reviewed performance of non-independent directors and the Board of Directors as a whole and performance of the Chairman of the Company. The Independent Directors also reviewed the quality, quantity and timeliness of flow of information between the management and the directors.

The Company proactively keeps its independent directors informed of the activities of the Company, its management and operations and provides an overall industry perspective as well as issues being faced by the industry. The Company also familiarized the independent directors with their role, functions and responsibilities. Details of the familiarization program for the Independent Directors are placed on the Company's weblink https://www.marksanspharma.com/pdf/familiarisation-programme-for-independent-directors-2025-26.pdf.

Changes in the Board of Directors during the financial year 2025-26 are as follows:

1) Mr. Seetharama Raju Buddharaju (DIN: 03630668) retired as an Independent Director of the Company on completion of his tenure on March 31, 2025.

2) Mr. Srinivas Mishra (DIN: 10052055) has been appointed as an Independent Director of the Company effective from April 01, 2025.

C. Board Committees

The Board currently has 5 Committees: 1) Audit Committee, 2) Nomination and Remuneration Committee, 3) Stakeholders' Relationship Committee, 4) Corporate Social Responsibility Committee and 5) Risk Management Committee. The terms of reference of the Board Committees are in compliance with the provisions of the Companies Act, 2013, SEBI (LODR) Regulations and are also reviewed by the Board from time to time. The Board is responsible for constituting, assigning and co-opting the members of the Committees. The meetings of each Board Committee are convened by the Company Secretary in consultation with the respective Committee Chairpersons. The role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are stated herein below.

1. Audit Committee:

The Audit Committee consists of three (3) members, namely Mr. Digant Mahesh Parikh (Chairman), Mr. Abhinna Sundar Mohanty and Dr. Sunny Sharma. All members of the Audit Committee have knowledge of financial matters and the ability to read and understand financial statements and one member holds an MBA in finance. The Managing Director and Chief Financial Officer are invited to the audit committee meetings. Company Secretary acts as the Secretary to the Committee. The constitution, functions and the terms of reference of the Committee are those prescribed under Regulation 18 and Schedule II Part C of the SEBI (LODR) Regulations, 2015 as well as under Section 177 of the Companies Act, 2013.

Terms of reference of the Committee, inter alia, include the following:

1. Oversight of financial reporting process and disclosure of its financial information.
2. Reviewing with the management, the annual financial statements, quarterly financial statements and auditors' report/limited review report.
3. Recommendation for appointments, remuneration and terms of appointment of auditors.
4. Reviewing and monitoring the auditors' independence and performance and effectiveness of audit process.
5. Scrutiny of inter-corporate loans and investments.
6. Evaluation of internal financial controls and risk management systems.
7. Reviewing with the management, performance of statutory auditors and internal auditors, adequacy of internal control systems.
8. Reviewing the adequacy of internal audit function.
9. Reviewing the functioning of the whistle blower mechanism.
10. Reviewing the statement of significant related party transactions.
11. Reviewing the internal audit reports.

During the financial year under review, the Audit Committee met six (6) times on 19.05.2025, 11.07.2025, 25.07.2025, 12.08.2025, 13.11.2025 and 05.02.2026. The necessary quorum was present at all the meetings. The time gap between any two consecutive meetings was not more than 120 days. The Chairman of the Committee was present at the last Annual General Meeting.

The composition and attendance of members at the Committee meetings are given below:

Sr. No.	Name of Committee Member	Position	Category	Meetings Attended out of 6 held
1.	Mr. Digant Mahesh Parikh	Chairman	Non-executive & Independent	6
2.	Dr. Sunny Sharma	Member	Non-executive & Non-Independent	5
3.	Mr. Abhinna Sundar Mohanty	Member	Non-executive & Independent	6

2. **Nomination and Remuneration Committee:**

The Nomination and Remuneration Committee of the Company consists of three (3) members, namely Mr. Abhinna Sundar Mohanty (Chairman), Mr. Digant Mahesh Parikh and Dr. Sunny Sharma. All members of the committee are non-executive directors. The constitution, functions and the terms of reference of the Committee are those prescribed under Regulation 19 and Schedule II Part D – Para A of the SEBI (LODR) Regulations, 2015 as well as under Section 178 of the Companies Act, 2013.

Terms of reference of the Committee, inter alia, include the following:

1. Formulation of criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy relating to the remuneration of directors, key managerial personnel and other employees.
2. Formulation of policy on Board diversity, criteria for evaluation of performance of individual directors, Board and its committees.
3. Identifying persons who are qualified to become directors and who may be appointed in senior management and recommend to the Board their appointment and removal.
4. Determining whether to extend or continue the terms of appointment of the independent directors on the basis of their performance evaluation.
5. Recommend to the Board all remuneration, in whatever form, payable to senior management.

During the financial year under review, the Nomination and Remuneration Committee met five (5) times on 19.05.2025, 11.07.2025, 25.07.2025, 24.09.2025 and 05.02.2026. The necessary quorum was present at all the meetings. The Chairman of the Committee was present at the last Annual General Meeting.

The composition and attendance of members at the Committee meetings are given below:

Sr. No.	Name of Committee Member	Position	Category	Meetings Attended out of 5 held
1.	Mr. Abhinna Sundar Mohanty	Chairman	Non-executive & Independent	5
2.	Mr. Digant Mahesh Parikh	Member	Non-executive & Independent	5
3.	Dr. Sunny Sharma	Member	Non-executive & Non-independent	4

Nomination and Remuneration Policy:

The Company has in place a Nomination and Remuneration Policy in accordance with Section 178 of the Companies Act, 2013. The Nomination and Remuneration Policy, inter alia, provides for the following:

1. The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director in terms of Diversity Policy of the Board and recommend to the Board for his/ her appointment.

2. For the appointments of KMP (other than Managing/ Whole-time Director) or Senior Management, a person should possess adequate qualification, expertise and experience for the position he/she is considered for the appointment. For administrative convenience, the Managing Director is authorized to identify and appoint a suitable person for the position of KMP (other than Managing/Whole-time Director) and Senior Management.

3. Remuneration / compensation / commission, etc., as the case may be, to the Managing / Whole-time Director is determined by the Committee and recommended to the Board for approval. Remuneration / compensation / commission, etc., as the case may be, are subject to approval of the shareholders of the Company and are in accordance with provisions of the Companies Act, 2013 and Rules made thereunder. The Managing Director of the Company is authorized to decide the remuneration of KMP (other than Managing/Whole-time Director) and Senior Management based on the standard market practice and prevailing HR policies of the Company.

4. Remuneration / commission / sitting fees, as the case may be, to the Non-Executive/ Independent Director, is in accordance with the provisions of the Companies Act, 2013 and the Rules made thereunder for the time being in force or as may be decided by the Committee / Board / Shareholders.

5. An Independent Director is not entitled to any stock option of the Company.

Remuneration of Directors

Criteria for making payment to Executive Directors

The executive directors are paid remuneration under the applicable provisions of the Companies Act, 2013 read with SEBI Listing Regulations, subject to approval of the shareholders in the General Meeting.

The details of remuneration paid to Executive Directors during the financial year ending March 31, 2026 are as follows:

(In ₹)

Name of Directors	Basic	Allowances	Bonus	Perquisite	Medical Reimbursement	Total
Mr. Mark Saldanha	4,80,00,000	41,01,600	60,000	1,19,71,082	--	6,41,32,682
Mrs. Sandra Saldanha	10,80,000	59,22,564	12,000	39,600	15,000	70,69,164
Mr. Varddhman Vikramaditya Jain	90,00,000	1,19,72,100	50,00,000	3,37,322	15,000	2,63,24,422

Note:

- The above figures do not include provisions for the Company's Contribution to Provident Fund & Gratuity and other perquisites.
- Pursuant to Marksans Employees Stock Option Scheme 2024, the Company has granted 1,00,000 stock options to Mr. Varddhman Vikramaditya Jain.

Criteria for making payment to Non-Executive Directors

The Company has formulated a Nomination and Remuneration Policy which indicates criteria for making payment to Non-Executive Directors. Non-Executive Directors are not paid any remuneration except sitting fees for attending the meeting of the Board and Committees. Apart from this, there is no pecuniary relationship or transaction between any non-executive directors (including Independent Directors) and the Company.

Details of sitting fees paid to Non-executive Directors during the financial year ending March 31, 2026 are given below:

Name of Directors	Sitting Fees#
Mr. Digant Mahesh Parikh	5,00,000
Mr. Abhinna Sundar Mohanty	3,10,000
Mrs. Shailaja Vardhan	5,00,000
Mr. Srinivas Mishra	4,00,000

The above figures are inclusive of fees paid for attending Board and Committee meetings.

Performance Evaluation criteria for directors including independent directors as set out by the Nomination and Remuneration Committee and approved by the Board of Directors:

1. Attendance and contribution at Board and Committee meetings.

2. Stature, appropriate mix of expertise, skills, behavior, experience, leadership qualities, sense of sobriety and understanding of business, strategic direction to align company's value and standards.
3. Knowledge of finance, accounts, legal, investment, marketing, foreign exchange/ hedging, internal controls, risk management, assessment and mitigation, business operations, processes and Corporate Governance.
4. The ability to create a performance culture that drives value creation and a high quality of debate with robust and probing discussions.
5. Effective decisions making ability to respond positively and constructively to implement the same to encourage more transparency.
6. Open channels of communication with executive management and other colleagues on the Board to maintain high standards of integrity and probity.
7. Recognize role, which is expected to be played, internal Board Relationships to make decisions objectively and collectively in the best interest of the Company to achieve organizational successes and harmonizing the Board.
8. Global presence, rationale, physical and mental fitness, broader thinking, vision on corporate social responsibility etc.
9. Quality of decision making on sourcing of raw material/ procurement of roughs, export marketing, understanding financial statements and business performance, raising of finance, best source of finance, working capital requirement, forex dealings, geopolitics, human resources etc.
10. The ability to monitor the performance of management and satisfy oneself with integrity of the financial controls and systems in place by ensuring the right level of contact with external stakeholders.
11. Contribution to enhance the overall brand image of the Company.
12. Adherence to various codes of conduct and policies framed by the Company as applicable.

Pursuant to the provisions of Companies Act and the SEBI Listing Regulations, the Board has carried out an annual evaluation of its own performance, performance of the Directors individually and the Committees of the Board.

3. Stakeholders' Relationship Committee:

The Stakeholders' Relationship Committee consists of three (3) members, namely Mr. Abhinna Sundar Mohanty (Chairman), Mr. Varddhman Vikramaditya Jain and Mr. Digant Mahesh Parikh. Mr. Harshavardhan Panigrahi, Company Secretary, acts as the Company's Compliance Officer.

The Committee looks into the shareholders' and Investors' grievances. The Committee also oversees the performance of the Registrar and Share Transfer Agent and recommends measures to enhance the level of investor services.

Number of complaints received during the year:	Nil
Number of complaints not resolved to the satisfaction of complainants :	NA
Number of complaints outstanding as on 31.03.2026 :	Nil

During the financial year under review, Stakeholder's Relationship Committee met four (4) times on 19.05.2025, 12.08.2025, 13.11.2025 and 05.02.2026. The necessary quorum was present at all the meetings. The Chairman of the Committee was present at the last Annual General Meeting.

The composition and attendance of members at the Committee meetings are given below:

Sr. No.	Name of Committee Member	Position	Category	Meetings Attended out of 4 held
1	Mr. Abhinna Sundar Mohanty	Chairman	Non-executive & Independent	4
2.	Mr. Varddhman Vikramaditya Jain	Member	Executive & Non-independent	4
3.	Mr. Digant Mahesh Parikh	Member	Non-executive & Independent	4

4. Corporate Social Responsibility (CSR) Committee:

The CSR Committee of the Company consists of (3) members, namely Mr. Varddhman Vikramaditya Jain (Chairman), Mrs. Sandra Saldanha and Mr. Abhinna Sundar Mohanty. The Company has in place a CSR Policy formulated by the CSR Committee and approved by the Board of the Company.

The constitution, functions and the terms of reference of the Committee are those prescribed under the Companies Act, 2013. The terms of reference of the CSR Committee, inter alia, include the following:

1. To formulate and recommend to the Board of Directors, a CSR policy which shall indicate the activities to be undertaken by the Company as per Schedule VII to the Act.

2. To review and recommend the amount of expenditure to be incurred on the activities to be undertaken by the Company.

3. To monitor the CSR policy of the Company from time to time.

4. Any other matter as the CSR Committee may deem appropriate after approval of the Board or as may be directed by the Board from time to time.

During the financial year under review, the CSR Committee met two (2) times on 19.05.2025 and 05.02.2026. Necessary quorum was present at all the meetings.

The composition and attendance of members at the Committee meetings are given below:

Sr. No.	Name of Committee Member	Position	Category	Meetings Attended out of 2 held
1.	Mr. Varddhman Vikramaditya Jain	Chairman	Executive & Non-independent	2
2.	Mrs. Sandra Saldanha	Member	Executive & Non-independent	2
3.	Mr. Abhinna Sundar Mohanty	Member	Non-executive & Independent	2

5. **Risk Management Committee:**

The Risk Management Committee of the Company consists of three (3) members, namely Mr. Varddhman Vikramaditya Jain (Chairman), Mr. Abhinna Sundar Mohanty and Mr. Jitendra Sharma. The Company has a Risk Management Policy formulated by the Risk Management Committee and approved by the Board of the Company.

The terms of reference of the Committee are those prescribed under Regulation 21 read with Schedule II Part D - Para C of the SEBI (LODR) Regulations, 2015. The Committee is responsible for implementing and monitoring risk assessment and minimization procedures and periodically report to the Board a risk assessment report and recommend to the Board risk mitigation measures, if any, for approval.

During the financial year under review, the Risk Management Committee met two (2) times on 25.07.2025 and 05.02.2026. Necessary quorum was present at all the meetings.

The composition and attendance of members at the Committee meetings are given below:

Sr. No.	Name of Committee Member	Position	Category	Meetings Attended out of 2 held
1.	Mr. Varddhman Vikramaditya Jain	Chairman	Executive & Non-independent	2
2.	Mr. Abhinna Sundar Mohanty	Member	Non-Executive & Independent	2
3.	Mr. Jitendra Sharma	Member	Chief Financial Officer	2

D. General Body Meetings

Annual General Meeting	Date	Time	Venue / Mode of conducting the meeting	No. of Special Resolutions
Thirty Third	08.08.2025	09:00 AM	Through electronic mode video conferencing ('VC') / other audio visual means ('OAVM'). The deemed venue of the AGM was the Registered Office of the Company.	3
Thirty Second	24.09.2024	09:30 AM	Through electronic mode video conferencing ('VC') / other audio visual means ('OAVM'). The deemed venue of the AGM was the Registered Office of the Company.	3
Thirty First	28.08.2023	04:30 PM	Through electronic mode video conferencing ('VC') / other audio visual means ('OAVM'). The deemed venue of the AGM was the Registered Office of the Company.	4

The following special resolutions were passed by the Shareholders at the last three Annual General Meetings:

Year	Date	Resolution
2024-25	08.08.2025	• Approval of the appointment of Mr. Srinivas Mishra (DIN: 10052055) as an Independent Director of the Company. • Approval of the amendment to Marksans Employees Stock Option Scheme 2024. • Approval of the grant of employee stock options to the employees of subsidiaries of the Company.
2023-24	24.09.2024	• Approval of re-appointment of Mr. Abhinna Sundar Mohanty (DIN: 00007995) as an Independent Director of the Company. • Approval of re-appointment of Mr. Varddhman Vikramaditya Jain (DIN: 08338573) as a Whole-time Director of the Company and remuneration payable to him. • Approval of Marksans Employee Stock Option Scheme 2024.
2022-23	28.08.2023	• Approval of the appointment of Mrs. Shailaja Vardhan (DIN: 10172764) as an Independent Director of the Company. • Approval of re-appointment of and remuneration to Mrs. Sandra Saldanha (DIN: 00021023) as a Whole-time Director. • Approval of Alteration in Articles of Association of the Company. • Approval of Marksans Employee Stock Option Scheme 2023.

E. Postal Ballot

The Company has not passed any resolution through postal ballot in reporting financial year nor is it proposing to pass any resolution through postal ballot as of date. However, if a resolution is proposed to be passed by way of postal ballot, the Company will follow the process as per regulatory requirements.

F. Means of Communication

Quarterly, Half-yearly, and Annual results of the Company are published in one English newspaper (Business Standard) and one Marathi newspaper (Lakshadeep). These results are also submitted to the stock exchanges in accordance with the Listing Regulations and are available on the website of BSE (www.bseindia.com) & NSE (www.nseindia.com) and also on the Company's website (www.marksanspharma.com). The Company also displays official news releases on its website from time to time. The Company also makes presentations to institutional investors or analysts and is displayed on its website. The Annual Report is circulated to all the Members, Statutory Auditors, Secretarial Auditor, Directors and such other persons who are entitled to receive the Annual Report.

G. Share Transfer System

The Company has appointed Bigshare Services Private Limited as its Registrar and Share Transfer Agent for both physical and demat segment. The Company has authorized Mr. Mark Saldanha, Managing Director, Mr. Jitendra Sharma, Chief Financial Officer and Mr. Harshavardhan Panigrahi, Company Secretary of the Company, to approve dematerialization/ rematerialization of shares, issue of duplicate share certificate on surrender of defaced/damaged/mutilated share certificates. The shares lodged for the above purposes are given effect and credited into the shareholder's demat account in 15 days from the date of receipt, so long as the documents are complete in all respects. The Company obtains certificates from a Practicing Company Secretary and submits to the Stock Exchanges, on a quarterly basis, for timely dematerialization of shares of the Company and for reconciliation of the share capital of the Company, as required under SEBI (Depositories and Participants) Regulations, 1996. Vide Gazette Notification dated June 8, 2018 and as amended, SEBI has mandated that with effect from January 24, 2022, transfer/ transmission/ transposition of shares as well as issuance of duplicates thereof or issuance of new certificates of the Company would be carried out in dematerialized form only. No physical shares are issued from that date.

The Board has designated Mr. Harshavardhan Panigrahi, Company Secretary of the Company, as Compliance Officer.

H. Details of the Company's material subsidiary

Name: Time Cap Laboratories Inc.

Name of the Statutory Auditors	: BDO India LLP
Date of appointment of Statutory Auditors	: May 31, 2022
Date of Incorporation	: December 11, 2014
Place of Incorporation	: New York, USA

Name: Bell, Sons & Co. (Druggists) Limited

Name of the Statutory Auditors	: PBG Associates Limited
Date of appointment of Statutory Auditors	: February 2018
Date of Incorporation	: July 16, 2012

Place of Incorporation : England & Wales, UK

Name: Relonchem Limited

Name of the Statutory Auditors : PBG Associates Limited
Date of appointment of Statutory Auditors : February 2018
Date of Incorporation : July 16, 2012
Place of Incorporation : England & Wales, UK

I. Other Disclosures

a) During the year, there were no transactions of material nature with the directors, management, their relatives or the subsidiaries, which had potential conflict with the interests of the Company.

b) Related Parties Transactions: The Company has been selling goods to its subsidiaries, namely Bell, Sons & Co (Druggists) Limited, Relonchem Limited, Time-Cap Laboratories Inc. and Nova Pharmaceuticals Australasia Pty Ltd. from time to time. These subsidiaries are related parties and are wholly owned subsidiaries of the Company except Nova Pharmaceuticals Australasia Pty Ltd. The Audit Committee has granted omnibus (ad hoc) approval for sales to Nova Pharmaceuticals Australasia Pty. Ltd., in which the Company holds 60% of the share capital for smooth operation, which is in the interest of the Company. The said approval is in accordance with the Company's Policy on Related Party Transactions and it is within the limit of the Omnibus (ad hoc) approval of the Audit Committee of the Company. The transactions entered with Time-Cap Laboratories Inc. exceed the materiality limit as provided under the SEBI Listing Regulations. However, since Time-Cap Laboratories Inc. is a wholly owned subsidiary, neither audit committee nor shareholders prior approval are required. Further, all the transactions with these subsidiaries are in the ordinary course of business at arm's length basis and are repetitive in nature. These transactions are entered in the Register of Contracts and placed before the Board of Directors on a regular basis. The details of these related party transactions are also placed before the Audit Committee for review. Details of related party transactions during the year ending 31st March, 2026 has been set out under Note No. 38(c) of the Notes annexed to the Financial Statements for the year ended 31st March, 2026. There are no materially significant related party transaction that may have potential conflict with the interests of the Company. Company's policy on dealing with Related Party Transactions and policy for determining material subsidiaries are available on the Company's weblink at http://marksanspharma.com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf & http://marksanspharma.com/pdf/policy-on-material-subsidiary.pdf respectively.

c) There were no instances of non-compliance by the Company, penalties, strictures imposed on the Company by Stock Exchange(s) or SEBI or any statutory authority, on any matter related to capital markets, during the last three years.

d) The Company has in place a Whistle Blower Policy to deal with instances of fraud and mismanagement, if any. Under the policy, an effective vigil mechanism for directors and employees has been established to report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct. Details of the Whistle Blower Policy are available on the Company's web link at http://marksanspharma.com/pdf/whistle-blower-policy.pdf. The said vigil mechanism also provides for adequate safeguard against victimisation of the person who uses such mechanism and direct access to the chairperson of the Audit Committee. During the financial year 2025-26, there were no instances of any unethical behaviour, actual or suspicious fraud or violation of the Company's operational policies and codes of conduct and no employee of the Company sought access to the Audit Committee.

e) The web link with respect to the policy for determining material subsidiaries and policy on dealing with related party transactions are mentioned in the Board's Report.

f) The Company has complied with the Corporate Governance requirements specified in Regulations 17 to 27 and clauses (b) to (i) of Regulation 46(2), as applicable and other applicable provisions of the SEBI Listing Regulations.

g) As on March 31, 2026, the Company has fully utilized Rs. 372.40 crore raised through issue of 5,03,24,324 Equity Shares @ Rs. 74.00 each pursuant to the conversion of convertible warrants on preferential basis.

h) A certificate from M/s. Jinesh Dedhia & Associates, Practising Company Secretaries (Membership No. 54731, Certificate of Practice No. 20229) that none of the directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by SEBI/Ministry of Corporate Affairs or any such statutory authority is annexed herewith as a part of the report.

i) During the financial year under review, the Board has accepted all the recommendations of the Committees of Directors.

j) Total fee for all services paid by the Company and its subsidiaries on a consolidated basis to the statutory auditors is Rs.10.75 million for the year ended March 31, 2026.

k) Disclosure in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:-

  a. Number of complaints filed during the financial year 2025-26 : Nil

  b. Number of complaints disposed of during the financial year 2025-26 : NA

  c. Number of complaints pending at end of the financial year 2025-26 : Nil

l) During the financial year under review, neither the Company nor its subsidiaries has given any Loans and advances in the nature of loans to any firms/companies in which directors of the Company are interested.

m) The Company is not into any commodity trading activities.

n) The entire revenue of the Company is derived from the export market. The Company also imports some of the raw materials. Therefore, the Company is exposed to foreign exchange fluctuation risk. The Company manages these risks by taking adequate forward cover from time to time.

o) The Company is fully compliant with the corporate governance requirements specified in the Companies Act, 2013 and in Schedule V of SEBI (LODR) Regulations, 2015 to the extent applicable.

p) Disclosure regarding adoption of discretionary requirements as specified in Part E of Schedule II of SEBI (LODR) Regulations, 2015:

  i. The Company has an executive chairperson.

  ii. Half-yearly declaration of financial performance including summary of the significant events in the last six months are presently not being sent to the shareholders.

  iii. Every endeavor is made to make the financial statements with unmodified audit opinion.

  iv. Currently, Chairperson and Managing Director are the same.

  v. The internal auditors' reports are placed before the Audit Committee from time to time.

  vi Currently, the independent directors are holding one meeting in a year without the presence of non-independent directors and members of the management.

  vii The Company has a Risk Management Committee in terms of the regulations.

q) During the year ended March 31, 2026, there were no shares in the demat suspense account/unclaimed suspense account of the Company.

r) The Audit Committee of the Company reviews the financial statements of its subsidiary companies. Minutes of the meetings of the subsidiary companies are also placed before the Board of Directors of the Company from time to time.

s) The Company has in place Succession Plans for appointments to the Board of Directors and Senior Management.

t) During the year ended March 31, 2026, all members of the Board and Senior Management Personnel of the Company have affirmed due observance of the Code of Conduct framed pursuant to SEBI (LODR) Regulations, 2015, in so far as it is applicable to them.

Disclosure of compliance with corporate governance requirements specified in Regulation 17 to 27 and Clauses (b) to (i) of sub-regulation (2) of Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Regulation No.	Particulars	Compliance Status
17	Board of Directors	Yes
18	Audit Committee	Yes
19	Nomination and Remuneration Committee	Yes
20	Stakeholders Relationship Committee	Yes
21	Risk Management Committee	Yes
22	Vigil Mechanism	Yes
23	Related Party Transactions	Yes
24	Subsidiary Company.	Yes
25	Independent Directors	Yes
26	Directors and Senior Management	Yes
27	Other Corporate Governance Requirements	Yes
46(2)(b) to (i)	Website	Yes

J. Management Discussion & Analysis Report

The Annual Report has a separate and detailed chapter on Management Discussion & Analysis covering Industry structure and development, financial and operational performance of the Company, risks, concerns, opportunities, threat and outlook forming part of this report.

K. Compliance with Secretarial Standards

The Institute of Company Secretaries of India, a Statutory Body, has issued Secretarial Standards on various aspects of corporate law and practices. The Company has complied with them to the extent applicable.

L. General Shareholder Information

AGM – Date, Time & Venue	Thirty-fourth (34th) Annual General Meeting on Thursday, 27 August, 2026 at 11:00 a.m. through video conferencing / other audio- visual means (deemed venue -Registered Office of the Company)
Financial Year	April 2025 to March 2026
Financial calendar (Tentative schedule)	Financial Year - April to March First Quarter Results – 2nd week of August Second Quarter Results – 2nd week of November Third Quarter Results – 2nd week of February Last Quarter Results – 3rd / 4th week of May
Record Date for dividend payment	Thursday, 20 August, 2026 as the record date for dividend payment
Dividend payment date	On or after 08 September, 2026
Listing on Stock Exchanges along with address	1. BSE Limited (BSE), Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai–400 001 2. The National Stock Exchange of India Limited (NSE), Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai–400 051
Listing Fee Payment	The annual listing fees for the financial year 2025-26 have been paid to the above Stock Exchanges.
Stock Code	BSE: 524404 NSE: MARKSANS
ISIN	INE750C01026
Depositories	Central Depository Services (India) Limited National Securities Depository Limited

M. Distribution of Shareholding as on 31.03.2026

Category (Shares)	Shareholders		Shareholding	
	Number	%	Number	%
Upto 5000	2,48,070	98.54	7,02,36,755	15.50
5001 – 10000	1,955	0.78	1,41,91,193	3.13
10001 – 20000	923	0.37	1,31,80,871	2.91
20001 – 30000	268	0.11	67,61,155	1.49
30001 – 40000	110	0.04	38,27,526	0.84
40001 – 50000	77	0.03	35,29,531	0.78
50001 – 100000	160	0.06	1,13,04,147	2.49
100001 and above	177	0.07	33,01,32,568	72.86
Total	**2,51,740**	**100**	**45,31,63,746**	**100**

Note - Number of Folios are not PAN clubbed.

N. Dematerialization of Shares

The Company's shares are required to be compulsorily traded on the Stock Exchanges in dematerialized form.

The numbers of shares held in dematerialised and physical form are as under:

Particulars	No. of Shares	%
National Securities Depository Limited ("NSDL")	37,44,13,552	82.62
Central Depository Services (India) Limited ("CDSL")	7,85,28,384	17.33
Physical	2,21,810	0.05
TOTAL	**45,31,63,746**	**100**



Dematerialization of the Shares and Liquidity	Based on SEBI directives, the Company's shares are traded in dematerialized mode only. As on 31.03.2026, 99.95% of the paid-up equity share capital of the Company was in dematerialized form.
Registrar and Transfer Agents	Bigshare Services Pvt. Ltd. Office No S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai – 400093 Ph. No. 022-62638200 Fax No. 022-62638299 E-mail: investor@bigshareonline.com Website: www.bigshareonline.com The Company's RTA has launched Gen-Next Investor Interface Module "iBoss" the most advanced tool to interact with investors. Shareholders are requested to login into "iBoss" and help them to serve you better. The Company's RTA has also implemented a user-friendly online portal for processing investor service requests and complaints, which is now available on their website under the heading iConnect https://iconnect.bigshareonline.com/Account/Login For the shareholders, they also have a dedicated grievance link through which shareholders can directly raise a query: https://www.bigshareonline.com/InvestorLogin.aspx
In case the securities are suspended from trading, the directors report shall explain the reason thereof	Not Applicable
Outstanding GDR/ADR/ Warrants or any convertible instruments, conversion dates and likely impact on equity	The Company does not have any outstanding GDRs / ADRs / Warrants or any Convertible instruments as on March 31, 2026.
Commodity price risk or foreign exchange risk and hedging activities	The Company is not into any commodity trading activities. The entire revenue of the Company is derived from the export market. The Company also imports some of the raw materials. Therefore, the Company is exposed to foreign exchange fluctuation risk. The Company manages these risks by taking adequate forward cover from time to time
Plant Locations	**India Formulation Plant** Marksans Pharma Limited 1. Plot No. L-82 & L-83, Verna Industrial Estate, Verna, Goa- 403 722 2. Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa - 403722 **U.K. Plant** Bell, Sons & Co (Druggists) Ltd. Slaidburn Crescent, Southport, PR9 9AL. **U.S.A. Plant** Time-Cap Laboratories Inc. 7, Michael Avenue, Farmingdale, New York- 11735, USA.

Address for Correspondence	Mr. Harshavardhan Panigrahi Company Secretary & Compliance Officer Marksans Pharma Limited 11th Floor, Grandeur, Veera-Desai Extension Road, Oshiwara, Andheri (West), Mumbai 400 053. Tel. No. : 022- 40012000 Email: companysecretary@marksanspharma.com

O. Credit Rating

CARE Ratings Limited has upgraded outlook for the Company's long-term bank facilities to CARE AA- Stable and reaffirmed outlook for short-term bank facilities at CARE A1+.

P. Disclosures with Respect to Demat Suspense Account/ Unclaimed Suspense Account

The requisite disclosures as per Schedule V (F) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard are given below:

a) Aggregate number of shareholders and the outstanding shares in the suspense account lying at the beginning of the Year – NIL

b) Number of shareholders who approached listed entity for transfer of shares from suspense account during the year - NA;

c) Number of shareholders to whom shares were transferred from suspense account during the year – NA

d) Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of year – NIL;

Q. Transfer of amounts / shares to Investor Education and Protection Fund ("IEPF")

Pursuant to the provisions of Sections 124 and 125 of the Act read with the IEPF (Accounting, Audit, Transfer and Refund) Rules, 2016, dividend / interest / refund of application money which remains unclaimed / unpaid for a period of 7 years is required to be transferred to IEPF. Further, the IEPF Rules mandate the companies transfer all shares on which dividend remains unclaimed / unpaid for a period of 7 consecutive years to the demat account of the IEPF Authority.

During the year under review, the Company transferred to IEPF a sum of Rs. 2,15,706.50 being the amount towards unclaimed dividend on equity shares of the Company that remained unclaimed pertaining to FY 2017-18.

Further, 57,200 shares in respect of which the dividend remained unclaimed for a period of 7 consecutive years were also transferred to IEPF.

Dividend declared for the FY2018-19 and remaining unclaimed for a period exceeding 7 years is falling due on November 01, 2026 for transfer to IEPF. Subsequently, the shares in respect of which dividend will remain unclaimed for a period of 7 consecutive years will also be transferred to IEPF. The details of unclaimed dividend lying with the Company as on August 08, 2025 (date of last AGM) are available on the website of the Company at https://www.marksanspharma.com/unclaimed-dividend.html and Ministry of Corporate Affairs at https://www.iepf.gov.in. The Company requests the Members to claim the unclaimed dividend within the prescribed period. The Members can contact M/s. Bigshare Services Private Limited, the Registrar and Share Transfer Agents of the Company, to claim their unclaimed dividend lying with the Company. The Members / claimants whose shares or unclaimed dividends get transferred to IEPF, may claim the shares or apply for refund of dividend from the IEPF Authority by following the refund procedure as detailed on the website of IEPF Authority at https://www.iepf.gov.in/IEPF/refund.html.

Details of Directors seeking approval of Members for re-appointment at the Thirty-fourth (34th) AGM of the Company

[Pursuant to Regulation 36(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Secretarial Standards-2 on General Meetings issued by the Institute of Company Secretaries of India]

Name	Dr. Sunny Sharma	Mrs. Sandra Saldanha
DIN	02267273	00021023
Date of Birth / Age	31/08/1974 (52 years)	11/12/1971 (54 years)
Nationality	Indian	Indian
Qualification	MBA & MBBS	Master of Arts (Sociology)
Date of first appointment on Board	11/08/2021	25/09/2014
Nature of expertise in specific functional areas	Corporate Finance and Investment Banking	Human Resource Management, Business Development, Projects and Supply Chain Management

Brief profile including experience	Dr. Sunny Sharma is a Senior Managing Director of OrbiMed Asia. Previously, he was with Investor Growth Capital (IGC), the investment arm of Investor AB in North America, and before that with Easton Capital in New York. Earlier in his career. Dr. Sharma worked in the healthcare investment banking group of Lehman Brothers in London.	Mrs. Sandra Saldanha has a master's degree in arts (Sociology). She has vast experience in the field of Human Resource Management, Business Development, Projects and Supply Chain Management.
Directorships held in other companies as on date of Notice (Including Listed Entities)	1. Lattice Medtech Private Limited 2. Arcatron Mobility Private Limited 3. Innovation Imaging Technologies Private Limited 4. Innvolution Healthcare Private Limited 5. Adret Retail Private Limited 6. Orbimed Advisors India Private Limited 7. Kims Health Care and Research Center Limited 8. Lifecell International Private Limited 9. Advanced Enzyme Technologies Limited 10. Shasun Pharmaceuticals Limited 11. Redcliffe Hygiene Private Limited	1. Marksans Pharma (UK) Limited 2. Marksans Holdings Limited 3. Relonchem Limited 4. Bell, Sons & Co. (Druggists) Limited 5. Time-Cap Laboratories Inc.
Memberships/ Chairpersonship of committees across companies as on date of notice (only Statutory Committees as required to be constituted under the Act considered)	2 (Two) membership	Nil
In case of independent directors, the skills and capabilities required for the role and the manner in which the proposed person meets such requirements	NA	NA
Listed entities from which the Director has resigned in the past three years	Nil	Nil
No. of shares held in the Company (as on date of notice)	Nil	330,456
No. of board meetings attended during the year 2025-2026	5 (five) out of 6 (six) held	5 (five) out of 6 (six) held
Inter-se Relationship between Directors and Key Managerial Personnel of the Company	Nil	Relative of Mr. Mark Saldanha
Terms and conditions of appointment/reappointment	He is a non-executive non-independent director.	As per the terms mentioned in the resolution at Item No. 4 of the notice proposed to be passed at 34th AGM re-appointing her as a whole-time director.
Remuneration proposed to be paid	Nil	As per the terms mentioned in the resolution at Item No. 4 of the notice proposed to be passed at 34th AGM re-appointing her as a whole-time director.
Remuneration last drawn (including sitting fees, if any)	Nil	Rs. 70,69,164.00 (as whole-time director)

Certificate on Compliance with the Corporate Governance requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Members of
Marksans Pharma Limited
11th Floor, Grandeur
Veera Desai Extension Road
Oshiwara, Andheri (West)
Mumbai – 400 053

We have examined the compliance of conditions of corporate governance by **Marksans Pharma Limited** (CIN: L24110MH1992PLC066364) (the Company) for the financial year ended March 31, 2026, as prescribed in the Regulations 17 to 27, 46 (2) (b) to (i), and Paragraphs C, D and E of Schedule V of Chapter IV of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations).

The compliance of conditions of Corporate Governance is the responsibility of the management, and our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance under the Listing Regulations. It is neither an audit nor an expression of opinion on the financial statements of the Company or the Corporate Governance Report of the Company.

In our opinion and to the best of our information and according to the explanations given to us and the representation made by the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the Listing Regulations.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

This certificate is issued solely for the purposes of complying with the aforesaid Regulations and may not be suitable for any other purpose.

For Jinesh Dedhia & Associates
Company Secretaries

Jinesh Dedhia
Proprietor
Peer Review Certificate No.:1914/2022
ACS:54731 CP. 20229
UDIN: A054731H000485931

Place: Mumbai
Date: 26 May 2026

CHIEF EXECUTIVE OFFICER (CEO) & CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

[Issued in accordance with the provisions of Regulation 17(8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015]

To,
The Board of Directors
Marksans Pharma Limited

This is to certify with reference to the Annual Accounts of the Company for the year ended March 31, 2026 that:-

a. We have reviewed financial statements and the cash flow statement for the year ended on 31st March, 2026 and that to the best of our knowledge and belief:

   i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

   ii. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

b. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.

c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. We have not come across any reportable deficiencies in the design or operation of such internal controls.

d. We have indicated to the Auditors and the Audit committee:

   i. That there is no significant changes in internal control over financial reporting during the year;

   ii. That there are no significant changes in accounting policies during the year; and

   iii. That there is no instance of any fraud which we have become aware of.

For Marksans Pharma Limited

Place: Mumbai
Date: 26 May 2026

Mark Saldanha
Managing Director

Jitendra Sharma
Chief Financial Officer

Declaration on Compliance of the Company's Code of Conduct

This is to confirm that during the year ended March 31, 2026, all the members of the Board and Senior Management Personnel of the Company have affirmed due observance of the Code of Conduct, framed pursuant to Schedule V of the SEBI (LODR) Regulations, 2015, in so far as it is applicable to them.

For Marksans Pharma Limited

Place: Mumbai
Date: 26 May 2026

Mark Saldanha
Managing Director

Annexure - E

Annexure to the Report of the Board of Directors

Information required pursuant to Section 197 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

1. Ratio of remuneration of each Director to the median remuneration of employees:

    a. Mr. Mark Saldanha, Managing Director: 266.18

    b. Mrs. Sandra Saldanha, Whole-time Director: 29.34

    c. Mr. Varddhman Vikramaditya Jain, Whole-time Director: 109.26

2. Percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary in the financial year ended March 31, 2026:

    a) Mr. Mark Saldanha, Managing Director: -

    b) Mrs. Sandra Saldanha, Whole-time Director: -

    c) Mr. Varddhman Vikramaditya Jain, Whole-time Director: 9.76

    d) Mr. Jitendra Sharma, Chief Financial Officer: 9.33

    e) Mr. Harshavardhan Panigrahi, Company Secretary: 5.02

3. Percentage increase in the median remuneration of employees in the financial year ended March 31, 2026 in comparison to the financial year ended March 31, 2025: 4.25

4. **Number of permanent employees as on March 31, 2026 is 1,685.**

    a) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year: 12.15

    b) Percentile increase in the managerial remuneration in the last financial year:

        i. Mr. Mark Saldanha, Managing Director: -

        ii. Mrs. Sandra Saldanha, Whole-time Director: -

        iii. Mr. Varddhman Vikramaditya Jain, Whole-time Director: 27.92

        iv. Mr. Jitendra Sharma, Chief Financial Officer: - 40.06

        v. Mr. Harshavardhan Panigrahi, Company Secretary: 3.47

    c) Justification of the above: Remuneration is based on individual performance.

    d) Any exceptional circumstances for increase in the managerial remuneration: None

5. The remuneration of all the Directors, Key Managerial Personnel and other employees are as per the remuneration policy of the Company.

Annexure - F

Annexure to the Report of the Board of directors

BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT 2025-26

SECTION A: GENERAL DISCLOSURES

I. Details of the listed entity

Sr. No.	Particulars	Details
1.	Corporate Identity Number (CIN) of the Listed Entity	L24110MH1992PLC066364
2.	Name of the Listed Entity	MARKSANS PHARMA LIMITED
3.	Year of incorporation	1992
4.	Registered Office address	11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053
5.	Corporate address	11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053
6.	E-mail id	companysecretary@markanspharma.com
7.	Telephone	(022) 4001 2000
8.	Website	www.marksanspharma.com
9.	Financial Year for which reporting is being done	April 01, 2025 to March 31, 2026
10.	Name of the Stock Exchange(s) where shares are listed	National Stock Exchange of India Limited BSE Limited
11.	Paid-up Capital	Rs. 45,31,63,746
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Name: Harshavardhan Panigrahi Designation: Company Secretary Phone No.: (022) 4001 2000 E-mail ID: companysecretary@marksanspharma.com
13.	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements taken together).	Standalone
14.	Name of assurance provider	-
15.	Type of assurance obtained	-

II. Products/services

16. Details of business activities (accounting for 90% of the turnover):

Sr. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1.	Pharmaceutical Formulation	Research, manufacturing and sales of generics, speciality, OTC and Rx pharmaceutical products in pain management, upper respiratory, CVS, CNS, gastrointestinal, anti- diabetic, anti-infective, anti-allergic, oncology, etc.	100

17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

Sr. No.	Product/Service	NIC Code	% of total Turnover contributed
1.	Solid Orals, Tablets, Capsules (including Soft Gelatin Capsules), Ointments, Liquids and Creams.	2100	100

III. Operations

18. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of plants	Number of offices	Total
National	2	2	4
International	2	4	6

19. Markets served by the entity:

a) Number of locations

Locations	Number
National (No. of States)	-
International (No. of Countries)	50+

b) What is the contribution of exports as a percentage of the total turnover of the entity?

100%

c) A brief on types of customers

The Company serves a broad customer base across key therapeutic areas. These products address the needs of a wide range of patients, through a comprehensive distribution network that includes wholesalers, distributors, retail chains, pharmacy stores, hospitals and government institutions. Furthermore, the Company extends its global presence by exporting products to international markets through both its subsidiaries and third-party distributors.

IV. Employees

20. Details at the end of Financial Year:

a) Employees and workers (including differently abled):

Sr. No	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
	Employees					
1.	Permanent (D)	1159	999	86.20	160	13.80
2.	Other than Permanent (E)	72	53	73.61	19	26.39
3.	**Total employees (D + E)**	**1231**	**1052**	**85.46**	**179**	**14.54**
	Workers					
4.	Permanent (F)	526	526	100	0	0
5.	Other than Permanent (G)	478	360	75.31	118	24.69
6.	**Total workers (F + G)**	**1004**	**886**	**88.25**	**118**	**11.75**

b) Differently abled Employees and workers:

Sr. No	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
	DIFFERENTLY ABLED EMPLOYEES					
1.	Permanent (D)	0	0	0	0	0
2.	Other than Permanent (E)	0	0	0	0	0
3.	**Total differently abled employees (D + E)**	**0**	**0**	**0**	**0**	**0**
	DIFFERENTLY ABLED WORKERS					
4.	Permanent (F)	0	0	0	0	0
5.	Other than Permanent (G)	0	0	0	0	0
6.	**Total differently abled workers (F + G)**	**0**	**0**	**0**	**0**	**0**

21. Participation/Inclusion/Representation of women:

	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors	8	2	25%
Key Management Personnel	2	0	0

22. Turnover rate for permanent employees and workers (for the past 3 years):

	FY (2025-26) (Turnover rate in current FY)			FY (2024-25) (Turnover rate in previous FY)			FY (2023-24) (Turnover rate in the year prior to the previous FY)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	25.17	6.38	22.29	14.77	17.99	15.32	15	3	18
Permanent Workers	12.31	0	11.40	12.57	0	12.57	12	0	12

V. Holding, Subsidiary and Associate Companies (including joint ventures)

23. Names of holding / subsidiary / associate companies / joint ventures:

Sr. No	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1.	Marksans Pharma (UK) Limited	Subsidiary	100	No
2.	Marksans Holdings Limited	Step down Subsidiary	100	No
3.	Bell, Sons & Co. (Druggists) Limited	Step down Subsidiary	100	No
4.	Relonchem Limited	Step down Subsidiary	100	No
5.	Marksans Pharma Inc.	Subsidiary	100	No
6.	Time-Cap Laboratories Inc.	Step down Subsidiary	100	No
7.	Custom Coatings Inc.	Step down Subsidiary	100	No
8.	Marksans Realty LLC	Step down Subsidiary	100	No
9.	Marise Ann Inc.	Step down Subsidiary	100	No
10.	Nova Pharmaceuticals Australasia Pty. Ltd.	Subsidiary	60	No
11.	Nova Pharmaceuticals NZ Limited	Step down Subsidiary	100	No
12.	Access Healthcare for Medical Products LLC	Subsidiary	100	No
13.	Marksans Pharma GmbH	Subsidiary	100	No
14.	Marksans Pharma (Europe) Limited	Subsidiary	100	No
15.	Marksans (Canada) Inc.	Subsidiary	100	No

VI. CSR Details

24. i. Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes

ii. Turnover (in Rs.): 1341.47 crores

iii. Net worth (in Rs.): 1,652.31 crores

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redressal policy)	FY2025-26			FY2024-25		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	The Company reaches out to daily wage laborers, people below poverty line and other economically backward and underprivileged people in the peripheral area of its operating locations and address their food/nutritional and healthcare needs through Company's CSR initiatives. https://www.marksanspharma.com/pdf/CSR-Poilcy.pdf	Nil	NA	-	Nil	NA	-
Investors (other than shareholders)	Yes https://www.marksanspharma.com/investor-contact.html	Nil	NA	-	Nil	NA	Nil
Shareholders	Yes. https://www.marksanspharma.com/pdf/shareholders-grievance-redressal-policy.pdf	Nil	NA	-	2	Nil	-
Employees and workers	Yes. The Company has in place policies/procedures to address employees/workers grievances. These policies/procedures are internally made available to employees/workers. Besides, the Company has in place Human Rights Policy, POSH Policy and Whistle Blower Policy. https://www.marksanspharma.com/codes-policies.html	Nil	NA	-	Nil	NA	-
Customers	Yes. https://www.marksanspharma.com/adverse-event.html	Nil	NA	-	Nil	NA	-
Value Chain Partners	Yes. https://www.marksanspharma.com/adverse-event.html	Nil	NA	-	Nil	NA	-

26. Overview of the entity's material responsible business conduct issues:

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications.

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1.	Governance	Risks & Opportunity	**Risk** Companies that do not have effective corporate governance practices are often prone to fraud and mismanagement. Poor corporate governance practices weaken Company's ability to capitalise business opportunities, thereby resulting in financial losses. This may further lead to a loss of stakeholder confidence and trust as well as increased Government/ regulatory oversight/sanctions/ fines.	Implementing checks and balances to have appropriate controls and oversight responsibilities Instituting a Board and Committee structure and implementing board effectiveness measures in line with the stakeholders' long-term interests.	Negative
			Opportunity Strong corporate governance will result in increased stakeholder confidence and trust, higher ESG ratings, and stronger brand equity.		Positive
2.	Business Ethics	Risks	Non-adherence to and non-compliance with ethical standards can put pharma companies at risk of fines, penalties, damaged reputation, business disruption, regulatory sanctions and erosion of trust and market capital.	Establishing processes and controls to strengthen compliance with the Company's established codes of conduct as well as applicable policies, followed by periodic review. Institutionalising effective whistleblower and grievance redressal mechanisms. Creating a culture of following the highest standards of governance.	Negative
3.	Talent attraction And retention	Opportunity	People are the biggest asset. Attracting and retaining the right talent fuels organisational growth.		Positive

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
4.	Regulatory Compliance	Risk	Regulatory guidelines and requirements heavily regulate the manufacturing of products, including manufacturing quality standards. Periodic inspections are conducted on the Company's manufacturing sites, and if the regulatory and quality standards and systems are not found adequate, it could result in observations. This might impact company's ability to meet patient demand and generate value for the stakeholders.	Creating a strong ethical organisational culture with a focus on transparency and compliance. Regularly carrying out risk assessments and audits to identify areas of potential exposure to compliance related risks. Compliance training.	Negative
5	Return on Equity/Return to Shareholders	Opportunity	ROE reflects a company's profitability, financial health, and business resilience. Strong ROE helps a business attract investors, gain greater access to capital, and create value for stakeholders.		Positive
6	Resource Efficiency	Opportunity	Focusing on how efficiently and effectively company uses natural resources and raw materials during its manufacturing and business activities.		Positive
7	Diversity, Equity and Inclusion	Opportunity	Promoting diversity, inclusion and equity in Company, and providing fair and equal remuneration and advancement opportunities to all employees. Ensuring there is no discrimination based on race, ethnicity, caste, colour, age, sex, disability, sexual orientation and the socioeconomic status of an individual. This will enhance organizational performance because it brings together people with varying views and perspectives. This, in turn, leads to better talent attraction and retention, increases greater employee engagement and results in higher efficiency. Diversity also results in better innovation and problem-solving skills and improves talent attraction.		Positive

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
8	Waste Management	Risks & Opportunity	**Risks** Disposal of wastewater and other wastes without proper treatment leads to legal action by central & state pollution control boards and local regulatory agencies as well as may have adverse consequences on the environment.	Implement water conservation measures by deployment of water efficient equipment and processes. Ensure treatment and reuse of wastewater in various activities to reduce dependency on freshwater resources. Recycling of waste reduces dependency on natural resources. Ensure compliance with waste management rules. Adopt measures to reduce waste generation during manufacturing and packaging of products. Ensure sustainable waste management practices such as waste reused, waste recycled, co-processed and safely disposed.	Negative
			Opportunity Wastewater treatment helps in conservation of water resources thereby mitigating water related risks. Implementing waste management plans i.e. Reduce, Reuse and Recycle conserves resources and minimizes operational expenditure and brings about positive impact on environment.		Positive

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
9	Occupational Health & Safety	Risks & Opportunity	**Risks** Exposure of employees and workers to toxic or hazardous chemicals, solvents and active pharmaceutical ingredients may lead to several occupational related health diseases. Operations in the Company may involve working with heavy equipment and may pose threats of higher temperatures, chemical and physical hazards.	Identify the potential hazards at workplace such as chemical exposure, equipment operation risks, ergonomic issues and mitigate the risks by following appropriate safety practices. Conduct regular training programs on health and safety. Prepare and implement emergency preparedness plan. Ensure compliance with health & safety related laws, regulations and guidelines and Company's health and safety manual and policy. Monthly review of EHS performance metrics and safety campaigns are carried out. Ensure PPE is mandatory to all employees and workers while entering plant premises. Conduct health & safety and fire safety audits to identify and mitigate health & safety related risks.	Negative
			Opportunity Ensuring safe and healthy work environment boosts employee's morale which in turn increase operational efficiency & productivity, reduce absenteeism & turnover rates, improve quality control practices by adopting safe material handling practices.		Positive

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
10	Supply Chain Management	Risks & Opportunity	**Risks** Disruption of supply chain could potentially impact the supply and sales of products in a timely manner. Delay in supply of products to patients and health care providers may affect the treatment process. Non-availability of products in a timely manner affects the brand value and reputation of the Company.	Evaluate the suppliers on reliability, quality and compliance with the regulatory standards. Conduct regular audits of suppliers to ensure adherence to quality and safety standards. Implement digital solutions for tracking and monitoring of supply chain management for better visibility, forecasting and real time monitoring of inventory and logistics. Diversify the suppliers to mitigate the risks associated with supply chain disruptions. Develop contingency plans for timely supply of products from alternate production sites or warehouses in case of potential supply chain disruptions.	Negative
			Opportunity Efficient supply chain management system can streamline operations, reduce redundancies, effective logistics and inventory management practices. Strategic collaborations in supply chain management builds strong relationship with logistic partners, suppliers, distributors, and other partners. Optimization of resources in supply chain management minimizes operational expenditure and resources of the Company.		Positive

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
11	Research & Development	Opportunity	**Opportunity** Company's research & development activities such as new product development, new process development for finished dosage form, testing and defining quality of products, setting up specifications of developed products, current regulatory updates and conforming to the requirements, create competitive edge and facilitate in rapid expansion of business into new geographies and markets and generate additional revenue and reputation of the Company. Development of innovative pharmaceutical products addressing the unmet medical needs shows the commitment of the Company to deliver exceptional services promoting well-being of patients.		Positive
12	Product Quality & Safety	Risks & Opportunity	**Risk** Non-compliance with stringent regulatory requirements enforced by global health authorities such as US FDA, UK MHRA, Australian TGA and others can result in imposition of fines, product recalls and suspension of manufacturing licenses. Any lapses in quality control mechanisms and testing may pose a severe risk to patient health.	Adhere to Good Manufacturing Practice (GMP) compliance across all operations of the Company. Adopt pharmacovigilance processes, quality control standards and Standard Operating Procedures (SOPs) for all manufacturing processes including production, testing and packaging of products. Implement the risk mitigation plans for the potential product quality and safety risks in the life cycle of the products. Ensure regular testing of product prior to dispatch. Conduct periodic audits to ensure quality and safety of the product in line with the quality control standards.	Negative

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
			Opportunity Adhering to stringent product quality and safety standards help in getting regulatory approvals and provides access for market entry in various geographies. Fulfilling the stringent quality and safety requirements enhance the reputation and trust of the Company thereby leading to higher acceptance and demand for products.		Positive
13	Cybersecurity & Data Privacy	Risks	**Risk** Cyber-attacks may lead to theft of confidential information such as patient data, clinical results data, proprietary research and intellectual property rights etc. and hampers business growth, incurs financial loss and negatively affects the brand value and reputation of the Company. Inadequate prevention, detection, and remediation of data security threats can lead to disruption of operations, and negatively affects the reputation of the Company.	Implementation of strong IT management system with multiple controls, multi-factor authentication and protection systems such as anti-virus and firewalls to ensure data security. Implementation of strict access controls mechanisms to ensure only authorized personnel can access the confidential information. Ensure regulatory compliance. Develop an incident response plan and appropriate procedure for responding to cybersecurity incidents. Conduct regular training programs for employees on end point & network security controls and best practices to mitigate potential IT threats. Proactive monitoring and analysis of any new vulnerabilities and threats through regular scanning of systems and networks.	Negative

Sr. No	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
14	Risk Management	Opportunity	**Opportunity** Robust risk management framework for proactive identification and mitigation of business risks help in achieving business resilience of the Company. Mitigation of enterprise related risks in timely manner improves operational efficiency and productivity of the Company.		Positive
15	Access to new markets and affordability of medicines	Opportunity	**Opportunity** Expanding access to underserved markets present a strong growth opportunity by increasing sales, revenue, and market share. Enhancing the availability and affordability of medicines strengthen brand reputation and supports better public health outcomes. These efforts also align with global health priorities, government tenders, and inclusion in national health programs, further driving business growth.		Positive

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
Policy and management processes									
1. a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes								
b. Has the policy been approved by the Board? (Yes/ No)	Yes, the Company has developed comprehensive policies covering these principles, and some of the policies have been approved by the Board as per relevant statutory requirements.								
c. Web Link of the Policies, if available	http://marksanspharma.com/codes-policies.html Some of the Company's codes/policies/procedures are available on the Company's website in the above link in compliance with applicable regulatory requirements. Other codes/policies/procedures are internally made available to employees/workers/other stakeholders concerned.								
2. Whether the entity has translated the policy into procedures. (Yes / No)	Yes								
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes. Some of the policies relevant to value chain partners extend to them.								
4. Name of the national and international codes/ certifications/labels/ standards (e.g. Forest Stewardship Council, Rainforest Alliance Trustee) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	The Company adheres to cGMP standards and norms of international health regulatory authorities such as USFDA, UKMHRA, Australian TGA, WHO, etc. Additionally, the Company's plants have also undergone Sedex Members Ethical Trade Audit (SMETA) covering labour standards, health & safety, environment and business ethics and Supplier Compliance Audit Network (SCAN) audits.								
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	1. To increase use of recycled packaging materials. 2. To explore avenues for using renewable energy in the plants. 3. To reduce NOx, SOx and Particulate Matter air emissions. 4. To reduce scope 1 and scope 2 greenhouse gas emissions. 5. To increase waste recovery through recycling.								
6. Performance of the entity against specific commitments, goals and targets along-with reasons in case the same are not met.	1. Use of recycled packaging materials increased by over 400%. 2. There is considerable reduction in NOx and Particulate Matter air emissions. 3. There is considerable reduction in Scope 1 greenhouse gas emission. 4. Use of recycled waste water and other materials has increased.								
Governance, leadership and oversight									
7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements. Refer to the Chairman's address in the Annual Report.									
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy(ies).	Mr. Mark Saldanha Chairman & Managing Director								
9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	Currently Mr. Mark Saldanha, Chairman & Managing Director oversees the sustainability related issues.								

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9

10. Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
Performance against above policies and follow up action	Yes									Annually/Biennially								
Compliance with statutory requirements of relevance to the principles, and rectification of any non-compliances	Yes									Whenever required								

11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No) If yes, provide name of the agency.	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
	No. The Company internally reviews the working of its codes/policies/ procedures.								

12. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated:

Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
The entity does not consider the principles material to its business (Yes/No)	Not Applicable								
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)									
The entity does not have the financial or/human and technical resources available for the task (Yes/No)									
It is planned to be done in the next financial year (Yes/No)									
Any other reason (please specify)									

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

PRINCIPLE 1

Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

The Company has in place policies and procedures to ensure a high level of governance and ethics, transparency and accountability in business transactions. The Company has also in place a whistle blower policy under which directors and employees can report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct. During the year, the Company has not received any complaints about unethical practices.

Essential Indicators

1. Percentage coverage by training and awareness programs on any of the principles during the financial year:

Segment	Total number of training and awareness programs held	Topics / principles covered under the training and its impact	% age of person in respective category covered by the awareness programs
Board of Directors	1	The Company conducts familiarization programmes for its Directors on an annual basis covering their roles, functions, responsibilities and duties.	100
Key Managerial Personnel	1	KMPs are imparted professional training through programmes conducted by respective professional bodies such as ICAI and ICSI.	100
Employees other than BOD and KMPs	2	Employees undergo orientation programme during which they are apprised of the HR manuals and policies, company's codes of conduct and various policies. During the said orientation, the Company also conducts training programme covering their roles, functions, responsibilities and duties. The above orientation programme is conducted when an employee joins the Company as well as once every year.	100

Segment	Total number of training and awareness programs held	Topics / principles covered under the training and its impact	% age of person in respective category covered by the awareness programs
Workers	2	Workers undergo orientation programme during which they are apprised of the HR manuals and policies, company's codes of conduct and various policies. During the said orientation, the Company also conducts training programme covering their roles, functions, responsibilities and duties. The above orientation programme is conducted when a worker joins the Company as well as once every year.	100

2. **Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):**

Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine	Nil	-	-	-	-
Settlement	Nil	-	-	-	-
Compounding fee	Nil	-	-	-	-

Non-Monetary				
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	None	-	-	-
Punishment	None	-	-	-

3. **Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed:**

Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
Not Applicable	

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide web-link to the policy:**

Yes. Marksans' Bribery and Facilitation Payment Policy emphasize on zero tolerance approach to bribery and corruption. The policy provides information and guidance on how to recognize and deal with bribery and corruption issues. It guides the employees to act professionally, fairly and with utmost integrity in all business dealings and relationships, wherever the Company operates. https://www.marksanspharma.com/pdf/anti-corruption-policy.pdf

5. **Number of Directors/KMPs/Employees/Workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:**

	FY 2025-26	FY 2024-25
Directors	Nil	Nil
KMPs		
Employees		
Workers		

6. **Details of complaints with regard to conflict of interest:**

	FY 2025-26		FY 2024-25	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of Directors	Nil	-	Nil	-
Number of complaints received in relation to issues of Conflict of Interest of KMPs	Nil	-	Nil	-

7. **Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest:**

Not Applicable

8. **Number of days of accounts payables (Accounts payable *365)/ Cost of goods/services procured) in the following format:**

	FY 2025-26	FY 2024-25
Number of days of accounts payables	97	116

9. **Open-ness of business:**

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics	FY 2025-26	FY 2024-25
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	Nil	Nil
	b. Number of trading houses where purchases are made from	Nil	Nil
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	Nil	Nil
Concentration of Sales	a. Sales to dealers / distributors as % of total sales	7.04	11
	b. Number of dealers / distributors to whom sales are made	27	17
	c. Sales to top 10 dealers / distributors as % of total sales to dealers / distributors	87	75
Share of RPTs in	a. Purchases (Purchases with related parties / Total Purchases)	Nil	Nil
	b. Sales (Sales to related parties / Total Sales)	90	87
	c. Loans & advances (Loans & advances given to related parties / Total loans & advances)	Nil	Nil
	d. Investments (Investments in related parties / Total Investments made)	100% (investments are only in subsidiaries)	100% (investments are only in subsidiaries)

Leadership Indicators

1. Awareness programs conducted for value chain partners on any of the principles during the financial year:

Total number of awareness programs held	Topics / principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programs
	Nil	

2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If yes, provide details of the same:

Yes. The Company has in place policies and procedures to ensure a high level of governance and ethics, transparency and accountability in business transactions. The Company has also in place a whistle blower policy under which directors and employees can report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct and policies. The Company has also in place a comprehensive Code of Conduct for Directors and Senior Management. Every Board member discloses the names of the entities or arrangements in which they are interested which is brought to the attention of the Board. The Company does not enter into any business dealings with the Directors and KMPs, or anybody or individuals, where they have interest, that may have any potential conflict with the interest of the Company.

PRINCIPLE 2

Businesses should provide goods and services in a manner that is sustainable and safe

With strong R&D capability, the Company manufactures quality products that meet the standards of major health authorities globally. The Company has a relentless focus on Quality Control and Quality Assurance. Strict adherence to cGMP norms as well as our efforts towards continuous improvement of product, process and the skill of work force enables us to improve our offerings to our customers and consumers on a regular basis. The Company makes optimum utilization of resources in its manufacturing processes.

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively:

	Current Financial Year (FY 2025-26)	Previous Financial Year (2024-25)	Details of improvements in environmental and social impacts
R&D	-	-	
Capex	-	-	

*Note: The Company is planning to install solar panels to generate clean energy for its plants in Goa.

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes. Raw Materials/formulations are sourced from suppliers approved by regulatory authorities.

b. If yes, what percentage of inputs were sourced sustainably?

Majority of raw materials/formulations are sourced from sustainable suppliers.

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for

a) Plastics (including packaging) –

The waste generated is given to the authorized scrap dealer Re-processor.

b) E-waste –

E-waste generated is given to Authorized recycler.

c) **Hazardous waste –**

Hazardous waste (including Other Hazardous Waste as ETP Sludge, Date Expiry Products, OFF specification products) generated such as used / spent oil is given to the authorized recycler for recycling and the process waste & residue generated is sent to the authorized cement industry for co processing.

d) **Other waste –**

NA

4. **Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No) – Yes**

If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? - Yes.

Leadership Indicators

1. **Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? -** No

If yes, provide details in the following format:

NIC Code	Name of Product / Service	% of total Turnover contributed	Boundary for which the Life Cycle Perspective / Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link
-	-	-	-	-	-

2. **If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same:**

Name of Product / Service	Description of the risk / concern	Action Taken
NA	-	-

3. **Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry):**

Indicate input material	Recycled or re-used input material to total material	
	FY 2025-26	FY 2024-25
None	In pharmaceutical Industry, we can't use recycled or reused input materials in the manufacturing process due to contamination issues as well as the nature of products.	

4. **Of the products and packaging reclaimed at end of life of products, amount (in metric tons) reused, recycled, and safely disposed, as per the following format:**

	FY 2025-26			FY 2024-25		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	0	283.578	0	0	68.762	0
E-waste	0	0.766	0	0	0.510	0
Hazardous waste	0	38.500	808.530	0	1.000	773.350
Other waste	0	0	4.958	0	0	0

5. Reclaimed products and their packaging materials (as percentage of products sold) for each product category:

Indicate product category	Reclaimed products and their packaging materials as % of total products sold in respective category
None	-

PRINCIPLE 3

Businesses should respect and promote the well-being of all employees, including those in their value chains

The Company is committed to ensuring safety, sound health and overall wellbeing of the employees at all the workplaces. The Company provides equal opportunity in employee recruitment irrespective of caste, creed, gender, race and religion. The Company does not employ child labor, forced labor, or any form of involuntary labor. It provides a healthy work environment for its employees.

The Company is fully committed to uphold and maintain dignity of women working in the Company and has zero tolerance towards any actions which may fall under the ambit of sexual harassment at workplace. To ensure this, the Company has in place a Prevention of Sexual Harassment Policy.

As on March 31, 2026, the Company has 160 women employees out of the total permanent employee strength of 1685 (These include workers).

No complaint pertaining to child labor, forced labor or involuntary labor was reported during the year. Further, no complaint related to sexual harassment of woman at the workplace was received.

Safety and skill upgradation training is imparted to the employees periodically.

Essential Indicators

1. a. Details of measures for the well-being of employees:

Category	Total (A)	% of employees covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A
Permanent employees											
Male	999	999	100%	999	100	-	-	-	-	-	-
Female	160	160	100%	160	100	160	100	-	-	-	-
Total	**1159**	**1159**	**100%**	**1159**	**100**	**160**	**100**	**-**	**-**	**-**	**-**
Other than Permanent employees											
Male	53	53	100%	53	100	-	-	-	-	-	-
Female	19	19	100%	19	100	19	100	-	-	-	-
Total	**72**	**72**	**100%**	**72**	**100**	**19**	**100**	**-**	**-**	**-**	**-**

b. Details of measures for the well-being of workers:

Category	Total (A)	% of workers covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A
Permanent workers											
Male	526	526	100%	526	100%	-	-	-	-	-	-
Female	0	0	-	0	-	-	-	-	-	-	-
Total	**526**	**526**	**100%**	**526**	**100%**	**-**	**-**	**-**	**-**	**-**	**-**
Other than Permanent workers											
Male	360	360	100%	360	100%	-	-	-	-	-	-
Female	118	118	100%	118	100%	118	100%	-	-	-	-
Total	**478**	**478**	**100%**	**478**	**100%**	**118**	**100%**				

c. **Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format –**

	FY 2025-26	FY 2024-25
Cost incurred on well-being measures as a % of total revenue of the company	0.05%	0.05%

2. **Details of retirement benefits, for Current FY and Previous Financial Year:**

Benefits	FY 2025-26			FY 2024-25		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100	100	y	100	100	y
Gratuity	100	100	y	100	100	y
ESI	39.00	84.50	y	40.79	42.25	y
Others – please specify	-	-	-	-	-	-

3. **Accessibility of workplaces:**

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard

Yes

4. **Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web link to the policy:**

Yes

https://www.marksanspharma.com/pdf/human-rights-policy.pdf

5. **Return to work and Retention rates of permanent employees and workers that took parental leave:**

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	100%	100%	100%	100%
Female	100%	100%	100%	100%
Total	**100%**	**100%**	**100%**	**100%**

6. **Is there a mechanism available to receive and redress grievances for the following categories of employees and workers? If yes, give details of the mechanism in brief:**

Yes

	Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Workers	Yes
Other than Permanent Workers	
Permanent Employees	
Other than Permanent Employees	

The organization has a Whistle Blower policy in place which provides all employees and workers an opportunity to raise any issues/ grievances anonymously, where the identity of the whistleblower is kept confidential. A dedicated email ID has been created at an organizational level, to which the employee and workers can write their concerns. A dedicated single point contact (SPOC) is assigned to look into all matters independently and fairly.

Marksans Pharma has established a well-placed process for addressing employee grievances. An employee with a grievance can reach out to his immediate superior as the first point of contact. In case of no resolution, the respective business HR is the next point of contact, responsible for investigation and resolution in a fair & transparent manner.

For POSH-related matters, the employee is expected to raise it with the HR team or to the dedicated email ID for the Internal Committee. This can be escalated to the Chairperson of the Internal Committee. The final level of escalation is to the HR Head of the organization.

7. Membership of employees and workers in association(s) or Unions recognized by the listed entity:

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category (A)	No. of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees / workers in respective category, who are part of association(s) or Union (D)	% (D / C
Total Permanent Employees	**1159**	**0**	**0**	**1349**	**0**	**0**
- Male	999	0	0	1196	0	0
- Female	160	0	0	153	0	0
Total Permanent Workers	**526**	**0**	**0**	**491**	**0**	**0**
- Male	526	52	9.88	491	90	18.33
- Female	0	0	0	0	0	0

8. Details of training given to employees and workers:

Category	FY 2025-26					FY 2024-25				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Male	999	999	100	0	0	1196	1196	100	0	0
Female	160	160	100	0	0	153	153	100	0	0
Total	**1159**	**1159**	**100**	**0**	**0**	**1349**	**1349**	**100**	**0**	**0**
Workers										
Male	526	526	100	0	0	491	491	100	0	0
Female	0	0	100	0	0	0	0	0	0	0
Total	**526**	**526**	**100**	**0**	**0**	**491**	**491**	**100**	**0**	**0**

9. Details of performance and career development reviews of employees and workers:

Category	FY 2025-26			FY 2024-25		
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	% (D / C)
Employees						
Male	999	999	100	1196	1196	100
Female	160	160	100	153	153	100
Total	**1159**	**1159**	**100**	**1349**	**1349**	**100**
Workers						
Male	526	526	100	491	491	100
Female	0	0	100	0	0	0
Total	**526**	**526**	**100**	**491**	**491**	**100**

10. Health and safety management system:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?

- Yes, the Company has an Occupational Health and Safety Management system implemented at our site covering the following but not limited to:

  1. Occupational Safety and Health Policy
  2. OS&H Organizational Setup
  3. Education and Training
  4. Employee Participation in OS&H Management
  5. Motivational and Promotional Measures for OS&H
  6. Safety Manual and Rules
  7. Compliance of Statutory Requirements
  8. Accident reporting, analysis, investigation and implementation of recommendation.
  9. Risk Assessment including Hazard Identification
  10. Safety inspections
  11. First aid facility - Occupational Health Centre
  12. Personal Protective Equipment
  13. Ventilation, Illumination and Noise
  14. Work Permit System
  15. Fire Prevention, Protection and Fighting System
  16. Hazardous waste Treatment and Disposal
  17. Emergency Preparedness Plans

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

- The Company has a process for Risk Management which is essential for preventing incidents, injuries, occupational disease, emergency preparedness and business continuity. There is a structured Risk Assessment and Management process which is regularly reviewed, and mitigation plans are put in place to reduce the risk. For all the activities including routine or non-routine, hazards are identified by a trained cross functional tram and risk assessment is done through standard operating procedures (SOP) which is referred to before starting any activity. Identified hazards and associated risks are addressed through operational control measures using hierarchy of control approach.

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)

- Yes, we have Safety Suggestion Schemes for employees/workers to report work related hazards and Suggestion box is provided at prime location. Also, we have Grievance Committee to address any work related hazards.

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)

Yes

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category*	FY 2025-26	FY 2024-25
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	0	0
	Workers	0	0
Total recordable work-related injuries	Employees	0	0
	Workers	0	0
No. of fatalities	Employees	0	0
	Workers	0	0
High consequences for work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	0

*Including in the contract workforce

12. Describe the measures taken by the entity to ensure a safe and healthy workplace:

The Company undertakes periodic internal and external audits to assess the safety practices and procedures. The Company endeavors to prevent negative health impact on the employees through the provision of medical facilities and medical insurance benefits.

13. Number of Complaints on the following made by employees and workers:

	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	0	0		0	0	
Health & Safety	0	0		0	0	

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100%. Occupational Health and Safety audit is conducted once in three years through competent person authorized by Inspectorate of Factories & Boilers, Govt. of Goa.
Working Conditions	100%. An industrial hygiene survey is conducted through competent person authorized by Inspectorate of Factories & Boilers, Govt. of Goa which includes illumination, noise and ventilation of working conditions. Further, safety audit and Hygiene study was conducted in January 2025.

15. Provide details of any corrective action taken or underway to address safety related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions:

Not Applicable

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of :

(A) Employees (Y/N)

Yes, Company has medical insurance scheme which covers the employees & their families. The Company also has in place a group accidental policy for the employees of the Company.

(B) Workers (Y/N)

Yes, Covered under Employee State Insurance Corp. Scheme & Medical insurance scheme.

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners:

- The Company reviews and checks monthly statutory dues deducted and deposited by the value chain partners.
- The Company also conducts monthly audit and verifies statutory registers such as wage register, muster roll, online challan, etc of its value chain partners.

3. Provide the number of employees / workers having suffered high consequences for work-related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Employees	Nil	Nil	NA	NA
Workers	Nil	Nil	NA	NA

4. **Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)**

   Yes

5. **Details on assessment of value chain partners:**

	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	NIL
Working Conditions	NIL

6. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners:**

   Not Applicable.

PRINCIPLE 4

Businesses should respect the interests of and be responsive to all their stakeholders

The company provides its highest attention to the needs of disadvantaged and marginalized stakeholders and has mapped its internal and external stakeholders.

Essential Indicators

1. **Describe the processes for identifying key stakeholder groups of the entity:**

   Marksans Pharma believes in partnering with its various stakeholders to build shared value and uses a structured approach of stakeholder identification. The Company's stakeholders include both individuals and organizations, within and outside the Company, who are significantly impacted by its business operations. Marksans ongoing engagements are designed to determine the needs and priorities of stakeholders, communicate the Company's efforts to fulfill their expectations, and provide speedy resolution of grievances. Marksans uses a variety of structured engagement channels to gain insights into stakeholder views and concerns.

2. **List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group:**

Stakeholder Group	Whether identified as Vulnerable &Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
1. Employees and workers	No	Telephones, SMSs, E-mails, Notice Board, Personal Meetings, Website, etc.	Quarterly, Monthly (need based)	• Talent management • Employee engagement • Learning and development • Productivity • Work-life balance • Staff welfare and Health & Safety • Remuneration and employee benefits

Stakeholder Group	Whether identified as Vulnerable &Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
2. Suppliers	No	Telephones, SMSs, E-mails, Personal Meetings, Website, etc.	Monthly, Quarterly and Annually (need based)	• Fair contractual terms and adherence thereto • Organizational ESG consciousness • Transparent, ethical and long-term business relations • Regular exchange of technical know-how
3. Distributors	No	Telephones, SMSs, E-mails, Personal Meetings, Website, etc.	As per prevalent need	• As per prevalent need
4. End Customers	Yes	Telephones, SMSs, E-mails, Website, etc.	Monthly, Quarterly and Annually (need based)	• Effective customer grievance redressal mechanism • Maintaining customer data privacy and security • Suitability of products and service • Transparent and fair advice • Providing quality products
5. Shareholders	No	E-mails, newspapers, website, stock exchanges, investors presentation, investors calls, shareholders meeting	Quarterly, annually and event based	• Market outlook • Business strategy • Operational efficiency • Long-term business performance • ESG/Market risks and opportunities in business • Technology in business
6. Regulators	No	E-mail, Physical Documents, Physical visits	Need based	• Compliance with rules and regulations • Corporate governance framework • Long-term business performance • Financial performance • Prudent business practices

Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board:**
   - The Company has always maintained a constant and proactive engagement with our key stakeholders that enables the Company to better communicate its strategies and performance. Continuous engagement helps align expectations, thereby enabling the Company to better serve its stakeholders. The Board is kept abreast of various developments and feedback on the same is sought from the Directors.

2. **Whether stakeholder consultation is used to support the identification and management of environmental and social topics (Yes / No). If so, provide details of instances as to how the input received from stakeholders on these topics was incorporated into policies and activities of the entity:**
   - Yes.

     Marksans Pharma has established channels for active engagement with all stakeholder groups. It is through this continued practice that the Company is offering competitive edge with the brand trust. We interact with critical stakeholders on a regular basis to ensure that our business is aligned with the stakeholder interests in a sustainable manner while being a profitable proposition. Based on such discussions with the investment community, we have aligned our goals on environmental management and amended our Policies and internal systems for environmental management.

3. **Provide details of instances of engagement with, and actions taken to address the concerns of vulnerable/ marginalized stakeholder groups:**

   Marksans Pharma has fostered an active engagement channel with end customers for addressing any grievances relating to our products and assisting them in every way possible.

PRINCIPLE 5

Businesses should respect and promote human rights

Marksans believes that all its employees live with social and economic dignity and freedom regardless of nationality, gender, race, economic status or religion. All its business associates, like suppliers, service providers and customers, should be treated likewise and also they should not suffer in any respect due to any action or inaction of the Company. Therefore, Marksans ensure that they uphold the spirit of human rights. Marksans believes business should support the protection of internationally proclaimed human rights and make sure to not be complicit in human right abuses. The Company has in place a policy on the protection of human rights. During the year, the Company has not received any complaints about human rights violation.

Essential Indicators

1. **Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:**

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category (A)	No. of employees / workers covered (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees / workers covered (D)	% (D / C
Employees						
Permanent	1159	1159	100%	1349	1349	100%
Other than permanent	72	72	100%	124	124	100%
Total Employees	**1231**	**1231**	**100%**	**1473**	**1473**	**100%**
Workers						
Permanent	526	526	100%	491	491	100%
Other than permanent	478	478	100%	693	693	100%
Total Workers	**1004**	**1004**	**100%**	**1184**	**1184**	**100%**

2. **Details of minimum wages paid to employees and workers, in the following format:**

Category	FY 2025-26					FY 2024-25				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Permanent	1159	99	8.54	1060	91.46	1349	193	14.31	1156	85.69
Male	999	79	7.91	920	92.09	1196	163	13.62	1033	86.38
Female	160	20	12.5	140	87.5	153	30	19.61	123	80.39
Other than Permanent	72	62	86.11	10	13.89	124	124	100	0	0
Male	53	45	84.91	8	15.09	93	93	100	0	0
Female	19	17	89.48	2	10.52	31	31	100	0	0
Workers										
Permanent	526	196	37.26	330	62.74	491	41	8.35	450	91.65
Male	526	196	37.26	330	62.74	491	41	8.35	450	91.65
Female	0	0	0	0	0	0	0	0	0	0
Other than Permanent	478	478	100	0	0	693	693	100	0	0
Male	360	360	100	0	0	603	603	100	0	0
Female	118	118	100	0	0	90	90	100	0	0

3. **Details of remuneration/salary/wages:**

a. **Median remuneration / wages:**

	Male		Female	
	Number	Median remuneration /salary/wages of respective category	Number	Median remuneration/ salary/wages of respective category
Board of Directors (BOD)	2	4,52,28,552.00	1	70,69,164.00
Key Managerial Personnel	2	1,13,77,612.00	0	-
Employees other than BOD and KMP	1260	2,48,890.71	193	2,51,674.90
Workers	727	2,29,113.60	26	1,65,990.21

* Median remuneration for workers and employees other than BOD& KMP who are in payroll for more than 90 days have been taken in calculation.

b. **Gross wages paid to females as % of total wages paid by the entity, in the following format:**

	FY 2025-26	FY 2024-25
Gross wages paid to females as % of total wages	8.91%	9.20%

4. **Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)**

Yes

The Company has a Whistle Blower policy in place to encourage employees to report issues without fear of retaliation, discrimination, or disadvantage. Through designated channels, the employees may report their concerns to the Chairman of the Company's Audit Committee, or the Company Secretary. The employees may further report their grievances to the HR team. Additionally, POSH Members serve as the focal point for resolving issues related to discrimination and its effects.

5. **Describe the internal mechanisms in place to redress grievances related to human rights issues:**

The Organization has multiple policies and platforms to address the employee grievances related to human rights. These are as under:

i. **Human Resource (HR) Assistance:** Every geography/business facility of the Company has dedicated HR personnel who can be reached out by respective employees to raise any concerns or grievances with respect to any human rights issue, or otherwise. In case the issue remains unresolved, an escalation matrix is defined to enable employees to reach out to the next level authorities.

ii. **Whistle Blower (WB) Policy:** The organization has a WB policy in place which provides all employees with an option and opportunity to raise any issues/grievances anonymously, where the identity of the whistle blower is kept confidential.

iii. **Prevention of Sexual Harassment Guidelines (POSH):** With an aim to provide a safe and equal opportunity to both the genders, the organization has in place the guidelines for POSH. The Organization aims to create awareness from time to time so that any untoward situation of harassment is witnessed, one can reach out to the Internal Committee of the Organization. Employees can also reach out to the HR team alternatively to report the matter. An Internal committee is formed for each plant/office as prescribed by POSH Act to conduct investigation and take necessary action, as and when required.

6. Number of Complaints on the following made by employees and workers:

Category	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	0	0	-	0	0	-
Discrimination at workplace	0	0	-	0	0	-
Child Labour	0	0	-	0	0	-
Forced Labour/Involuntary Labour	0	0	-	0	0	-
Wages	0	0	-	0	0	-
Other human rights related issues	0	0	-	0	0	-

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2025-26	FY 2024-25
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	NIL	NIL
Complaints on POSH as a % of female employees / workers	NIL	NIL
Complaints on POSH upheld	NA	NA

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases:

To safeguard the complainant against any adverse consequences, the Company maintains utmost confidentiality of the Complainant. All related parties against whom the Complaint has been reported are sensitized of any retaliatory action against the complainant. In case any incident of retaliation is observed or brought to notice of the management, Company takes appropriate action on the reported matter and ensures that the complainant does not undergo adverse consequences.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Not applicable

10. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labor	The Company does not employ child labor, forced labor, involuntary labor, or any other sort of discriminatory hiring practices. Marksans Pharma complies with all relevant legal requirements. Currently, no external audits are carried out.
Forced/involuntary labor	
Sexual harassment	
Discrimination at workplace	
Wages	
Others – please specify	

11. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above:**

NA

Leadership Indicators

1. **Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints:**

Not Applicable

2. **Details of the scope and coverage of any Human rights due diligence conducted:**

At present, no such exercise has been conducted in the reporting period.

3. **Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?**

Yes

4. **Details on assessment of value chain partners:**

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Sexual Harassment	-
Discrimination at workplace	-
Child Labor	-
Forced Labor/Involuntary Labor	-
Wages	-
Others – please specify	-

5. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above:**

Not Applicable

PRINCIPLE 6 Businesses should respect and make efforts to protect and restore the environment

The Company continuously endeavors to protect the environment through all possible ways. Company's processes are more resource efficient, use renewable energy sources and minimize release of waste in the environment. Emissions/Wastes generated by the Company are within the permissible limits and during the year, the Company has not received any show cause or legal notice on environment issue. The Company's plants are in compliance with environmental regulations.

Essential Indicators

1 **Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:**

Parameter	FY 2025-26 (MJ)	FY 2024-25 (MJ)
From renewable sources		
Total electricity consumption (A)	0	0
Total fuel consumption (B)	0	0
Energy consumption through other sources (C)	0	0
Total energy consumed from renewable sources (A+B+C)	**0**	**0**

Parameter	FY 2025-26 (MJ)	FY 2024-25 (MJ)
From non-renewable sources		
Total electricity consumption (D)	126689814	110157473.56
Total fuel consumption (E)	17046100	20246248
Energy consumption through other sources (F)	120510773	31814446
Total energy consumed from non-renewable sources (D+E+F)	**264246687**	**162218167.56**
Total energy consumed (A+B+C+D+E+F)	**264246687**	**162218167.56**
Energy intensity per rupee of turnover (Total energy consumed / Revenue from operations) MJ/Rs.	0.01969819842	0.01381316573
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total energy consumed / Revenue from operations adjusted for PPP)	0.40066135587	0.28538000401
Energy intensity in terms of physical output (MJ/Ton of Product)	31822.57	28369.73
Energy intensity (optional) – the relevant metric may be selected by the entity	-	-

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency:

No

2. **Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any:**

   No

3. **Provide details of the following disclosures related to water, in the following format:**

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)		
i. Surface water	0	0
ii. Groundwater	598	210
iii. Third party water	177436	123141.80
iv. Seawater / desalinated water	0	0
v. Others	0	67458
Total volume of water withdrawal (in kiloliters) (i + ii + iii + iv + v)	**178034**	**190809.80**
Total volume of water consumption (in kiloliters)	178034	190809.80
Water intensity per rupee of turnover (Total water consumption / Revenue from operations)	0.00001327150	0.00001624779
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total water consumption / Revenue from operations adjusted for PPP)	0.00026994224	0.00033567942
Water intensity in terms of physical output (KL/Ton of Product)	21.44	33.37
Water intensity (optional) – the relevant metric may be selected by the entity	-	-

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

4. Provide the following details related to water discharged:

Parameter	FY 2025-26	FY 2024-25
Water discharge by destination and level of treatment (in kilolitres)		
i. To Surface water		
• No treatment	0	0
• With treatment – please specify level of treatment	58361	53995
ii. To Groundwater		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
iii. To Seawater		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
iv. Sent to third parties		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
v. Others		
• No treatment	0	0
• With treatment – please specify level of treatment	0	0
Total water discharged (in kilolitres)	**58361**	**53995**

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation:

Yes, the ETP treated water is used for Gardening purpose.

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Air Emission (Consolidated)

Parameter	Please specify unit	FY 2025-26	FY 2024-25
NOx	g/kw-hr	342.34	519.57
SOx	kg/hr	61.04	6.54
Particulate matter (PM)	g/kw-hr	517.66	758.19
Persistent organic pollutants (POP)	NA	NA	NA
Volatile organic compounds (VOC)	NA	NA	NA
Hazardous air pollutants (HAP)	NA	NA	NA
Others – please specify	NA	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

Yes,

M/s. Sadekar Enviro Engineering Pvt. Ltd

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tons of CO2 equivalent	1164.72	19912.486
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tons of CO2 equivalent	30290.73	1530.493
Total Scope 1 and Scope 2 emission intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	MT/ Rs.	0.0000023448	0.0000018259

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	MT/Revenue adjusted to PPP	0.00004769401	0.00003772325
Total Scope 1 and Scope 2 emission intensity in terms of physical output (MT/Ton of Product)	(MT/Ton of Product)	3.78	3.75
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	-	-	-

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency?

No

(Y/N) If yes, name of the external agency.

8. Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details:

Yes, we have an energy management policy in place and we monitor the targets annually.

9. Provide details related to waste management by the entity, in the following format:

Parameter	FY 2025-26	FY 2024-25
Total Waste generated (in metric tonnes)		
Plastic waste **(A)**	283.578	114.502
E-waste **(B)**	0.696	0.511
Bio-medical waste **(C)**	4.978	1.770
Construction and demolition waste **(D)**	0	0
Battery waste **(E)**	0	0
Radioactive waste **(F)**	0	0
Other Hazardous waste. Please specify, if any. **(G)**	515.100	0
Other Non-hazardous waste generated (H) Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)	660.852	436.860
Total (A+B + C + D + E + F + G + H)	**1465.204**	**553.643**
Waste intensity per rupee of turnover (Total waste generated / Revenue from operations)	0.00000010922	0.00000004714
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated / Revenue from operations adjusted for PPP)	0.00000222160	0.00000097398
Waste intensity in terms of physical output (MT/Ton of Product)	0.17	0.09
Waste intensity (optional) – the relevant metric may be selected by the entity	-	-
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste		
i. Recycled	111.189	68.762
ii. Re-used	0	0
iii. Other recovery operations	0	0
Total	**111.189**	**68.762**
For each category of waste generated, total waste disposed of by nature of disposal method (in metric tons)		
i. Incineration	0	0
ii. Landfilling	0	0
iii. Other disposal operations	1463.59	801.65
Total	**1463.59**	**801.65**

*PPP – IMF conversion factors for FY2026: 20.34 and FY2025: 20.66

(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

Yes. By Hazardous Waste Management Systems

10. **Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such waste:**

Hazardous Waste disposal is done through GSPCB authorized vendor as per the Environment Protection Act 1986 guidelines. A manifest system (form 10 and form 9) as per rule 19 for disposal of hazardous waste is endorsed by dispatchers, transporters and receiver of hazardous waste. The endorsed copy is submitted to GSPCB on the official website

11. **If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:**

Sr. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
Not Applicable			

12. **Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:**

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
Not Applicable since we have the Consent issued by GSPCB.					

13. **Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:**

Sr. No.	Specify the law / regulation / guidelines which were not complied with	Provide details of the non- compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
The Company is in compliance with all applicable laws as per mandatory requirements.				

Leadership Indicators

1. **Water withdrawal, consumption and discharge in areas of water stress (in kiloliters):**

For each facility / plant located in areas of water stress, provide the following information:

i. Name of the area - Not Applicable

ii. Nature of operations - Not Applicable

iii. Water withdrawal, consumption and discharge in the following format:

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)	NA	NA
i. Surface water		
ii. Groundwater		
iii. Third party water		
iv. Seawater / desalinated water		
v. Others		
Total volume of water withdrawal (in kiloliters)		
Total volume of water consumption (in kiloliters)		
Water intensity per rupee of turnover		
(Water consumed / turnover)		
Water intensity (optional) – the relevant metric may be selected by the entity		
Water discharge by destination and level of treatment (in kiloliters)	NA	NA
1. Into Surface water		
• No treatment		
• With treatment – please specify level of treatment		
2. Into Groundwater		
• No treatment		
• With treatment – please specify level of treatment		
3. Into Seawater		
• No treatment		
• With treatment – please specify level of treatment		
4. Sent to third parties		
• No treatment		
• With treatment – please specify level of treatment		
5. Others		
• No treatment		
• With treatment – please specify level of treatment		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

NA

2. **Please provide details of total Scope 3 emissions and their intensity, in the following format:**

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tons of CO2 equivalent	-	-
Total Scope 3 emissions per rupee of turnover	MT/Rs. mn	-	-
Total Scope 3 emission intensity (optional) – the relevant metric may be selected by the entity	-	-	-

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N):

No

3. **With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities:**

Not Applicable

4. **If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:**

Sr. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along with summary)	Outcome of the initiative
1.	Upgradation & Separation of existing STP from ETP	Presently ETP and STP are clubbed as one unit, but problems are encountered below. 1) Final treated / Recycled Water is not clear and remains turbid, though the Ph and other parameters are within limits. 2) Due to mixing of Effluents and Sewage water, biomass increases and remains on higher side @70% (Limit is 30 to 40%) thus increasing the load and more consumption of treatment chemicals. 3) Increased power consumption	1) The cost of chemicals used for treatment will be reduced. 2) Savings in power bills. 3) Hazardous Sludge will be reduced by reducing the disposal cost. 4) Saving in cost of additional tanker requirement for disposing of excess effluents. 5) Biomass of ETP water will be maintained within limits. 6) The quality of treated water will be improved. 7) Requirement of additional tankers to dispose of the excess effluents will be eliminated

5. **Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link:**

Yes.

Marksans Business Continuity is the creation of a plan to resume its critical business processes after a disruption. The goal of the plan is to prevent loss of life, reduce property damage and minimise the impact on the overall business functions. The overall objective of the plan is to provide the information and procedures necessary to rapidly respond to a disaster or emergency situation, notify necessary trained personnel, assemble business recovery teams, rapidly recover services to clients, and to rapidly resume normal business functions.

6. **Disclose any significant adverse impact on the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard?**

None

7. **Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts:**

None

PRINCIPLE 7

Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

The Company is a member of Bombay Chamber of Commerce and does participate in presenting industry-related issues to the Government.

Essential Indicators

1. a. **Number of affiliations with trade and industry chambers/ associations:**

One

b. **List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to:**

Sr. No	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National)
1.	Bombay Chamber of Commerce	National

2. **Provide details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based on adverse orders from regulatory authorities:**

Name of authority	Brief of the case	Corrective action taken
Not Applicable		

Leadership Indicators

1. **Details of public policy positions advocated by the entity:**

Sr. No	Public policy advocated	Method resorted for such advocacy	Whether information is available in public domain? (Yes/No)	Frequency of Review by Board (Annually/ Half yearly/ Quarterly / Others – please specify)	Web Link, if available
Not Applicable					

PRINCIPLE 8

Businesses should respect and make efforts to protect and restore the environment

The Company is continuously exploring various focus areas for its CSR activities and is also in the process of identifying NGOs working in the areas of health and education to support them in their endeavors.

Essential Indicators

1. **Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year:**

Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
Not Applicable					

2. **Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:**

Sr. No.	Name of Project for which R&R is ongoing	State	District	Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (In INR)
Not Applicable						

3. **Describe the mechanisms to receive and redress grievances of the community:**

The Company engages its community members through in-person meetings.

4. **Percentage of input material (inputs to total inputs by value) sourced from suppliers:**

Parameter	FY 2025-26	FY 2024-25
Directly sourced from MSMEs/ small producers	4.86	9.40
Sourced from other than MSMEs within India	65.70	68.88
Imports	29.44	21.72

5. **Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost:**

Location	FY2025-26	FY2024-25
Rural	0	0
Semi-urban	0	0
Urban	74.77	72.52
Metropolitan	25.23	27.48

Note: Place categorized as per RBI Classification System - rural / semi-urban / urban / metropolitan and based Census 2011.

Leadership Indicators

1. **Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):**

Details of negative social impact identified	Corrective action taken
Not Applicable	

2. **Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:**

Sr. No	State	Aspirational District	Amount spent (In INR)
None			

3. **(a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)**

No, since we have to source our materials from suppliers approved by global health regulatory bodies only.

(b) From which marginalized /vulnerable groups do you procure?

Not Applicable

(c) What percentage of total procurement (by value) does it constitute?

Not Applicable

4. **Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:**

Sr. No	Intellectual Property based on traditional knowledge	Owned/ Acquired (Yes/No)	Benefit shared (Yes / No)	Basis of calculating benefit share
Not Applicable				

5. **Details of corrective actions taken or underway, based on any adverse order intellectual property related disputes wherein usage of traditional knowledge is involved:**

Name of authority	Brief of the Case	Corrective action taken
Not Applicable		

6. **Details of beneficiaries of CSR Projects:**

Sr. No	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1.	Organized free health check-up camps and distributed free medicines and other medical supplies to underprivileged people in the state of Goa.	-	-
2.	Distribution of free food items to daily wage labourers, people below poverty line and other economically backward people who do not have regular income.	-	-
3.	Building and upkeep of public garden/park and tree plantation in Verna Industrial area, Goa.	-	-
4.	Contributions towards women and child development, professionalizing Anganwadis and national nutrition mission in Goa.	-	-
5.	Various other projects undertaken from time to time as per CSR policy of the Company in the areas of education, healthcare and disaster management.	-	-

PRINCIPLE 9

Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. **Describe the mechanisms in place to receive and respond to consumer complaints and feedback:**

Every endeavor is made to achieve maximum customer satisfaction by manufacturing world-class quality products and ensuring fair treatment in all customer dealings. The Company complies with all applicable labeling standards. Customers' complaints are attended on a priority basis.

There are no customer complaints/ consumer cases pending resolutions at the end of the financial year. There is no case against the Company regarding unfair trade practice, irresponsible advertising, anti-competitive behavior during the last five years. The Company conducts consumer survey periodically.

2. **Turnover of products/services as a percentage of turnover from all products/services that carry information about:**

	As a percentage to total turnover
Environmental and social parameters relevant to the product	We comply with relevant laws and regulations of the countries we operate in with respect to disclosure of information on environmental and social parameters relevant to the products. 100% of our formulation products, representing 100% of our overall revenue, carry information about safe and responsible usage on product labelling and package inserts. Further, based on the legal requirements, guidelines and customer requirements in the countries of our operations, we include instructions on recycling and/ or safe disposal of products.
Safe and responsible usage	
Recycling and/or safe disposal	

3. Number of consumer complaints in respect of the following:

	FY 2025-26			FY 2024-25		
	Received during the year	Pending resolution at end of year	Remarks	Received during the year	Pending resolution at end of year	Remarks
Data privacy	Nil	Nil	-	Nil	Nil	-
Advertising	Nil	Nil	-	Nil	Nil	-
Cyber-security	Nil	Nil	-	Nil	Nil	-
Delivery of essential services	Nil	Nil	-	Nil	Nil	-
Restrictive Trade Practices	Nil	Nil	-	Nil	Nil	-
Unfair Trade Practices	Nil	Nil	-	Nil	Nil	-
Other	Nil	Nil	-	Nil	Nil	-

4. Details of instances of product recalls on account of safety issues:

	Number	Reasons for recall
Voluntary recalls	Nil	-
Forced recalls	Nil	-

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy:

Yes. The Company has a framework on cyber security and risks related to data privacy as a part of Risk Management Policy.

https://www.marksanspharma.com/pdf/risk-management-policy.pdf

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services:

None

7. Provide the following information relating to data breaches:

a. Number of instances of data breaches: Nil

b. Percentage of data breaches involving personally identifiable information of customers: Nil

c. Impact, if any, of the data breaches: NA

Leadership Indicators

1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available):

www.marksanspharma.com

2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services:

At Marksans, sustainable innovation is a core part of Company's DNA. The Company continues to work together with our partners and customers to explore new ways to incorporate sustainable materials across our product range and bring them to new markets, including increased communications. The Company conducts consumer survey periodically.

3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services:

Issues that are bound to arise in any customer/supplier relationship, there is continual communication maintained with customers. This helps to identify problems before they become serious and allows both the parties to work towards mutually beneficial solutions. The Company focuses on quality and customer service and continues to strengthen our relationship and position as a trusted partner.

4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable)

No

Did your entity carry out any survey about consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)

Yes

Annexure - G

Annexure to the Report of the Board of Directors

FORM NO. MR-3

SECRETARIAL AUDIT REPORT

For The Financial Year Ended on 31st March 2026

[Pursuant to section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To
The Members
Marksans Pharma Limited
11th Floor, Grandeur
Veera Desai Extension Road
Oshiwara, Andheri (West)
Mumbai – 400 053

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Marksans Pharma Limited** (CIN: L24110MH1992PLC066364) (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2026 ('Audit Period') complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2026 according to the provisions of:

i. The Companies Act, 2013 (the Act) and the rules made thereunder;

ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;

iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

iv. The Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment and Overseas Direct Investment;

v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-

a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 **(Not Applicable during the review period);**

d. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021;

e. The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 **(Not Applicable during the review period);**

f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;

g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 **(Not Applicable to the Company during the Audit Period)**;

h. The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 **(Not Applicable to the Company during the Audit Period)**; and

i. The Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 [SEBI (LODR)].

We have also examined compliance with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India.

During the period under review, the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, standards etc. mentioned above.

We further report that, having regard to the compliance system prevailing in the Company and on examination of the relevant documents and records in pursuance thereof on test-check basis, the Company has complied with following Acts, Laws and Regulations applicable specifically to the Company:

1. Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945;

2. Air (Prevention and Control of Pollution) Act, 1974;

3. Water (Prevention and Control of Pollution) Act, 1981.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors and Committees of the Board, as the case may be.

We further report that, there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, there were no specific events/actions having major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc..

For Jinesh Dedhia & Associates
Company Secretaries

Jinesh Damji Dedhia
Proprietor
Peer Review Certificate No.1914/2022
ACS: 54731, CP: 20229
UDIN: A054731H000486008

Place: Mumbai
Date: 26 May, 2026

Annexure A

To
The Members
Marksans Pharma Limited
11th Floor, Grandeur
Veera Desai Extension Road
Oshiwara, Andheri (West)
Mumbai – 400053

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

6. The secretarial audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Jinesh Dedhia & Associates
Company Secretaries

Jinesh Damji Dedhia
Proprietor
Peer Review Certificate No.1914/2022
ACS: 54731, CP: 20229
UDIN: A054731H000486008

Place: Mumbai
Date: 26 May, 2026

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members of
MARKSANS PHARMA LIMITED
11th Floor, Grandeur
Veera Desai Extension Road Oshiwara
Andheri (W) Mumbai 400053

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Marksans Pharma Limited** (CIN:L24110MH1992PLC066364) and having registered office at 11th Floor, Grandeur, Veera Desai Extension Road Oshiwara, Andheri (W) Mumbai 400053 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No.	Name of the Director	DIN	Date of appointment
1.	Mark Saldanha	00020983	06/10/2015
2.	Sandra Saldanha	00021023	25/09/2014
3.	Varddhman Vikramaditya Jain	08338573	24/01/2019
4.	Digant Mahesh Parikh	00212589	14/03/2018
5.	Abhinna Mohanty Sundar	00007995	11/07/2019
6.	Sunny Sharma	02267273	11/08/2021
7.	Shailaja Vardhan	10172764	30/05/2023
8.	Srinivas Mishra	10052055	01/04/2025

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Jinesh Dedhia & Associates
Company Secretaries

Jinesh Dedhia
Proprietor
Peer Review Certificate No.:1914/2022
ACS:54731 CP. 20229
UDIN: A054731H000486096

Place: Mumbai
Date: 26 May, 2026

Annexure - H

ANNEXURE TO THE REPORT OF THE BOARD OF DIRECTORS

Form AOC - 1

Pursuant to first proviso to Section 129(3) read with Rule 5 of Companies (Accounts) Rules, 2014.
Statement containing salient features of the financial statements of subsidiaries, associate companies and joint ventures.

Part - A: Subsidiaries

(All amount in millions of Indian Rupee, unless otherwise stated)

SR. NO.	PARTICULARS					
1.	Name of the Subsidiary	**Marksans Pharma (UK) Limited**	**Nova Pharmaceuticals Australasia Pty Ltd**	**Marksans Pharma Inc.**	**Access Healthcare for Medical Products LLC**	**Marksans Pharma GmbH**
2.	Date of acquisition	2007	2005	2015	2022	
3.	Reporting period for the subsidiary	31 March 2026	31 March 2026	31 March 2026	31 March 2026	31 March 2026
4.	Reporting currency	GBP	AUD	USD	AED	EUR
	Closing exchange rate	123.77	64.48	93.68	25.50	108.10
	Average exchange rate	118.45	58.49	88.37	24.06	102.50
5.	Share capital	1,064.04	0.01	2,471.44	8.26	0.05
6.	Reserve and surplus	10,495.67	738.10	1,954.72	394.13	-5.71
7.	Total assets	12,574.64	1,604.33	13,570.98	421.53	39.60
8.	Total Liabilities	1,014.93	866.22	9,144.82	19.14	45.26
9.	Investments	-	-	-	-	-
10.	Turnover	10,140.65	2,897.62	14,950.25	179.20	-
11.	Profit before taxation	1,628.16	75.28	613.14	71.62	-5.43
12.	Provision for taxation	435.45	21.17	120.92	3.88	-
13.	Profit after taxation	1,192.71	54.11	492.22	67.74	-5.43
14.	Proposed Dividend	-	-	-	-	-
15.	Extent of shareholding	100%	60%	100%	100%	100%

Name of subsidiaries which are yet to commence operations : 1 Marksans (Canada) Inc.
2 Marksans Pharma (Europe) Limited

Name of subsidiaries which have been liquidated or sold during the year : None

Part - B: Associate and Joint Venture: None

For and on behalf of the Board of Directors of
Marksans Pharma Limited

Mark Saldanha
Chairman & Managing Director
DIN: 00020983

Place: Mumbai
Dated: May 26, 2026

Standalone Financial Statements

Independent Auditor's Report

To the Members of **Marksans Pharma Limited**

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of Marksans Pharma Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2026, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including material accounting policy information and other explanatory information (hereinafter referred to as the "standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its profit (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matter described below to be the key audit matter to be communicated in our report.

Key Audit Matter	How the Key Audit Matter was addressed in our audit
Revenue from sale of products is recognised when the Company satisfies the performance obligation under the contract / sales arrangement and transfers control of the goods to the customer, at a point in time. The Company's multi-geography operations, the specific point at which control passes and accordingly, the period in which revenue is appropriately recognised is influenced by a variety of factors, including the applicable international commercial terms governing each customer contract / sales arrangement. Accordingly, due to the significant risk associated with revenue recognition in accordance with terms of Ind AS 115 'Revenue from contracts with customers', it has been determined to be a key audit matter in our audit of the standalone financial statements. Refer Note 26 to the Standalone Financial Statements	Our audit procedures included the following: 1. Evaluated the Company's accounting policy for recognition of revenue from sale of products and assessed whether it is in compliance with applicable accounting standards. 2. Obtained an understanding, assessed the design and tested the operating effectiveness of key internal controls related to revenue recognition. 3. Selected a sample of revenue transactions recognised during the year (including year-end cutoff testing) and tested the underlying documentation to assess and analyze the timing of recognition of revenue and contractual terms. 4. Performed analytical procedures on revenue and tested journal entries over revenue to identify any unusual items. 5. Verified that the presentation and disclosure of revenue in the financial statements are in compliance with applicable accounting standards and reporting framework.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Management Discussion and Analysis, Director's Report, Corporate Governance Report and Business Responsibility and Sustainability Report but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Board of Directors for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Board of Directors of the Company are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Standalone Financial Statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid standalone financial statements.

   (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid standalone financial statements have been kept by the Company so far as it appears from our examination of those books, except for the matters stated in the paragraph 2 (h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rule, 2014.

   (c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account maintained for the purpose of preparation of the standalone financial statements.

   (d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

   (e) On the basis of the written representations received from the directors as on April 1, 2026 taken on record by the Board of Directors, none of the directors are disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

   (f) The reservation relating to the maintenance of accounts and other matters connected therewith are as stated in paragraph 2 (b) above on reporting under Section 143(3)(b) of the Act and paragraph 2 (h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rule, 2014.

   (g) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure C".

   (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

      i. The Company does not have any pending litigations which would impact its financial position.

      ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

      iii. There has been no delay in transferring amounts, to the Investor Education and Protection Fund by the Company during the year ended March 31, 2026.

iv. a) The Management has represented that, to the best of its knowledge and belief, as disclosed in the Note 46(h)(1) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

b) The Management has represented that, to the best of its knowledge and belief, as disclosed in the Note 46(h)(2) to the standalone financial statements, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.

v. On the basis of our verification, we report that:

a) The Final dividend paid by the Company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.

b) The Board of Directors of the Company have proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend. Refer Note 43 to the standalone financial statements.

vi. Based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility, except that no audit trail feature was enabled at the database level in respect of an accounting software to log any direct data changes as explained in Note 46(m) to the standalone financial statements.

Further, where enabled, audit trail feature has been operated for all relevant transactions recorded in the accounting software. Also, during the course of our audit, we did not come across any instance of audit trail feature being tampered with in respect of such accounting software. Additionally, the audit trail of prior years has been preserved by the Company as per the statutory requirements for record retention to the extent it was enabled and recorded in respective years.

3. In our opinion, according to information, explanations given to us , the remuneration paid or provided by the Company to its directors is within the limits laid prescribed under Section 197 read with Schedule V of the Act.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894HSPOFW5298

Place: Mumbai
Date: May 26, 2026

ANNEXURE A

To the Independent Auditor's Report of even date on the Standalone Financial Statements of Marksans Pharma Limited

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management and Board of Directors.

- Conclude on the appropriateness of Management and Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of current period and are therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894HSPOFW5298

Place: Mumbai
Date: May 26, 2026

ANNEXURE B

To the Independent Auditor's Report of even date on the Standalone Financial Statements of Marksans Pharma Limited

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

i. (a) A The Company has maintained proper records showing full particulars including quantitative details and situation of property, plant and equipment and relevant details of right-of-use assets.

B The Company has maintained proper records showing full particulars of intangible assets.

(b) All the Property, Plant and Equipment and right of use assets have not been physically verified by the management during the year but there is a regular programme of verification, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us, the title deeds of immovable properties (other than properties where the Company is the lessee, and the lease agreements are duly executed in favour of the lessee) as disclosed in the Standalone Financial Statements are held in the name of the Company.

(d) According to the information and explanations given to us, the Company has not revalued its property, plant and equipment (including right of use assets) and intangible assets during the year. Accordingly, the provisions stated under clause 3(i)(d) of the Order are not applicable to the Company.

(e) According to the information and explanations given to us, no proceeding has been initiated or pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988, as amended and rules made thereunder. Accordingly, the provisions stated under clause 3(i)(e) of the Order are not applicable to the Company.

ii. (a) The inventory (excluding stocks-in-transit) has been physically verified by the management during the year. In respect of goods in transit, the goods have been received subsequent to the year end. In our opinion, the frequency, coverage and procedure of such verification is reasonable and appropriate, having regard to the size of the Company and the nature of its operations. The discrepancies noticed on physical verification of inventory as compared to book records were not 10% or more in aggregate for each class of inventory.

(b) The Company has been sanctioned working capital limits in excess of ₹ 5 crores rupees, in aggregate from Banks, on the basis of security of current assets. Based on the records examined by us in the normal course of audit of the Standalone Financial Statements, quarterly returns / statements filed with such Banks are in agreement with the books of accounts of the Company. Refer Note 45(b) to the Standalone Financial Statements.

iii. According to the information and explanations provided to us, the Company has not made any investments in, or provided any guarantee or security, or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the provisions stated under clause 3(iii) of the Order are not applicable to the Company.

iv. According to the information and explanations given to us, there are no loans, investments, guarantees, and security in respect of which provisions of sections 185 and 186 of the Companies Act, 2013, are applicable and accordingly, the requirement to report under clause 3(iv) of the Order is not applicable to the Company.

v. According to the information and explanations given to us, the Company has neither accepted any deposits from the public nor any amounts which are deemed to be deposits, within the meaning of the provisions of Sections 73 to 76 of the Companies Act, 2013 and the rules framed there under. Accordingly, the requirement to report under clause 3(v) of the Order is not applicable to the Company.

vi. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Companies Act, 2013 in respect of its products. We have broadly reviewed the same, and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.

vii. (a) According to the information and explanations given to us and the records examined by us, in our opinion, undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, duty of customs, cess, and other statutory dues have been regularly deposited by the Company with appropriate authorities in all cases during the year. No undisputed amounts payable in respect of these statutory dues were outstanding as at March 31, 2026, for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and the records examined by us, dues relating to income tax which have not been deposited as on March 31, 2026, on account of any dispute, are as follows:

Name of the statute	Nature of dues	Amount Demanded ₹ Million	Amount Paid ₹ Million	Period to which the amount relates	Forum where dispute is pending
Income Tax Act, 1961	Income Tax	18.71	--	FY 2005-06	Hon'ble High Court of Bombay
Income Tax Act, 1961	Income Tax	14.07	--	FY 2014-15	Commissioner of Income Tax (Appeals)

There are no dues relating to goods and services tax, provident fund, employees' state insurance, duty of customs, cess, and other statutory dues which have not been deposited on account of any dispute.

viii. According to the information and explanations given to us, there are no transaction which are not recorded in the books of account which have been surrendered or disclosed as income during the year in Income-tax Assessment under the Income Tax Act, 1961. Accordingly, the requirement to report as stated under clause 3(viii) of the Order is not applicable to the Company.

ix. (a) The Company does not have any loans or borrowings or interest thereon due to any lenders during the year. Accordingly, the requirement to report under clause 3(ix)(a) of the Order is not applicable to the Company.

(b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

(c) In our opinion and according to the information and explanations provided to us, no money was raised by way of term loans. Accordingly, the requirement to report under clause 3(ix)(c) of the Order is not applicable to the Company.

(d) According to the information and explanations given to us, there were no funds raised during the year. Accordingly, the requirement to report under clause 3(ix)(d) of the Order is not applicable to the Company.

(e) According to the information and explanations given to us and on an overall examination of the Standalone Financial Statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries. Accordingly, the requirement to report under Clause 3(ix)(f) of the order is not applicable to the Company.

x. (a) In our opinion and according to the information and explanations given to us, the Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, the reporting requirement under clause 3(x)(a) of the Order is not applicable to the Company.

(b) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partly, or optionally convertible) during the year. Accordingly, the requirements to report under clause 3(x)(b) of the Order is not applicable to the Company.

xi. (a) Based on our examination of the books and records of the Company and according to the information and explanations given to us, we report that no fraud by the Company or no fraud on the Company has been noticed or reported during the year in the course of our audit.

(b) During the year no report under Section 143(12) of the Act, has been filed in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the Management, there are no whistle-blower complaints received by the Company during the year.

xii. The Company is not a Nidhi Company. Accordingly, the provisions stated under clause 3(xii)(a) to (c) of the Order are not applicable to the Company.

xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with Sections 177 and 188 of the Companies Act, 2013, where applicable and details of such transactions have been disclosed in the Standalone Financial Statements as required by the applicable accounting standards.

xiv. (a) In our opinion and based on our examination, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till the date of our audit report, for the period under audit.

xv. According to the information and explanations given to us, and based on our examination of the records of the Company, in our opinion during the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and accordingly, the requirement to report on clause 3(xv) of the Order is not applicable to the Company.

xvi. (a) The Company is not required to be registered under Section 45 IA of the Reserve Bank of India Act, 1934 (2 of 1934) and accordingly, the requirements to report under clause 3(xvi)(a) of the Order is not applicable to the Company.

(b) The Company is not engaged in any Non-Banking Financial or Housing Finance activities during the year and accordingly, the provisions stated under clause 3 (xvi)(b) of the Order are not applicable to the Company.

(c) The Company is not a Core investment Company (CIC) as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report under clause 3 (xvi)(c) of the Order is not applicable to the Company.

(d) The Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) does not have more than one Core Investment Company as a part of its group. Accordingly, the reporting under clause 3(xvi)(d) of the Order is not applicable to the Company.

xvii. Based on the overall review of Standalone Financial Statements, the Company has not incurred cash losses in the current financial year and in the immediately preceding financial year. Accordingly, the requirement to report under clause 3(xvii) of the Order is not applicable to the Company.

xviii. There has been no resignation of the statutory auditors during the year. Accordingly, reporting under clause 3(xviii) of the Order is not applicable to the Company.

xix. According to the information and explanations given to us and on the basis of the financial ratios (as disclosed in Note 44 to the Standalone Financial Statements), ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the Standalone Financial Statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. According to the information and explanations given to us and based on our verification, the provisions of Section 135 of the Companies Act, 2013, are applicable to the Company. The Company has made the required contributions during the year and there are no unspent amounts which are required to be transferred either to a Fund specified in schedule VII of the Companies Act, 2013 or to a Special Account as per the provisions of Section 135 of the Companies Act, 2013 read with schedule VII to the Companies Act, 2013. Accordingly, reporting under clause 3(xx)(a) and 3(xx)(b) of the Order is not applicable to the Company.

xxi. The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of Standalone Financial Statements. Accordingly, no comment in respect of the said Clause has been included in the report.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894HSPOFW5298

Place: Mumbai
Date: May 26, 2026

ANNEXURE C

To the Independent Auditor's Report of even date on the Standalone Financial Statements of Marksans Pharma Limited

Referred to in paragraph 2 (g) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditor's Report of even date to the Members of Marksans Pharma Limited on the Standalone Financial Statements for the year ended March 31, 2026

Report on the Internal Financial Controls with reference to standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

Opinion

We have audited the internal financial controls with reference to standalone financial statements of Marksans Pharma Limited ("the Company") as of March 31, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, and to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2026, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ('ICAI').

Management's and Board of Director's Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894HSPOFW5298

Place: Mumbai
Date: May 26, 2026

Standalone Balance Sheet

as at 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Note No.	As at 31 March 2026	As at 31 March 2025
Assets			
Non-current assets			
Property, plant and equipment	3a	3,686.75	3,535.94
Right of use assets	3b	275.23	273.03
Other intangible assets	4	17.59	24.74
Financial assets			
(i) Investments	5	2,672.13	2,657.53
(ii) Other financial assets	6	11.46	10.84
Other non-current assets	7	175.54	217.60
Non Current tax assets (net)	8	10.81	11.11
Total non-current assets		**6,849.51**	**6,730.79**
Current assets			
Inventories	9	1,891.30	2,052.10
Financial assets			
(i) Investments	10	–	7.42
(ii) Trade receivables	11	6,234.62	5,495.81
(iii) Cash and cash equivalents	12a	912.50	602.68
(iv) Bank balances other than (iii) above	12b	3,555.15	2,084.23
(v) Other financial assets	13	33.33	22.91
Other current assets	14	463.88	557.08
Total current assets		**13,090.78**	**10,822.23**
Total Assets		**19,940.29**	**17,553.02**
Equity and liabilities			
Equity			
Equity share capital	15	453.16	453.16
Other equity	16	16,069.94	13,381.70
Total equity		**16,523.10**	**13,834.86**
Liabilities			
Non-current liabilities			
Financial liabilities			
Lease liabilities	17	87.21	82.58
Provisions	18	56.91	57.70
Deferred tax liabilities (net)	19	170.57	121.53
Total non current liabilities		**314.69**	**261.81**
Current liabilities			
Financial liabilities			
(i) Lease liabilities	20	34.08	25.84
(ii) Trade payables	21		
a) Total outstanding dues of micro and small enterprises		20.12	36.33
b) Total outstanding dues of other than micro and small enterprises		1,788.01	1,999.01
(iii) Other financial liabilities	22	252.91	191.99
Other current liabilities	23	769.06	1,083.45
Provisions	24	3.18	14.47
Current tax liabilities (net)	25	235.14	105.26
Total current liabilities		**3,102.50**	**3,456.35**
Total liabilities		**3,417.19**	**3,718.16**
Total equity and liabilities		**19,940.29**	**17,553.02**

The accompanying notes form an integral part of these standalone financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Standalone Statement of Profit and Loss

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Note No.	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Income			
Revenue from operations	26	13,414.76	11,743.74
Other income	27	1,035.33	657.87
Total Income		**14,450.09**	**12,401.61**
Expenses			
Cost of materials consumed	28	6,024.27	5,371.77
Purchases of stock-in-trade		730.62	1,020.61
Changes in inventories of finished goods, work-in-progress and stock-in-trade	29	32.95	6.98
Employee benefits expense	30	1,219.77	1,016.78
Finance costs	31	13.27	11.74
Depreciation and amortization expense	32	342.30	294.52
Other expenses	33	2,171.48	2,246.62
Total expenses		**10,534.66**	**9,969.02**
Profit before tax		**3,915.43**	**2,432.59**
Tax expense:			
(1) Current tax		851.21	513.83
(2) Tax adjustments for earlier years		11.70	7.61
(3) Deferred tax		45.54	28.43
Total tax expenses		**908.45**	**549.87**
Profit for the year		**3,006.98**	**1,882.72**
Other comprehensive income			
Items that will not be reclassified to profit or loss			
- Remeasurements of post-employment benefit obligations		13.91	(4.02)
- Income tax relating to above		(3.50)	1.01
Other comprehensive income for the year, net of tax		**10.41**	**(3.01)**
Total comprehensive income for the year		**3,017.39**	**1,879.71**
Earnings per equity share (face value per equity share - ₹ 1)	37		
(1) Basic (in ₹)		6.64	4.15
(2) Diluted (in ₹)		6.63	4.15

The accompanying notes form an integral part of these standalone financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Standalone Statement of Changes in Equity

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

A Equity share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Equity shares outstanding at the beginning of the year	453,163,746	453.16	453,163,746	453.16
Equity shares outstanding at the end of the year	**453,163,746**	**453.16**	**453,163,746**	**453.16**

B Other equity (Refer note.16)

Particulars	Capital reserve	Capital redemption reserve	Securities premium	General reserve	Share-based Payments Reserve (Equity)	Retained earnings	Total
Balance as at 1 April 2025	0.12	141.47	5,044.98	3,137.37	–	5,057.76	13,381.70
Profit for the year	–	–	–	–	–	3,006.98	3,006.98
Other comprehensive income (net of taxes)	–	–	–	–	–	10.41	10.41
Total comprehensive income for the year	**–**	**–**	**–**	**–**	**–**	**3,017.39**	**3,017.39**
Equity-settled share-based payments	–	–	–	–	33.38	–	33.38
Dividend paid on equity shares	–	–	–	–	–	(362.53)	(362.53)
Balance as at 31 March 2026	**0.12**	**141.47**	**5,044.98**	**3,137.37**	**33.38**	**7,712.62**	**16,069.94**

Particulars	Capital reserve	Capital redemption reserve	Securities premium	General reserve	Share-based Payments Reserve (Equity)	Retained earnings	Total
Balance as at 1 April 2024	**0.12**	**141.47**	**5,044.98**	**3,137.37**	**–**	**3,449.95**	**11,773.89**
Profit for the year	–	–	–	–	–	1,882.72	1,882.72
Other comprehensive Income (net of taxes)	–	–	–	–	–	(3.01)	(3.01)
Total comprehensive income for the year	**–**	**–**	**–**	**–**	**–**	**1,879.71**	**1,879.71**
Dividend paid on equity shares	–	–	–	–	–	(271.90)	(271.90)
Balance as at 31 March 2025	**0.12**	**141.47**	**5,044.98**	**3,137.37**	**–**	**5,057.76**	**13,381.70**

C Nature and purpose of reserves:

1 Capital reserve

The Capital Reserve was created as per the requirements of earlier provision of the Companies Act, 1956. Such reserve is not available for distribution to the shareholders.

2 Capital redemption reserve

The Company had redeemed 1,350,000 7% redeemable cumulative preference shares of ₹100/- each face value at par out of profits of the Company on various dates. Accordingly, a sum equal to the nominal amount of the preference shares i.e. ₹135 million, out of the profits, was transferred to capital redemption reserve, as and when Preference Shares were redeemed.

The Company had bought back and accounted buy back of 6,474,276 equity shares on various dates. As per Companies Act, 2013, capital redemption reserve is created when company purchases its own shares out of free reserves or securities premium. A sum equal to the nominal value of the shares so purchased is transferred to capital redemption reserve. Accordingly, ₹6.47 million was transferred from retained earnings to capital redemption reserve. The reserve is utilised in accordance with the provisions of Section 69 of the Companies Act, 2013.

3 Securities premium

Securities premium comprises of the premium on issue of shares. The reserve can be utilised in accordance with the specific provision of the Companies Act, 2013.

Standalone Statement of Changes in Equity

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated) *(Contd.)*

4 General reserve

The Company has transferred a portion of the net profit before declaring dividend to general reserve pursuant to the earlier provisions of the Companies Act, 1956. Transfer to general reserve is not mandatorily required under the Companies Act, 2013.

5 Share-based payments reserve

The share-based payments reserve is used to recognise the grant date fair value of options issued to employees of the Company and it's subsidiaries under the Company's Employee stock option plan.

6 Retained earnings

Retained earnings are the profits earned till date, less any transfers to other reserves and dividends distributed.

The accompanying notes form an integral part of these standalone financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Standalone Cash Flow Statement

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
A. Cash flow from operating activities		
Profit before tax	3,915.43	2,432.59
Adjustments to reconcile profit before tax to net cash provided by operating activities		
– Depreciation and amortisation expenses	342.30	294.52
– Unrealised exchange differences on translation of assets and liabilities, net	(223.73)	(48.77)
– Loss on sale of property, plant and equipment, net	0.64	0.33
– Gain on redemption of mutual fund investments	(12.27)	(6.94)
– Finance costs	13.27	11.74
– Employee Share based compensation expenses	18.78	–
– Dividend income from a subsidiary	(386.16)	(263.69)
– Interest income	(157.53)	(182.16)
– Loss arising on financial instruments measured at FVTPL, net	29.25	40.06
– Loss on lease termination	0.17	–
– Allowance for credit losses on trade receivables (Including bad debts)	128.65	79.04
Operating profit before working capital changes	**3,668.80**	**2,356.72**
Changes in working capital:		
Inventories	160.80	(143.61)
Trade receivables	(631.18)	(1,826.86)
Non-current/current financial and other assets	94.78	(149.72)
Non-current/current financial and other liabilities/provisions/trade payables	(452.27)	539.05
Cash generated from operations	**2,840.93**	**775.58**
Income taxes paid (net)	(730.07)	(465.40)
Net cash generated from operating activities (A)	**2,110.86**	**310.18**
B. Cash flow from investing activities:		
Payments to acquire property, plant and equipment and intangible assets	(487.77)	(1,199.10)
Proceeds from sale of property, plant and equipment	5.12	1.01
(Investment) / Proceeds from deposits (net)	(1,469.34)	618.77
Purchase of mutual fund Investments	(1,490.00)	–
Proceeds from sale of mutual fund investments	1,509.69	269.87
Dividend income from a subsidiary	386.16	263.69
Interest received	143.22	218.16
Net Cash (used in) / generated from investing activities (B)	**(1,402.92)**	**172.40**
C. Cash flow from financing activities:		
Dividend paid	(362.53)	(271.90)
Payment of principal portion of lease liabilities (including interest on lease liabilities)	(29.80)	(27.29)
Net Cash used in financing activities (C)	**(392.33)**	**(299.19)**
Net increase in cash and cash equivalents (A+B+C)	**315.61**	**183.39**
Cash and cash equivalents at the beginning of the year	602.68	419.29
Effect of exchange differences on translation of foreign currency cash and cash equivalents	(5.79)	#
Cash and cash equivalents at the end of the year	**912.50**	**602.68**

Amount below rounding off criteria

Notes:

1 Reconciliation of cash and cash equivalents as per the statement of cash flows

Particulars	As at 31 March 2026	As at 31 March 2025
Cash and cash equivalents (Refer note 12a)		
Balances with bank		
In current accounts	368.82	450.68
In Exchange Earners' Foreign Currency account (EEFC)	193.60	0.01
Fixed deposit with original maturity less than 3 months	350.00	151.89
Cash in hand	0.08	0.10
Balances as per statement of cash flows	**912.50**	**602.68**

Standalone Cash Flow Statement

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated) *(Contd.)*

2 The above Cash Flow Statement is prepared under the "Indirect Method" as set out in Ind AS 7,' Statement of Cash Flows'.

3 Amounts in bracket represent cash outflow.

4 **Net debt reconciliation**

Analysis of net debt and the movements in net debt for each year are presented below

Description	Liabilities from Financing Activities	
	As at 31 March 2026	As at 31 March 2025
Cash and cash equivalents	912.50	602.68
Lease Liabilities	121.29	108.42
Net Debt	**791.21**	**494.26**
Net Debt at the beginning of the year	494.26	338.02
Cash Flows	309.82	183.39
New Leases	(43.65)	(42.70)
Lease Termination	14.25	–
Interest Expense	(13.27)	(11.74)
Payments	29.80	27.29
Net Debt at the end of the year	**791.21**	**494.26**

The accompanying notes form an integral part of these standalone financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

1. Corporate information

Marksans Pharma Limited (the "Company") [CIN: L24110MH1992PLC066364] is a public limited company incorporated in Mumbai, India. The registered office of the Company is at 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai - 400053, India.

The Company is primarily engaged in the business of research, manufacture, marketing and selling pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centers; one located in Goa and the other in Navi Mumbai, Maharashtra.

The Company's shares are listed on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") in India.

2. Material accounting policy information

2.1. (i) Statement of compliance and basis of preparation and presentation

These standalone financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) read with Section 133 of the Companies Act, 2013 ("the Act") and presentation requirements of Division II of Schedule III of the Act and other relevant provisions of the Act as applicable. These standalone financial statements have been prepared on accrual basis under the historical cost convention, except the following assets and liabilities, which have been measured at fair value as required by the relevant Ind AS:

- Certain financial assets and liabilities (refer accounting policy regarding financial instruments including derivative financial instruments and investments in mutual funds measured at fair value through profit or loss) and;
- Defined employee benefit plans (measured on the basis of actuarial valuation using the Projected Unit Credit Method).

These standalone financial statements were approved by the Company's Board of Directors and authorized for issue on 26 May 2026.

The standalone financial statements have been prepared on the assumption that the Company is a going concern and will continue its operations for the foreseeable future.

(ii) Functional and Presentation Currency

The financial statements are presented in Indian Rupee (₹) which is the functional currency of the Company. All amounts are rounded to two decimal places to the nearest Million, unless otherwise stated.

(iii) Current versus non-current classification

The Company presents assets and liabilities in the Standalone Balance Sheet based on current/ non-current classification.

An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realized within twelve months after the reporting period; or
- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is treated as current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(iv) New accounting standards, amendments and interpretations adopted by the Company effective from 1 April 2025

The Ministry of Corporate Affairs ("MCA") notified amendments on 7 May 2025 and 13 August 2025 under the Companies (Indian Accounting Standards) Amendment Rules, 2025 and the Companies (Indian Accounting Standards) Second Amendment Rules, 2025, respectively, which is effective from annual reporting periods beginning on or after 1 April 2025.

a) Amendment to Ind AS 7 and Ind AS 107 - Supplier Finance Arrangement:

The amendments to Ind AS 7 'Statement of Cash Flows' and Ind AS 107 'Financial Instruments: Disclosures' clarify the characteristics of supplier finance arrangements and require additional disclosures for such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.

The Company does not have any supplier finance arrangements during the reporting period.

b) Amendment to Ind AS 1 - Classification of liabilities as current or non-current and non-current liabilities with covenants:

The amendment specifies the requirements for classifying liabilities as current or non-current in the balance sheet, and clarifies the following:

An entity's right to defer settlement of a liability for at least twelve months after the reporting period must have substance and must exist at the end of the reporting period. The classification of a liability as current or non-current is unaffected by the likelihood that the entity will exercise its right to defer settlement.

If an entity's right to defer settlement of a liability is subject to covenants, such covenants affect whether that right exists at the end of the reporting period only if the entity is required to comply with the covenant on or before the end of the reporting period.

In case of a liability that can be settled, at the option of the counterparty, by the transfer of the entity's own equity instruments, such settlement terms do not affect the classification of the liability as current or non-current only if the option is classified as an equity instrument.

These amendments have no effect on the measurement of any items in the financial statements of the Company. The Company did not make retrospective adjustments as a result of adopting the amendments to Ind AS 1.

c) Amendment to Ind AS 12 – Pillar-Two Tax Reforms:

The Company is not within the scope of the OECD Pillar Two Model Rules, as Pillar Two legislation has not yet been enacted in any of the jurisdictions in which the Company operates.

d) Amendment to Ind AS 21-Lack of exchangeability:

The Amendments introduces requirement to assess when a currency is exchangeable into another currency and when it is not. The amendment requires an entity to estimate the spot exchange rate when it concludes that a currency is not exchangeable into another currency. These amendments had no effect on the financial statements of the Company.

(v) Standards issued but not yet effective

Amendment to Ind AS 1 - Classification of Liabilities as Current or Non-current and non-current liabilities with covenants:

The amendment includes specific provisions that will take effect for reporting periods beginning on or after 1 April 2026, retrospectively, as outlined below:

a) Breach of material covenant for long-term loan arrangement on or before end of reporting period with effect that liability becomes payable on demand as on reporting date, then it shall be classified as current liability, if lender agreed after reporting period and before approval of financial statements to not demand payment as a consequence of breach.

b) Classify as non-current liability, if lender agreed by end of reporting period to provide grace period ending at least 12 months after reporting period within which entity can rectify the breach provided lender does not demand immediate repayment.

c) Disclose information about the timing of settlement to understand the impact of the liability on the financial statements.

The Company does not expect this amendment to have an impact on its operations or on its financial statements.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

2.2. Fair value measurements and hierarchy

The Company measures financial instruments, such as investments (other than equity investments in subsidiaries) at fair value at each Balance Sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

(a) In the principal market for the asset or liability; or

(b) In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their best economic interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use, or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances, and for which sufficient data are available to measure the fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy based on its nature, characteristics, and risks:

- Level 1 - inputs are quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 - valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 - valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

2.3. Use of estimates and judgements

The preparation of standalone financial statements in conformity with Ind AS requires management to make judgements, estimates and assumptions, that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses at the date of these standalone financial statements and the reported amounts of revenues and expenses for the year presented. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed at each balance sheet date. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods affected.

Estimates and judgments involved in applying accounting policies is in respect of:

- Useful lives of property, plant and equipment
- Useful lives of intangible assets
- Estimation of defined benefit obligations
- Estimation of deferred tax expense and liability
- Estimation of expected credit loss

Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances.

2.4. Property, plant and equipment (including Capital Work-in-Progress)

The cost of an item of property, plant and equipment shall be recognized as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Property, plant and equipment are stated at cost of acquisition or construction less accumulated depreciation and accumulated impairment, if any. Cost includes financing cost relating to borrowed funds attributable to the construction or acquisition of qualifying tangible assets if the recognition criteria is met up to the date the assets are ready for use.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date is disclosed as capital advance under non-current assets.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company, and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is de-recognized when replaced. All other repairs and maintenance are charged to the Standalone Statement of Profit and Loss, during the reporting period in which they are incurred.

An item of property, plant and equipment is de-recognized upon disposal or when no future economic benefits are expected from the use. Any profit or loss on such de-recognition of the asset is calculated as difference between net disposal proceeds and the carrying amount of property, plant and equipment and recognized in the Statement of Profit and Loss.

Depreciation is provided on straight-line basis for property, plant and equipment so as to expense the depreciable amount, i.e., the cost less estimated residual value, over its estimated useful lives. The estimated useful lives and residual values are reviewed annually and the effect of any changes in estimate is accounted for on a prospective basis.

The management's estimate of useful lives is in accordance with Schedule II to the Companies Act, 2013.

Capital Work-in-Progress included in non-current assets represents Property, plant and equipment that are not ready for their intended use as at the reporting date. Capital work-in-progress are not depreciated as these assets are not yet available for use.

2.5. Other Intangible assets

Other Intangible assets are initially recognized at cost. Following initial recognition, other intangible assets are carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

Other Intangible assets with definite useful lives are amortized on a straight-line basis so as to reflect the pattern in which the asset's economic benefits are consumed.

Other Intangible assets pertaining to computer software and product related intangibles are amortized over their estimated life on straight-line method over period of 10 years.

Gains or losses arising from de-recognition of an other intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Standalone Statement of Profit and Loss when the asset is de-recognized.

Revenue expenditure pertaining to research is charged to the Statement of Profit and Loss. Development costs of products are also charged to the Statement of Profit and Loss unless a product's technical feasibility has been established, in which case such expenditure is capitalized.

2.6. Impairment of non-financial assets

At the end of each reporting period, the Company reviews the carrying amounts of its assets to determine whether there is any indication of impairment based on internal/ external factors. An impairment loss, if any, is charged to the Standalone Statement of Profit and Loss in the year in which an asset is identified as impaired. An asset's recoverable amount is higher of an asset or cash-generating unit's (CGUs) fair value, less costs of disposal and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate, that reflects current market assessment of the time value of money and the risks specific to the asset for which estimates of future cash flows have not been adjusted. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. Impairment losses of continuing operations, including impairment on inventories, are recognized in the Standalone Statement of Profit and Loss.

Reversal of impairment losses is recorded when there is an indication that the impairment losses recognized for the assets no longer exist or have decreased.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

2.7. Inventories

Inventories consist of raw materials, packing materials, work-in-progress, stock-in-trade and finished goods. Inventories are valued at lower of cost and net realizable value (NRV). Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sales.

Cost is determined on a weighted average basis. Cost of raw materials and packing materials includes cost of purchases and other costs incurred in bringing the inventories to their present location and condition. Cost of work-in-progress and finished goods includes direct materials, labor and proportion of manufacturing overheads based on the normal operating capacity, wherever applicable. The cost of finished goods includes other costs incurred in bringing the inventories to their present location and condition.

2.8. Foreign exchange transactions and translations

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in the Statement of Profit and Loss.

All non-monetary items denominated in foreign currency are carried at historical cost or other similar valuation and are reported using the exchange rate that existed when the values were determined.

2.9. Financial instruments

A financial instrument is any contract that gives rise to a financial asset for one entity and a financial liability or equity instrument for another entity.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument.

Financial assets:

Classification

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through the Statement of Profit and Loss), and
- those measured at amortized cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

Initial recognition and measurement

Financial assets are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through Profit and Loss, transaction costs that are attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through Profit and Loss are expensed in the Statement of Profit and Loss.

Subsequent measurement

After initial recognition, financial assets are measured at:

- fair value (either through other comprehensive income or through Profit and Loss), or
- amortized cost

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset

When the Company has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognized. Where the Company has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not derecognized.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Where the Company has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of financial asset, the financial asset is derecognized if the Company has not retained control over the financial asset. Where the Company retains control of the financial asset, the asset continues to be recognized to the extent of continuing involvement in the financial asset.

Write-off

The gross carrying amount of a financial asset is written off when the Company has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof.

Income recognition

Dividend is accounted when the right to receive payment is established. Interest income from financial assets is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably.

Cash and cash equivalents

Cash and cash equivalents consists of cash on hand, short demand deposits and highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value. Short term means investments with original maturities / holding period of three months or less from the date of investments. Bank overdrafts that are repayable on demand and form an integral part of the Company's cash management are included as a component of cash and cash equivalent for the purpose of statement of cash flow.

Investments

Investments in mutual funds are primarily held for the Company's temporary cash requirements and can be readily convertible in cash. These investments are initially recorded at fair value and classified as fair value through profit or loss.

The Company measures investment in subsidiaries at cost less provision for impairment, if any.

Trade receivables

Trade receivables are amounts due from customers for the sale of goods or services performed in the ordinary course of business. Trade receivables are initially recognized at their transaction price, which is considered to be its fair value and are classified as current assets as it is expected to be received within the normal operating cycle of the business. The Company measures the loss allowance for trade receivables at an amount equal to lifetime expected credit losses. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as forecast direction of conditions at the reporting date.

Financial liabilities:

Initial recognition and measurement

Financial liabilities are initially measured at its fair value plus or minus, in the case of a financial liability not at FVTPL, transaction costs that are directly attributable to the issue/origination of the financial liability.

Subsequent measurement

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in the Statement of Profit and Loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in the Statement of Profit and Loss. Any gain or loss on derecognition is also recognized in the Statement of Profit and Loss.

Classification as debt or equity

Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. The repurchase of the Company's own equity instruments is recognized and deducted directly in equity. No gain or loss is recognized in profit or loss on the purchase, sale, issue or cancellation of the Company's own equity instruments.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Derecognition of financial liabilities

Financial liability is derecognized when the obligation specified in the contract is discharged, cancelled or expires. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss.

Trade Payables

Trade payables are amounts due to vendors for purchase of goods or services acquired in the ordinary course of business and are classified as current liabilities to the extent it is expected to be paid within the normal operating cycle of the business.

Derivative financial instruments:

The Company uses derivative financial instruments, such as foreign exchange forward contracts, to manage its exposure to interest rates and foreign exchange risks. Such derivative financial instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value.

Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

The Company enters into derivative contracts to hedge risks which are not designated in any hedging relationship i.e., hedge accounting is not followed. Such contracts are accounted for at FVTPL.

Offsetting financial instruments:

Financial assets and liabilities are off-set and the net amount is reported in the Balance Sheet where there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

2.10.Revenue recognition

The Company derives revenue principally from sales of pharma products. Revenue from the sale of products is recognized when the Company satisfies a performance obligation in accordance with the provisions of the contract with the customer. This is achieved when control of the product has been transferred to the customer, which is generally determined when title, ownership, risk of obsolescence and loss pass to the customer and the Company has the present right to payment. Revenue is measured at the transaction price, being the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods, net of returns and allowances, trade discount and volume rebates, and goods and service tax.

Interest income

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition. Interest income is included in 'Other Income' in the Statement of Profit and Loss.

Dividend income

Dividend income from investment is recognized as revenue when the right to receive is established.

2.11.Contract Liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognized when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Company performs under the contract.

2.12.Employee Benefits

Short-term benefits

Short-term benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Defined contribution plans

The Company makes defined contributions to the Government Employee Provident Fund, which is recognized in the Standalone Statement of Profit and Loss, on an accrual basis. The Company recognizes contribution payable to the provident fund scheme as an expense when an employee renders the related service. The Company has no obligation other than the contribution payable to the provident fund.

Defined benefit plans

The Company operates a funded defined benefit gratuity plan for its eligible employees. The gratuity plan is governed by the applicable provisions of the Code on Social Security, 2020, read with the relevant rules thereunder, which have subsumed the earlier provisions of the Payment of Gratuity Act, 1972.

The Company's liabilities are determined on the basis of actuarial valuation made at the end of each financial year using the projected unit credit method. Obligation is measured at the present value of estimated future cash flows using a discounted rate that is determined by reference to market yields at the Standalone Balance Sheet date on Government bonds, where the terms of the Government bonds are consistent with the estimated terms of the defined benefit obligation. The Company has established a gratuity trust and has taken out a group gratuity policy to partially fund its gratuity obligation. Plan assets are measured at fair value at the balance sheet date. The net defined benefit liability (or asset) represents the present value of the defined benefit obligation less the fair value of plan assets.

The net interest cost is calculated by applying the discount rate to the defined benefit obligation. This cost is included in the 'Employee benefits expense' in the Standalone Statement of Profit and Loss. Re-measurement gains or losses arising from changes in actuarial assumptions are recognized in the period in which they occur, directly in OCI. These are presented as re-measurement gains or losses on defined benefit plans under other comprehensive income in other equity. Remeasurement gains or losses are not reclassified subsequently to the Standalone Statement of Profit and Loss.

Compensated absences

The employees of the Company are entitled to compensated absences. Accumulated compensated absences, which are expected to be encashed beyond twelve months from the end of the year, are treated as long-term employee benefits. Liability for such benefit is provided on the basis of actual leave balance as at the Balance Sheet date. The Company records an obligation for compensated absences in the period in which the employee renders the services that increases this entitlement. The Company measures the expected cost of compensated absences as the additional amount that the Company expects to pay as a result of the unused entitlement that has accumulated at the end of the reporting period. The Company recognizes accumulated compensated absences based on actuarial valuation in the Standalone Statement of Profit and Loss.

2.13.Income Taxes

Current tax

The Income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

Income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in India.

The management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is recognized on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognized for all taxable temporary differences, except when the deferred tax liability arises from the initial recognition of goodwill or an asset or a liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor the taxable profit or loss.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized, except when the deferred tax

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

asset relating to the deductible temporary difference arises from the initial recognition of an asset or a liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor the taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date.

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

2.14.Provisions, Contingent Liabilities and Contingent Assets

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, it's carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount can be reliably estimated. The expense relating to a provision is presented in the Standalone Statement of Profit and Loss, net of any reimbursements.

A present obligation that arises from past events, where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made, is disclosed as a contingent liability. Contingent liabilities are also disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company (Refer Note 40).

Claims against the Company, where the possibility of any outflow of resources in settlement is remote, are not disclosed as contingent liabilities.

Contingent assets are not recognized in financial statements since this may result in the recognition of income that may never be realized. However, when the realization of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each Balance Sheet date.

2.15.Leases – Company as a Lessee

At inception of a contract, the Company assesses whether a contract is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified assets for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset the Company assesses whether contract involves the use of an identified asset, the Company has a right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use and the Company has the right to direct the use of the asset.

At the inception date, right-of-use asset is recognized at cost which includes present value of lease payments adjusted for any payments made on or before the commencement of lease and initial direct cost, if any. It is subsequently measured at cost less accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. Right-of-use asset is depreciated using the straight-line method from the commencement date over the earlier of useful life of the asset or the lease term. When the Company has purchase option available under lease and cost of right-of-use assets reflects that purchase option will be exercised, right-of-use asset is depreciated over the useful life of underlying asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognized in the statement of profit and loss.

At the inception date, lease liability is recognized at present value of lease payments that are not made at the commencement of lease. Lease liability is subsequently measured by adjusting the carrying amount to reflect interest, lease payments and remeasurement, if any.

Lease payments are discounted using the incremental borrowing rate or interest rate implicit in the lease if the rate can be determined.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

The Company has elected not to apply the requirements of Ind AS 116 to leases that has a term of 12 months or less and leases for which the underlying asset is of low value.

2.16.Dividends

Dividends are recognised when they become legally payable. In the case of interim dividends to equity shareholders, this is when declared by the directors. In the case of final dividends, this is when approved by the shareholders at the annual general meeting.

2.17.Segment Information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Chief Operating decision-maker is responsible for allocating resources and assessing the performance of the operating segments and makes strategic decisions.

2.18.Goods and Services Tax (GST) paid on acquisition of assets or on incurring expenses

Expenses and assets are recognised net of the amount of GST, except when the tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable; when receivables and payables are stated with the amount of tax included. The net amount of tax recoverable from, or payable to, the taxation authority is included as part of other current/non-current assets/ liabilities in the balance sheet.

2.19.Events after the reporting period

If the Company receives information after the reporting period, but prior to the date when the financial statements are approved for issue, about conditions that existed at the end of the reporting period, it will assess whether the information affects the amounts that it recognises in its standalone financial statements. The Company will adjust the amounts recognised in its standalone financial statements to reflect any adjusting events after the reporting period and update the disclosures that relate to those conditions considering the new information. For non-adjusting events after the reporting period, the Company will not change the amounts recognised in its standalone financial statements but will disclose the nature of the non-adjusting event and an estimate of its financial effect, or a statement that such an estimate cannot be made, if applicable.

2.20.Share-based payments

The Company operates an equity-settled share-based compensation plan under which the Company receives services from employees as consideration for equity instruments (options) of the Company. The fair value of the employee services received in exchange for the grant of the options is recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest. It recognises the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity (share-based payment reserve). When the options are exercised, the Company issues new shares. The proceeds received are credited to share capital and securities premium. The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

The Company also recognises the cost of options granted to employees of subsidiary companies as an increase in the cost of investment in the respective subsidiary, with a corresponding increase in equity (share-based payment reserve).

2.21.Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss attributable to equity holders of the Company by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders of the Company and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.3a : Property, plant and equipment

The changes in the carrying value of property, plant and equipment for the year ended 31 March 2026 are as follows:

Particulars	Buildings	Plant and equipment	Furniture and fixtures	Vehicles	Office equipment	Computer	Total
Cost							
Balance as at 1 April 2025	1,192.85	3,527.88	234.16	68.33	14.59	83.87	5,121.68
Additions	20.86	413.16	–	25.33	0.22	4.16	463.73
Disposals/ Deletions	–	(12.19)	(1.50)	–	–	–	(13.69)
Balance as at 31 March 2026	**1,213.71**	**3,928.85**	**232.66**	**93.66**	**14.81**	**88.03**	**5,571.72**
Accumulated depreciation							
Balance as at 1 April 2025	218.09	1,126.50	94.62	62.58	13.14	70.81	1,585.74
Depreciation	44.57	229.02	27.12	1.86	0.28	4.31	307.16
Disposals/ Deletions	–	(7.93)	–	–	–	–	(7.93)
Balance as at 31 March 2026	**262.66**	**1,347.59**	**121.74**	**64.44**	**13.42**	**75.12**	**1,884.97**
Net carrying value							
Balance as at 31 March 2026	**951.05**	**2,581.26**	**110.92**	**29.22**	**1.39**	**12.91**	**3,686.75**

The changes in the carrying value of property, plant and equipment for the year ended 31 March 2025 are as follows:

Particulars	Buildings	Plant and equipment	Furniture and fixtures	Vehicles	Office equipment	Computer	Total
Cost							
Balance as at 1 April 2024	817.64	2,613.35	161.98	67.25	14.42	81.07	3,755.71
Additions	375.21	917.70	72.18	1.08	0.17	2.80	1,369.14
Disposals/ Deletions	–	(3.17)	–	–	–	–	(3.17)
Balance as at 31 March 2025	**1,192.85**	**3,527.88**	**234.16**	**68.33**	**14.59**	**83.87**	**5,121.68**
Accumulated depreciation							
Balance as at 1 April 2024	179.93	935.47	69.98	61.10	12.61	66.76	1,325.85
Depreciation	38.16	192.86	24.64	1.48	0.53	4.05	261.72
Disposals/ Deletions	–	(1.83)	–	–	–	–	(1.83)
Balance as at 31 March 2025	**218.09**	**1,126.50**	**94.62**	**62.58**	**13.14**	**70.81**	**1,585.74**
Net carrying value							
Balance as at 31 March 2025	**974.76**	**2,401.38**	**139.54**	**5.75**	**1.45**	**13.06**	**3,535.94**

(i) Addition to property, plant and equipment include capital expenditure

Description	As at 31 March 2026	As at 31 March 2025
Capital Expenditure (R & D)	2.23	6.74

Assets charged as security

The Company does not have any outstanding loans or borrowings and repayment to lenders during the current and previous year. The Company has been sanctioned working capital limits from consortium banks through collateral security of equitable / registered mortgage on first pari-passu charge basis of whole of the movable fixed assets including without limitation movable plant and machinery, capital work in process, machinery spares, tools and accessories and other movables, present and future, Land bearing plot number L-82 & L-83, Phase II - E admeasuring 23,900 sq. mtrs. of the property situated at Verna Industrial Estate in Goa together with all buildings and structures, machinery etc. on the said properties and hypothecation on first pari-passu charge over the Company's entire current assets both present and future.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.3b : Right of use assets

The Company's lease asset classes primarily consist of leases for land and buildings.The changes in the carrying value of right of use assets for the year ended 31 March 2026 are as follows:

Particulars	Leasehold Land	Building	Total
Cost			
Balance as at 1 April 2025	224.41	152.91	377.32
Additions	–	44.61	44.61
Deletions	–	(15.18)	(15.18)
Balance as at 31 March 2026	**224.41**	**182.34**	**406.75**
Accumulated depreciation			
Balance as at 1 April 2025	15.67	88.62	104.29
Depreciation	7.65	20.34	27.99
Deletions	–	(0.76)	(0.76)
Balance as at 31 March 2026	**23.32**	**108.20**	**131.52**
Net carrying value			
Balance as at 31 March 2026	**201.09**	**74.14**	**275.23**

The changes in the carrying value of right of use assets for the year ended 31 March 2025 are as follows:

Particulars	Leasehold Land	Building	Total
Cost			
Balance as at 1 April 2024	224.41	109.37	333.78
Additions	–	43.54	43.54
Balance as at 31 March 2025	**224.41**	**152.91**	**377.32**
Accumulated Depreciation			
Balance as at 1 April 2024	8.02	70.53	78.55
Depreciation	7.65	18.09	25.74
Balance as at 31 March 2025	**15.67**	**88.62**	**104.29**
Net carrying value			
Balance as at 31 March 2025	**208.74**	**64.29**	**273.03**

The following is the break-up of current and non-current lease liabilities:

Particulars	As at 31 March 2026	As at 31 March 2025
Non-current (Refer note 17)	87.21	82.58
Current (Refer note 20)	34.08	25.84
	121.29	**108.42**

The following is the movement in lease liabilities.

Particulars	As at 31 March 2026	As at 31 March 2025
Balance recognised at the beginning of the year	108.42	81.27
Additions	43.65	42.70
Lease Termination	(14.25)	–
Finance cost accrued	13.27	11.74
Payment of lease liabilities	(29.80)	(27.29)
Balance recognised at the end of the year	**121.29**	**108.42**

Incremental borrowing rate applied to lease liabilities is 11.93% (31 March 2025: 11.93%).

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

The table below provides details regarding the contractual maturities of lease liabilities on an undiscounted basis:

Particulars	As at 31 March 2026	As at 31 March 2025
Less than 1 year	25.93	25.93
1 year to 5 years	111.53	72.71
More than 5 years	199.51	179.88

The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

The following are the amounts recognised in the statement of profit and loss:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Depreciation expense of right of use assets	27.99	25.74
Interest expense on lease liabilities	13.27	11.74
	41.26	**37.48**

The Company had total cash outflows for leases of ₹29.80 million during the year ended 31 March 2026 (31 March 2025: ₹27.29 million).

Short term lease recognised as an expense for the year ended 31 March 2026 is aggregating to ₹16.99 million (31 March 2025: ₹26.41 million).

Note No.4 : Other intangible assets

The changes in the carrying value of other intangibles assets for the year ended 31 March 2026 are as follows:

Particulars	Product related intangibles *	Software	Total
Cost			
Balance as at 1 April 2025	32.23	20.37	52.60
Balance as at 31 March 2026	**32.23**	**20.37**	**52.60**
Accumulated amortisation			
Balance as at 1 April 2025	21.87	5.99	27.86
Amortisation for the year	3.22	3.93	7.15
Balance as at 31 March 2026	**25.09**	**9.92**	**35.01**
Net carrying value			
Balance as at 31 March 2026	**7.14**	**10.45**	**17.59**

The changes in the carrying value of other intangibles assets for the year ended 31 March 2025 are as follows:

Particulars	Product related intangibles *	Software	Total
Cost			
Balance as at 1 April 2024	32.23	19.23	51.46
Additions	–	1.14	1.14
Balance as at 31 March 2025	**32.23**	**20.37**	**52.60**
Accumulated amortisation			
Balance as at 1 April 2024	18.65	2.15	20.80
Amortisation for the year	3.22	3.84	7.06
Balance as at 31 March 2025	**21.87**	**5.99**	**27.86**
Net carrying value			
Balance as at 31 March 2025	**10.36**	**14.38**	**24.74**

*Product related Intangibles consists of 'acquired' intangible assets.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.5 : Investments (Non-current)

Equity instruments of subsidiaries (fully paid)

Investment carried at cost (unquoted)

Particulars	Place of business / Country of Incorporation	Extent of holding	Face Value	No of shares	As at 31 March 2026 Amount	As at 31 March 2025 Amount
Nova Pharmaceuticals Australasia Pty Ltd.	Australia	60%	AUD 1	90	15.91	15.91
Marksans Pharma (UK) Limited	United Kingdom	100%	GBP 1	8,596,941	677.57	669.23
Marksans Pharma Inc.	United State of America	100%	USD 0.01	110	1,681.86	1,675.60
Access Healthcare for Medical Products LLC	United Arab Emirates	100%	AED 1000	324	296.79	296.79
Equity shares outstanding at the end of the year					**2,672.13**	**2,657.53**
None of the subsidiaries are listed on any stock exchange outside India and these investments are carried at cost. There is no accumulated impairment as at current or previous year end.						
Additions due to Share-based Payments (Refer Note 1 below)						
Marksans Pharma (UK) Limited	United Kingdom				8.34	-
Marksans Pharma Inc.	United State of America				6.26	-
					14.60	**–**
Aggregate amount of quoted investment					–	–
Aggregate amount of market value of quoted investments					–	–
Aggregate amount of Un-quoted investment					2,672.13	2,657.53
Aggregate amount of impairment in the value of investments					–	–

Notes:

1. During the year ended 31 March 2026, the Board of Directors and Shareholders of the Company approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 2,300,000 equity share of face value of ₹ 1/- each. Under the said Scheme, the Company has granted 400,000 equity stock options of face value of ₹ 1/- each on 24 September 2025 to certain eligible employees of the Company and its subsidiary companies. Consequently, for the options granted to the eligible employees of the subsidiary companies, the Company has recognised an increase in the cost of investment in subsidiaries.

2. During the year ended 31 March 2026, the Company incorporated two wholly owned subsidiaries, namely Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada, on 16 January 2026 and 22 January 2026, respectively. As at 31 March 2026, no capital contribution or other investment has been made by the Company in these subsidiaries and, accordingly, the carrying amount of investment in these subsidiaries is Nil.

Note No.6 : Other financial assets (non-current)

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Security deposits	11.36	9.16
Bank Deposit with more than 12 months maturity #	0.10	1.68
	11.46	**10.84**

Includes deposits amounting to ₹ Nil (31 March 2025: ₹1.58 million) given against bank guarantees.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.7 : Other non-current assets

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Capital advances	5.86	44.40
Balances with government authorities	169.68	173.20
	175.54	**217.60**

Note No.8 : Non-current tax assets (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Advance tax (net)	10.81	11.11
	10.81	**11.11**

Note No.9 : Inventories

Particulars	As at 31 March 2026	As at 31 March 2025
a. Raw materials and packing materials	1,620.42	1,748.27
b. Work-in-progress	181.33	241.07
c. Finished Goods	81.69	51.14
d. Stock-in-Trade	7.86	11.62
	1,891.30	**2,052.10**

The Write-downs of inventories to net realisable value as at 31 March 2026 was ₹ 7.14 million (31 March 2025 : ₹4.95 million).

Note No.10 : Investments (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Investments carried at fair value through profit or loss (Quoted)		
Liquid mutual funds	–	7.42
	–	**7.42**
Aggregate amount of quoted investments and market value thereof	–	7.42
Aggregate amount of Un-quoted investment	–	–
Aggregate amount of impairment in the value of investments	–	–

Note No.11 : Trade receivables

Particulars	As at 31 March 2026	As at 31 March 2025
Trade receivables from contract with customers	448.05	519.07
Trade receivables from contract with customers - related parties (Refer note 38 - Related party disclosures)	5,786.57	4,991.89
	6,234.62	**5,510.96**
Breakup of security details		
Trade receivables considered good - secured	–	–
Trade receivables considered good - unsecured	6,234.62	5,508.83
Trade receivables considered good which have significant increase in credit risk	–	–
Trade receivables - Credit impaired	–	2.13
	6,234.62	**5,510.96**
Less:- Loss allowance	–	(15.15)
	6,234.62	**5,495.81**

No trade receivables are due from directors or other officers of the Company either severally or jointly with any other person.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Ageing of Trade receivable as on 31 March 2026

Particulars	Outstanding for following period from the due date of payments						
	Not due	Less than 6 Months	6 Months to 1 Year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables							
Considered good	5,370.87	863.28	0.47	–	–	–	6,234.62
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	–	–	–	–	–
Disputed Trade Receivables							
Considered good	–	–	–	–	–	–	–
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	–	–	–	–	–
Total	**5,370.87**	**863.28**	**0.47**	**–**	**–**	**–**	**6,234.62**
Less: Loss Allowances (including Expected credit loss)							–
Net Trade Receivable							6,234.62
Expected credit loss provision	–	–	–	–	–	–	–
Exepected loss rate	–	–	–	–	–	–	

During the year ended 31 March 2026, certain trade receivables against which loss allowance had been recognised were written off. Consequently, the loss allowance has been utilised, resulting in Nil closing loss allowance.

Ageing of Trade receivable as on 31 March 2025

Particulars	Outstanding for following period from the due date of payments						
	Not due	Less than 6 Months	6 Months to 1 Year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade receivables							
Considered good	4,589.95	724.43	159.76	34.69	–	–	5,508.83
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	–	2.13	–	–	2.13
Disputed Trade receivables							
Considered good	–	–	–	–	–	–	–
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	–	–	–	–	–
Total	**4,589.95**	**724.43**	**159.76**	**36.82**	**–**	**–**	**5,510.96**
Less: Loss Allowances (including Expected credit loss)							(15.15)
Net Trade Receivable							5,495.81
Expected credit loss provision	–	6.31	0.16	6.55	–	–	13.02
Exepected loss rate	–	0.87%	0.10%	18.89%	–	–	

Loss allowances includes provision of ₹ Nil (Year ended 31 March 2025: ₹13.02 million) made on account of expected credit loss on Trade Receivables.

Note No.12a : Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Balances with bank		
In current accounts	368.82	450.68
In Exchange Earners' Foreign Currency account (EEFC)	193.60	0.01
Fixed deposit with original maturity less than 3 months	350.00	151.89
Cash in hand	0.08	0.10
	912.50	**602.68**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.12b : Bank balances other than above

Particulars	As at 31 March 2026	As at 31 March 2025
Earmarked balances with banks *	3.87	3.93
Term deposits with original maturity of more than three months but less than twelve months	3,551.28	2,080.30
	3,555.15	**2,084.23**

* Earmarked balances with banks represent balance maintained in specific bank accounts for payment of dividends. The use of these funds is restricted and can only be used to pay dividend. The corresponding liability for payment of dividends is included in other current financial liabilities (Refer note 22).

Note No.13 : Other financial assets (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Deposits	0.24	1.47
Interest accrued on fixed deposits	33.09	21.44
	33.33	**22.91**

Note No.14 : Other current assets

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Advance to vendors	51.46	49.26
Prepaid expenses	82.24	68.20
Balances with government authorities	320.36	429.92
Other advances	9.82	9.70
	463.88	**557.08**

Note No.15 : Share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Authorised				
Equity shares of ₹ 1/- each	550,000,000	550.00	550,000,000	550.00
7% Redeemable cumulative preference shares of ₹ 100/- each	1,400,000	140.00	1,400,000	140.00
Total	**551,400,000**	**690.00**	**551,400,000**	**690.00**
Issued, subscribed & fully paid up				
Equity shares of H1/- each	453,163,746	453.16	453,163,746	453.16
	453,163,746	**453.16**	**453,163,746**	**453.16**

a. Reconciliation of the equity shares outstanding is set out below:

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Equity shares outstanding at the beginning of the year	453,163,746	453.16	453,163,746	453.16
Equity shares outstanding at the end of the year	**453,163,746**	**453.16**	**453,163,746**	**453.16**

b. Terms/rights attached to equity shares

The Company has only one class of equity shares having a face value of ₹1/- per share. All the equity shares rank pari passu in all respect. Every holder of equity shares present at a meeting in person or by proxy is entitled to one vote, and upon a poll each share is entitled to one vote. The equity share holders are entitled to dividend, if declared by the shareholders in an Annual General Meeting, in proportion to the number of equity shares held by the shareholders. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

c. The Company has not issued bonus shares during the period of five years immediately preceding the reporting date.

d. During FY 2022 - 23, the Board of Directors at its meeting held on 08 July 2022 had approved the proposal to buy back its own fully paid up Equity Shares of face value ₹1/- each up to a maximum price of ₹60 per Equity Share ("Maximum Buyback Price") payable in cash for an aggregate buy back consideration not exceeding ₹600 million ("Maximum Offer Size") through the open market route on the stock exchanges from the equity shareholders / beneficial owners of the Equity Shares of the Company (other than those who are promoters, members of the promoter group and persons in control of the Company). In FY 2022 - 23, the Company bought back and accounted buy back of 6,474,276 equity shares which were extinguished on or before 18 January 2023 and completed the aforesaid buyback offer. Aforesaid buyback offer resulted in a cash outflow of ₹401.66 million (including transaction costs of ₹7.22 million and tax on buyback of ₹73.30 million). The volume weighted average buyback price was ₹49.60 per equity share comprising 1.58% of the pre buyback paid up equity share capital of the Company. The Company funded the buy back from its free reserves, including securities premium, as explained in Section 68 of the Companies Act, 2013. In accordance with Section 69 of the Companies Act, 2013, the Company had created "Capital Redemption Reserve" of ₹6.47 million equal to the nominal value of the shares bought back as an appropriation from retained earnings. The Company has not bought back equity shares for consideration other than cash during the period of five years immediately preceding the reporting date.

e. **Details of equity shares held by promoters**

Promoters for the purpose of this disclosure means promoters as defined under Section 2(69) of Companies Act, 2013.

Name of shareholder	As at 31 March 2026		As at 31 March 2025		% changed during the year
	No. of shares held at the end of the year	% of total shares	No. of shares held at the end of the year	% of total shares	
Equity shares of ₹1/- each fully paid					
Mr. Mark Saldanha	198,491,553	43.80	198,491,553	43.80	–
Mrs. Sandra Saldanha	330,456	0.07	330,456	0.07	–

The percentage shareholding above has been computed considering the outstanding number of shares of 453,163,746 and 453,163,746 as at 31 March 2026 and 31 March 2025, respectively.

f. **Details of shareholders holding more than 5% shares in the Company**

Name of shareholder	As at 31 March 2026		As at 31 March 2025		Change in current year
	No. of shares held	% of Holding	No. of shares held	% of Holding	
Equity shares of ₹1/- each fully paid					
Mr. Mark Saldanha	198,491,553	43.80	198,491,553	43.80	–
OrbiMed Asia IV Mauritius FVCI Limited	39,050,881	8.62	49,324,324	10.88	20.83%

g. The Company has not issued any shares for consideration other than cash during the period of five years immediately preceding the reporting date.

h. Information relating to the Company's Employee Option Plan, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period is set out in note 34.1.

Note No.16 : Other equity

Particulars	As at 31 March 2026	As at 31 March 2025
a. Capital reserves		
Opening balance	0.12	0.12
Closing balance	**0.12**	**0.12**
b. Capital redemption reserve		
Opening balance	141.47	141.47
Closing balance	**141.47**	**141.47**
c. Securities premium account		
Opening balance	5,044.98	5,044.98
Closing balance	**5,044.98**	**5,044.98**
d. General reserve		
Opening balance	3,137.37	3,137.37
Closing balance	**3,137.37**	**3,137.37**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	As at 31 March 2026	As at 31 March 2025
e. Share-based Payments Reserve (Equity)		
Opening Balance	–	–
Share-based payment expenses	33.38	–
Closing balance	**33.38**	**–**
f. Retained earnings		
Opening balance	5,057.76	3,449.95
(+) Net Profit for the current year	3,006.98	1,882.72
(-) Dividend paid on equity shares *	(362.53)	(271.90)
(-/+) Other comprehensive income	10.41	(3.01)
Closing balance	**7,712.62**	**5,057.76**
	16,069.94	**13,381.70**

* Dividend paid during the year is as follows:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Dividend per share (in absolute ₹)	0.80	0.60
Dividend paid during the year	362.53	271.90

The Board of Directors, in the meeting held on 26 May 2026, has recommended final dividend of ₹0.90 per equity share of ₹1/- each (90%) for the financial year 2025-26.

Note No.17 : Lease liabilities (non-current)

Particulars	As at 31 March 2026	As at 31 March 2025
Lease liabilities (Refer Note 3b - right of use assets)	87.21	82.58
	87.21	**82.58**

Note No.18 : Provisions (non-current)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for gratuity (Refer note 34 - Post-Employment Benefits)	44.88	47.97
Provision for compensated absences	12.03	9.73
	56.91	**57.70**

Note No.19 : Deferred tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred tax liabilities		
Tax effect of items resulting in taxable temporary differences		
Allowance on property, plant and equipment, intangible assets and Right of Use Assets	187.51	149.00
Total Deferred tax liabilities	**187.51**	**149.00**
Deferred tax assets		
Tax effect of items resulting in deductible temporary differences		
Employee benefit obligations	18.62	18.16
Deferred tax on account of leases (Ind AS 116)	5.26	4.41
Loss Allowance for trade receivables	(3.81)	3.81
Change in fair valuation of financial assets	0.37	0.08
Total deferred tax assets	**20.44**	**26.46**
Deferred tax on other comprehensive income assets / (liabilities)	3.50	(1.01)
Deferred tax liabilities (net)	**170.57**	**121.53**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.19.1 Current Tax:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Amounts recognised in profit or loss		
Current tax	851.21	513.83
Tax adjustments of earlier years	11.70	7.61
	862.91	**521.44**
Deferred tax :		
Current year origination and reversal of temporary differences	45.54	28.43
Deferred tax expense	**45.54**	**28.43**
Total income tax recognised in profit or loss	**908.45**	**549.87**
Amounts recognised in other comprehensive income		
Remeasurements of post-employment benefit obligations	(3.50)	1.01
Total income tax recognised in other comprehensive income	**(3.50)**	**1.01**

Reconciliation of effective tax rate	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Profit before tax	3,915.43	2,432.59
Enacted tax rate in India	25.17%	25.17%
Expected income tax expenses	985.44	612.23
Tax effect of:		
Expenses not deductible in determining Taxable Profit	8.88	7.04
Effect of concessions (Section 80JJAA and Section 80M of the Income-tax Act, 1961)	(104.82)	(75.90)
Difference on account of different tax rate for short term capital gains	(0.39)	–
Tax adjustment for earlier years - Current tax	11.70	7.61
Tax adjustment for earlier years - Deferred tax - Others	–	(3.77)
Others	7.64	2.66
Tax expenses as per statement of profit and loss	**908.45**	**549.87**

Note No.20 : Lease liabilities (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Lease liabilities (Refer Note 3b - right of use assets)	34.08	25.84
	34.08	**25.84**

Note No.21 : Trade payables

Particulars	As at 31 March 2026	As at 31 March 2025
a) Total outstanding dues of micro and small enterprises *	20.12	36.33
b) Total outstanding dues of other than micro and small enterprises #	1,788.01	1,999.01
	1,808.13	**2,035.34**

* The information as required to be disclosed pursuant under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006) has been determined to the extent such parties have been identified based on the information available with the Company.

Trade payables include amount due to related parties ₹1.64 million (31 March 2025: ₹14.01 million), refer note 38 - related party disclosures.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	As at 31 March 2026	As at 31 March 2025
Amount remaining unpaid:		
Principal	20.12	36.33
Interest	–	–
Interest paid by the Company under MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day	–	–
Interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006;	–	–
Interest accrued and remaining unpaid at the end of the year	–	–
Interest remaining due and payable (pertaining to prior years), until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under Section 23 of MSMED Act 2006.	–	–

Ageing of Trade payable as on 31 March 2026

Particulars	Outstanding for following period from the due date of payments					
	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed - MSME	9.20	10.92	–	–	–	20.12
Undisputed - Others	739.96	1,037.66	9.40	0.96	0.03	1,788.01
Disputed - MSME	–	–	–	–	–	–
Disputed -Others	–	–	–	–	–	–
Total	**749.16**	**1,048.58**	**9.40**	**0.96**	**0.03**	**1,808.13**

Ageing of Trade payable as on 31 March 2025

Particulars	Outstanding for following period from the due date of payments					
	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed - MSME	12.36	23.97	–	–	–	36.33
Undisputed - Others	900.59	1082.78	14.39	0.07	1.18	1,999.01
Disputed - MSME	–	–	–	–	–	–
Disputed -Others	–	–	–	–	–	–
Total	**912.95**	**1,106.75**	**14.39**	**0.07**	**1.18**	**2,035.34**

Note No.22 : Other financial liabilities (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Employee benefits payable	167.59	138.77
Unclaimed dividend *	3.87	3.93
Security deposits received	4.39	2.21
Derivative financial liabilities - forward contract	68.62	39.37
Others	8.44	7.71
	252.91	**191.99**

* There are no dividend unclaimed for seven consecutive years or more to be credited to investor education and protection fund.

Note No. 23 : Other current liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Advance from customers - others	0.01	6.23
Advance from customers - related parties (Refer note 38)	711.92	957.05
Capital creditors	31.70	94.29
Statutory dues payable	25.43	25.88
	769.06	**1,083.45**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.24 : Provisions (Current)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for gratuity (Refer note 34 - Post-Employment Benefits)	–	11.31
Provision for compensated absences	3.18	3.16
	3.18	**14.47**

Note No.25 : Current tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for Income tax (net)	235.14	105.26
(Net of advance tax ₹616.07 million (31 March 2025: ₹408.57 million)		
	235.14	**105.26**

Note No.26 : Revenue from operations

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Revenue from contracts with customers		
Sale of products	13,321.81	11,659.74
Other operating revenues :-		
Scrap sales	44.93	29.50
Export incentives	48.02	54.50
	13,414.76	**11,743.74**

Reconciliation of revenue recognised in the standalone statement of profit and loss with the contracted price :

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Revenue as per contracted price	13,770.01	11,785.65
Less : Trade discounts	355.25	41.91
Less : Sales returns	–	–
Revenue from operations	**13,414.76**	**11,743.74**

Analysis of revenues by geography:

Region	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
US & North America	9,218.57	7,318.77
Europe and UK	2,609.04	2,927.41
Australia and New Zealand	772.01	513.12
Rest of World	815.14	984.44
	13,414.76	**11,743.74**

The performance obligation is satisfied when control of the goods are transferred to the customers based on the contractual terms. Payment terms with customers vary depending upon the contractual terms of each contract.

Contract Liabilities from contracts with customers :

The Company records a contract liability when cash payments are received in advance of it's performance.

Particulars	As at 31 March 2026	As at 31 March 2025
Contract liabilities from contracts with customers (Refer note 23)	711.93	963.28

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.27 : Other income

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Interest Income on bank deposits at amortised costs	157.53	182.16
Fair value gain on financial instruments measured at fair value through profit or loss	–	0.41
Short term gain on redemption of mutual funds	12.27	6.94
Exchange gain in foreign currency translation & transaction-(net)	474.27	194.79
Dividend from equity investments in subsidiaries	386.16	263.69
Bad debts recovery	3.61	–
Miscellaneous income	1.49	9.88
	1,035.33	**657.87**

Note No.28 : Cost of materials consumed

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Raw materials and packing materials		
Inventory at the beginning of the year	1,748.27	1,597.68
Add: Purchases	5,896.42	5,522.36
Less: Inventory at the end of the year	(1,620.42)	(1,748.27)
	6,024.27	**5,371.77**

Note No.29 : Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Inventory at the beginning of the year		
Work-in-progress	241.07	238.76
Finished goods	51.14	63.96
Stock-in-trade	11.62	8.09
	303.83	**310.81**
Less: Inventory at the end of the year		
Work-in-progress	181.33	241.07
Finished goods	81.69	51.14
Stock-in-trade	7.86	11.62
	270.88	**303.83**
	32.95	**6.98**

Note No.30 : Employee benefits expense

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Salaries and wages including bonus	1,080.88	929.63
Contribution to provident and other funds	69.59	62.57
Compensated absences	7.37	8.36
Gratuity expenses (Refer note 34 - Employee post- retirement benefits)	36.05	10.03
Employee share-based payment expense	18.78	–
Staff welfare expenses	7.10	6.19
	1,219.77	**1,016.78**

Note No.31 : Finance costs

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Interest on lease liabilities	13.27	11.74
	13.27	**11.74**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.32 : Depreciation and amortization expense

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Depreciation on property, plant and equipment	307.16	261.72
Depreciation on right-of-use assets	27.99	25.74
Amortization of intangible assets	7.15	7.06
	342.30	**294.52**

Note No.33 : Other expenses

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Water, power & fuel	329.53	307.28
Repairs & maintenance - plant and equipments	193.91	150.60
Repairs & maintenance - building	2.07	5.03
Repairs & maintenance - others	14.86	18.63
Contract labour and other manufacturing expenses	448.55	471.95
Rent	16.99	26.41
Rates & taxes	1.32	1.38
Travel and conveyance expenses	71.39	64.85
Communication expenses	3.69	2.88
Courier & postage expenses	5.87	4.60
Printing & stationery	14.15	15.49
Auditors remuneration (Refer note 33.1)	7.01	6.98
Legal & professional fees	37.43	34.39
Loss on lease termination	0.17	–
Corporate social responsibility expenses (Refer note 42)	35.28	27.98
Loss on sale of property, plant and equipment	0.64	0.33
Compliance fees (US FDA and others)	158.47	205.44
Freight outward & export clearing expenses	613.28	737.85
Bad debts	128.65	63.89
Loss allowance on trade receivables	–	15.15
Selling & distribution expenses	37.47	29.67
Miscellaneous expenses	50.75	55.84
	2,171.48	**2,246.62**

Note No.33.1 : Details of payments to the auditors

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Audit fees	6.60	6.60
Other services (Certification)	0.18	0.15
Reimbursement of out of pocket expenses	0.23	0.23
	7.01	**6.98**

Note No.34 : Post-Employment Benefits

The following are the employee benefit plans applicable to the employees of the Company:

i Defined Contribution Plan

The Company has a defined contribution plan in the form of Provident Fund and National Pension Scheme. Contributions are made to provident fund in India for employees at the rate of 12% of basic salary as per regulations. The contributions are made to registered provident fund administered by the government. The obligation of the Company is limited to the amount contributed and it has no further contractual nor any constructive obligation.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

The Company's contribution to provident fund ₹61.89 million (31 March 2025: ₹55.58 million) has been recognised in profit or loss under the head employee benefits expense.

The Company's contribution to national pension scheme ₹2.36 million (31 March 2025: ₹2.17 million) has been recognised in profit or loss under the head employee benefits expense.

ii Gratuity (Defined benefit plan)

The Company operates a funded defined benefit gratuity plan for its eligible employees. The gratuity plan is governed by the applicable provisions of the Code on Social Security, 2020, read with the relevant rules thereunder, which have subsumed the earlier provisions of the Payment of Gratuity Act, 1972. Under the plan, eligible employees are entitled to gratuity benefits on completion of the requisite period of continuous service, as applicable, at the time of cessation of employment. The gratuity benefit payable is determined with reference to the employee's length of service and last drawn salary / wages, in accordance with the statutory provisions and the terms of the plan.

The gratuity plan is funded through a gratuity trust. The plan assets are administered by the Board of Trustees, which is responsible for the administration of the trust, including oversight of the investment of plan assets and monitoring of the funding position of the plan in accordance with the trust deed and applicable regulatory requirements.

The Company's defined benefit obligation is actuarially valued by an independent actuary using the projected unit credit method.

The Board of Trustees periodically reviews the funding position of the gratuity plan, including the asset-liability position, investment performance and funding requirements. The Company makes contributions to the gratuity fund based on the actuarial valuation, funding requirements and applicable statutory requirements.

a Expense recognised in the statement of profit and loss for the year:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Current service cost	8.87	6.72
Past service cost	23.53	–
Interest cost on benefit obligation (net)	3.65	3.31
Total expenses included in employee benefits expense	**36.05**	**10.03**

b Expense / (Income) recognised in Other comprehensive Income (OCI):

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Actuarial (Gain) / Loss due to Demographic Assumption changes in defined benefit obligations	–	1.48
Actuarial (Gain) / Loss due to Financial Assumption changes in defined benefit obligations	(9.78)	1.65
Actuarial changes arising from changes in experience of defined benefit obligations	(3.77)	0.89
Return on Plan Assets (Greater) / Less than Discount rate	(0.36)	–
OCI for the year	**(13.91)**	**4.02**

c The following table shows the change in present value of defined benefit obligations, the change in plan assets and the funded status:

Particulars	As at 31 March 2026	As at 31 March 2025
Defined benefit obligations (DBO)	75.24	59.28
Fair Value of plan assets	30.36	–
Net (assets) / liabilities	**44.88**	**59.28**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

d Break-up of the defined benefit plan related balance sheet amounts is shown below:

Particulars	As at 31 March 2026	As at 31 March 2025
Current liability (Refer note 24)	–	11.31
Non-current liability (Refer note 18)	44.88	47.97
	44.88	**59.28**

e The movements in the net Defined Benefit Obligations (DBO) recognised within the balance sheet are as follows:

Particulars	As at 31 March 2026	As at 31 March 2025
DBO at the beginning of the year	59.28	54.82
Current service cost	8.87	6.72
Past service cost	23.53	–
Interest cost on benefit obligation (net)	3.65	3.31
Employer contributions	(30.00)	–
Benefits paid	(6.54)	(9.59)
Remeasurements due to actuarial loss /(gain)	(13.91)	4.02
DBO at the end of the year	**44.88**	**59.28**

f Change in Defined Benefit Obligation

Particulars	As at 31 March 2026	As at 31 March 2025
Defined Benefit Obligation as of Prior Year end	59.28	54.82
Service Cost		
a. Current service cost	8.87	6.72
b. Past service cost	23.53	–
Interest Cost	3.65	3.31
Benefit payments from plan assets	–	–
Benefit payments directly by employer	(6.54)	(9.59)
Actuarial (Gain) / Loss - Demographic Assumptions	–	1.48
Actuarial (Gain) / Loss - Financial Assumptions	(9.78)	1.65
Actuarial (Gain) / Loss - Experience	(3.77)	0.89
Defined Benefit Obligation as of Current Year end	**75.24**	**59.28**

g Change in Fair Value of Plan Assets

Particulars	As at 31 March 2026	As at 31 March 2025
Fair value of plan assets at end of prior year		
Employer contributions	30.00	–
Actuarial Gain/(Loss) on Plan Assets	0.36	–
Fair value of plan assets at end of year	**30.36**	**–**

h Plan Assets

Particulars	As at 31 March 2026	As at 31 March 2025
The weighted-average asset allocations at the year end were as follows:		
Pooled assets with an insurance company	100.00%	0.00%
Actual return on plan assets	0.36	–

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

i Change in fair value of assets for the period ending as at 31 March 2026 and 31 March 2025:

The Company has started investing in Plan Assets during the year ended 31 March 2026 through an approved Gratuity Trust, which has taken a group gratuity policy from SBI Life Insurance Company Limited.

The fund is managed and invested by SBI Life Insurance Company Limited.

j Actuarial assumptions

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Discount rate (per annum)	6.59%	6.54%
Rate of salary increase	5.00%	8.00%
Mortality rate	Indian Assured Lives Mortality (2012-14) Ultimate	Indian Assured Lives Mortality (2012-14) Ultimate
Withdrawal Rate		
Up to 35 years	45.00%	45.00%
36 years to 45 years	18.00%	18.00%
46 years to 55 years	10.00%	10.00%
56 years and above	0.00%	0.00%

1. The discount rate is based on the prevailing market yields of Indian Government securities as at the balance sheet date for the estimated term of the obligation.

2. The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion, and other relevant factors, such as supply and demand in the employment market.

k Retirement Age

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Retirement age	58 Years	58 Years

l Sensitivity analysis

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	For the year ended 31 March 2026	For the year ended 31 March 2025
	Amount	Amount	%	%
Base scenario	75.24	59.28		
Discount rate: increase by 1%	72.17	56.58	(4.09%)	(4.56%)
Discount rate: decrease by 1%	78.60	62.26	4.47%	5.02%
Salary escalation rate: increase by 1%	78.28	61.90	4.05%	4.41%
Salary escalation rate: decrease by 1%	72.35	56.86	(3.84%)	(4.09%)

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligations as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated. Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligations has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

m Maturity profile

Projected benefits payable in future years from the date of reporting	Gratuity	
Particulars	As at 31 March 2026	As at 31 March 2025
1 Year (within next 12 months)	14.61	11.31
2 to 10 years	69.07	53.13
Above 10 years	21.13	21.58

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

- Through its defined benefit plan, the Company is exposed to a number of risks, the most significant of which are detailed below:
  1. Changes in bond yields: A decrease in bond yields will increase plan liabilities.
  2. Longevity risk: The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
  3. Salary growth risk: The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. An increase in the salary of the plan participants will increase the plan's liability.

iii Other long term employee benefits:

Compensated absences: [included as a part of salaries and wages in Note 30 amounts to ₹7.37 million (31 March 2025: ₹8.36 million) - employee benefits expense] all eligible employees can carry forward and avail / encash leave as per Company's policies. The Company has applied the same actuarial assumptions that were used for the valuation of gratuity liability.

34.1 Employee Stock Option Plan

Pursuant to the Marksans Employees Stock Option Scheme 2024, approved by resolution passed by the members of the Company at the 32nd Annual General Meeting held on 24 September 2024 and amended at the 33rd Annual General Meeting held on 08 August 2025, the Company has granted 400,000 stock options of face value of Re. 1/- each on 24 September 2025 to certain eligible employees of the Company and its subsidiaries.

Under the plan, participants are granted options which vest upon completion of one year from the grant date. Once vested, the options remain exercisable for a period of one year.

When exercisable, each option is convertible into one equity share. The exercise price of the options is ₹10/-.

Tabulated below is the summary of options granted under the plan. Since the employee stock options were granted during the current year, the related disclosures are applicable for the current year only; accordingly, comparative information for the previous year has not been presented.

Description	31-Mar-26	
	Average exercise price per share option (₹)	Number of Options
Opening Balance	NA	NA
Granted during the year	10	400,000
Exercised during the year	–	–
Forfeited during the year	–	–
Closing balance	–	400,000
Vested and exercisable	–	–

No options expired during the periods covered in the above tables.

Share options outstanding at the end of the year have the following expiry date and exercise prices:

	Grant Date	Expiry Date	Exercise Price (₹)	Share options 31 March 2026
	24-Sep-25	24-Sep-27	10	400,000
Weighted average remaining contractual life of options outstanding at end of period				1.5 years

The fair value at grant date of options granted during the year ended 31 March 2026 was ₹161.18 per option. The fair value at grant date is independently determined using the Black-Scholes Model which takes into account the exercise price, the term of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.

The model inputs for options granted during the year ended 31 March 2026 included:

Vested options are exercisable for a period of one year after vesting.

Exercise price: ₹10

Grant Date: 24 September 2025

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Expiry Date: 24 September 2027
Share Price at Grant Date: ₹171.32
Expected volatility of Company's share: 50.83%
Expected dividend yield: 0.38%
Risk-free interest rate: 5.82%
Resultant fair value per option: ₹161.18

Expense arising from share-based payment transactions

Total expenses arising from share-based payment transactions recognised in profit or loss as part of employee benefit expense were as follows:

	31-Mar-26
Employee stock option plan	18.78

Note No.34.2

The Code on Social Security, 2020

Effective 21 November 2025, the Government of India consolidated 29 existing labour regulations into four Labour Codes, namely the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes").

The implementation of the New Labour Codes resulted in an increase in provision for employee benefits on account of recognition of past service cost. In accordance with the requirements of the New Labour Codes and the applicable accounting standards, the Company assessed the related impact. Consequently ₹ 26.09 million has been recognised as Employee Benefits Expense in the standalone financial statements for the year ended 31 March 2026.

Note No.35

Capital management

For the purpose of the Company's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity holders of the Company. The primary objective of the Company's capital management is to safeguard the Company's ability to remain as a going concern and maximise the shareholder value. The Company manages its capital structure and makes adjustments in light of changes in economic conditions, annual operating plans and long-term and other strategic investment plans. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders or issue new shares. The current capital structure of the Company is equity based with no financing through borrowings except through leasing. The Company is not subject to any externally imposed capital requirements.

Particulars	As at 31 March 2026	As at 31 March 2025
Total shareholders' equity as reported in balance sheet (A)	**16,523.10**	**13,834.86**
Gross Debt		
Lease liability (including current lease liability)	121.29	108.42
Gross debt	**121.29**	**108.42**
Less: Cash & cash equivalents	912.50	602.68
Net debt (B)	**(791.21)**	**(494.26)**
Total capital deployed (A-B)	**17,314.31**	**14,329.12**
Net debt to equity ratio (B/A)	**(0.05)**	**(0.04)**

The Company does not have any debt apart from lease liabilities. The net debt to equity ratio for the current year improved as a result of increase in operating cash flows and cash held by the Company at the end of the year.

Note No.36 : Financial Instruments – fair values and risk management

A. Accounting classification and fair values

The fair value of financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

The following methods and assumptions were used to estimate the fair values:

Fair value of cash and bank balances, trade receivables and other financial assets, trade payables, other financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Methods and assumptions used to estimate the fair values are consistent with those used for the previous year.

During the reporting period ending 31 March 2026 and 31 March 2025, there were no transfers between Level 1 and Level 2 fair value measurements.

Fair value hierarchy :

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of following:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities included in level 3.

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

As at 31 March 2026

	As at 31 March 2026			As at 31 March 2026		
	Carrying amount			Fair Value		
	FVTPL	FVOCI	Amortised cost	Level 1	Level 2	Level 3
Financial assets						
Other Non-current financial assets	–	–	11.46	–	–	–
Trade receivables	–	–	6,234.62	–	–	–
Cash and cash equivalents	–	–	912.50	–	–	–
Bank balances other than above	–	–	3,555.15	–	–	–
Other current financial assets	–	–	33.33	–	–	–
	–	**–**	**10,747.06**	**–**	**–**	**–**
Financial Liabilities						
Trade payables	–	–	1,808.13	–	–	–
Derivative financial liabilities - forward contract @	68.62	–	–	–	68.62	–
Other current financial liabilities	–	–	184.29	–	–	–
	68.62	**–**	**1,992.42**	**–**	**68.62**	**–**

As at 31 March 2025

	As at 31 March 2025			As at 31 March 2025		
	Carrying amount			Fair Value		
	FVTPL	FVOCI	Amortised cost	Level 1	Level 2	Level 3
Financial assets						
Other Non-current financial assets	–	–	10.84	–	–	–
Investment-current #	7.42	–	–	7.42	–	–
Trade receivables	–	–	5,495.81	–	–	–
Cash and cash equivalents	–	–	602.68	–	–	–
Bank balances other than above	–	–	2,084.23	–	–	–
Other current financial assets	–	–	22.91	–	–	–
	7.42	**–**	**8,216.47**	**7.42**	**–**	**–**
Financial Liabilities						
Trade payables	–	–	2,035.34	–	–	–
Derivative financial liabilities - forward contract @	39.37	–	–	–	39.37	–
Other current financial liabilities	–	–	152.62	–	–	–
	39.37	**–**	**2,187.96**	**–**	**39.37**	**–**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Investment in mutual funds: The fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.

@ The fair values of the foreign exchange forward contract has been determined using valuation techniques with adequate observable inputs. This model incorporates various inputs including the credit quality of counter parties and foreign exchange forward rates.

B. Financial risk management framework

The Company's activities expose it to variety of financial risks namely market risk, credit risk and liquidity risk. The Company has various financial assets such as deposits, trade and other receivables and cash and bank balances directly related to their business operations. The Company's principal financial liabilities comprise of trade and other payables.

The Company's senior management's focus is to foresee the unpredictability and minimize potential adverse effects on the Company's financial performance. The Company's overall risk management procedures to minimise the potential adverse effects of financial market on the Company's performance are as follows :

(i) Credit risk analysis

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables.

The Company has significant concentration of credit risk with respect to the sale of goods as the Company sells majority of the productions to the group companies. Management closely monitors the credit quality and collectability of receivables. Since majority of the Company's sales are to the group companies, there is no credit risk attached to the Company's receivables. Outstanding customer receivables other than group companies are regularly monitored and any shipments to new overseas customers are generally covered by letters of credit or other forms of credit insurance. The management continuously monitors the credit exposure towards the customers and makes provision against those balances considered doubtful of recovery. The Company establishes an allowances for credit losses and impairment that represents its estimates of expected credit loss (ECL)."

Cash and cash equivalents and other bank balances

The Company held cash and cash equivalents and other bank balances of ₹4,467.65 million at 31 March 2026 (31 March 2025: ₹2,686.91 million). The cash and cash equivalents are held with bank and financial institution counterparties with good credit ratings.

Trade and other receivables

As of the year ended 31 March 2026 and (31 March 2025), trade receivables from one and (two) customers, respectively, exceeded 10% of the Company's total trade receivables.

The Company continuously monitors defaults of customers and other counterparties, identified either individually or by the Company, and incorporates this information into its credit risk controls. The Company's policy is to deal only with creditworthy counterparties.

The Company's management considers that all the above financial assets that are not impaired at each of the reporting dates and are of good credit quality, including those that are past due.

Summary of the Company's exposure to credit risk by age of the outstanding from various customers is in Note 11.

Further, management believes that the unimpaired amounts that are past due by more than 180 days are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk.

Reconciliation of Loss Allowance

Loss allowance as at 31 March 2024	**–**
Loss allowance	15.15
Loss allowance as at 31 March 2025	**15.15**
Loss allowance	–
Loss allowance (utilised against bad debts)	(15.15)
Loss allowance as at 31 March 2026	**–**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(ii) Liquidity risk analysis

Liquidity risk is the risk that Company will not be able to meet its financial obligations as they fall due. Liquidity risk arises because of the possibility that the Company could be required to pay its liabilities earlier than expected or encounters difficulty in raising funds to meet commitments associated with financial liabilities as they fall due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. The Company manages liquidity risk by maintaining sufficient cash and bank balance and availability of funding through adequate amount of committed credit facilities.

The details of the contractual maturities of significant liabilities as at 31 March 2026 are as follows :

Particulars	Current	Non-current	
	Within 1 year	1 to 5 years	More than 5 years
Trade payables	1,808.13	–	–
Lease liabilities	25.93	111.53	199.51
Other current financial liabilities	252.91	–	–
	2,086.97	**111.53**	**199.51**

The details of the contractual maturities of significant liabilities as at 31 March 2025 are as follows :

Particulars	Current	Non-current	
	Within 1 year	1 to 5 years	More than 5 years
Trade payables	2,035.34	–	–
Lease liabilities	25.93	72.71	179.88
Other current financial liabilities	191.99	–	–
	2,253.26	**72.71**	**179.88**

(iii) Market risk analysis

The Company's activities are exposed to variety of financial risks. These risks include market risk (including foreign exchange risk and interest rate risks).

(a) Foreign Currency risk

The Company's foreign currency risk arises from its foreign operations, investments in foreign subsidiaries and foreign currency transactions. The fluctuation in foreign currency exchange rates may have potential impact on the income statement and equity, where any transaction references more than one currency or where assets/liabilities are denominated in a currency other than the functional currency of the Company.

Since a major part of the Company's revenue is in foreign currency and major part of the costs are in Indian Rupees, any movement in currency rates would have impact on the Company's performance. Consequently, the overall objective of the foreign currency risk management is to minimize the short term currency impact on its revenue and cash-flow in order to improve the predictability of the financial performance.

The major foreign currency exposures for the Company are denominated in USD, GBP, AED & EURO. Additionally, there are transactions which are entered into in other currencies and are not significant in relation to the total volume of the foreign currency exposures. The Company hedges its trade receivables based on historical trends, budgets and monthly sales estimates. The foreign exchange forward contracts are denominated in the same currency as the highly probable forecast sales.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Exposure to currency risk

The Company's exposure to foreign currency risk is as follows :

Particulars	As at 31 March 2026				As at 31 March 2025			
	USD	GBP	JPY	EUR	USD	GBP	JPY	EUR
Financial assets								
Other current assets	19.87	–	3.29	0.40	19.75	–	0.47	–
Other non-current assets	–	–	–	–	–	–	–	23.73
Trade receivables	6,201.28	–	–	–	5,258.13	229.11	–	12.08
Total (A)	**6,221.15**	**–**	**3.29**	**0.40**	**5,277.88**	**229.11**	**0.47**	**35.81**
Financial liabilities								
Other current liabilities	–	711.92	–	4.82	5.80	957.05	–	–
Trade payables	175.98	1.64	–	14.72	241.78	–	–	0.88
Total (B)	**175.98**	**713.56**	**–**	**19.54**	**247.58**	**957.05**	**–**	**0.88**
Hedged (C)	427.60				1,552.93			
Net unhedged (A-B-C)	**5,617.57**	**(713.56)**	**3.29**	**(19.14)**	**3,477.37**	**(727.94)**	**0.47**	**34.93**

A 10% strengthening / weakening of the respective foreign currencies with respect to functional currency of the Company would result in increase or decrease in profit or loss and equity as shown in table below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases. The following analysis has been worked out based on the exposures as of the date of statements of financial position.

Particulars	As at 31 March 2026				As at 31 March 2025			
	USD	GBP	JPY	EUR	USD	GBP	JPY	EUR
Strengthening	561.76	(71.36)	0.33	(1.91)	347.74	(72.79)	0.05	3.49
Weakening	(561.76)	71.36	(0.33)	1.91	(347.74)	72.79	(0.05)	(3.49)

(b) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Since the Company does not have any interest bearing borrowings, the exposure to risk of changes in market interest rates is minimal.

(c) Other price risk

The Company's equity exposure in Subsidiaries, are carried at cost or deemed cost and these are subject to impairment testing as per the policy followed in this respect.

The Company's current investments which are fair valued through profit and loss and are not material. Accordingly, other price risk of the financial instrument to which the Company is exposed is not expected to be material.

Exposure to interest rate risk

Since the Company does not have any interest bearing financial liabilities, a change in interest rates at the reporting date would not have any significant impact on the financial statements of the Company. The Company's investments are primarily in fixed rate interest bearing investments. Hence, the Company is not significantly exposed to interest rate risk.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.37 : Earning per share

Earning per share is calculated by dividing the profit after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year as computed below:

Particulars	As at 31 March 2026	As at 31 March 2025
Earning per share (EPS)		
1) Net profit as per the statement of profit and loss available for equity shareholders	3,006.98	1,882.72
2) Weighted average number of equity shares for earning per share computation		
a) For basic earning per share of ₹1/- each	453.16	453.16
b) For diluted earning per share of ₹1/- each	453.36	453.16
3) Earning per share (weighted average)		
Basic (in ₹)	**6.64**	**4.15**
Diluted (in ₹)	**6.63**	**4.15**

Particulars	As at 31 March 2026	As at 31 March 2025
Weighted average number of equity shares used as the denominator in calculating basic earnings per share	453.16	453.16
Adjustments for calculation of diluted earnings per share:		
Options	0.20	–
Weighted average number of equity shares and potential equity shares used as the denominator in calculating diluted earnings per share	**453.36**	**453.16**

Information concerning the classification of securities - Options

Options granted to the eligible employees are considered to be potential equity shares. They have been included in the determination of diluted earnings per share to the extent to which they are dilutive. The options have not been included in the determination of basic earnings per share. Details relating to the options are set out in note 34.1.

Note No.38 : Related party disclosures

(a) Related parties where control exists

1) Marksans Pharma (UK) Limited (Subsidiary)
2) Marksans Holdings Limited (Step-down subsidiary)
3) Bell, Sons and Co. (Druggists) Limited (Step-down subsidiary)
4) Relonchem Limited (Step-down subsidiary)
5) Marksans Pharma Inc. (Subsidiary)
6) Time-Cap Laboratories Inc. (Step-down subsidiary)
7) Custom Coatings Inc. (Step-down subsidiary)
8) Marksans Realty LLC (Step-down subsidiary)
9) Marise Ann Inc. (Step-down subsidiary)
10) Nova Pharmaceuticals Australasia Pty Ltd (Subsidiary)
11) Nova Pharmaceuticals NZ Ltd. (Step-down subsidiary)
12) Access Healthcare for Medical Products LLC. (Subsidiary)
13) Marksans Pharma GmbH (Subsidiary)
14) Marksans Pharma (Europe) Limited (Subsidiary) - (w.e.f. 16 January 2026)
15) Marksans (Canada) Inc. (Subsidiary) - (w.e.f. 22 January 2026)

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(b) Key management personnel (KMP)/Directors

Mr. Mark Saldanha	:	Managing Director
Mrs. Sandra Saldanha	:	Whole-time Director
Mr. Varddhman Vikramaditya Jain	:	Whole-time Director
Mr. Jitendra Sharma	:	Chief Financial Officer
Mr. Harshavardhan Panigrahi	:	Company Secretary
Mr. Abhinna Sundar Mohanty	:	Independent Director
Mr. Digant Mahesh Parikh	:	Independent Director
Mr. Seetharama Raju Buddharaju (Up to 31 March 2025)	:	Independent Director
Dr. Sunny Sharma	:	Non-executive Director
Mrs. Shailaja Vardhan	:	Independent Director
Mr. Srinivas Mishra (w.e.f. 01 April 2025)	:	Independent Director

(c) List of related parties with whom transactions have taken place during the year are as follows:

Nature of transactions	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Sale of goods	**12,058.78**	**10,270.64**
Nova Pharmaceuticals Australasia Pty Ltd	633.86	326.11
Bell, Sons and Co. (Druggists) Limited	753.70	919.91
Relonchem Limited	1,844.38	1,900.93
Time-Cap Laboratories Inc.	8,826.84	7,121.61
Access Healthcare for Medical Products LLC	–	2.08
Sale of property, plant & equipment	**0.51**	**0.42**
Time-Cap Laboratories Inc.	0.51	0.42
Reimbursement of expenses incurred on behalf of	**127.52**	**12.12**
Relonchem Limited	127.52	12.12
Dividend received	**386.16**	**263.69**
Marksans Pharma (UK) Limited	386.16	263.69
Purchase of goods	**9.30**	**18.03**
Bell, Sons and Co. (Druggists) Limited	1.10	1.91
Relonchem Limited	0.99	–
Time-Cap Laboratories Inc.	7.21	16.12
Purchase of property, plant & equipment	**–**	**0.51**
Time-Cap Laboratories Inc.	–	0.51
Rent paid	**10.65**	**10.65**
Mr. Mark Saldanha	10.65	10.65
Share-based payment expense provided for	**16.70**	**–**
Mr. Varddhman Vikramaditya Jain	8.35	–
Mr. Jitendra Sharma	8.35	–
Investment in Subsidiaries (Share Based Payments)	**14.60**	**–**
Marksans Pharma (UK) Limited	8.34	–
Marksans Pharma Inc.	6.26	–
Managerial remuneration *	**120.28**	**115.74**
Mr. Mark Saldanha	64.13	63.76
Mrs. Sandra Saldanha	7.07	7.07
Mr. Varddhman Vikramaditya Jain	26.32	23.98
Mr. Jitendra Sharma	19.67	17.99
Mr. Harshavardhan Panigrahi	3.09	2.94
* Provision made based on actuarial valuation on an overall Company basis are not included in remuneration to key management personnel.		
Director Sitting Fees #	**1.71**	**0.84**
Mr. Abhinna Sundar Mohanty	0.31	0.02
Mr. Seetharama Raju Bhuddharaju	–	0.02
Mr. Digant Mahesh Parikh	0.50	0.40
Mrs. Shailaja Vardhan	0.50	0.40
Mr. Srinivas Mishra	0.40	–
# Included in legal and professional fees.		

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(d) Balances outstanding at the end of the year

Particulars	As at 31 March 2026	As at 31 March 2025
Trade receivables	**5,786.57**	**4,991.89**
Nova Pharmaceuticals Australasia Pty Ltd	392.09	425.42
Time-Cap Laboratories Inc.	5,394.48	4,333.05
Bell, Sons and Co. (Druggists) Limited	–	229.11
Access Healthcare for Medical Products LLC	–	4.31
Advance from customers	**711.92**	**957.05**
Bell, Sons and Co. (Druggists) Limited	73.18	–
Relonchem Limited	638.74	957.05
Trade payables	**1.64**	**14.01**
Bell, Sons and Co. (Druggists) Limited	1.09	–
Relonchem Limited	0.55	–
Time-Cap Laboratories Inc.	–	14.01
Share-based payments Reserve	**16.70**	**–**
Mr. Varddhman Vikramaditya Jain	8.35	–
Mr. Jitendra Sharma	8.35	–
Investment in Subsidiaries	**2672.13**	**2657.53**
Nova Pharmaceuticals Australasia Pty. Ltd.	15.91	15.91
Marksans Pharma (UK) Limited	677.57	669.23
Marksans Pharma Inc.	1,681.86	1,675.60
Access Healthcare for Medical Products LLC	296.79	296.79
Managerial remuneration	**4.24**	**5.08**
Mr. Mark Saldanha	1.83	2.75
Mrs. Sandra Saldanha	0.42	0.41
Mr. Varddhman Vikramaditya Jain	0.99	0.91
Mr. Jitendra Sharma	0.80	0.76
Mr. Harshavardhan Panigrahi	0.20	0.25
Guarantee given on behalf of	**655.76**	**598.29**
Time-Cap Laboratories Inc.	655.76	598.29

Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. The Company has not recorded any impairment for receivables. This assessment is undertaken each financial year through examining the financial position of the related parties and the market in which related parties operate.

Note No.39 : Segment information

A. Operating Segments

The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'.

B. Geographical Information

Analysis of revenues by geography:

The following table shows the distribution of the Company's revenues (excluding other operating income) by country, based on the location of the customers:

Region	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
US & North America	9,218.57	7,318.77
Europe and UK	2,609.04	2,927.41
Australia and New Zealand	772.01	513.12
Rest of World	815.14	984.44
	13,414.76	**11,743.74**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Analysis of non current assets by geography:

The following table shows the distribution of the Company's non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:

Region	As at 31 March 2026	As at 31 March 2025
US & North America	–	–
Europe and UK	–	15.90
Australia and New Zealand	–	–
India	6,849.51	6,707.06
Rest of World	–	7.83
	6,849.51	**6,730.79**

C. Information about major customers

During the year ended 31 March 2026, revenues from transactions with customers that amounted to 10% or more of the Company's total revenues included two customers (31 March 2025: two customers). The total revenues from these significant customers amounted to ₹10,671.22 million for the year ended 31 March 2026 (31 March 2025: ₹9,022.54 million).

Note No.40 : Contingent liabilities, contingent assets and commitments

Contingent liabilities

The Company neither had any contingent liabilities as on 31 March 2026 nor on 31 March 2025.

Contingent assets

The Company neither had any contingent assets as on 31 March 2026 nor on 31 March 2025.

Commitments

Particulars	As at 31 March 2026	As at 31 March 2025
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances)	211.61	238.86

Note No.41 : Research and development expenditure

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
a) Break-up of research and development expenses included in statement of profit and loss under below heads:		
Material Cost	107.68	109.51
Employee benefits expense		
Salaries, Wages and Bonus	48.71	39.48
Contribution to Provident and other funds	2.95	1.32
	51.66	**40.80**
Other expenses		
Power and Fuel	3.64	3.78
Laboratory goods and testing expenses	46.84	7.35
Clinical research expense	12.92	126.81
General charges	36.08	34.73
	99.48	**172.67**
b) Capital Expenditure	2.23	6.74
Total	**261.05**	**329.72**

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.42 : Corporate social responsibility (CSR)

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. A CSR committee has been formed by the Company as per the Act. The funds were primarily utilized through the year on below mentioned activities which are specified in Schedule VII of the Companies Act, 2013:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
a) Gross amount required to be spent by the Company during the year	37.18	29.29
b) Amount approved by the Board to be spent during the year	37.18	29.29
c) Amount spent during the year on :		
(i) Construction / acquisition of any asset	–	–
(ii) On purposes other than (i) above	35.28	27.98
d) Shortfall at the end of the year	–	–
e) Total of previous year shortfall	–	–
f) Reason for shortfall	NA	NA
g) Excess spent of previous year brought forward to current year	1.92	3.23
h) Excess spent of current year carried forward to next year	0.02	1.92
i) Contribution to section 8 companies, which are related parties, included in (c) above, in relation to CSR expenditure	NA	NA
j) Nature of CSR activities:	Promoting healthcare, education & disaster management, eradicating hunger & malnutrition, environment sustainability and ecological balance.	
The Company does not have any ongoing CSR projects for both the years. No expenditure has been paid to a related party, in relation to CSR expenditure. There are no short falls at the end of the year.		

Note No.43

Subsequent events

The Board of Directors (in the meeting held on 26 May 2026) has recommended final dividend of ₹0.90 per equity share of ₹1/- each (90%) for the Financial Year 2025-2026.

Note No.44

Ratio analysis

Particulars	Numerator	Denominator	As at 31 March 2026	As at 31 March 2025	Variance in%	Footnotes
a. Current ratio	Current assets	Current liabilities	4.22	3.13	34.82	1
b. Debt equity ratio	Lease liabilities	Shareholder's equity	0.01	0.01	–	
c. Debt service coverage ratio	Profit/(loss) after tax + finance costs + depreciation and amortisation+gain/(loss)on sale of Property, Plant and equipment	Interest + lease payments	78.09	56.09	39.22	2
d. Return on equity ratio (%)	Net profit/(loss) after tax	Average shareholder's equity	19.81%	14.45%	37.09	3
e. Inventory turnover ratio	Cost of goods sold	Average inventory	3.44	3.23	6.50	
f. Trade receivables turnover ratio	Revenue from operation	Average trade receivables	2.29	2.55	(10.20)	
g. Trade payable turnover ratio	Purchases	Average trade payables	3.45	3.60	(4.17)	
h. Net capital turnover ratio	Revenue from operation	Working capital	1.34	1.59	(15.72)	
i. Net profit ratio (%)	Net profit/(loss) after tax	Revenue from operation	22.42%	16.03%	39.86	4
j. Return on capital employed (%)	Profit/(loss) before tax + finance costs	Tangible net worth + total debt + deferred tax liability	23.39%	17.41%	34.35	5
k. Return on investment (%)	Profit/(loss) before tax + finance costs	Average Total Assets	20.96%	14.94%	40.29	6

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

1 Current ratio increased due to increase in cash generated from operations.

2 The Debt Service Coverage Ratio has improved significantly due to increase in profit after tax, the improvement reflects enhanced profitability during the year, resulting in a stronger internal accrual base available to service the Company's lease-related obligations.

3 The Return on Equity improvement is primarily driven by increase in net profit after tax. The enhanced Return on Equity reflects better returns generated for shareholders through improved operational performance and effective capital utilization during the year.

4 The net profit ratio increased primarily due to a higher profit after tax during the year.

5 The return on capital employed increased primarily due to an increase in profit before tax during the year.

6 The return on investment increased primarily due to an increase in profit before tax during the year.

Note No.45 : Other statutory information

a. Details of benami property held

No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

b. Borrowing secured against current assets

The Company has been sanctioned working capital limits in excess of ₹50 million in aggregate from consortium of banks on the basis of security of current assets. Quarterly returns filed with such Bank are in agreement with the books of account.

c. Wilful defaulter

The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

d. Relationship with struck off companies

The Company has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956.

e. Registration of charges or satisfaction with registrar of companies (ROC)

There are no charges or satisfaction which are yet to be registered with the registrar of companies beyond the statutory period.

f. Compliance with number of layers of companies

The Company has complied with the number of layers prescribed under the Companies Act, 2013.

g. Compliance with approved schemes of arrangements

The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

h. Utilisation of borrowed funds and share premium

1. The Company has not advanced or loaned or invested funds to any other persons or entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

   (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or

   (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

2. The Company has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

   (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or

   (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

i. Undisclosed income

There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.

Notes to the Standalone Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

j. Details of crypto currency or virtual currency

The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

k. Valuation of PP&E and intangible asset

The Company has not revalued its property, plant and equipment (including right of use assets) or intangible assets for both during the current or previous year.

l. Title deeds of immovable properties

Title deeds of all immovable properties are held in the name of the Company.

m. The Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility, except that audit trail feature was not enabled at the database level in respect of an accounting software to log any direct data changes.

Further, to the extent enabled, audit trail feature has operated throughout the year for all relevant transactions recorded in the accounting software. Also, there were no instances of audit trail feature being tampered with. Additionally, the audit trail of prior year has been preserved by the Company as per the statutory requirements for record retention to the extent it was enabled and recorded in respective years.

The accompanying notes form an integral part of these standalone financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Consolidated Financial Statements

Independent Auditor's Report

To the Members of **Marksans Pharma Limited**

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Marksans Pharma Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2026, and the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on consideration of reports of other auditors on separate / consolidated financial statements of subsidiaries, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS") and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group as at March 31, 2026, of consolidated profit (including other comprehensive income), consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in terms of the Code of Ethics issued by Institute of Chartered Accountant of India, and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained and on consideration of audit reports of other auditors referred to in paragraph (a) of the "Other Matters" section below, is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our report:

Key Audit Matter	How the Key Audit Matter was addressed in our audit
Revenue from sale of products is recognized when the Group satisfies the performance obligation under the contract / sales arrangement and transfers control of the goods to the customer, at a point in time. The Group's multi-geography operations, the specific point at which control passes and accordingly, the period in which revenue is appropriately recognized is influenced by a variety of factors, including the applicable international commercial terms governing each customer contract / sales arrangement. Accordingly, due to the significant risk associated with revenue recognition in accordance with terms of Ind AS 115 Revenue from contracts with customers, it has been determined to be a key audit matter in our audit of the financial statements. Refer Note 31 to the Consolidated Financial Statements	Our audit procedures included the following: 1. Evaluated the Group's accounting policy for recognition of revenue from sale of products and assessed whether it is in compliance with applicable accounting standards. 2. Obtained an understanding, assessed the design and tested the operating effectiveness of key internal controls related to revenue recognition. 3. Selected a sample of revenue transactions recognized during the year (including year-end cutoff testing) and tested the underlying documentation to assess and analyze the timing of recognition of revenue and contractual terms. 4. Performed analytical procedures on revenue and tested journal entries over revenue to identify any unusual items. 5. Verified that the presentation and disclosure of revenue in the financial statements are in compliance with applicable accounting standards and reporting framework.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Management Discussion and Analysis, Director's Report, Corporate Governance Report and Business Responsibility and Sustainability Report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Board of Directors for the Consolidated Financial Statements

The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in terms of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated changes in equity and consolidated cash flows of the Group, in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under section 133 of the Act. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.

Other Matters:

a) We did not audit the separate / consolidated financial statements of 12 subsidiaries, whose financial statements (before consolidation adjustments) reflect Group's share of total assets of ₹ 28,791.63 million as at March 31, 2026, Group's share of total revenues of ₹ 28,167.72 million, Group's share of net profit (including other comprehensive income) of ₹ 1,833.17 million and Group's net cash inflows amounting to ₹1,073.68 million for the year ended on that date, as considered in the consolidated financial statements. These separate / consolidated financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries is based solely on the reports of the other auditors.

b) The above subsidiaries are located outside India whose financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

c) We did not audit the financial information of 3 subsidiaries whose financial information reflect Group's share of total assets of ₹ Nil as at March 31, 2026, Group's share of total revenues of ₹ Nil, Group's share of net profit (including other comprehensive income) of ₹ Nil and net cash inflows amounting to ₹ Nil for the year ended on that date, as considered in the consolidated financial statements. These financial information are unaudited and have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial information are not material to the Group.

Our opinion on the consolidated financial statements and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements / financial information certified by the Management.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit and on the consideration of the reports of the other auditors on separate / consolidated financial statements of the subsidiaries, referred to paragraph (a) in the Other Matters section above, we report, to the extent applicable, that:

    (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

    (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors except for the matters stated in paragraph 1(h) vi below on reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014.

    (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including other comprehensive income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

    (d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act.

    (e) On the basis of the written representations received from the directors of the Holding Company as on April 1, 2026 taken on record by the Board of Directors of the Holding Company none of the directors of the Holding company, are disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

    (f) The reservation relating to the maintenance of accounts and other matters connected therewith are as stated in paragraph 1(b) above on reporting under Section 143(3) (b) and paragraph 1 (h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

    (g) With respect to the adequacy of internal financial controls with reference to consolidated financial statements of the Group, and the operating effectiveness of such controls, refer to our separate report in "Annexure B".

    (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

        i. There were no pending litigations which would impact the consolidated financial position of the Group.

        ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.

        iii. There has been no delay in transferring amounts to the Investor Education and Protection Fund by the Holding Company during the year ended March 31, 2026.

        iv. a) The Management of the Holding Company whose financial statements have been audited under the Act have represented to us that, to the best of their knowledge and belief, as disclosed in the Note 52 (h)(1) to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

        b) The Management of the Holding Company whose financial statements have been audited under the Act have represented to us that, to the best of their knowledge and belief, as disclosed in the Note 52 (h)(2) to consolidated financial statements, no funds have been received by the Holding Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us whose financial statements have been audited under the Act, nothing has come to our or other auditors' notice that has caused us or the other auditors to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (a) and (b) above contain any material mis-statement.

v. On the basis of our verification, we report that:

a. The final dividend paid by the Holding Company, during the year in respect of the same declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.

b. The Board of Directors of the Holding Company have proposed final dividend for the year which is subject to the approval of members at the ensuing Annual General Meeting. The dividend proposed is in accordance with section 123 of the Act to the extent it applies to recommendation of dividend. Refer Note 51 to the consolidated financial statements.

vi. Reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is not applicable to the subsidiaries, as they are incorporated outside India.

Based on our examination which included test checks, the Holding Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility, except that no audit trail feature was enabled at the database level in respect of an accounting software to log any direct data changes as explained in Note 52 (m) to the Consolidated Financial Statements.

Further, where enabled, audit trail feature has been operated for all relevant transactions recorded in the accounting software. Also, during the course of our audit, we did not come across any instance of audit trail feature being tampered with in respect of such accounting software. Additionally, the audit trail of prior year has been preserved by the Holding Company as per the statutory requirements for record retention to the extent it was enabled and recorded in respective years.

2. In our opinion, according to information, explanations given to us, the remuneration paid or provided by the Holding Company to its Directors is in accordance with the provisions of section 197 read with Schedule V to the Act. This reporting is not applicable to the subsidiaries, as they are incorporated outside India.

3. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 ("CARO") issued by the Central Government in terms of sub-section (11) of section 143 of the Act, to be included in the Auditor's report, according to the information and explanations given to us, based on the CARO report issued by us for the Holding Company included in the consolidated financial statements of the Group to which CARO is applicable, we report that there are no qualifications or adverse remarks.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894YJSMXE24

Place: Mumbai
Date: May 26, 2026

ANNEXURE A

To the Independent Auditor's Report of even date on the Consolidated Financial Statements of Marksans Pharma Limited

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.

- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities or business activities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894YJSMXE2438

Place: Mumbai
Date: May 26, 2026

ANNEXURE B

To the Independent Auditor's Report of even date on the Consolidated Financial Statements of Marksans Pharma Limited

Referred to in paragraph 1 (g) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditor's Report of even date to the Members of Marksans Pharma Limited on the Consolidated Financial Statements for the year ended March 31, 2026

Report on the Internal Financial Controls with reference to consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

Opinion

In conjunction with our audit of the consolidated financial statements of Marksans Pharma Limited (hereinafter referred to as "the Holding Company") as of and for the year ended March 31, 2026, we have audited the internal financial controls with reference to consolidated financial statements of the Holding Company.

Reporting under clause (i) of sub section 3 of Section 143 of the Act in respect of the adequacy of the internal financial controls with reference to financial statements is not applicable to 15 subsidiaries as they are incorporated outside India.

In our opinion, and to the best of our information and according to the explanations given to us, the Holding Company, has, in all material respects, an adequate internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2026, based on the internal financial controls with reference to financial statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI").

Management's and Board of Director's Responsibilities for Internal Financial Controls

The Management and the Board of Directors of the Holding Company, which is a company incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to consolidated financial statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Holding Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company, which is a company incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company, which is a company incorporated in India.

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **M S K A & Associates LLP**
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No. 105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894YJSMXE2438

Place: Mumbai
Date: May 26, 2026

Consolidated Balance Sheet

as at 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Note No.	As at 31 March 2026	As at 31 March 2025
Assets			
Non-current assets			
Property, plant and equipment	3a	6,250.06	5,794.78
Right of use assets	3b	3,008.70	3,069.31
Capital work-in-progress	4	147.82	90.00
Goodwill	5	452.56	409.28
Other intangible assets	6	729.74	546.23
Intangible assets under development	7	438.02	181.09
Financial assets			
(i) Other financial assets	8	38.72	35.71
Deferred tax assets (net)	9	129.65	–
Other non-current assets	10	175.54	217.60
Non Current tax assets (net)	11	10.81	11.11
Total non-current assets		**11,381.62**	**10,355.11**
Current assets			
Inventories	12	9,722.81	8,455.16
Financial assets			
(i) Investments	13	–	7.42
(ii) Trade receivables	14	6,445.66	5,400.43
(iii) Cash and cash equivalents	15a	6,341.37	4,957.86
(iv) Bank balances other than (iii) above	15b	3,555.14	2,084.23
(iv) Other financial assets	16	49.26	35.57
Other current assets	17	1,004.62	977.94
Current tax assets (net)	18	108.54	122.60
Total current assets		**27,227.40**	**22,041.21**
TOTAL ASSETS		**38,609.02**	**32,396.32**
Equity and liabilities			
Equity			
Equity share capital	19	453.16	453.16
Other equity	20	29,778.40	24,215.96
Equity attributable to owners of the Company		30,231.56	24,669.12
Non-controlling interest		295.24	224.70
Total equity		**30,526.80**	**24,893.82**
Liabilities			
Non-current liabilities			
Financial liabilities			
Lease liabilities	21	2,701.30	2,633.29
Provisions	22	59.15	59.20
Deferred tax liabilities (net)	23	50.87	36.62
Total non-current liabilities		**2,811.32**	**2,729.11**
Current liabilities			
Financial liabilities			
(i) Borrowings	24	295.91	230.85
(ii) Lease liabilities	25	436.58	354.92
(iii) Trade payables	26		
a) Total outstanding dues of micro and small enterprises		20.12	36.33
b) Total outstanding dues of other than micro and small enterprises		3,348.97	3,020.66
(iv) Other financial liabilities	27	301.30	236.49
Other current liabilities	28	449.01	580.26
Provisions	29	3.18	14.47
Current tax liabilities (net)	30	415.83	299.41
Total current liabilities		**5,270.90**	**4,773.39**
Total liabilities		**8,082.22**	**7,502.50**
Total equity and liabilities		**38,609.02**	**32,396.32**

The accompanying notes form an integral part of these Consolidated financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Consolidated Statement of Profit and Loss

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Note No.	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
INCOME			
Revenue from operations	31	29,509.38	26,228.45
Other income	32	825.33	663.29
Total Income		**30,334.71**	**26,891.74**
EXPENSES			
Cost of materials consumed	33	9,592.08	7,530.23
Purchases of stock-in-trade		4,544.88	5,744.77
Changes in inventories of finished goods, work-in-progress and stock-in-trade	34	(1,364.17)	(1,837.58)
Employee benefits expense	35	4,209.34	3,502.99
Finance costs	36	241.25	116.60
Depreciation and amortization expense	37	986.32	833.86
Other expenses	38	6,519.46	5,961.20
Total expenses		**24,729.16**	**21,852.07**
Profit before tax		**5,605.55**	**5,039.67**
Tax expense:			
(1) Current tax		1,499.64	1,272.82
(2) Tax adjustments for earlier years		30.34	13.08
(3) Deferred tax		(125.07)	(72.42)
Total tax expenses		**1,404.91**	**1,213.48**
Profit for the year		**4,200.64**	**3,826.19**
Other comprehensive Income			
Items that will not be reclassified to profit or loss			
- Remeasurements of post-employment benefit obligations		13.91	(4.02)
- Income tax relating to above		(3.50)	1.01
Items that will be reclassified to profit or loss			
Exchange differences on translation of financial statements of foreign operations		1,751.07	483.48
Other comprehensive income for the year, net of tax		**1,761.48**	**480.47**
Total comprehensive income for the year		**5,962.12**	**4,306.66**
Profit for the year attributable to:-			
Owners of the Company		4,179.00	3,805.75
Non-controlling interests		21.64	20.44
Other comprehensive Income attributable to:-			
Owners of the Company		1,712.59	484.73
Non-controlling interests		48.89	(4.26)
Total comprehensive Income attributable to:-			
Owners of the Company		5,891.59	4,290.48
Non-controlling interests		70.53	16.18
Earnings per equity share (face value per equity share - ₹ 1)	42		
(1) Basic (in ₹)		9.22	8.40
(2) Diluted (in ₹)		9.22	8.40

The accompanying notes form an integral part of these Consolidated financial statements.

As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Consolidated Statement of Changes in Equity

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

A Equity share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Equity shares outstanding at the beginning of the year	453,163,746	453.16	453,163,746	453.16
Equity shares outstanding at the end of the year	**453,163,746**	**453.16**	**453,163,746**	**453.16**

B Other equity (Refer note 20)

Particulars	Capital reserve	Capital redemption reserve	Securities premium	General reserve	Share-based Payments Reserve (Equity)	Retained earnings	Foreign currency translation reserve	Total attributable to owners of the Company	Non controlling interest	Total
Balance as at 1 April 2025	0.12	141.47	5,044.98	3,137.37	–	14,220.13	1,671.89	24,215.96	224.70	24,440.66
Profit for the year	–	–	–	–	–	4,179.00	–	4,179.00	21.64	4,200.64
Other comprehensive income (net of taxes)	–	–	–	–	–	10.41	–	10.41	–	10.41
Exchange difference on translation of foreign operation	–	–	–	–	–	–	1,702.18	1,702.18	48.89	1,751.07
Total comprehensive income for the year	**–**	**–**	**–**	**–**	**–**	**4,189.41**	**1,702.18**	**5,891.59**	**70.53**	**5,962.12**
Equity-settled share-based payments	–	–	–	–	33.38	–	–	33.38	–	33.38
Dividend paid on equity share	–	–	–	–	–	(362.53)	–	(362.53)	–	(362.53)
Balance as at 31 March 2026	**0.12**	**141.47**	**5,044.98**	**3,137.37**	**33.38**	**18,047.01**	**3,374.07**	**29,778.40**	**295.24**	**30,073.63**

Particulars	Capital reserve	Capital redemption reserve	Securities premium	General reserve	Share-based Payments Reserve (Equity)	Retained earnings	Foreign currency translation reserve	Total attributable to owners of the Company	Non controlling interest	Total
Balance as at 1 April 2024	**0.12**	**141.47**	**5,044.98**	**3,137.37**	**–**	**10,689.29**	**1,184.15**	**20,197.38**	**208.52**	**20,405.90**
Profit for the year	–	–	–	–	–	3,805.75	–	3,805.75	20.44	3,826.19
Other comprehensive income (net of taxes)	–	–	–	–	–	(3.01)	–	(3.01)	–	(3.01)
Exchange difference on translation of foreign operation	–	–	–	–	–	–	487.74	487.74	(4.26)	483.48
Total comprehensive income for the year	**–**	**–**	**–**	**–**	**–**	**3,802.74**	**487.74**	**4,290.48**	**16.18**	**4,306.66**
Dividend paid on equity share	–	–	–	–	–	(271.90)	–	(271.90)	–	(271.90)
Balance as at 31 March 2025	**0.12**	**141.47**	**5,044.98**	**3,137.37**	**–**	**14,220.13**	**1,671.89**	**24,215.96**	**224.70**	**24,440.66**

Consolidated Statement of Changes in Equity

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated) *(Contd.)*

C Nature and purpose of reserves:

1 Capital reserve

The Capital Reserve was created as per the requirements of earlier provision of the Companies Act, 1956. Such reserve is not available for distribution to the shareholders.

2 Capital redemption reserve

The Company had redeemed 1,350,000 7% redeemable cumulative preference shares of ₹100/- each face value at par out of profits of the Company on various dates. Accordingly, a sum equal to the nominal amount of the preference shares i.e. ₹135 million, out of the profits, was transferred to capital redemption reserve, as and when Preference Shares were redeemed.

The Company had bought back and accounted buy back of 6,474,276 equity shares on various dates. As per Companies Act, 2013, capital redemption reserve is created when company purchases its own shares out of free reserves or securities premium. A sum equal to the nominal value of the shares so purchased is transferred to capital redemption reserve. Accordingly, ₹6.47 million was transferred from retained earnings to capital redemption reserve. The reserve is utilised in accordance with the provisions of Section 69 of the Companies Act, 2013.

3 Securities premium

Securities premium comprises of the premium on issue of shares. The reserve can be utilised in accordance with the specific provision of the Companies Act, 2013.

4 General reserve

The Company has transferred a portion of the net profit before declaring dividend to general reserve pursuant to the earlier provisions of the Companies Act, 1956. Transfer to general reserve is not mandatorily required under the Companies Act, 2013.

5 Share-based payments reserve

The share-based payments reserve is used to recognise the grant date fair value of options issued to employees of the Holding Company and it's subsidiaries under the Company's Employee stock option plan.

6 Retained earnings

Retained earnings are the profits earned till date, less any transfers to other reserves and dividends distributed.

7 Foreign currency translation reserve

This reserve represents exchange differences arising on account of conversion of foreign operations to holding company's functional currency.

The accompanying notes form an integral part of these Consolidated financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Consolidated Cash Flow Statement

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
A. Cash flow from operating activities		
Profit before tax	5,605.55	5,039.67
Adjustments to reconcile profit before tax to net cash provided by operating activities		
– Depreciation and amortisation expenses	986.32	833.86
– Unrealised exchange differences on translation of assets and liabilities, net	(223.73)	(48.77)
– Loss on sale of property, plant and equipment, net	0.64	0.33
– Gain on redemption of mutual fund investments	(12.27)	(6.94)
– Finance costs	241.25	116.60
– Employee Share based compensation expenses	33.38	–
– Interest income	(276.78)	(301.97)
– Loss arising on financial instruments measured at FVTPL, net	29.25	40.06
– Loss/(Gain) on lease termination	0.17	(22.75)
– Allowance for credit losses on trade receivables (Including bad debts)	218.58	83.28
Operating profit before working capital changes	**6,602.36**	**5,733.37**
Changes in working capital:		
Inventories	(387.25)	(1,954.67)
Trade receivables	(313.90)	(777.90)
Non-current/current financial and other assets	(9.40)	(174.23)
Non-current/current financial and other liabilities/provisions/trade payables	85.98	499.06
Cash generated from operations	**5,977.79**	**3,325.63**
Income tax paid (net)	(1,396.54)	(1,258.99)
Net cash generated from operating activities (A)	**4,581.25**	**2,066.64**
B. Cash flow from investing activities:		
Payments to acquire property, plant and equipment and intangible assets	(1,305.27)	(1,729.19)
Proceeds from sale of property, plant and equipment	9.77	12.49
(Investment) / Proceeds from deposits (net)	(1,469.33)	618.77
Purchase of mutual fund Investments	(1,490.00)	–
Proceeds from sale of mutual fund investments	1,509.69	269.87
Interest received	262.47	337.97
Net Cash used in investing activities (B)	**(2,482.67)**	**(490.09)**
C. Cash flow from financing activities:		
Dividend paid	(362.53)	(271.90)
Proceeds/(repayment) of short term borrowings (net)	65.06	(60.06)
Payment of principal portion of lease liabilities (including interest on lease liabilities)	(383.96)	(295.65)
Interest cost paid	(27.85)	(23.85)
Net Cash used in financing activities (C)	**(709.28)**	**(651.46)**
Net increase in cash and cash equivalents (A+B+C)	**1,389.30**	**925.09**
Cash and cash equivalents at the beginning of the year	4,957.86	4,032.77
Effect of exchange differences on translation of foreign currency cash and cash equivalents	(5.79)	#
Cash and cash equivalents at the end of the year	**6,341.37**	**4,957.86**

Amount below rounding off criteria

Notes:

1 Reconciliation of cash and cash equivalents as per the statement of cash flows

Particulars	As at 31 March 2026	As at 31 March 2025
Cash and cash equivalents (Refer note 15a)		
Balances with bank		
In current accounts	2,891.15	2,785.36
In Exchange Earners' Foreign Currency account (EEFC)	193.60	0.01
Fixed deposit with original maturity less than 3 months	3,223.55	2,172.13
Cash in hand	33.07	0.36
Balances as per statement of cash flows	**6,341.37**	**4,957.86**

Consolidated Cash Flow Statement

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated) *(Contd.)*

2 The above Cash Flow Statement is prepared under the "Indirect Method" as set out in Ind AS 7,' Statement of Cash Flows'.

3 Amounts in bracket represent cash outflow.

4 **Net debt reconciliation**

Analysis of net debt and the movements in net debt for the year ended 31 March 2026

Description	As at 31 March 2026
Cash and cash equivalents	6,341.37
Lease Liabilities	3,137.88
Borrowings	295.91
Net Debt	**2,907.58**

Description	Other Assets	Liabilities from Financing Activities		Total
	Cash & Cash Equivalent	Lease Liabilities	Borrowings	
Net Debt at the beginning of the year	4,957.86	(2,988.21)	(230.85)	1,738.80
Cash Flows (including realised exchange differences)	1,383.51	(106.72)	(65.06)	1,211.73
New Leases	–	(57.19)	–	(57.19)
Lease Termination	–	14.24	–	14.24
Interest Expense	–	(213.40)	(27.85)	(241.25)
Interest Paid	–	213.40	27.85	241.25
Net Debt at the end of the year	**6,341.37**	**(3,137.88)**	**(295.91)**	**2,907.58**

Analysis of net debt and the movements in net debt for the year ended 31 March 2025

Description	As at 31 March 2025
Cash and cash equivalents	4,957.86
Lease Liabilities	2,988.21
Borrowings	230.85
Net Debt	**1,738.80**

Description	Other Assets	Liabilities from Financing Activities		Total
	Cash & Cash Equivalent	Lease Liabilities	Borrowings	
Net Debt at the beginning of the year	4,032.77	(2,149.70)	(290.91)	1,592.16
Cash Flows (including realised exchange differences)	925.09	153.58	60.06	1,138.73
New Leases	–	(1,341.34)	–	(1,341.34)
Lease Termination	–	349.25	–	349.25
Interest Expense	–	(92.75)	(23.85)	(116.60)
Interest Paid	–	92.75	23.85	116.60
Net Debt at the end of the year	**4,957.86**	**(2,988.21)**	**(230.85)**	**1,738.80**

The accompanying notes form an integral part of these Consolidated financial statements.

As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

1. Group information

Marksans Pharma Limited, ("Parent Company" or "Company" or "Holding Company") [CIN: L24110MH1992PLC066364] is a public limited company incorporated and domiciled in India with a focus on regulated markets, specializing in research, manufacturing and marketing of generic pharmaceutical formulations. The address of its registered office is at 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai - 400053, India. The Company is primarily engaged in the business of research, manufacture, marketing and selling pharmaceutical formulations. The Company's shares are listed on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") in India. The consolidated financial statements comprise the financial statements of the Parent Company Marksans Pharma Limited ("MPL") and the following subsidiaries / step-down subsidiaries (together referred to as "Group"):

Name of the Entity	Year End Date	Country of Incorporation	Ownership held by	% held either directly or through subsidiaries as at 31 March, 2026	% held either directly or through subsidiaries as at 31 March, 2025
Marksans Pharma Inc.	31 March 2026	USA	Marksans Pharma Limited	100%	100%
a) Time-Cap Laboratories Inc.	31 March 2026	USA	Marksans Pharma Inc.	100%	100%
– Custom Coatings Inc.	31 March 2026	USA	Time-Cap Laboratories Inc.	100%	100%
– Marksans Realty LLC	31 March 2026	USA	Time-Cap Laboratories Inc.	100%	100%
b) Marise Ann Inc.	31 March 2026	USA	Marksans Pharma Inc.	100%	100%
Nova Pharmaceuticals Australasia Pty Ltd	31 March 2026	Australia	Marksans Pharma Limited	60%	60%
Nova Pharmaceuticals NZ Limited	31 March 2026	Australia	Nova Pharmaceuticals Australasia Pty Ltd	100%	100%
Marksans Pharma (UK) Limited	31 March 2026	UK	Marksans Pharma Limited	100%	100%
a) Relonchem Limited	31 March 2026	UK	Marksans Pharma (UK) Limited	100%	100%
b) Marksans Holdings Limited	31 March 2026	UK	Marksans Pharma (UK) Limited	100%	100%
– Bell, Sons and Co. (Druggists) Limited	31 March 2026	UK	Marksans Holdings Limited	100%	100%
Access Healthcare for Medical Products L.L.C	31 March 2026	UAE	Marksans Pharma Limited	100%	100%
Marksans Pharma GmbH	31 March 2026	Germany	Marksans Pharma Limited	100%	100%
Marksans Pharma (Europe) Limited w.e.f. 16 January 2026	31 March 2026	Ireland	Marksans Pharma Limited	100%	NA
Marksans (Canada) Inc. w.e.f. 22 January 2026	31 March 2026	Canada	Marksans Pharma Limited	100%	NA

The Group operates two manufacturing facilities in Goa, one in the UK, and one in the USA. Additionally, the Group maintains four R&D centers located in Goa, Navi Mumbai, the UK, and the USA.

2. Material accounting policy information

2.1. (i) Statement of compliance and basis of preparation and presentation

These consolidated financial statements of the Group have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) read with Section 133 of the Companies Act, 2013 ("the Act") and presentation requirements of Division II of Schedule III of the Act and other relevant provisions of the Act as applicable. These consolidated financial statements have been prepared on accrual basis under the historical cost convention, except the following assets and liabilities, which have been measured at fair value as required by the relevant Ind AS:

- Certain financial assets and liabilities (refer accounting policy regarding financial instruments including derivative financial instruments and investments in mutual funds measured at fair value through profit or loss) and;
- Defined employee benefit plans (measured on the basis of actuarial valuation using the Projected Unit Credit Method).

These consolidated financial statements were approved by the Company's Board of Directors and authorized for issue on 26 May 2026.

The consolidated financial statements have been prepared on the assumption that the Group is a going concern and will continue its operations for the foreseeable future.

(ii) Functional and Presentation Currency

The consolidated financial statements are presented in Indian Rupee (₹) which is the functional currency of the parent company. All amounts are rounded to two decimal places to the nearest Million, unless otherwise stated.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(iii) Current versus non-current classification

The Company presents assets and liabilities in the Consolidated Balance Sheet based on current/ non-current classification.

An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realized within twelve months after the reporting period; or
- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is treated as current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Group has identified twelve months as its operating cycle.

(iv) New accounting standards, amendments and interpretations adopted by the Group effective from 1 April 2025

The Ministry of corporate Affairs ("MCA") notified amendments on 7 May 2025 and 13 August 2025 under the Companies (Indian Accounting Standards) Amendment Rules, 2025 and the Companies (Indian Accounting Standards) Second Amendment Rules, 2025, respectively, which is effective from annual reporting periods beginning on or after 1 April 2025.

a) Amendment to Ind AS 7 and Ind AS 107 - Supplier Finance Arrangement:

The amendments to Ind AS 7 'Statement of Cash Flows' and Ind AS 107 'Financial Instruments: Disclosures' clarify the characteristics of supplier finance arrangements and require additional disclosures for such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.

The Group does not have any supplier finance arrangements during the reporting period.

b) Amendment to Ind AS 1 - Classification of liabilities as current or non-current and non-current liabilities with covenants:

The amendment specifies the requirements for classifying liabilities as current or non-current in the balance sheet, and clarifies the following:

An entity's right to defer settlement of a liability for at least twelve months after the reporting period must have substance and must exist at the end of the reporting period. The classification of a liability as current or non-current is unaffected by the likelihood that the entity will exercise its right to defer settlement.

If an entity's right to defer settlement of a liability is subject to covenants, such covenants affect whether that right exists at the end of the reporting period only if the entity is required to comply with the covenant on or before the end of the reporting period.

In case of a liability that can be settled, at the option of the counterparty, by the transfer of the entity's own equity instruments, such settlement terms do not affect the classification of the liability as current or non-current only if the option is classified as an equity instrument.

These amendments have no effect on the measurement of any items in the financial statements of the Group. The Group did not make retrospective adjustments as a result of adopting the amendments to Ind AS 1.

c) Amendment to Ind AS 12 – Pillar-Two Tax Reforms

Based on an assessment of the Group's consolidated revenues and effective tax rates by jurisdiction, the Group does not currently meet the threshold for application of the Pillar Two rules. Accordingly, the Group is not within the scope of the OECD Pillar Two Model Rules.

d) Amendment to Ind AS 21-Lack of exchangeability

The Amendments introduces requirement to assess when a currency is exchangeable

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

into another currency and when it is not. The amendment requires an entity to estimate the spot exchange rate when it concludes that a currency is not exchangeable into another currency. These amendments had no effect on the financial statements of the Group.

(v) Standards issued but not yet effective

Amendment to Ind AS 1 - Classification of Liabilities as Current or Non-current and non-current liabilities with covenants:

The amendment includes specific provisions that will take effect for reporting periods beginning on or after 1 April 2026, retrospectively, as outlined below:

a) Breach of material covenant for long-term loan arrangement on or before end of reporting period with effect that liability becomes payable on demand as on reporting date, then it shall be classified as current liability, if lender agreed after reporting period and before approval of financial statements to not demand payment as a consequence of breach.

b) Classify as non-current liability, if lender agreed by end of reporting period to provide grace period ending at least 12 months after reporting period within which entity can rectify the breach provided lender does not demand immediate repayment.

c) Disclose information about the timing of settlement to understand the impact of the liability on the financial statements.

The Group does not expect this amendment to have an impact on its operations or on its financial statements.

2.2. Fair value measurements and hierarchy

The Group measures financial instruments, such as investments at fair value at each Balance Sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

(a) In the principal market for the asset or liability; or

(b) In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Group.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their best economic interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use, or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances, and for which sufficient data are available to measure the fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy based on its nature, characteristics, and risks:

- Level 1 - inputs are quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 - valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 - valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

2.3. Use of estimates and judgements

The preparation of consolidated financial statements in conformity with Ind AS requires management to make judgements, estimates and assumptions, that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses at the date of these consolidated financial statements and the reported amounts of revenues and expenses for the year presented. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed at each balance sheet date. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods affected.

Estimates and judgments involved in applying accounting policies, is in respect of:

- Useful lives of property, plant and equipment
- Useful lives of intangible assets
- Estimation of defined benefit obligations
- Estimation of deferred tax expense and liability
- Estimation of expected credit loss

Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances.

2.4. Property, plant and equipment (including Capital Work-in-Progress)

The cost of an item of property, plant and equipment shall be recognized as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.

Property, plant and equipment are stated at cost of acquisition or construction less accumulated depreciation and accumulated impairment, if any. Cost includes financing cost relating to borrowed funds attributable to the construction or acquisition of qualifying tangible assets if the recognition criteria is met up to the date the assets are ready for use.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date is disclosed as capital advance under non-current assets.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group, and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is de-recognized when replaced. All other repairs and maintenance are charged to the Consolidated Statement of Profit and Loss, during the reporting period in which they are incurred.

An item of property, plant and equipment is de-recognized upon disposal or when no future economic benefits are expected from the use. Any profit or loss on such de-recognition of the asset is calculated as difference between net disposal proceeds and the carrying amount of property, plant and equipment and recognized in the Consolidated Statement of Profit and Loss.

Depreciation is provided on straight-line basis for property, plant and equipment so as to expense the depreciable amount, i.e., the cost less estimated residual value, over its estimated useful lives. The estimated useful lives and residual values are reviewed annually and the effect of any changes in estimate is accounted for on a prospective basis.

The management's estimate of useful lives is as under:

Asset Category	Useful Life
Buildings-Freehold	30 - 60 years
Plant and Equipment	5 - 15 years
Furniture and Fixtures	5 - 15 years
Vehicles	5 & 10 years
Office equipment	5 - 15 years
Computer	3 - 6 years

Leasehold improvements are depreciated over the shorter of their useful life or the lease term.

Capital Work-in-Progress included in non-current assets represents property, plant and equipment that are not ready for their intended use as at the reporting date. Capital work-in-progress are not depreciated as these assets are not yet available for use.

2.5. Business combinations and goodwill

2.5.1 Business Combination

Business Combinations are accounted for using the acquisition method of accounting. Transaction costs incurred in connection with business combination are expensed in the statement of profit and loss. The identifiable assets and liabilities that meet the condition for recognition are recognised at their fair values at the acquisition date.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted through goodwill during the measurement period, or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognised at that date. These adjustments are called as measurement period adjustments. The measurement period does not exceed one year from the acquisition date.

2.5.2 Goodwill

Goodwill represents the excess of the consideration paid to acquire a business over underlying fair value of the identified assets acquired. Goodwill is carried at cost less accumulated impairment losses, if any. Goodwill is deemed to have an indefinite useful life and is tested for impairment annually or when events or circumstances indicate that the implied fair value of goodwill is less than its carrying amount.

For the purposes of impairment testing, goodwill is allocated to each of the Group's cash-generating units (CGUs) that is expected to benefit from the synergies of the combination. Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

2.6. Other Intangible assets

Other Intangible assets are initially recognized at cost. Following initial recognition, other intangible assets are carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

Other Intangible assets with definite useful lives are amortized on a straight-line basis so as to reflect the pattern in which the asset's economic benefits are consumed.

Other Intangible assets are amortized over their estimated life on straight-line method as follows:

Intangibles Category	Useful Life
Product Licences (including OTC Product Licences)	5-20 years
Product related intangibles	10 years & Indefinite
Registration Rights and Customer Contracts	3 years

Gains or losses arising from de-recognition of an other intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Consolidated Statement of Profit and Loss when the asset is de- recognized.

Expenditure on development are eligible for capitalization and carried as Intangible assets under development where such assets are not yet ready for their intended use.

Revenue expenditure pertaining to research is charged to the Consolidated Statement of Profit and Loss. Development costs of products are also charged to the Consolidated Statement of Profit and Loss unless a product's technical feasibility has been established, in which case such expenditure is capitalized.

2.7. Impairment of non-financial assets

At the end of each reporting period, the Group reviews the carrying amounts of its assets to determine whether there is any indication of impairment based on internal/ external factors. An impairment loss, if any, is charged to the Consolidated Statement of Profit and Loss in the year in which an asset is identified as impaired. An asset's recoverable amount is higher of an asset or cash-generating unit's (CGUs) fair value, less costs of disposal and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate, that reflects current market assessment of the time value of money and the risks specific to the asset for which estimates of future cash flows have not been adjusted. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. Impairment losses of continuing operations, including impairment on inventories, are recognized in the Consolidated Statement of Profit and Loss.

Reversal of impairment losses is recorded when there is an indication that the impairment losses recognized for the assets no longer exist or have decreased.

2.8. Inventories

Inventories consist of raw materials, packing materials, work-in-progress, stock-in-trade and finished goods. Inventories are valued at lower of cost and net realizable value (NRV). Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sales.

Cost is determined on weighted average basis.

Cost of raw materials and packing materials includes cost of purchases and other costs incurred in bringing the inventories to their present location and condition.

Cost of work-in-progress and finished goods includes direct materials, labor and proportion of manufacturing overheads based on the normal operating capacity, wherever applicable. The cost of finished goods includes other costs incurred in bringing the inventories to their present location and condition.

2.9. Foreign exchange transactions and translations

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in the Consolidated Statement of Profit and Loss.

All non-monetary items denominated in foreign currency are carried at historical cost or other similar valuation and are reported using the exchange rate that existed when the values were determined.

2.10. Financial instruments

A financial instrument is any contract that gives rise to a financial asset for one entity and a financial liability or equity instrument for another entity.

Financial assets and liabilities are recognized when the Group becomes a party to the contractual provisions of the instrument.

Financial assets:

Classification

The Group classifies its financial assets in the following measurement categories:

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

- those to be measured subsequently at fair value (either through other comprehensive income, or through the Statement of Profit and Loss), and
- those measured at amortized cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

Initial recognition and measurement

Financial assets are recognized when the Group becomes a party to the contractual provisions of the instrument. Financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through Profit and Loss, transaction costs that are attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through Profit and Loss are expensed in the Consolidated Statement of Profit and Loss.

Subsequent measurement

After initial recognition, financial assets are measured at:

- fair value (either through other comprehensive income or through Profit and Loss), or
- amortized cost

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Group has transferred its rights to receive cash flows from the asset

When the Group has transferred an asset, the Group evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognized. Where the Group has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not derecognized.

Where the Group has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of financial asset, the financial asset is derecognized if the Group has not retained control over the financial asset. Where the Group retains control of the financial asset, the asset continues to be recognized to the extent of continuing involvement in the financial asset.

Write-off

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof.

Income recognition

Dividend is accounted when the right to receive payment is established. Interest income from financial assets is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably.

Cash and cash equivalents

Cash and cash equivalents consists of cash on hand and short demand deposits which are subject to an insignificant risk of change in value. Short term means investments with original maturities / holding period of three months or less from the date of investments. Bank overdrafts that are repayable on demand and form an integral part of the Group's cash management are included as a component of cash and cash equivalent for the purpose of statement of cash flow.

Investments

Investments in mutual funds are primarily held for the Group's temporary cash requirements and can be readily convertible in cash. These investments are initially recorded at fair value and classified as fair value through profit or loss.

The Group measures investment in subsidiaries at cost less provision for impairment, if any.

Trade receivables

Trade receivables are amounts due from customers for the sale of goods or services performed in the ordinary course of business. Trade receivables are initially recognized at their transaction price, which is considered to be its fair value and are classified as current assets as it is expected to be received within the normal operating cycle of the business. The Group measures the loss allowance for trade receivables at an amount equal to lifetime expected credit losses. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as forecast direction of conditions at the reporting date.

Financial liabilities:

Initial recognition and measurement

Financial liabilities are initially measured at its fair value plus or minus, in the case of a financial liability not at FVTPL, transaction costs that are directly attributable to the issue/ origination of the financial liability.

Subsequent measurement

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

expense, are recognized in the Consolidated Statement of Profit and Loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in the Consolidated Statement of Profit and Loss. Any gain or loss on derecognition is also recognized in the Consolidated Statement of Profit and Loss.

Classification as debt or equity

Debt and equity instruments issued by the Group are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. The repurchase of the Group's own equity instruments is recognized and deducted directly in equity. No gain or loss is recognized in profit or loss on the purchase, sale, issue or cancellation of the Group's own equity instruments.

Derecognition of financial liabilities

Financial liability is derecognized when the obligation specified in the contract is discharged, cancelled or expires. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss.

Trade Payables

Trade payables are amounts due to vendors for purchase of goods or services acquired in the ordinary course of business and are classified as current liabilities to the extent it is expected to be paid within the normal operating cycle of the business.

Derivative financial instruments:

The Group uses derivative financial instruments, such as foreign exchange forward contracts, to manage its exposure to interest rates and foreign exchange risks. Such derivative financial instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value.

Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

The Group enters into derivative contracts to hedge risks which are not designated in any hedging relationship i.e., hedge accounting is not followed. Such contracts are accounted for at FVTPL.

Offsetting financial instruments:

Financial assets and liabilities are off-set and the net amount is reported in the Consolidated Balance Sheet where there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Group or the counterparty.

2.11. Revenue recognition

The Group derives revenue principally from sales of pharma products. Revenue from the sale of products is recognized when the Group satisfies a performance obligation in accordance with the provisions of the contract with the customer. This is achieved when control of the product has been transferred to the customer, which is generally determined when title, ownership, risk of obsolescence and loss pass to the customer and the Group has the present right to payment. Revenue is measured at the transaction price, being the amount of consideration to which the Group expects to be entitled in exchange for transferring the promised goods, net of returns and allowances, trade discount and volume rebates, and goods and service tax and applicable taxes.

Export incentives:

Export benefits available under prevalent schemes are accrued in the year in which the goods are exported and there is no uncertainty in receiving the same.

Interest income:

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition. Interest income is included in 'Other Income' in the Consolidated Statement of Profit and Loss.

Contract Liabilities:

A contract liability is the obligation to transfer goods or services to a customer for which the Group has received consideration from the customer. If a customer pays consideration before the Group transfers goods or services to the customer, a contract liability is recognized when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Group performs under the contract.

2.12. Employee Benefits

Short-term benefits

Short-term benefit obligations are measured on an undiscounted basis and are expensed as the related service is

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

The group pays provident fund contributions to publicly administered provident funds as per local regulations. The group has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognized as employee benefit expenses when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available.

The group sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to the maximum annual amount set by the Internal Revenue Service. There were no employer contributions under this plan.

Defined benefit plans

The Holding Company operates a funded defined benefit gratuity plan for its eligible employees. The gratuity plan is governed by the applicable provisions of the Code on Social Security, 2020, read with the relevant rules thereunder, which have subsumed the earlier provisions of the Payment of Gratuity Act, 1972.

The Holding Company's liabilities are determined on the basis of actuarial valuation made at the end of each financial year using the projected unit credit method.

Obligation is measured at the present value of estimated future cash flows using a discounted rate that is determined by reference to market yields at the Consolidated Balance Sheet date on Government bonds, where the terms of the Government bonds are consistent with the estimated terms of the defined benefit obligation. The Holding Company has established a gratuity trust and has taken out a group gratuity policy to partially fund its gratuity obligation. Plan assets are measured at fair value at the balance sheet date. The net defined benefit liability (or asset) represents the present value of the defined benefit obligation less the fair value of plan assets.

The net interest cost is calculated by applying the discount rate to the defined benefit obligation. This cost is included in the 'Employee benefits expense' in the Consolidated Statement of Profit and Loss. Re-measurement gains or losses arising from changes in actuarial assumptions are recognized in the period in which they occur, directly in OCI. These are presented as re-measurement gains or losses on defined benefit plans under other comprehensive income in other equity. Remeasurement gains or losses are not reclassified subsequently to the Consolidated Statement of Profit and Loss.

Compensated absences

The employees of the Group are entitled to compensated absences. Accumulated compensated absences, which are expected to be encashed beyond twelve months from the end of the year, are treated as long-term employee benefits. Liability for such benefit is provided on the basis of actual leave balance as at the Consolidated Balance Sheet date. The Group records an obligation for compensated absences in the period in which the employee renders the services that increases this entitlement. The Group measures the expected cost of compensated absences as the additional amount that the Group expects to pay as a result of the unused entitlement that has accumulated at the end of the reporting period. The Group recognizes accumulated compensated absences based on actuarial valuation in the Consolidated Statement of Profit and Loss.

2.13. Income Taxes

Current tax

The Income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

Income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.

The management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is recognized on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognized for all taxable temporary differences, except when the deferred tax liability arises from the initial recognition of goodwill or an asset or a liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor the taxable profit or loss.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized, except when the deferred tax asset relating

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

to the deductible temporary difference arises from the initial recognition of an asset or a liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor the taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date.

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

2.14. Provisions, Contingent Liabilities and Contingent Assets

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, it's carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

Provisions are recognized when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount can be reliably estimated. The expense relating to a provision is presented in the Consolidated Statement of Profit and Loss, net of any reimbursements.

A present obligation that arises from past events, where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made, is disclosed as a contingent liability. Contingent liabilities are also disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group.

Claims against the Group, where the possibility of any outflow of resources in settlement is remote, are not disclosed as contingent liabilities.

Contingent assets are not recognized in financial statements since this may result in the recognition of income that may never be realized. However, when the realization of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each Balance Sheet date.

2.15. Leases – Group as a Lessee

At inception of a contract, the Group assesses whether a contract is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified assets for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset the Group assesses whether contract involves the use of an identified asset, the Group has a right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use and the Group has the right to direct the use of the asset.

At the inception date, right-of-use asset is recognized at cost which includes present value of lease payments adjusted for any payments made on or before the commencement of lease and initial direct cost, if any. It is subsequently measured at cost less accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. Right-of-use asset is depreciated using the straight-line method from the commencement date over the earlier of useful life of the asset or the lease term. When the Group has purchase option available under lease and cost of right-of-use assets reflects that purchase option will be exercised, right-of-use asset is depreciated over the useful life of underlying asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognized in the Consolidated statement of profit and loss.

At the inception date, lease liability is recognized at present value of lease payments that are not made at the commencement of lease. Lease liability is subsequently measured by adjusting carrying amount to reflect interest, lease payments and remeasurement, if any.

Lease payments are discounted using the incremental borrowing rate or interest rate implicit in the lease if the rate can be determined.

The Group has elected not to apply the requirements of Ind AS 116 to leases that has a term of 12 months or less and leases for which the underlying asset is of low value.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

2.16. Dividends

Dividends are recognised when they become legally payable. In the case of interim dividends to equity shareholders, this is when declared by the directors. In the case of final dividends, this is when approved by the shareholders at the annual general meeting.

2.17. Segment Information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Chief Operating decision-maker is responsible for allocating resources and assessing the performance of the operating segments and makes strategic decisions.

2.18. Events after the reporting period

If the Group receives information after the reporting period, but prior to the date when the financial statements are approved for issue, about conditions that existed at the end of the reporting period, it will assess whether the information affects the amounts that it recognises in its consolidated financial statements. The Group will adjust the amounts recognised in its consolidated financial statements to reflect any adjusting events after the reporting period and update the disclosures that relate to those conditions considering the new information. For non-adjusting events after the reporting period, the Group will not change the amounts recognised in its consolidated financial statements but will disclose the nature of the non-adjusting event and an estimate of its financial effect, or a statement that such an estimate cannot be made, if applicable.

2.19. Share-based payments

The Group operates an equity-settled share-based compensation plan under which the Group receives services from employees as consideration for equity instruments (options) of the Holding Company. The fair value of the employee services received in exchange for the grant of the options is recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest. It recognises the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity (share-based payment reserve). When the options are exercised, the Holding Company issues new shares. The proceeds received are credited to share capital and securities premium. The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

2.20. Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss attributable to equity holders of the Group by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders of the Group and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.3a : Property, plant and equipment

The changes in the carrying value of property, plant and equipment for the year ended 31 March 2026 are as follows:

Particulars	Land-freehold	Buildings	Leasehold improvement	Plant and equipment	Furniture and fixtures	Vehicles	Office equipment	Computer	Total
Cost									
Balance as at 1 April 2025	**5.31**	**2,815.00**	**116.61**	**5,123.37**	**294.49**	**101.05**	**52.20**	**129.56**	**8,637.59**
Additions	–	138.06	14.83	543.43	29.31	30.76	1.81	21.47	779.67
Disposals/ Deletions	–	–	–	(12.19)	(1.50)	–	–	–	(13.69)
Translation adjustment	0.51	167.95	11.20	171.37	6.91	5.31	4.43	4.39	372.07
Balance as at 31 March 2026	**5.82**	**3,121.01**	**142.64**	**5,825.98**	**329.21**	**137.12**	**58.44**	**155.42**	**9,775.64**
Accumulated Depreciation									
Balance as at 1 April 2025	**–**	**536.16**	**13.78**	**1,937.75**	**143.02**	**84.00**	**45.90**	**82.20**	**2,842.81**
Depreciation	–	103.72	12.94	366.05	31.58	5.81	3.24	15.72	539.06
Disposals/ Deletions	–	–	–	(7.93)	–	–	–	–	(7.93)
Translation adjustment	–	36.83	2.10	97.55	5.94	3.57	3.87	1.78	151.64
Balance as at 31 March 2026	**–**	**676.71**	**28.82**	**2,393.42**	**180.54**	**93.38**	**53.01**	**99.70**	**3,525.58**
Net carrying value									
Balance as at 31 March 2026	**5.82**	**2,444.30**	**113.82**	**3,432.56**	**148.67**	**43.74**	**5.43**	**55.72**	**6,250.06**

The changes in the carrying value of property, plant and equipment for the year ended 31 March 2025 are as follows:

Particulars	Land-freehold	Buildings	Leasehold improvement	Plant and equipment	Furniture and fixtures	Vehicles	Office equipment	Computer	Total
Cost									
Balance as at 1 April 2024	5.18	2,286.53	105.64	3,962.58	211.02	99.99	51.04	120.15	6,842.13
Additions	–	482.72	8.32	1,135.83	81.26	1.08	0.54	8.43	1,718.18
Disposals/ Deletions	–	–	–	(22.48)	–	–	–	–	(22.48)
Translation adjustment	0.13	45.75	2.65	47.44	2.21	(0.02)	0.62	0.98	99.76
Balance as at 31 March 2025	**5.31**	**2,815.00**	**116.61**	**5,123.37**	**294.49**	**101.05**	**52.20**	**129.56**	**8,637.59**
Accumulated Depreciation									
Balance as at 1 April 2024	–	439.01	2.73	1,615.54	112.40	78.75	41.39	69.56	2,359.38
Depreciation	–	87.67	10.86	303.39	28.62	5.23	3.95	12.48	452.20
Disposals/ Deletions	–	–	–	(9.66)	–	–	–	–	(9.66)
Translation adjustment	–	9.48	0.19	28.48	2.00	0.02	0.56	0.16	40.89
Balance as at 31 March 2025	**–**	**536.16**	**13.78**	**1,937.75**	**143.02**	**84.00**	**45.90**	**82.20**	**2,842.81**
Net carrying value									
Balance as at 31 March 2025	**5.31**	**2,278.84**	**102.83**	**3,185.62**	**151.47**	**17.05**	**6.30**	**47.36**	**5,794.78**

(i) Addition to property, plant and equipment include capital expenditure as given below:

Description	As at 31 March 2026	As at 31 March 2025
Capital Expenditure (R & D)	32.41	6.74

For the details of charge created on property, plant and equipment. Refer note 24 - Borrowings.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.3b : Right of use assets

The Group's lease asset classes primarily consist of leases for land, buildings , plant and machinery and vehicles. The changes in the carrying value of right of use assets for the year ended 31 March 2026 are as follows:

Particulars	Leasehold Land	Building	Plant and equipment	Vehicles	Total
Cost					
Balance as at 1 April 2025	**224.41**	**3,315.12**	**185.74**	**12.19**	**3,737.46**
Additions	–	44.61	3.59	9.96	58.16
Deletions	–	(15.18)	–	–	(15.18)
Translation adjustment	–	313.91	22.55	1.48	337.94
Balance as at 31 March 2026	**224.41**	**3,658.46**	**211.88**	**23.63**	**4,118.38**
Accumulated depreciation					
Balance as at 1 April 2025	**15.67**	**620.36**	**24.58**	**7.54**	**668.15**
Depreciation	7.65	336.41	15.66	2.89	362.61
Deletions	–	(0.76)	–	–	(0.76)
Translation adjustment	–	74.94	3.69	1.05	79.68
Balance as at 31 March 2026	**23.32**	**1,030.95**	**43.93**	**11.48**	**1,109.68**
Net carrying value					
Balance as at 31 March 2026	**201.09**	**2,627.51**	**167.95**	**12.15**	**3,008.70**

The changes in the carrying value of right of use assets for the year ended 31 March 2025 are as follows:

Particulars	Leasehold Land	Building	Plant and Equipment	Vehicles	Total
Cost					
Balance as at 1 April 2024	224.41	2,434.71	177.17	9.38	2,845.67
Additions	–	1,339.81	–	2.36	1,342.17
Deletions	–	(515.00)	–	–	(515.00)
Translation adjustment	–	55.60	8.57	0.45	64.62
Balance as at 31 March 2025	**224.41**	**3,315.12**	**185.74**	**12.19**	**3,737.46**
Accumulated depreciation					
Balance as at 1 April 2024	8.02	548.26	9.53	5.51	571.32
Depreciation	7.65	245.83	14.26	1.72	269.46
Deletions	–	(188.46)	–	–	(188.46)
Translation adjustment	–	14.73	0.79	0.31	15.83
Balance as at 31 March 2025	**15.67**	**620.36**	**24.58**	**7.54**	**668.15**
Net carrying value					
Balance as at 31 March 2025	**208.74**	**2,694.76**	**161.16**	**4.65**	**3,069.31**

The following is the break-up of current and non-current lease liabilities:

Particulars	As at 31 March 2026	As at 31 March 2025
Non-current (Refer note 21)	2,701.30	2,633.29
Current (Refer note 25)	436.58	354.92
	3,137.88	**2,988.21**

The following is the movement in lease liabilities for the year ended

Particulars	As at 31 March 2026	As at 31 March 2025
Balance recognised at the beginning of the year	2,988.21	2,149.70
Additions	57.19	1,341.34
Lease Termination	(14.24)	(349.25)
Finance cost accrued	213.40	92.75
Payment of lease liabilities	(383.97)	(295.65)
Translation adjustment	277.29	49.32
Balance recognised at the end of the year	**3,137.88**	**2,988.21**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Incremental borrowing rate applied to lease liabilities is in the range of 2% to 11.93% (Previous year 2% to 11.93%).

The below table provides details regarding the contractual maturities of lease liabilities in an undiscounted basis:

Particulars	As at 31 March 2026	As at 31 March 2025
Less than 1 year	388.96	362.49
1 year to 5 years	2,204.17	1,595.59
More than 5 years	2,159.73	2,443.37

The following are the amounts recognised in the statement of profit and loss:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Depreciation expense of right of use assets	362.61	269.46
Interest expense on lease liabilities	213.40	92.75
	576.01	**362.21**

The Group had total cash outflows for leases of ₹383.97 million during the year ended 31 March 2026 (31 March 2025: ₹295.65 million).

Short term Lease recognised as an expense for the year ended 31 March 2026 is aggregating to ₹140.74 million (31 March 2025: ₹117.26 million).

Note No.4 : Capital work-in-progress

Particulars	As at 31 March 2026	As at 31 March 2025
Capital Work-in-progress (CWIP)	147.82	90.00

Ageing of Capital work in progress is as follows:

CWIP	Amount in CWIP for a period of 31 March 2026				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in Progress	142.10	5.72	–	–	147.82

Ageing of capital work in progress is as follows:

CWIP	Amount in CWIP for a period of 31 March 2025				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in Progress	82.73	7.27	–	–	90.00

There are no capital work-in-progress whose completion is overdue or has exceeded its cost compared to its original plan.

Note No.5 : Goodwill

Particulars	As at 31 March 2026	As at 31 March 2025
Opening balance	409.28	394.99
Effect of translation adjustments	43.28	14.29
Closing balance	**452.56**	**409.28**

For impairment testing, goodwill is allocated to the cash generating units (CGUs) which represents the lowest level within the group at which goodwill is monitored for internal management purposes. Goodwill acquired in business combination is allocated to the cash generating units (CGUs) that are expected to benefit from that business combination. The carrying amount of goodwill was allocated to the cash generating units as follows:

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	As at 31 March 2026	As at 31 March 2025
Marksans Pharma Inc.	112.38	102.53
Marksans Pharma (UK) Ltd	243.53	217.17
Nova Pharmaceuticals Australasia Pty Ltd	15.90	15.90
Access Healthcare for Medical Products LLC	80.75	73.68
	452.56	**409.28**

Refer footnote to Note No. 6 below for Impairment Testing of Goodwill

Note No.6 : Other intangible assets

The changes in the carrying value of other intangible assets for the year ended 31 March 2026 are as follows:

Particulars	Product related intangibles	Software	Marketing Rights	Total
Cost				
Balance as at 1 April 2025	1,120.28	20.37	205.25	**1,345.90**
Additions	208.46	–	–	208.46
Disposals/Deletions	(1.16)	–	–	(1.16)
Translation adjustment	134.05	–	19.67	153.72
Balance as at 31 March 2026	**1,461.63**	**20.37**	**224.92**	**1,706.92**
Accumulated amortisation				
Balance as at 1 April 2025	599.84	5.99	193.84	799.67
Amortisation	68.93	3.93	11.79	84.65
Translation adjustment	73.58	–	19.28	92.86
Balance as at 31 March 2026	**742.35**	**9.92**	**224.91**	**977.18**
Net carrying value				
Balance as at 31 March 2026	**719.28**	**10.45**	**0.01**	**729.74**

The changes in the carrying value of other intangible assets for the year ended 31 March 2025 are as follows:

Particulars	Product related intangibles	Software	Marketing Rights	Total
Cost				
Balance as at 1 April 2024	1,045.70	19.23	200.31	1,265.24
Additions	35.32	1.14	–	36.46
Translation adjustment	39.26	–	4.94	44.20
Balance as at 31 March 2025	**1,120.28**	**20.37**	**205.25**	**1,345.90**
Accumulated Amortisation				
Balance as at 1 April 2024	533.41	2.15	122.41	657.97
Amortisation	40.68	3.84	67.68	112.20
Translation adjustment	25.75	–	3.75	29.50
Balance as at 31 March 2025	**599.84**	**5.99**	**193.84**	**799.67**
Net carrying value				
Balance as at 31 March 2025	**520.44**	**14.38**	**11.41**	**546.23**

Impairment testing of goodwill and intangible assets with indefinite useful lives

Goodwill and intangible assets with indefinite useful lives have been allocated to the following cash-generating units ("CGUs"). This represents the lowest level within the Group at which goodwill and the related indefinite-life intangible assets are monitored for internal management purposes and at which largely independent cash inflows are generated.

The Group holds certain intangible assets with indefinite useful lives within its subsidiaries. While product-wise revenues may be identifiable, the related cash inflows are not considered largely independent, as the products are manufactured, distributed and commercially managed through the common infrastructure of the respective subsidiary. The products are manufactured, regulated, distributed and commercially managed through the common operating infrastructure of the respective subsidiary, including shared manufacturing facilities, regulatory and quality systems, customer relationships, supply chain, warehousing, sales and distribution arrangements and working capital management.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Product-level cash flows are not monitored by management and cannot be determined without arbitrary allocations of shared manufacturing overheads, regulatory costs, selling and distribution expenses, rebates / chargebacks, working capital and other common operating costs. The indefinite-life intangible assets are therefore not capable of being tested for impairment on a standalone product basis in a manner that would faithfully represent their recoverable amount.

Management monitors the performance of the business, allocates resources and assesses recoverability at the subsidiary level. Accordingly, the subsidiary represents the smallest identifiable group of assets that generates cash inflows largely independent of other assets or groups of assets. The indefinite-life intangible assets have therefore been allocated to the respective subsidiary-level CGU for impairment testing under Ind AS 36.

The allocation of goodwill and intangible assets with indefinite useful lives to CGUs is as follows:

Particulars	Goodwill as at 31 March 2026	Intangible assets with indefinite useful lives as at 31 March 2026	Goodwill as at 31 March 2025	Intangible assets with indefinite useful lives as at 31 March 2025
Marksans Pharma Inc.	112.38	219.68	102.53	194.44
Marksans Pharma (UK) Ltd	243.53	–	217.17	–
Nova Pharmaceuticals Australasia Pty Ltd	15.90	126.47	15.90	79.73
Access Healthcare for Medical Products LLC	80.75	–	73.68	–
	452.56	**346.15**	**409.28**	**274.17**

Goodwill and intangible assets with indefinite useful lives relating to foreign operations are expressed in the functional currency of the respective operation and retranslated at the closing rate at each reporting date, with the resulting exchange differences recognised in other comprehensive income and accumulated in the foreign currency translation reserve. The movement in the carrying amount of goodwill during the year arises solely from such exchange differences.

The Group tests goodwill and intangible assets with indefinite useful lives for impairment annually and additionally whenever events or changes in circumstances indicate that the carrying amount of a CGU may not be recoverable. The recoverable amount of each CGU has been determined on the basis of its value in use, calculated by discounting the estimated future cash flows of the CGU. For the purpose of impairment testing, the carrying amount of each CGU includes the carrying amount of goodwill, intangible assets with indefinite useful lives and other assets directly attributable or reasonably allocable to the respective CGU, determined on a basis consistent with the cash flows included in the value in use calculation.

Cash flows are projected in the functional currency of each CGU and discounted using a pre-tax discount rate appropriate to that currency and to the risks specific to the CGU. The value in use so determined is translated into Indian Rupees at the spot exchange rate on the date of the impairment test. Cash flow projections are based on financial budgets approved by Management covering a three-year period. Cash flows beyond that period are extrapolated using the terminal growth rates stated below, which do not exceed the long-term average growth rates for the products, industry and countries in which the respective CGUs operate.

Key assumptions used in the value in use calculations as at 31 March 2026:

Assumption	US CGU	UK CGU	Australia CGU	UAE CGU
Revenue growth over forecast period (CAGR)	10%	10%	10%	10%
Average EBITDA margin over forecast period	20%	20%	20%	20%
Terminal growth rate	2%	2%	2%	2%
Pre-tax discount rate	15%	16%	17%	14%

Key assumptions used in the value in use calculations as at 31 March 2025:

Assumption	US CGU	UK CGU	Australia CGU	UAE CGU
Revenue growth over forecast period (CAGR)	6%	6%	6%	6%
Average EBITDA margin over forecast period	20%	20%	20%	20%
Terminal growth rate	2%	2%	2%	2%
Pre-tax discount rate	12%	12%	12%	12%

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.7 : Intangible assets under development

Particulars	As at 31 March 2026	As at 31 March 2025
Intangible assets under development #	438.02	181.09

Intangible assets under development primarily comprise expenditure incurred on product-related development activities, including product dossiers, regulatory filings, market authorisations, product licences and other directly attributable costs relating to pharmaceutical products under development. These are incurred in relation to product-specific licences, product registrations, regulatory filings and other directly attributable costs incurred for obtaining approvals / authorisations for pharmaceutical products in various markets. These balances represent product-related intangible assets for which the related licences, registrations or regulatory approvals are under process as at the reporting date and, accordingly, the assets are not yet available for their intended use. Intangible assets under development are assessed for impairment annually, and whenever there is an indication that their carrying amount may not be recoverable. No impairment loss has been recognised in respect of these intangible assets under development for the year ended 31 March 2026 (31 March 2025: ₹ Nil).

Ageing of intangible assets under development is as follows:-

Intangible assets under development	Amount in intangible assets under development for a period of 31 March 2026				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in Progress	342.08	89.48	6.46	–	438.02

Ageing of intangible assets under development is as follows:-

Intangible assets under development	Amount in intangible assets under development for a period of 31 March 2025				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in Progress	173.84	7.25	–	–	181.09

There are no intangible assets under development whose completion is overdue or has exceeded its cost compared to its original plan.

Note No.8 : Other financial assets (non-current)

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Security deposits	38.62	34.03
Bank Deposit with more than 12 months maturity #	0.10	1.68
	38.72	**35.71**

Includes deposits amounting to ₹ Nil (31 March 2025: ₹1.58 million) given against bank guarantees.

Note No.9 : Deferred tax assets (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred Tax Assets		
Property, plant and equipment and intangible assets	0.39	–
Loss allowance on Trade Receivables	25.01	–
Leases	63.57	–
Employee Benefit Obligations including ESOPs	18.71	–
Inventory-related temporary differences, including unrealised profits and tax basis adjustments	325.15	–
Fair Valuation of Financial Assets	0.37	–
	433.20	**–**
Deferred Tax Liabilities		
Property, plant and equipment and intangible assets	(303.55)	–
	129.65	**–**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.10 : Other non-current assets

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Capital advances	5.86	44.40
Balances with government authorities	169.68	173.20
	175.54	**217.60**

Note No.11 : Non-current tax assets (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Advance tax (net)	10.81	11.11
	10.81	**11.11**

Note No.12 : Inventories

Particulars	As at 31 March 2026	As at 31 March 2025
a. Raw materials and packing materials	2,964.49	3,061.01
b. Work-in-progress	267.56	311.72
c. Finished Goods	4,494.98	3,243.34
d. Stock-in-Trade	1,995.78	1,839.09
	9,722.81	**8,455.16**

Refer Note 24 for hypothecation of above inventories.

Write-downs of inventories to net realisable value amounted to ₹7.14 million (31 March 2025: ₹93.31 million).

Note No.13 : Investments

Particulars	As at 31 March 2026	As at 31 March 2025
Investments carried at fair value through profit or loss (Quoted)		
Liquid mutual funds	–	7.42
	–	**7.42**
Aggregate amount of quoted investments and market value thereof	–	7.42
Aggregate amount of Un-quoted investment	–	–
Aggregate amount of impairment in the value of investments	–	–

Note No.14 : Trade receivables

Particulars	As at 31 March 2026	As at 31 March 2025
Trade receivables from contract with Customers	6,593.74	5,465.75
Breakup of security details		
Trade receivables considered good - secured	–	–
Trade receivables considered good - unsecured	6,552.25	5,415.12
Trade receivables considered good which have significant increase in credit risk	–	–
Trade receivables - credit impaired	41.49	50.63
	6,593.74	**5,465.75**
Less:- Loss allowance	(148.08)	(65.32)
	6,445.66	**5,400.43**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Ageing of Trade receivable as on 31 March 2026

Particulars	Outstanding for following period from the due date of payments						
	Not due	Less than 6 Months	6 Months to 1 Year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables							
Considered good	4,838.20	1,482.77	149.08	65.83	6.73	9.64	6,552.25
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	3.59	7.67	29.45	0.78	41.49
Disputed Trade Receivables							
Considered good	–	–	–	–	–	–	–
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	–	–	–	–	–
Total	**4,838.20**	**1,482.77**	**152.67**	**73.50**	**36.18**	**10.42**	**6,593.74**
Less: Loss Allowances (including Expected credit loss)							(148.08)
Net Trade Receivable							**6,445.66**
Expected credit loss provision	13.35	25.36	9.56	54.33	2.68	1.31	106.59
Exepected loss rate	0.28%	1.71%	6.41%	82.53%	39.82%	13.59%	

Ageing of Trade receivable as on 31 March 2025

Particulars	Outstanding for following period from the due date of payments						
	Not due	Less than 6 Months	6 Months to 1 Year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables							
Considered good	3,995.91	1,350.23	31.29	37.69	–	–	5,415.12
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	3.65	7.60	37.51	1.36	0.51	50.63
Disputed Trade receivables							
Considered good	–	–	–	–	–	–	–
Which have significant increase in credit risk	–	–	–	–	–	–	–
Credit Impaired	–	–	–	–	–	–	–
Total	**3,995.91**	**1,353.88**	**38.89**	**75.20**	**1.36**	**0.51**	**5,465.75**
Less: Loss Allowances (including Expected credit loss)							(65.32)
Net Trade Receivable							**5,400.43**
Expected credit loss provision	–	6.61	1.27	6.81	–	–	14.69
Exepected loss rate	–	0.49%	4.06%	18.07%	–	–	

Loss allowances includes provision of ₹106.59 million (Year ended 31 March 2025: ₹14.69 million) made on account of expected credit loss on Trade Receivables.

Note No.15a :Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Balances with bank		
In current accounts	2,891.15	2,785.36
In Exchange Earners' Foreign Currency account (EEFC)	193.60	0.01
Fixed deposit with original maturity less than 3 months	3,223.55	2,172.13
Cash in hand	33.07	0.36
	6,341.37	**4,957.86**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.15b : Bank balances other than above

Particulars	As at 31 March 2026	As at 31 March 2025
Earmarked balances with banks *	3.87	3.93
Term deposits with original maturity of more than three months but less than twelve months	3,551.27	2,080.30
	3,555.14	**2,084.23**

* Earmarked balances with banks represent balance maintained in specific bank accounts for payment of dividends. The use of these funds is restricted and can only be used to pay dividend. The corresponding liability for payment of dividends is included in other current financial liabilities (Refer note 27).

Note No.16 : Other financial assets (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Deposits	16.17	14.13
Interest accrued on fixed deposits	33.09	21.44
	49.26	**35.57**

Note No.17 : Other current assets

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Advance to vendors	173.99	127.14
Prepaid expenses	368.88	302.63
Balances with government authorities	320.85	429.92
Other advances	140.90	118.25
	1,004.62	**977.94**

Note No.18 : Current tax assets (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Income tax assets (net)	108.54	122.60
	108.54	**122.60**

Note No.19 : Share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Authorised				
Equity shares of ₹1/- each	550,000,000	550.00	550,000,000	550.00
7% Redeemable cumulative preference shares of ₹100/- each	1,400,000	140.00	1,400,000	140.00
	551,400,000	**690.00**	**551,400,000**	**690.00**
Issued, subscribed & fully paid up				
Equity shares of ₹1/- each	453,163,746	453.16	453,163,746	453.16
	453,163,746	**453.16**	**453,163,746**	**453.16**

a. Reconciliation of the equity shares outstanding is set out below:

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Equity shares outstanding at the beginning of the year	453,163,746	453.16	453,163,746	453.16
Equity shares outstanding at the end of the year	**453,163,746**	**453.16**	**453,163,746**	**453.16**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

b. Terms/rights attached to Equity Shares

The Company has only one class of equity shares having a face value of ₹1/- per share. All the equity shares rank pari passu in all respect. Every holder of equity shares present at a meeting in person or by proxy is entitled to one vote, and upon a poll each share is entitled to one vote. The equity share holders are entitled to dividend, if declared by the shareholders in an Annual General Meeting, in proportion to the number of equity shares held by the shareholders. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c. The Company has not issued bonus shares during the period of five years immediately preceding the reporting date.

d. During FY 2022 - 23, the Board of Directors at its meeting held on 08 July 2022 had approved the proposal to buy back its own fully paid up Equity Shares of face value ₹1/- each up to a maximum price of ₹60 per Equity Share ("Maximum Buyback Price") payable in cash for an aggregate buy back consideration not exceeding ₹600 million ("Maximum Offer Size") through the open market route on the stock exchanges from the equity shareholders / beneficial owners of the Equity Shares of the Company (other than those who are promoters, members of the promoter group and persons in control of the Company). In FY 2022 - 23, the Company bought back and accounted buy back of 6,474,276 equity shares which were extinguished on or before 18 January 2023 and completed the aforesaid buyback offer. Aforesaid buyback offer resulted in a cash outflow of ₹401.66 million (including transaction costs of ₹7.22 million and tax on buyback of ₹73.30 million). The volume weighted average buyback price was ₹49.60 per equity share comprising 1.58% of the pre buyback paid up equity share capital of the Company. The Company funded the buy back from its free reserves, including securities premium, as explained in Section 68 of the Companies Act, 2013. In accordance with Section 69 of the Companies Act, 2013, the Company had created "Capital Redemption Reserve" of ₹6.47 million equal to the nominal value of the shares bought back as an appropriation from retained earnings. The Company has not bought back equity shares for consideration other than cash during the period of five years immediately preceding the reporting date.

e. Details of equity shares held by promoters

Promoters for the purpose of this disclosure means promoters as defined under Section 2(69) of Companies Act, 2013.

Name of shareholder	As at 31 March 2026		As at 31 March 2025		% changed during the year
	No. of shares held at the end of the year	% of total shares	No. of shares held at the end of the year	% of total shares	
Equity shares of ₹1/- each fully paid					
Mr. Mark Saldanha	198,491,553	43.80	198,491,553	43.80	–
Mrs. Sandra Saldanha	330,456	0.07	330,456	0.07	–

The percentage shareholding above has been computed considering the outstanding number of shares of 453,163,746 and 453,163,746 as at 31 March 2026 and 31 March 2025, respectively.

f. Details of shareholders holding more than 5% shares in the Company

Name of shareholder	As at 31 March 2026		As at 31 March 2025		Change in current year
	No. of shares held	% of Holding	No. of shares held	% of Holding	
Equity shares of ₹1/- each fully paid					
Mr. Mark Saldanha	198,491,553	43.80	198,491,553	43.80	–
OrbiMed Asia IV Mauritius FVCI Limited	39,050,881	8.62	49,324,324	10.88	20.83%

g. The Holding Company has not issued any shares for consideration other than cash during the period of five years immediately preceding the reporting date.

h. Information relating to the Company's Employee Option Plan, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set out in note 39.1.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.20 : Other equity

Particulars	As at 31 March 2026	As at 31 March 2025
a. Capital Reserves		
Opening balance	0.12	0.12
Closing balance	**0.12**	**0.12**
b. Capital redemption reserve		
Opening balance	141.47	141.47
Closing balance	**141.47**	**141.47**
c. Securities premium account		
Opening balance	5,044.98	5,044.98
Closing balance	**5,044.98**	**5,044.98**
d. General reserve		
Opening balance	3,137.37	3,137.37
Closing Balance	**3,137.37**	**3,137.37**
e. Share-based Payments Reserve (Equity)		
Opening Balance	–	–
Share-based payment expenses	33.38	–
Closing balance	**33.38**	**–**
f. Retained earnings		
Opening balance	14,220.13	10,689.29
(+) Net Profit for the current year	4,179.00	3,805.75
(-) Dividend paid on equity shares *	(362.53)	(271.90)
(-/+) Other comprehensive income	10.41	(3.01)
Closing Balance	**18,047.01**	**14,220.13**
g. Foreign currency translation reserve		
Opening balance	1,671.89	1,184.15
(+) For the year	1,702.18	487.74
Closing balance	**3,374.07**	**1,671.89**
	29,778.40	**24,215.96**

* Dividend paid during the year is as follows:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Dividend per share (in absolute ₹)	0.80	0.60
Dividend paid during the year	362.53	271.90

The Board of Directors, in the meeting held on 26 May 2026, has recommended final dividend of ₹0.90 per equity share of ₹1/- each (90%) for the financial year 2025-26.

Note No.21 : Lease liabilities (non-current)

Particulars	As at 31 March 2026	As at 31 March 2025
Lease liabilities (Refer Note 3b - Right of use assets)	2,701.30	2,633.29
	2,701.30	**2,633.29**

Note No.22 : Provisions (non-current)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for gratuity (Refer note 39 - Post-Employment Benefits)	47.12	49.47
Provision for compensated absences	12.03	9.73
	59.15	**59.20**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.23 : Deferred tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred Tax Assets		
Leases	(2.27)	(4.41)
Employee benefit obligations	–	(19.17)
Loss allowance on Trade Receivables	–	(13.09)
Fair Valuation of Financial Assets	–	(0.08)
Inventory-related temporary differences, including unrealised profits and tax basis adjustments	–	(189.58)
Others	–	(27.20)
	(2.27)	**(253.53)**
Deferred Tax Liabilities		
Allowance on property, plant and equipment, intangible assets and Right of Use Assets	53.14	290.15
Net deferred tax liability	**50.87**	**36.62**

Note No.23.1 : Current Tax:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Amounts recognised in profit or loss		
Current tax	1,499.64	1,272.82
Tax adjustments of earlier years	30.34	13.08
	1,529.98	**1,285.90**
Deferred tax :		
Current year origination and reversal of temporary differences	(125.07)	(72.42)
Deferred tax expense	**(125.07)**	**(72.42)**
Total income tax recognised in profit or loss	**1,404.91**	**1,213.48**
Amounts recognised in other comprehensive income		
Remeasurements of post-employment benefit obligations	(3.50)	1.01
Total income tax recognised in other comprehensive income	**(3.50)**	**1.01**

Reconciliation of effective tax rate	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Profit before tax	5,605.55	5,039.67
Tax using the Company's domestic tax rate	25.17%	25.17%
Expected income tax expenses	**1,410.80**	**1,268.38**
Tax effect of:		
Effect of different tax rates in local and foreign tax jurisdictions	8.92	(60.26)
Expenses not deductible in determining Taxable Profit	39.89	7.04
Effect of concessions (Section 80JJAA and Section 80M of the Income-tax Act, 1961)	(104.82)	(75.90)
Difference on account of different tax rate for short term capital gains	(0.39)	–
Tax adjustment for earlier years - Current tax	30.34	13.08
Tax adjustment for earlier years - Deferred tax - Others	–	(3.77)
Others	20.17	64.91
Tax expenses as per statement of profit and loss	**1,404.91**	**1,213.48**

Note No.24 : Borrowings (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Secured		
Working capital facilities from Bank		
Borrowings	295.91	230.85
	295.91	**230.85**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

One of the subsidiaries, Time-Cap Laboratories Inc. has a working capital facility from bank repayable on demand. This borrowing bears interest at rate 3-month SOFR term rate + CSA (15 bps) + 250 bps p.a. The loan is secured by-

1. First charge on entire current and fixed assets of Marksans Pharma Inc. and its subsidiaries i.e. Time-Cap Laboratories Inc. (borrower), Marksans Realty LLC and Custom Coatings Inc.

2. First charge on the land and building situated at 7 Michael Avenue, Farmingdale, NY 11735 in name of Marksans Realty LLC.

3. Corporate guarantee of Marksans Pharma Ltd., Marksans Pharma Inc and Marksans Realty LLC.and Custom Coatings Inc.

Note No.25 : Lease liabilities (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Lease liabilities (Refer Note 3b - Right of use assets)	436.58	354.92
	436.58	**354.92**

Note No.26 : Trade payables

Particulars	As at 31 March 2026	As at 31 March 2025
a) Total outstanding dues of micro and small enterprises	20.12	36.33
b) Total outstanding dues of other than micro and small enterprises	3,348.97	3,020.66
	3,369.09	**3,056.99**

Ageing of Trade payable as on 31 March 2026

Particulars	Outstanding for following period from the due date of payments					
	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed - MSME	9.20	10.92	–	–	–	20.12
Undisputed - Others	1,588.67	1,747.03	11.57	0.96	0.74	3,348.97
Disputed - MSME	–	–	–	–	–	–
Disputed -Others	–	–	–	–	–	–
Total	**1,597.87**	**1,757.95**	**11.57**	**0.96**	**0.74**	**3,369.09**

Ageing of Trade payable as on 31 March 2025

Particulars	Outstanding for following period from the due date of payments					
	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed - MSME	12.36	23.97	–	–	–	36.33
Undisputed - Others	1768.62	1,234.25	13.59	2.38	1.82	3,020.66
Disputed - MSME	–	–	–	–	–	–
Disputed -Others	–	–	–	–	–	–
Total	**1,780.98**	**1,258.22**	**13.59**	**2.38**	**1.82**	**3,056.99**

Note No.27 : Other financial liabilities (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Employee benefits payable	215.98	183.27
Unclaimed Dividend *	3.87	3.93
Security Deposits received	4.39	2.21
Derivative financial liabilities - forward contract	68.62	39.37
Others	8.44	7.71
	301.30	**236.49**

* There are no dividend unclaimed for seven consecutive years or more to be credited to investor education and protection fund.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.28 : Other current liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Advance from customers	15.60	12.78
Capital creditors	51.68	120.91
Statutory dues payable	381.73	446.57
	449.01	**580.26**

Note No.29 : Provisions (current)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for gratuity (Refer note 39 - Post-Employment Benefits)	–	11.31
Provision for compensated absences	3.18	3.16
	3.18	**14.47**

Note No.30 : Current tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for income tax (net)	415.83	299.41
	415.83	**299.41**

Note No.31 : Revenue from operations

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Revenue from contracts with customers		
Sale of products	29,416.43	26,144.45
Other operating revenues :-		
Scrap sales	44.93	29.50
Export incentives	48.02	54.50
	29,509.38	**26,228.45**

Reconciliation of revenue recognised in the consolidated statement of profit and loss with the contracted price :

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Revenue as per contracted price	30,378.95	27,466.14
Less : Trade discounts	732.47	1,216.67
Less : Sales returns	137.10	21.02
Revenue from operations	**29,509.38**	**26,228.45**

Analysis of revenues by geography:

Region	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
US & North America	15,334.77	12,365.60
Europe and UK	10,149.52	10,298.17
Australia and New Zealand	3,030.75	2,528.07
Rest of World	994.34	1,036.61
	29,509.38	**26,228.45**

The performance obligation is satisfied when control of the goods are transferred to the customers based on the contractual terms. Payment terms with customers vary depending upon the contractual terms of each contract.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Contract Liabilities from contracts with customers

The Group records a contract liability when cash payments are received in advance of it's performance.

Particulars	As at 31 March 2026	As at 31 March 2025
Contract liabilities from contracts with customers (Refer note 28)	15.60	12.78

Note No.32 : Other income

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Interest Income on bank deposits at amortised costs	276.78	301.97
Fair value gain on financial instruments measured at fair value through profit or loss	–	0.41
Short term gain on redemption of mutual funds	12.27	6.94
Bad debts recovery	3.61	–
Exchange gain in foreign currency translation & transaction-(net)	500.95	193.11
Gain on lease modification	–	22.75
Miscellaneous income	31.72	138.11
	825.33	**663.29**

Note No.33 : Cost of materials consumed

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Raw materials and packing materials		
Inventory at the beginning of the year	3,061.01	2,622.87
Add: Purchases	9,495.56	7,968.37
Less: Inventory at the end of the year	(2,964.49)	(3,061.01)
	9,592.08	**7,530.23**

Note No.34 : Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Inventory at the beginning of the year		
Work-in-progress	311.72	248.00
Finished goods	3,243.34	2,018.18
Stock-in-trade	1,839.09	1,290.39
	5,394.15	**3,556.57**
Less: Inventory at the end of the year		
Work-in-progress	267.56	311.72
Finished goods	4,494.98	3,243.34
Stock-in-trade	1,995.78	1,839.09
	6,758.32	**5,394.15**
	(1,364.17)	**(1,837.58)**

Note No.35 : Employee benefits expense

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Salaries and wages including bonus	3,838.68	3,257.37
Contribution to provident and other funds	265.37	211.02
Compensated absences	7.37	8.36
Gratuity expenses (Refer note 39 - Post-Employment Benefits)	36.67	10.87
Employee share-based payment expense	33.38	–
Staff welfare expenses	27.87	15.37
	4,209.34	**3,502.99**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.36 : Finance costs

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Interest expense for financial liabilities measured at amortised cost	27.85	23.85
Interest on lease liabilities	213.40	92.75
	241.25	**116.60**

Note No.37 : Depreciation and amortization expense

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Depreciation on property, plant and equipment	539.06	452.20
Depreciation on right-of-use assets	362.61	269.46
Amortization of intangible assets	84.65	112.20
	986.32	**833.86**

Note No.38 : Other expenses

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Water, power & fuel	540.79	400.79
Repairs & maintenance - plant and equipments	290.97	264.47
Repairs & maintenance - building	255.93	224.01
Repairs & maintenance - others	58.90	55.20
Contract labour and other manufacturing expenses	952.98	857.14
Rent	140.74	117.26
Rates & taxes	31.28	32.14
Travel and conveyance expenses	135.17	117.64
Communication expenses	25.02	22.81
Courier & postage expenses	5.92	4.80
Printing & stationery	20.89	22.64
Auditors remuneration	10.75	9.45
Legal & professional fees	228.20	208.60
Loss on lease termination	0.17	–
Corporate social responsibility expenses (Refer note 48)	35.28	27.98
Loss on sale of property, plant and equipment	0.64	0.33
Compliance fees (US FDA and others)	501.89	640.65
Freight outward & export clearing expenses	1,347.37	1,437.09
Bad debts	130.85	63.89
Loss allowance on trade receivables	87.73	19.39
Selling & distribution expenses	1,255.27	1,129.27
Miscellaneous expenses	462.72	305.65
	6,519.46	**5,961.20**

Note No.39 : Post-Employment Benefits

The following are the employee benefit plans applicable to the employees of the holding company:

i Defined contribution Plan

The Holding Company has a defined contribution plan in the form of Provident Fund and National Pension Scheme. Contributions are made to provident fund in India for employees at the rate of 12% of basic salary as per regulations. The contributions are made to registered provident fund administered by the government. The obligation of the Company is limited to the amount contributed and it has no further contractual nor any constructive obligation.

The Holding Company's contribution to provident fund ₹61.89 million (31 March 2025: ₹55.58 million) has been recognised in profit or loss under the head employee benefits expense.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

The Holding Company's contribution to national pension scheme ₹2.36 million (31 March 2025: ₹2.17 million) has been recognised in profit or loss under the head employee benefits expense.

ii Gratuity (defined benefit plan)

The Holding Company operates a funded defined benefit gratuity plan for its eligible employees. The gratuity plan is governed by the applicable provisions of the Code on Social Security, 2020, read with the relevant rules thereunder, which have subsumed the earlier provisions of the Payment of Gratuity Act, 1972. Under the plan, eligible employees are entitled to gratuity benefits on completion of the requisite period of continuous service, as applicable, at the time of cessation of employment. The gratuity benefit payable is determined with reference to the employee's length of service and last drawn salary / wages, in accordance with the statutory provisions and the terms of the plan.

The gratuity plan is funded through a gratuity trust. The plan assets are administered by the Board of Trustees, which is responsible for the administration of the trust, including oversight of the investment of plan assets and monitoring of the funding position of the plan in accordance with the trust deed and applicable regulatory requirements.

The Company's defined benefit obligation is actuarially valued by an independent actuary using the projected unit credit method.

The Board of Trustees periodically reviews the funding position of the gratuity plan, including the asset-liability position, investment performance and funding requirements. The Holding Company makes contributions to the gratuity fund based on the actuarial valuation, funding requirements and applicable statutory requirements.

a Expense recognised in the statement of profit and loss for the year:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Current service cost	8.87	6.72
Past service cost	23.53	–
Interest cost on benefit obligation (net)	3.65	3.31
Total expenses included in employee benefits expense	**36.05**	**10.03**

b Expense / (Income) Recognised in Other Comprehensive Income (OCI):

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Actuarial (Gain) / Loss due to Demographic Assumption changes in defined benefit obligations	–	1.48
Actuarial (Gain) / Loss due to Financial Assumption changes in defined benefit obligations	(9.78)	1.65
Actuarial changes arising from changes in experience of defined benefit obligations	(3.77)	0.89
Return on Plan Assets (Greater) / Less than Discount rate	(0.36)	–
OCI for the year	**(13.91)**	**4.02**

c The following table shows the change in present value of defined benefit obligations, the change in plan assets and the funded status:

Particulars	As at 31 March 2026	As at 31 March 2025
Defined benefit obligations (DBO)	75.24	59.28
Fair Value of plan assets	30.36	–
Net (assets) / liabilities	**44.88**	**59.28**

d Break-up of the defined benefit plan related balance sheet amounts is shown below:

Particulars	As at 31 March 2026	As at 31 March 2025
Current liability (Refer note 29)	–	11.31
Non-current liability (Refer note 22)	44.88	47.97
	44.88	**59.28**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

e **The movements in the net Defined benefit obligations (DBO) recognised within the balance sheet are as follows:**

Particulars	As at 31 March 2026	As at 31 March 2025
DBO at the beginning of the year	59.28	54.82
Current Service Cost	8.87	6.72
Past service cost	23.53	–
Interest cost on benefit obligation (net)	3.65	3.31
Employer contributions	(30.00)	–
Benefits paid	(6.54)	(9.59)
Remeasurements due to actuarial loss /(gain)	(13.91)	4.02
DBO at the end of the year	**44.88**	**59.28**

f **Change in Defined Benefit Obligation**

Particulars	As at 31 March 2026	As at 31 March 2025
Defined Benefit Obligation as of Prior Year end	59.28	54.82
Service Cost		
a. Current service cost	8.87	6.72
b. Past service cost	23.53	–
Interest Cost	3.65	3.31
Benefit payments from plan assets	–	–
Benefit payments directly by employer	(6.54)	(9.59)
Actuarial (Gain) / Loss - Demographic Assumptions	–	1.48
Actuarial (Gain) / Loss - Financial Assumptions	(9.78)	1.65
Actuarial (Gain) / Loss - Experience	(3.77)	0.89
Defined Benefit Obligation as of Current Year end	**75.24**	**59.28**

g **Change in Fair Value of Plan Assets**

Particulars	As at 31 March 2026	As at 31 March 2025
Fair value of plan assets at end of prior year		
Employer contributions	30.00	–
Actuarial Gain/(Loss) on Plan Assets	0.36	–
Fair value of plan assets at end of year	**30.36**	**–**

h **Plan Assets**

Particulars	As at 31 March 2026	As at 31 March 2025
The weighted-average asset allocations at the year end were as follows:		
Pooled assets with an insurance company	100.00%	0.00%
Actual return on plan assets	0.36	–

i **Change in fair value of assets for the period ending as at 31 March 2026 and 31 March 2025:**

The Company has started investing in Plan Assets during the year ended 31 March 2026 through an approved Gratuity Trust, which has taken a group gratuity policy from SBI Life Insurance Company Limited.

The fund is managed and invested by SBI Life Insurance Company Limited.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

j Actuarial assumptions

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Discount Rate (per annum)	6.59%	6.54%
Rate of salary increase	5.00%	8.00%
Mortality rate	Indian Assured Lives Mortality (2012-14) Ultimate	Indian Assured Lives Mortality (2012-14) Ultimate
Withdrawal rate		
Up to 35 years	45.00%	45.00%
36 years to 45 years	18.00%	18.00%
46 years to 55 years	10.00%	10.00%
56 years and above	0.00%	0.00%

1. The discount rate is based on the prevailing market yields of Indian Government securities as at the balance sheet date for the estimated term of the obligation.

2. The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion, and other relevant factors, such as supply and demand in the employment market.

k Retirement age

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Retirement Age	58 Years	58 Years

l Sensitivity analysis

Particulars	For the year ended 31 March 2026 Amount	For the year ended 31 March 2025 Amount	For the year ended 31 March 2026 %	For the year ended 31 March 2025 %
Base scenario	75.24	59.28		
Discount rate: increase by 1%	72.17	56.58	(4.09%)	(4.56%)
Discount rate: decrease by 1%	78.60	62.26	4.47%	5.02%
Salary escalation rate: increase by 1%	78.28	61.90	4.05%	4.41%
Salary escalation rate: decrease by 1%	72.35	56.86	(3.84%)	(4.09%)

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligations as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated. Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligations has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

m Maturity profile

Projected benefits payable in future years from the date of reporting	Gratuity	
Particulars	As at 31 March 2026	As at 31 March 2025
1 Year (within next 12 Months)	14.61	11.31
2 to 10 Years	69.07	53.13
Above 10 Years	21.13	21.58

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

n Through its defined benefit plan, the Holding Company is exposed to a number of risks, the most significant of which are detailed below:

1. Changes in bond yields: A decrease in bond yields will increase plan liabilities

2. Longevity risk: The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

3. Salary growth risk: The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. An increase in the salary of the plan participants will increase the plan's liability."

iii Other long term employee benefits:

Compensated absences: [included as a part of salaries and wages in Note 35 amounts to ₹7.37 million (31 March 2025: ₹8.36 million) - employee benefits expense] all eligible employees can carry forward and avail / encash leave as per The Holding Company's policies. The Holding Company has applied the same actuarial assumptions that were used for the valuation of gratuity liability.

iv Other contribution plans for foreign entities:

In the United Kingdom, certain social security benefits (such as pension and social security) are funded by employers and employees through mandatory National Insurance contributions. The contribution amounts are determined based upon the employee's salary. The Group has no further obligations under the plan beyond its monthly contributions. The Group contributed ₹160.93 million and ₹122.34 million to the National Insurance during the years ended 31 March 2026 and 31 March 2025, respectively.

In the United States, medicare and social security benefits are funded by employers and employees. The contribution amounts are determined based upon the employee's salary. The Group has no further obligations under the plan beyond its monthly contributions. The Group contributed ₹94.76 million and ₹76.38 million during the years ended 31 March 2026 and 31 March 2025, respectively.

39.1 Employee Stock Option Plan

Pursuant to the Marksans Employees Stock Option Scheme 2024, approved by resolution passed by the members of the Company at the 32nd Annual General Meeting held on 24 September 2024 and amended at the 33rd Annual General Meeting held on 08 August 2025, the Company has granted 400,000 stock options of face value of Re. 1/- each on 24 September 2025 to certain eligible employees of the Company and its subsidiaries.

Under the plan, participants are granted options which vest upon completion of one year from the grant date. Once vested, the options remain exercisable for a period of one year.

When exercisable, each option is convertible into one equity share. The exercise price of the options is ₹10/-

Tabulated below is the summary of options granted under the plan. Since the employee stock options were granted during the current year, the related disclosures are applicable for the current year only; accordingly, comparative information for the previous year has not been presented.

Description	31-Mar-26	
	Average exercise price per share option (₹)	Number of Options
Opening Balance	NA	NA
Granted during the year	10	400,000
Exercised during the year	–	–
Forfeited during the year	–	–
Closing balance	–	400,000
Vested and exercisable	–	–

No options expired during the periods covered in the above tables.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Share options outstanding at the end of the year have the following expiry date and exercise prices:

Grant Date	Expiry Date	Exercise Price (₹)	Share options 31 March 2026
24-Sep-25	24-Sep-27	10	400,000
Weighted average remaining contractual life of options outstanding at end of period			1.5 years

The fair value at grant date of options granted during the year ended 31 March 2026 was ₹161.18 per option. The fair value at grant date is independently determined using the Black-Scholes Model which takes into account the exercise price, the term of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.

The model inputs for options granted during the year ended 31 March 2026 included:

Vested options are exercisable for a period of one year after vesting.

Exercise price: ₹10

Grant Date: 24 September 2025

Expiry Date: 24 September 2027

Share Price at Grant Date: ₹171.32

Expected volatility of Company's share: 50.83%

Expected dividend yield: 0.38%

Risk-free interest rate: 5.82%

Resultant fair value per option: ₹161.18

Expense arising from share-based payment transactions

Total expenses arising from share-based payment transactions recognised in profit or loss as part of employee benefit expense were as follows:

	31-Mar-26
Employee stock option plan	33.38

Note No. 39.2 : The Code on Social Security, 2020

Effective 21 November 2025, the Government of India consolidated 29 existing labour regulations into four Labour Codes, namely the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes").

The implementation of the New Labour Codes resulted in an increase in provision for employee benefits on account of recognition of past service cost. In accordance with the requirements of the New Labour Codes and the applicable accounting standards, the Holding Company assessed the related impact. Consequently ₹ 26.09 million has been recognised as Employee Benefits Expense in the consolidated financial statements for the year ended 31 March 2026.

Note No.40 : Capital management

The Group's capital management strategy is to effectively determine, raise and deploy capital so as to create value for its shareholders. The same is done through a mix of either equity and/or preference and/or convertible and/or combination of short term/long term debt as may be appropriate.

The Group manages its capital structure and makes adjustments in light of changes in economic conditions, annual operating plans and long-term and other strategic investment plans. In order to maintain or adjust the capital structure, the Group may adjust the amount of

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

dividends paid to shareholders, return capital to shareholders or issue new shares. The current capital structure of the Group consists of net debt (borrowings as detailed in note 24 and lease liabilities in note 3b offset by cash and cash equivalents balance in note 15a) and total equity of the Group. The Group is not subject to any externally imposed capital requirements. Net debt and equity is given in the table below:

Particulars	As at 31 March 2026	As at 31 March 2025
Total shareholders' equity as reported in balance sheet (A)	**30,526.80**	**24,893.82**
Gross Debt		
Lease liability (including current lease liability)	3,137.88	2,988.21
Current financial liabilities (borrowings)	295.91	230.85
Gross Debt	**3,433.79**	**3,219.06**
Less: Cash & cash equivalents	6,341.37	4,957.86
Net Debt (B)	**(2,907.58)**	**(1,738.80)**
Total Capital deployed (A-B)	**33,434.38**	**26,632.62**
Net debt to equity ratio (B/A)	**(0.10)**	**(0.07)**

The net debt to equity ratio for the current year improved as a result of increase in operating cash flows and cash held by the Group at the end of the year.

Note No.41 : Financial instruments – fair values and risk management

A. Accounting classification and fair values

The fair value of financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair values:

Fair value of cash and bank balances, trade receivables and other financial assets, trade payables, other financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Methods and assumptions used to estimate the fair values are consistent with those used for the previous year.

During the reporting period ending March 31, 2026 and March 31, 2025, there were no transfers between Level 1 and Level 2 fair value measurements.

Fair value hierarchy :

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of following:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities included in level 3.

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

Particulars	As at 31 March 2026			As at 31 March 2026		
	Carrying amount			Fair Value		
	FVTPL	FVOCI	Amortised cost	Level 1	Level 2	Level 3
Financial assets						
Other Non-current financial assets	–	–	38.72	–	–	–
Trade receivables	–	–	6,445.66	–	–	–
Cash and cash equivalents	–	–	6,341.37	–	–	–

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	As at 31 March 2026 Carrying amount			As at 31 March 2026 Fair Value		
	FVTPL	FVOCI	Amortised cost	Level 1	Level 2	Level 3
Bank balances other than above	–	–	3,555.14	–	–	–
Other current financial assets	–	–	49.26	–	–	–
Total	**–**	**–**	**16,430.15**	**–**	**–**	**–**
Financial Liabilities						
Short term borrowings	–	–	295.91	–	–	–
Trade payables	–	–	3,369.09	–	–	–
Derivative financial liabilities - forward contract @	68.62	–	–	–	68.62	–
Other current financial liabilities	–	–	232.68	–	–	–
Total	**68.62**	**–**	**3,897.68**	**–**	**68.62**	**–**

Particulars	As at 31 March 2025 Carrying amount			As at 31 March 2025 Fair Value		
	FVTPL	FVOCI	Amortised cost	Level 1	Level 2	Level 3
Financial assets						
Other Non-current financial assets	–	–	35.71	–	–	–
Trade receivables	–	–	5,400.43	–	–	–
Investment-Current #	7.42	–	–	7.42	–	–
Cash and cash equivalents	–	–	4,957.86	–	–	–
Bank balances other than above	–	–	2,084.23	–	–	–
Other current financial assets	–	–	35.57	–	–	–
Total	**7.42**	**–**	**12,513.80**	**7.42**	**–**	**–**
Financial Liabilities						
Short term borrowings	–	–	230.85	–	–	–
Trade payables	–	–	3,056.99	–	–	–
Derivative financial liabilities - forward contract @	39.37	–	–	–	39.37	–
Other current financial liabilities	–	–	197.12	–	–	–
Total	**39.37**	**–**	**3,484.96**	**–**	**39.37**	**–**

Investment in mutual funds: The fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.

@ The fair values of the foreign exchange forward contract has been determined using valuation techniques with adequate observable inputs. This model incorporate various inputs including the credit quality of counter parties and foreign exchange forward rates.

B. Financial risk management framework

The Group's activities expose it to variety of financial risks namely market risk, credit risk and liquidity risk. The Group has various financial assets such as deposits, trade and other receivables and cash and bank balances directly related to their business operations. The Group's principal financial liabilities comprise of trade and other payables.

The Group's senior management's focus is to foresee the unpredictability and minimize potential adverse effects on the Group's financial performance. The Group's overall risk management procedures to minimise the potential adverse effects of financial market on the Group's performance are as follows :

(i) Credit risk analysis

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers and investment securities. The Group establishes an allowance for doubtful debts and impairment that represents its estimate of expected losses in respect of trade and other receivables and investments.

Cash and cash equivalents and other bank balances

The Group held cash and cash equivalents and other bank balances of ₹9,896.51 million at 31 March 2026 (31 March 2025: ₹7,042.09 million). The cash and cash equivalents are held with bank and financial institution counterparties with good credit ratings.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Trade and other receivables

As at the year ending 31 March 2026 and 31 March 2025, one customer is exceeding 10% of the Group's total trade receivables.

The Group continuously monitors defaults of customers and other counterparties, identified either individually or by the Group, and incorporates this information into its credit risk controls. The Group's policy is to deal only with creditworthy counterparties.

The Group's management considers that all the above financial assets that are not impaired at each of the reporting dates and are of good credit quality, including those that are past due.

Summary of the Company's exposure to credit risk by age of the outstanding from various customers is in Note 14.

Further, management believes that the unimpaired amounts that are past due by more than 180 days are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk.

Reconciliation of Loss Allowance

Loss allowance as at 31 March 2024	**52.68**
Loss allowance	19.39
Loss allowance (utilised against bad debts)	(8.40)
Translation adjustment	1.65
Loss allowance as at 31 March 2025	**65.32**
Loss allowance	87.73
Loss allowance (utilised against bad debts)	(15.15)
Translation adjustment	10.18
Loss allowance as at 31 March 2026	**148.08**

(ii) Liquidity risk analysis

Liquidity risk is the risk that Group will not be able to meet its financial obligations as they fall due. Liquidity risk arises because of the possibility that the Group could be required to pay its liabilities earlier than expected or encounters difficulty in raising funds to meet commitments associated with financial liabilities as they fall due. The Group's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. The Group manages liquidity risk by maintaining sufficient cash and bank balance and availability of funding through adequate amount of committed credit facilities.

The details of the contractual maturities of significant liabilities as at 31 March 2026 are as follows :

Particulars	Current	Non-current	
	Within 1 year	1 to 5 years	More than 5 years
Short term borrowings	295.91	–	–
Trade payables	3,369.09	–	–
Lease liabilities	388.96	2,204.17	2,159.73
Other current financial liabilities	301.30	–	–
	4,355.26	**2,204.17**	**2,159.73**

The details of the contractual maturities of significant liabilities as at 31 March 2025 are as follows :

Particulars	Current	Non-current	
	Within 1 year	1 to 5 years	More than 5 years
Short term borrowings	230.85	–	–
Trade payables	3,056.99	–	–
Lease liabilities	362.49	1,595.59	2,443.37
Other current financial liabilities	236.49	–	–
	3,886.82	**1,595.59**	**2,443.37**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(iii) Market risk analysis

The Group's activities are exposed to variety of financial risks. These risks include market risk (including foreign exchange risk and interest rate risks).

(a) Foreign currency risk

The Group's foreign currency risk arises from its foreign operations, investments in foreign subsidiaries and foreign currency transactions. The fluctuation in foreign currency exchange rates may have potential impact on the income statement and equity, where any transaction references more than one currency or where assets/liabilities are denominated in a currency other than the functional currency of the Group.

Since a major part of the Group's revenue is in foreign currency and major part of the costs are in Indian Rupees, any movement in currency rates would have impact on the Group's performance. Consequently, the overall objective of the foreign currency risk management is to minimize the short term currency impact on its revenue and cash-flow in order to improve the predictability of the financial performance.

The major foreign currency exposures for the Group is denominated in USD. Additionally, there are transactions which are entered into in other currencies and are not significant in relation to the total volume of the foreign currency exposures. The Group hedges its trade receivables based on historical trends, budgets and monthly sales estimates. The foreign exchange forward contracts are denominated in the same currency as the highly probable forecast sales.

Exposure to currency risk

The Group's exposure to foreign currency risk is as follows :

Particulars	As at 31 March 2026			As at 31 March 2025		
	USD	JPY	EUR	USD	JPY	EUR
Financial assets						
Other current assets	19.87	3.29	0.40	19.75	0.47	–
Other non-current assets	–	–	–	–	–	23.73
Trade receivables	414.72	–	–	495.35	–	12.08
Total	**434.59**	**3.29**	**0.40**	**515.10**	**0.47**	**35.81**
Financial liabilities						
Other Current liability	–	–	4.82	5.80	–	–
Trade payables	175.98	–	14.72	227.76	–	0.88
Total	**175.98**	**–**	**19.54**	**233.56**	**–**	**0.88**
Net	**258.61**	**3.29**	**(19.14)**	**281.54**	**0.47**	**34.93**

A 10% strengthening / weakening of the respective foreign currencies with respect to functional currency of the Group would result in increase or decrease in profit or loss and equity as shown in table below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases. The following analysis has been worked out based on the exposures as of the date of statements of financial position.

Particulars	As at 31 March 2026			As at 31 March 2025		
	USD	JPY	EUR	USD	AED	EUR
Strengthening	25.86	0.33	(1.91)	28.15	0.05	3.49
Weakening	(25.86)	(0.33)	1.91	(28.15)	(0.05)	(3.49)

(b) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's short term borrowing with floating interest rates. The Group constantly monitors the credit markets and rebalances its financing strategies to achieve an optimal maturity profile and financing cost.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

The borrowings profile of the Group's interest bearing financial instruments as reported to the management of the Group is as follows:

Particulars	Currency	As at 31 March 2026	As at 31 March 2025
Short term borrowings	USD	230.77	230.85
Short term borrowings	AUD	65.14	–
		295.91	**230.85**

Cash flow risk in respect of variable rate instruments:

A change of 100 basis points in interest rate at the reporting date would have increased/ (decreased) profit by ₹2.95 million (Previous year: ₹2.31 million). This analysis assumes that all other variables remains constant and change occurs on reporting date. The year end balances are not representative of the average borrowings during the year.

Note No.42 : Earning per share

Earning per share is calculated by dividing the profit after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year as computed below:

Particulars	As at 31 March 2026	As at 31 March 2025
Earning Per Share (EPS)		
1) Net profit as per the statement of profit and loss available for equity shareholders (excluding Non-controlling interests)	4,179.00	3,805.75
2) Weighted average number of equity shares for Earning Per Share computation		
a) For Basic earning per share of ₹1/- each	453.16	453.16
b) For diluted earning per share of ₹1/- each	453.36	453.16
3) Earning per share (weighted average)		
Basic (in ₹)	**9.22**	**8.40**
Diluted (in ₹)	**9.22**	**8.40**

Particulars	As at 31 March 2026	As at 31 March 2025
Weighted average number of equity shares used as the denominator in calculating basic earnings per share	453.16	453.16
Adjustments for calculation of diluted earnings per share:		
Options	0.20	–
Weighted average number of equity shares and potential equity shares used as the denominator in calculating diluted earnings per share	**453.36**	**453.16**

Information concerning the classification of securities - Options

Options granted to the eligible employees are considered to be potential equity shares. They have been included in the determination of diluted earnings per share to the extent to which they are dilutive. The options have not been included in the determination of basic earnings per share. Details relating to the options are set out in note 39.1.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.43 :

The Group's subsidiaries at 31 March 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of equity shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.

Name of entity	Place of business/ country of incorporation	Ownership interest held by the group (%)		Ownership interest held by the Non Controlling Interest (%)		Principal activities
		31 March 2026	31 March 2025	31 March 2026	31 March 2025	
Marksans Pharma (UK) Limited (Wholly owned subsidiary)	UK	100	100	–	–	Investment entity
Marksans Holdings Limited (Step-down subsidiary)	UK	100	100	–	–	Investment entity
Bell, Sons and Co. (Druggists) Limited (Step-down subsidiary)	UK	100	100	–	–	Manufacture of pharmaceutical products
Relonchem Limited (Step-down subsidiary)	UK	100	100	–	–	Marketing and Distribution of pharmaceutical products
Marksans Pharma Inc. (Wholly owned subsidiary)	US	100	100	–	–	Investment entity
Time-Cap Laboratories Inc. (Step-down subsidiary)	US	100	100	–	–	Manufacture of pharmaceutical products
Custom Coatings Inc. (Step-down subsidiary)	US	100	100	–	–	Manufacture of pharmaceutical products
Marksans Realty LLC (Step-down subsidiary)	US	100	100	–	–	Investment entity
Marise Ann Inc. (Step-down subsidiary)	US	100	100	–	–	Marketing and promotion of branded OTC products
Nova Pharmaceuticals Australasia Pty Ltd (Subsidiary)	Australia	60	60	40	40	Marketing and Distribution of pharmaceutical products
Nova Pharmaceuticals NZ Ltd. (Step-down subsidiary)	Australia	100	100	–	–	Investment entity
Access Healthcare for Medical Products LLC. (Wholly owned subsidiary)	UAE	100	100	–	–	Marketing and Distribution of pharmaceutical products
Marksans Pharma GmbH (Wholly owned subsidiary)	Germany	100	100	–	–	Marketing and Distribution of pharmaceutical products
Marksans Pharma (Europe) Limited (Wholly owned subsidiary) - (w.e.f. 16 January 2026)	Ireland	100	100			Marketing and Distribution of pharmaceutical products
Marksans (Canada) Inc. (Wholly owned subsidiary) - (w.e.f. 22 January 2026)	Canada	100	100			Marketing and Distribution of pharmaceutical products

Note No.44 : Related Party Disclosures

(a) Key Management Personnel (KMP)/Directors

Mr. Mark Saldanha	:	Managing Director
Mrs. Sandra Saldanha	:	Whole-time Director
Mr. Varddhman Vikramaditya Jain	:	Whole-time Director
Mr. Jitendra Sharma	:	Chief Financial Officer
Mr. Harshavardhan Panigrahi	:	Company Secretary
Mr. Abhinna Sundar Mohanty	:	Independent Director
Mr. Digant Mahesh Parikh	:	Independent Director
Mr. Seetharama Raju Buddharaju (Up to 31 March 2025)	:	Independent Director
Dr. Sunny Sharma	:	Non-executive Director
Mrs. Shailaja Vardhan	:	Independent Director
Mr. Srinivas Mishra (w.e.f. 01 April 2025)	:	Independent Director

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

(b) List of related parties with whom transactions have taken place during the year are as follows:

Nature of transactions	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
Rent paid	**10.65**	**10.65**
Mr. Mark Saldanha	10.65	10.65
Share-based payment expense provided for	**16.70**	**–**
Mr. Varddhman Vikramaditya Jain	8.35	–
Mr. Jitendra Sharma	8.35	–
Managerial remuneration *	**133.01**	**127.92**
Mr. Mark Saldanha	76.86	75.94
Mrs. Sandra Saldanha	7.07	7.07
Mr. Varddhman Vikramaditya Jain	26.32	23.98
Mr. Jitendra Sharma	19.67	17.99
Mr. Harshavardhan Panigrahi	3.09	2.94
* Provision made based on actuarial valuation on an overall Group basis are not included in remuneration to key management personnel.		
Director Sitting Fees #	**1.71**	**0.84**
Mr. Abhinna Sundar Mohanty	0.31	0.02
Mr. Seetharama Raju Bhuddharaju	–	0.02
Mr. Digant Mahesh Parikh	0.50	0.40
Mrs. Shailaja Vardhan	0.50	0.40
Mr. Srinivas Mishra	0.40	–
# Included in legal and professional fees.		

(c) Balances outstanding at the end of the year

Particulars	As at 31 March 2026	As at 31 March 2025
Share-based payments Reserve	**16.70**	**–**
Mr. Varddhman Vikramaditya Jain	8.35	–
Mr. Jitendra Sharma	8.35	–
Managerial remuneration	**5.30**	**6.09**
Mr. Mark Saldanha	2.89	3.76
Mrs. Sandra Saldanha	0.42	0.41
Mr. Varddhman Vikramaditya Jain	0.99	0.91
Mr. Jitendra Sharma	0.80	0.76
Mr. Harshavardhan Panigrahi	0.20	0.25

Note No.45 : Segment information

A. Operating Segments

The Group operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'.

B. Geographical Information:

Analysis of revenues by geography:

The following table shows the distribution of the Group's revenues (excluding other operating income) by country, based on the location of the customers:

Region	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
US & North America	15,334.77	12,365.60
Europe and UK	10,149.52	10,298.17
Australia and New Zealand	3,030.75	2,528.07
Rest of World	994.34	1,036.61
	29,509.38	**26,228.45**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Analysis of non current assets by geography:

The following table shows the distribution of the Group's non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:

Region	As at 31 March 2026	As at 31 March 2025
US & North America	4,704.01	4,486.85
Europe and UK	2,129.24	1,618.72
Australia and New Zealand	160.43	106.90
Rest of World	4,258.29	4,142.64
	11,251.97	**10,355.11**

C. Information about major customers

During the year ended 31 March 2026, revenues from transactions with customers that amounted to 10% or more of the Group's total revenues included two customers (31 March 2025: Nil). The total revenues from these significant customers amounted to ₹ 6,790.61 million for the year ended 31 March 2026 (31 March 2025 : ₹ Nil).

Note No.46 : Contingent liabilities, contingent assets and commitments

Contingent liabilities

The Group neither had any contingent liabilities as on 31 March 2026 nor on 31 March 2025.

Contingent assets

The Group neither had any contingent assets as on 31 March 2026 nor on 31 March 2025.

Commitments

Particulars	As at 31 March 2026	As at 31 March 2025
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances)	538.78	341.54

Note No.47 : Research and development expenditure

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
a) Break-up of research and development expenses included in statement of profit and loss under below heads:		
Material Cost	706.83	359.76
Employee benefits expense		
Salaries, Wages and Bonus	48.71	39.48
Contribution to Provident and other funds	2.95	1.32
	51.66	**40.80**
Other expenses		
Power and Fuel	3.64	3.78
Laboratory goods and testing expenses	46.84	7.35
Clinical research expense	12.92	126.81
General charges	36.08	34.73
	99.48	**172.67**
b) Capital Expenditure	32.41	6.74
	890.38	**579.97**

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.48 : Corporate social responsibility (CSR)

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. A CSR committee has been formed by the Holding Company as per the Act. The funds were primarily utilized through the year on below mentioned activities which are specified in Schedule VII of the Companies Act, 2013:

Particulars	For the Year Ended 31 March 2026	For the Year Ended 31 March 2025
a) Gross amount required to be spent by the Holding Company during the year	37.18	29.29
b) Amount approved by the Board to be spent during the year	37.18	29.29
c) Amount spent during the year on :		
(i) Construction / acquisition of any asset	–	–
(ii) On purposes other than (i) above	35.28	27.98
d) Shortfall at the end of the year	–	–
e) Total of previous year shortfall	–	–
f) Reason for shortfall	NA	NA
g) Excess spent of previous year brought forward to current year	1.92	3.23
h) Excess spent of current year carried forward to next year	0.02	1.92
i) Contribution to section 8 companies, which are related parties, included in (c) above, in relation to CSR expenditure	NA	NA
j) Nature of CSR activities:	Promoting healthcare, education & disaster management, eradicating hunger & malnutrition, environment sustainability and ecological balance.	
The Holding Company does not have any ongoing CSR projects for both the years. No expenditure has been paid to a related party, in relation to CSR expenditure. There are no short falls at the end of the year.		

Note No.49

Disclosure of additional information pertaining to the parent company, subsidiaries and associates as per Schedule III of Companies Act, 2013 :

As at/year ended 31 March 2026

Particulars	Net Assets i.e. total assets minus total liabilities		Share in profit or loss		Share in other comprehensive income		Share in total comprehensive income	
	As% of consolidated net assets	Amount	As% of consolidated profit or loss	Amount	As% of Other consolidated comprehensive Income	Amount	As% of consolidated Total comprehensive income	Amount
Parent								
Marksans Pharma Limited	**48.59**	**16,523.10**	**62.13**	**3,006.98**	**0.59**	**10.41**	**45.71**	**3,017.39**
Subsidiaries								
Marksans Pharma (UK) Limited (consolidated)	34.49	11,729.81	25.32	1,226.12	68.57	1,207.67	36.87	2,433.79
Nova Pharmaceuticals Australasia Pty Ltd (consolidated)	2.17	738.10	1.12	54.11	6.94	122.23	2.67	176.34
Marksans Pharma Inc.(consolidated)	13.35	4,538.54	10.38	502.40	21.63	381.06	13.38	883.46
Access Healthcare for Medical Products LLC	1.42	483.14	1.16	55.95	2.29	40.41	1.46	96.36
Marksans Pharma GmbH	(0.02)	(5.67)	(0.11)	(5.43)	(0.02)	(0.30)	(0.09)	(5.73)
Sub –Total	**100.00**	**34,007.02**	**100.00**	**4,840.13**	**100.00**	**1,761.48**	**100.00**	**6,601.61**
Less: Effect of intercompany adjustment/ eliminations		(3,775.46)		(639.49)		-		(639.49)
Grand total		**30,231.56**		**4,200.64**		**1,761.48**		**5,962.12**
Non controlling interest in a subsidiary		295.24		21.64		48.89		70.53

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

As at/year ended 31 March 2025

Particulars	Net Assets i.e. total assets minus total liabilities		Share in profit or loss		Share in Other Comprehensive Income		Share in Total Comprehensive Income	
	As % of consolidated net assets	Amount	As % of consolidated profit or loss	Amount	As % of Other consolidated Comprehensive Income	Amount	As % of consolidated Total Comprehensive Income	Amount
Parent								
Marksans Pharma Limited	**49.22**	**13,834.86**	**43.09**	**1,882.72**	**(0.63)**	**(3.01)**	**38.76**	**1,879.71**
Subsidiaries								
Marksans Pharma (UK) Limited (consolidated)	34.42	9,673.84	39.37	1,719.76	84.40	405.49	43.83	2,125.25
Nova Pharmaceuticals Australasia Pty Ltd (consolidated)	2.00	561.76	1.17	51.09	(2.21)	(10.64)	0.83	40.45
Marksans Pharma Inc. (consolidated)	12.98	3,648.82	16.58	724.56	16.48	79.20	16.57	803.76
Access Healthcare for Medical Products LLC	1.38	386.77	(0.21)	(9.18)	1.96	9.43	0.01	0.25
Marksans Pharma GmbH	–	–	–	–	–	–	–	–
Sub –Total	**100.00**	**28,106.05**	**100.00**	**4,368.95**	**100.00**	**480.47**	**100.00**	**4,849.42**
Less: Effect of intercompany adjustment/ eliminations		(3,436.93)		(542.76)		–		(542.76)
Grand Total		**24,669.12**		**3,826.19**		**480.47**		**4,306.66**
Non controlling interest in a subsidiary		224.70		20.44		(4.26)		16.18

Note No.50

Summarised financial information in respect of each of the Group's subsidiaries that has material non-controlling interests is set out below. The summarised financial information below represents amounts before intragroup eliminations and are based on their standalone financial statements.

Name of the subsidiary	Principal place of business	Country of incorporation	Held by non-controlling interest	
			As at 31 March 2026	As at 31 March 2025
Nova Pharmaceuticals Australasia Pty Ltd	Australia	Australia	40%	40%

Particulars	As at 31 March 2026	As at 31 March 2025
Current assets	1,459.80	1,037.51
Non-current assets	144.53	91.00
Current liabilities	866.22	566.75
Non-current liabilities	–	–
Equity interest attributable to the owners	442.86	337.06
Non controlling interest	295.24	224.71
Revenue	2,927.05	2,362.07
Expenses	2,851.78	2,289.08
Profit/(Loss) for the year	54.11	51.09
Profit/(Loss) attributable to the owners of the company	32.47	30.65
Profit/(Loss) attributable to the non-controlling interest	21.64	20.44
Opening cash & cash equivalents	111.69	35.19
Closing cash & cash equivalents	1.26	111.69
Net Cash inflow/(outflow)	(110.43)	76.50

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

Note No.51 : Subsequent events

The Board of Directors, in the meeting held on 26 May 2026, has recommended final dividend of ₹0.90 per equity share of ₹1/- each (90%) for the financial year 2025-26.

Note No.52 : Other statutory information

a. Details of benami property held

No proceedings have been initiated on or are pending against the Group for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

b. Borrowing secured against current assets

The Group has been sanctioned working capital limits in excess of ₹50 million in aggregate from consortium Bank on the basis of security of current assets. Quarterly returns filed with such Bank are in agreement with the books of account.

c. Wilful defaulter

The Group has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

d. Relationship with struck off companies

The Group has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956.

e. Registration of charges or satisfaction with registrar of companies (ROC)

There are no charges or satisfaction which are yet to be registered with the registrar of companies beyond the statutory period.

f. Compliance with number of layers of companies

The Group has complied with the number of layers prescribed under the Companies Act, 2013.

g. Compliance with approved schemes of arrangements

The Group has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

h. Utilisation of borrowed funds and share premium

1. The Group has not advanced or loaned or invested funds to any other persons or entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

   (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or

   (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

2. The Group has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

   (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or

   (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

i. Undisclosed income

There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.

j. Details of crypto currency or virtual currency

The Group has not traded or invested in crypto currency or virtual currency during the current or previous year.

k. Valuation of PP&E and intangible asset

The Group has not revalued its property, plant and equipment (including right of use assets) or intangible assets for both during the current or previous year.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2026 (All amounts in million of Indian Rupees, unless otherwise stated)

l. Title deeds of Immovable Properties

Title deeds of all immovable properties are held in the name of the Group.

m. The Holding Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility, except that audit trail feature was not enabled at the database level in respect of an accounting software to log any direct data changes.

Further, to the extent enabled, audit trail feature has operated throughout the year for all relevant transactions recorded in the accounting software. Also, there were no instances of audit trail feature being tampered with. Additionally, the audit trail of prior year has been preserved by the Holding Company as per the statutory requirements for record retention to the extent it was enabled and recorded in respective years.

The accompanying notes form an integral part of these Consolidated financial statements.
As per our report of even date

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.: 105047W/W101187

NITIN TIWARI
Partner
Membership No.: 118894
Place : Mumbai
Date : 26 May 2026

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364

MARK SALDANHA
Chairman & Managing Director
DIN: 00020983
Place : Mumbai
Date : 26 May 2026

SANDRA SALDANHA
Whole - time Director
DIN: 00021023
Place : Mumbai
Date : 26 May 2026

JITENDRA SHARMA
Chief Financial Officer
Place : Mumbai
Date : 26 May 2026

HARSHAVARDHAN PANIGRAHI
Company Secretary & Compliance Officer
Membership No.: FCS11133
Place : Mumbai
Date : 26 May 2026

Marksans Pharma Limited

CIN: L24110MH1992PLC066364
Regd. Office: 11th Floor, Grandeur, Veera Desai Extension Road,
Oshiwara, Andheri (West), Mumbai – 400053
Phone. No. 022-40012000
E-mail: companysecretary@marksanspharma.com Website: www.marksanspharma.com

NOTICE

To
The Members of
Marksans Pharma Limited

NOTICE is hereby given that the Thirty-Fourth (34th) Annual General Meeting of the Members of Marksans Pharma Limited will be held on **Thursday, 27 August 2026 at 11:00 am** through video conferencing / other audio-visual means (VC), to transact the following businesses:

ORDINARY BUSINESS

1. To receive, consider and adopt

   a) the Audited Standalone Financial Statements of the Company for the Financial Year ended 31 March 2026, comprising of the Audited Standalone Balance Sheet as at 31 March 2026, the Statement of Standalone Profit & Loss and Standalone Cash Flow Statement for the Financial Year 01 April 2025 to 31 March 2026 including its Schedules and the Notes attached thereto and forming part thereof along with the reports of the Board of Directors and the Statutory Auditors thereon; and

   b) the Audited Consolidated Financial Statements of the Company for the Financial Year ended 31 March 2026, comprising of the Audited Consolidated Balance Sheet as at 31 March 2026, the Statement of Consolidated Profit & Loss and Consolidated Cash Flow Statement for the Financial Year 01 April 2025 to 31 March 2026 including its Schedules and the Notes attached thereto and forming part thereof along with the reports of the Statutory Auditors thereon.

2. To declare dividend on equity shares recommended by the Board of Directors at its meeting held on 26 May 2026. The Board of Directors has recommended final dividend of ₹ 0.90 (90%) per equity share of Re. 1/- each face value.

3. To appoint a director in place of Dr. Sunny Sharma (DIN: 02267273) who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS

4. To approve the re-appointment of and remuneration to Mrs. Sandra Saldanha (DIN: 00021023) as a Whole-time Director and in this regard to consider and if thought fit, to pass the following resolution as **Special Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Sections 196, 197 and other applicable provisions, if any, of the Companies Act, 2013 read with Schedule V of the said Act and the rules made thereunder, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modifications or re-enactment thereof for the time being in force), and on the basis of recommendation of Nomination and Remuneration Committee, re-appointment of Mrs. Sandra Saldanha (DIN: 00021023) as a Whole-time Director of the Company be and is hereby approved for a further period of Three (3) years with effect from 25th September, 2026 on the following remuneration:

Particulars	Amount in ₹ Per Month
Basic	2,95,000.00
Special Allowance	2,54,654.00
Leave Travel Allowance	1,000.00
Medical Allowance	1,250.00
Provident Fund (12%)	35,400.00
Gratuity (4.81%)	14,190.00
Total Remuneration Per Month	**6,01,494.00**
Total Remuneration Per Annum	**72,17,928.00**

"**RESOLVED FURTHER THAT** Mrs. Sandra Saldanha shall be provided with Company's car with driver for use in company's business."

"**RESOLVED FURTHER THAT** remuneration payable to Mrs. Sandra Saldanha shall be subject to deduction of tax as per the provisions of the Income Tax Act."

"**RESOLVED FURTHER THAT** the remuneration payable to Mrs. Sandra Saldanha shall not exceed the limits laid down in Section 197 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013."

"**RESOLVED FURTHER THAT** in case in any financial year during the currency of the tenure of Mrs. Sandra Saldanha, the Company has no profit or its profits are inadequate, the Company will pay remuneration as specified above as the minimum remuneration, provided that the total remuneration shall not exceed the ceiling as provided in Section II of Part II of Schedule V of the Companies Act, 2013."

"**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorised to increase or revise the remuneration of Mrs. Sandra Saldanha during her tenure within the limits laid down in Section 197 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013."

"**RESOLVED FURTHER THAT** any of the Directors of the Company and Key Managerial Personnel of the Company be and are hereby authorized severally to do all such acts, deeds and things as may be required to give effect to the above resolutions."

Place: Mumbai
Dated: 03 July 2026

Registered Office:
11th Floor, Grandeur
Veera Desai Extension Road
Oshiwara, Andheri (West)
Mumbai - 400053

For and on behalf of the Board of Directors of
Marksans Pharma Limited

Sd/-
Harshavardhan Panigrahi
Company Secretary

NOTES:

i. The 34th Annual General Meeting (AGM) is being held through Video Conferencing ("VC") or Other Audio Visual Means ("OAVM") in accordance with the General Circular Nos. 14/2020, 17/2020, 20/2020, dated 8th April 2020, 13th April 2020, 5th May, 2020 respectively and subsequent circulars issued in this regard, the latest being circular dated September 22, 2025 issued by the Ministry of Corporate Affairs and Circular SEBI/HO/CFD/PoD-2/P/CIR/2024/133 dated October 3, 2024 issued by SEBI in relation to "Clarification on holding of AGM through VC or OAVM (hereinafter referred collectively as "e-AGM circulars"). The Members shall attend the AGM through VC by following instructions annexed to this Notice. For the purpose of recording the proceedings, the AGM will be deemed to be held at the registered office of the Company at 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai, India. The Members are requested to attend the AGM from their respective locations through VC and do not visit the registered office to attend the AGM.

ii. Since the AGM is being held pursuant to the e-AGM circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxy by the Members will not be available for the AGM and hence, the Proxy Form, Attendance Slip, and route map of the AGM venue are not annexed to this Notice. Members who are body corporate may appoint such person as they think fit to act as their representative on their behalf to attend the AGM through VC/OAVM and cast their votes through e-voting.

iii. An electronic copy of the Annual Report for 2025-26 including the Notice which includes procedure for e-voting and manner of attending the AGM through VC/OAVM, is being sent to those Members whose e-mail addresses are registered with the Company / Depositories in view of the e-AGM circulars. The Members may also note that the Notice of the AGM and the Annual Report for 2025-26 are available on the website of the Company at http://marksanspharma.com/annual-reports.html, which can be downloaded.

iv. Members who still hold share certificate(s) in physical form are advised to dematerialize their shareholding to avail the benefits of dematerialization, which includes easy liquidity since trading is permitted in dematerialized form only, electronic transfer and elimination of any possibility of loss of documents. Any requests for transfer of securities are not permitted unless the securities are held in dematerialized form with a depository. Further, transmission or transposition of securities held in physical form can be effected only in dematerialized form.

v. As part of green initiative, the members holding physical shares who have not registered their e-mail address are requested to register with the Company to receive e-communication from the Company. For registering e-mail address, the Members are requested to provide name, folio no., mobile No., e-mail address, scanned copies of self attested share certificate(s) (both sides) through e-mail on companysecretary@marksanspharma.com or alternatively, members can register their e-mail address with the Company's RTA through website link at https://www.bigshareonline.com//InvestorRegistration.aspx.

vi. In line with MCA Circulars and circulars issued by SEBI, the Notice calling the AGM along with the Report is being sent through electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories. A Member can request for a physical copy of the Report by sending an e-mail to the Company at companysecretary@marksanspharma.com. Members may note that the Report will also be available on the website of the Company at https://www.marksanspharma.com/annual-reports.html, the website of the Stock Exchanges i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and https://www.nseindia.com respectively.

vii. The Register of Directors and Key Managerial Personnel and their shareholding, the Register of Contracts or Arrangements in which the Directors are interested and all other documents referred to in the accompanying Notice will be available for inspection by the Members electronically. Members seeking to inspect such documents physically can inspect at the registered office of the Company on all working days, except Saturdays and Sundays, between 11.00 a.m. to 1.00 p.m. up to the last date of remote e-voting. For inspection, physically or electronically, the Members are requested to send a request through e-mail on companysecretary@marksanspharma.com with folio no. or DP/Client Id at least three working days in advance.

viii. The Members desiring any information relating to the accounts or have any questions, are requested to write to the Company on companysecretary@marksanspharma.com at least seven working days before the date of the AGM so as to enable the Management to keep the information ready and provide it at the AGM.

ix. Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered e-mail address mentioning their name, DP ID and Client ID/folio no., mobile number along with their queries at companysecretary@marksanspharma.com at least 7 working days before the date of AGM. Those Members who have registered themselves as a speaker will be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

x. The Company has fixed **Thursday, 20 August 2026** as the record date for determining entitlement of Members to receive dividend for the financial year ended 31 March 2026, if approved by the Members at the AGM.

xi. If the dividend as recommended by the Board is approved at the AGM, payment of such dividend will be made on or after 08 September 2026 subject to deduction of tax at source, as applicable:

- to all the Members in respect of shares held in physical form whose names appear in the Company's Register of Members as at the close of business hours on the record date; and

- to all Beneficial Owners in respect of shares held in dematerialized form whose names appear in the list of Beneficial Owners furnished by Depositories as at the close of business hours on the record date.

xii Members holding shares in dematerialized form may note that bank particulars registered against their respective depository accounts will be used by the Company for payment of dividend. The Company or its RTA, M/s Bigshare Services Private Limited cannot act on any request received directly from the members holding shares in dematerialized form for any change of bank particulars or bank mandates. Such changes are to be advised only to their Depository Participant by the members. Members holding shares in physical form are requested to intimate their bank particulars and/or change in bank particulars to the Company's RTA.

xiii. Dividend income on equity shares is taxable in the hands of shareholders, and the Company is required to deduct tax at source from dividend paid to shareholders at the prescribed rates in accordance with the provisions of the Income Tax Law. The shareholders are requested to update their PAN with the Company/Registrar & Transfer Agents viz. M/s Bigshare Services Private Limited ("RTA") (in case of shares held in physical form) and with the Depositories/Depository Participants ("DPs") (in case of shares held in demat form).

xiv. Pursuant to the provision of Section 124 and 125 of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules"), dividend declared by the Company for the financial year 2013-14, 2014-15, 2015-16, 2016-17 and 2017-18 which remained unclaimed till its due date along with corresponding shares in respect of which dividend remained unclaimed for seven consecutive years till its due date have been transferred to the Investor Education and Protection Fund (IEPF) in compliance with the provisions of the Rules.

However, such shareholder whose dividend/shares have been transferred to IEPF, can claim from IEPF Authority both unclaimed dividend amount and the shares transferred to IEPF by making an application in Form IEPF-5 online and send the physical copy of the same duly signed along with requisite documents enumerated in the said Form IEPF-5 to the Company at its Registered Office or to M/s Bigshare Services Private Limited, RTA of the Company for verification of claim. The Company will then send a verification report to IEPF Authority for a refund of the unclaimed dividend amount and transfer of the shares back to the credit of the shareholder.

xv. Pursuant to the provision of Section 124 and 125 of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules"), dividend declared by the Company for the financial year 2018-19, which will remain unclaimed for a period of seven years till 01 November 2026 shall be transferred to the IEPF and the corresponding shares on which dividend will remain unclaimed for seven consecutive years shall also be transferred to IEPF as per the procedure set out in the Rules. In this regard, the Company will send individual notice to each concerned member requesting them to claim their unpaid dividend and avoid the transfer of shares to IEPF on or before 01 November 2026 and the Company will also upload full details of such members on the website of the Company at http://marksanspharma.com/shares-liable-for-transfer-to-iepf.html.

xvi. Members who have not encashed their dividend warrant(s)/ demand drafts or who have not received dividend through ECS for the FY 2018-19 and thereafter are requested to make their claims to the Company's RTA, M/s Bigshare Services Private Limited, without any delay.

Due dates for transfer of unclaimed dividend to IEPF are as under:

Year of Dividend	Dividend rate per share (₹)	Date of Declaration	Due date of transfer to IEPF
2018-19	0.05	26th September, 2019	1st November, 2026
2019-20	0.10	29th September, 2020	1st November, 2027
2020-21	0.25	23rd September, 2021	28th October, 2028
2021-22	0.25	29th August, 2022	3rd October, 2029
2022-23	0.50	30th May, 2023	4th July, 2030
2023-24	0.60	24th September, 2024	29th October, 2031
2024-25	0.80	08th August, 2025	12th September, 2032

Note: Shares on which dividend declared for the FY 2018-19 and remaining unclaimed for 7 (Seven) consecutive years, will also be transferred to IEPF.

xvii. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/mobile numbers, Permanent Account Number (PAN), mandates, nominations, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc for shares held in electronic form to their Depository Participants (DPs) and for shares held in physical form to the Company/ Registrar and Transfer Agents (RTA) in prescribed Form ISR-1, Form ISR-2 and Form ISR-3 (as applicable) the format of which can be downloaded from the website of the Company at http://marksanspharma.com/forms.html. Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023, in the absence of any of the required documents in a folio, on or after October 1, 2023, the folio shall be frozen by the RTA. Intimation letters along with Business Reply Envelopes for furnishing the required details have already been sent by the Company.

xviii. In accordance with Regulation 40 of the SEBI (LODR) Regulations, 2015, as amended, all requests for transfer of securities shall be processed only if the securities are held in dematerialized form. Therefore, Members holding shares of the Company in physical form are requested to kindly get their shares dematerialized in case they wish to transfer their shares since physical transfer/issuance of equity shares has been disallowed by SEBI. Members can contact Company's RTA at investor@bigshareonline.com for assistance in this regard. Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the Listed Companies to issue securities in dematerialized form only while processing service requests viz. Issue of duplicate securities certificate; claim from Unclaimed Suspense Account; Renewal/ Exchange of securities certificate; Endorsement; Sub-division/ Splitting of securities certificate; Consolidation of securities certificates/ folios; Transmission and Transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR – 4, the format of which can be downloaded from the Company's website at http://marksanspharma.com/forms.html.

xix. As per the provisions of Section 72 of the Companies Act, 2013, the facility for making nominations is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. If a member desires to cancel the earlier nomination and record fresh nomination, he/she may submit the same in Form ISR-3 or Form SH-14. The said form can be downloaded from the Company's website at http://marksanspharma.com/forms.html. Members are requested to submit the said form to their Depository Participant in case the shares are held in dematerialized form and to the Company's RTA at investor@bigshareonline.com in case the shares are held in physical form.

xx In terms of Section 108 of the Companies Act, 2013 read with Rule 20(2) of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of SEBI (LODR) Regulations, 2015, the Company is providing the facility to its Members, being eligible to vote, to exercise their right to vote by electronic means on any or all of the businesses specified in the accompanying Notice.

xxi In compliance with Rule 20 of the Companies (Management and Administration) Rules, 2014, the Company has considered **Thursday, 20 August 2026** to determine the eligibility of members to vote by electronic means **(Cut-off date)**. The person whose name appears on the Register of Members/List of Beneficial Owners as on Cut-off date would be entitled to vote through electronic means.

xxii. The Company has engaged the services of National Securities Depository Limited (NSDL) to provide e-voting facilities for enabling the members to cast their vote in a secured manner and to attend the meeting through VC/OAVM. The members may cast their votes on the electronic voting system and attend the meeting from their respective locations. The remote e-voting facility will be available during the following Period:

Commencement of remote e-voting: **Monday, 24 August 2026 at 09:00 a.m.**

Conclusion of remote e-voting: **Wednesday, 26 August 2026 at 05:00 p.m.**

The remote e-voting will not be allowed beyond the aforesaid date and time and the e-voting module shall be disabled by NSDL upon expiry of aforesaid period. However, remote e-voting facility will be available during the period of the AGM on Thursday, 27 August 2026.

xxiii. Instructions and other information relating to e-voting and attending AGM through VC are annexed to this notice for information of the members. Any person who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice and holding shares as on the Cut-off date i.e. Thursday, 20 August 2026 shall follow the same instructions relating to e-voting and attending AGM through VC as given in the accompanying Notice.

xxiv. In case of joint holders, only such joint holder who is higher in the order of names will be entitled to vote during the AGM.

xxv. Only those Members who are present at the AGM through VC/OAVM and have not cast their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting during the AGM.

xxvi. The scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and submit, not later than two working days of conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favor or against, if any, to the Chairman of the Company or the person authorized by him, who shall countersign the same.

xxvii. Based on the scrutinizer's report, the Company will submit within two working days of the conclusion of the AGM to the Stock Exchanges, details of the voting results as required under Regulation 44(3) of the SEBI Listing Regulations.

xxviii. The results declared along with the scrutinizer's report, will be hosted on the website of the Company at https://www.marksanspharma.com/shareholders-meeting.html immediately after the declaration of the results by the Chairman or a person authorized by him in writing and communicated to the Stock Exchanges.

xxix. Brief resume of Directors seeking re-appointment, as required under Regulation 36 of SEBI (LODR) Regulations, 2015 are also provided in the Corporate Governance Report forming part of the Annual Report.

xxx. A statement pursuant to Section 102(1) of the Companies Act, 2013, relating to the Special Business to be transacted at the AGM is annexed hereto.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013.

The following Statement sets out all material facts relating to the Special Business mentioned in the accompanying Notice.

Item No. 4

The tenure of Mrs. Sandra Saldanha as a Whole-time Director of the Company will expire on 24 September 2026. In terms of Section 196 read with Schedule V of the Companies Act, 2013, the Board of Directors of the Company, on recommendation of the Nomination and Remuneration Committee and subject to approval of Members of the Company at the ensuing Annual General Meeting, re-appointed Mrs. Sandra Saldanha as a Whole-time Director of the Company for a further period of three (3) years with effect from 25 September 2026. The re-appointment of and remuneration to Mrs. Sandra Saldanha has also the approval of the Audit Committee of the Company.

Mrs. Sandra Saldanha has a master's degree in arts (Sociology). Mrs. Sandra Saldanha has vast experience in the field of Human Resource Management, Business Development, Projects and Supply Chain Management. The Company will continue to benefit by her expertise. Mrs. Sandra Saldanha is not disqualified from being re-appointed as a Director in terms of Section 164 of the Companies Act, 2013 and has given her consent to act as a Director of the Company. She also satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 for being eligible for the re-appointment.

The remuneration payable to Mrs. Sandra Saldanha has been recommended by the Nomination and Remuneration Committee and is in line with the remuneration package that is necessary to encourage good professionals to important position such as that occupied by Mrs. Sandra Saldanha and is commensurate with the functions and responsibilities that is being discharged by her.

Accordingly, the resolution in item no. 4 of the notice for approving the re-appointment of and remuneration to Mrs. Sandra Saldanha as a Whole-time Director is being proposed for consideration of the members.

Brief resume of Mrs. Sandra Saldanha as stipulated under the Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and details as required under SS-2 (Secretarial Standard-2 on General Meeting) is given hereinbelow:

Name of the Director	Mrs. Sandra Saldanha
DIN	00021023
Date of Birth	11/12/1971
Age	54 years
Date of first appointment on the Board	25/09/2014
Qualification	Master of Arts (Sociology)
Brief resume of the Director	Mrs. Sandra Saldanha has a master's degree in arts (Sociology). She has vast experience in the field of Human Resource Management, Business Development, Projects and Supply Chain Management.
Nature of expertise in specific functional areas	Human Resource Management, Business Development, Projects and Supply Chain Management
Terms and conditions of re-appointment	As mentioned in the resolution under Item 4 of the notice
Remuneration last drawn	₹ 70,69,164.00/-
No. of Board meetings attended during FY 2025-26	5 (Five) out of 6 (Six) held
Directorship held in other companies	Marksans Pharma (UK) Limited Marksans Holdings Limited Relonchem Limited Bell, Sons & Co. (Druggists) Limited Time-Cap Laboratories Inc.
Listed entities from which the person has resigned in the past three years	Nil
Membership/ Chairmanships of Audit Committee and Stakeholders' Relationship Committee of other public Companies	Nil
Inter-se relationship between Directors and Key Managerial Personnel of the Company	Relative of Mr. Mark Saldanha
Number of shares held in the Company (by Director himself, including shareholding as a beneficial owner, singly or jointly as first holder) as on 03 July 2026.	330,456
Whether attended last AGM	Yes

Mrs. Sandra Saldanha is holding 330,456 equity shares in the Company and accordingly, she may be deemed to be concerned or interested, financially or otherwise, to the extent of the aforesaid shareholding in respect of her re-appointment as a Whole-time Director. Mr. Mark

Saldanha who is her relative and the Managing Director of the Company, may be deemed to be concerned or interested in the re-appointment of Mrs. Sandra Saldanha.

Save and except the above, none of the other Directors/Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise in the resolution set out at Item No. 4 of the Notice.

The Board recommends the Special Resolution set out at Item No. 4 of the Notice for approval of the Members.

For and on behalf of the Board of Directors of **Marksans Pharma Limited**

Sd/-
Harshavardhan Panigrahi
Company Secretary

Place: Mumbai
Dated: 03 July 2026

Details of Directors seeking approval of Members for re-appointment at the Thirty-Fourth (34th) AGM of the Company

[Pursuant to Regulation 36(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Secretarial Standards-2 on General Meetings issued by the Institute of Company Secretaries of India]

Name	Dr. Sunny Sharma	Mrs. Sandra Saldanha
DIN	02267273	00021023
Date of Birth / Age	31/08/1974 (52 years)	11/12/1971 (54 years)
Nationality	Indian	Indian
Qualification	MBA & MBBS	Master of Arts (Sociology)
Date of first appointment on Board	11/08/2021	25/09/2014
Nature of expertise in specific functional areas	Corporate Finance and Investment Banking	Human Resource Management, Business Development, Projects and Supply Chain Management
Brief profile including experience	Dr. Sunny Sharma is a Senior Managing Director of OrbiMed Asia. Previously, he was with Investor Growth Capital (IGC), the investment arm of Investor AB in North America, and before that with Easton Capital in New York. Earlier in his career. Dr. Sharma worked in the healthcare investment banking group of Lehman Brothers in London.	Mrs. Sandra Saldanha has a master's degree in arts (Sociology). She has vast experience in the field of Human Resource Management, Business Development, Projects and Supply Chain Management.
Directorships held in other companies as on date of Notice (Including Listed Entities)	1. Lattice Medtech Private Limited 2. Arcatron Mobility Private Limited 3. Innovation Imaging Technologies Private Limited 4. Innvolution Healthcare Private Limited 5. Retail Private Limited 6. Orbimed Advisors India Private Limited 7. Kims Health Care and Research Center Limited 8. Lifecell International Private Limited 9. Advanced Enzyme Technologies Limited 10. Shasun Pharmaceuticals Limited 11. Redcliffe Hygiene Private Limited	1. Marksans Pharma (UK) Limited 2. Marksans Holdings Limited 3. Relonchem Limited 4. Bell, Sons & Co. (Druggists) Limited 5. Time-Cap Laboratories Inc.
Memberships/ Chairpersonship of committees across companies as on date of notice (only Statutory Committees as required to be constituted under the Act considered)	2 (Two) membership	Nil
In case of independent directors, the skills and capabilities required for the role and the manner in which the proposed person meets such requirements	NA	NA
Listed entities from which the Director has resigned in the past three years	Nil	Nil
No. of shares held in the Company (as on date of notice)	Nil	330,456
No. of board meetings attended during the year 2025-2026	5 (Five) out of 6 (Six) held	5 (Five) out of 6 (Six) held
Inter-se relationship between Directors and Key Managerial Personnel of the Company	Nil	Relative of Mr. Mark Saldanha
Terms and conditions of appointment/reappointment	He is a non-executive non-independent director.	As per the terms mentioned in the resolution at Item No. 4 proposed to be passed at 34th AGM to re-appoint her as a whole-time director.
Remuneration proposed to be paid	Nil	As per the terms mentioned in the resolution at Item No. 4 proposed to be passed at 34th AGM to re-appoint her as a whole-time director.
Remuneration last drawn (including sitting fees, if any)	Nil	Rs. 70,69,164.00 (as whole-time director)

SHAREHOLDERS INSTRUCTION FOR E-VOTING AND JOINING VIRTUAL MEETING

1. Pursuant to the General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, AGM shall be conducted through VC / OAVM.

2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting.

3. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), the Secretarial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time, the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the AGM will be provided by NSDL.

6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.marksanspharma.com. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

7. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circulars issued from time to time

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Monday, 24 August 2026 at 09:00 A.M. and ends on Wednesday, 26 August 2026 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. **The Members, whose names appear in the Register of Members / Beneficial Owners as on the cut-off date i.e. Thursday, 20 August 2026, may cast their vote electronically**. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date being 20 August 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section. This will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. 

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then use your existing my easi username & password. 2. After successful login, the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the e-voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) **Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.

2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.

3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example, if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example, if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example, if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:

   a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

   c) How to retrieve your 'initial password'?

      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

      (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered**.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

   a) Click on "**Forgot User Details/Password?**"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

   b) **Physical User Reset Password?**" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.

   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by

e-mail to jinesh@csjdedhia.in with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request at evoting@nsdl.com

Process for those shareholders whose e-mail ids are not registered with the depositories for procuring user id and password and registration of e-mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode, please provide folio No., name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by e-mail to companysecretary@marksanspharma.com.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), name, client master or copy of consolidated account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to companysecretary@marksanspharma.com. If you are an individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

3. Alternatively, shareholders/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and e-mail ID correctly in their demat account in order to access e-voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

2. Only those members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not cast their vote on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

3. Members who have voted through remote e-voting will be eligible to attend the AGM. However, they will not be eligible to vote during the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-voting on the day of the AGM shall be the same person mentioned for remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Members will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-voting system. Members may access by following the steps mentioned above for Access to NSDL e-voting system. After successful login, you can see link of "VC/OAVM" placed under "Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further, Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore, recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

INSTRUCTIONS ON DEDUCTION OF TAX AT SOURCE ON DIVIDEND

Dear Shareholders,

We are pleased to inform you that the Board of Directors of the Company at their Meeting held on May 26, 2026 has recommended final dividend of ₹ 0.90/- (90%) per equity share of face value of ₹ 1/- each fully-paid up of the Company, for the Financial Year 2025-26.

The dividend, as recommended by the Board of Directors, is subject to approval of shareholders at the ensuing 34th Annual General Meeting ("AGM") of the Company and will be paid to those shareholders whose names appear in the Register of Members / Register of Beneficial Owner of the Company as on Thursday, August 20, 2026 ("Record Date").

Shareholders are hereby informed that bank particulars registered with their respective Depository Participants, with whom they maintain their demat accounts, will be used by the Company for the payment of dividend. Shareholders are requested to intimate any change in their address and / or bank mandate to their Depository Participants only. Shareholders are requested to update their PAN, KYC details and Choice of Nomination with their respective Depository Participants before the Record Date to ensure timely credit of dividends.

The Company is required to withhold taxes at the prescribed rates on the dividend paid to its shareholders in accordance with Income Tax Act, 2025 (''the Act'') effective from April 01, 2026. The withholding tax rate varies depending on the residential status of the shareholder and the documents submitted by them and accepted by the Company. The Company shall, therefore, be required to deduct tax at source at the time of making the payment of the dividend, if approved by the shareholders at the forthcoming AGM. The shareholders are requested to update / verify the PAN, address, e-mail address, category and the residential status as per the Act, if not already done, with the Depository Participants. The Company will rely on the details as available with the Registrar to Issue and Share Transfer Agent ("RTA") of the Company viz. Bigshare Services Private Limited.

This communication summarizes the applicable TDS provisions of the Act for various shareholder categories, including Resident and Non-Resident shareholders. Shareholders are requested to take note of the following TDS rates and provide additional information to the Company, if applicable:

I. Resident Shareholders:

A. Tax deductible at source for Resident Individual Shareholders:

Category	TDS Rate	Applicable Conditions / Documents Required
Section 393 Resident Shareholders	Nil	- Aggregate amount of dividend payable to Resident Individual Shareholders during the Tax Year 2026-27 does not exceed ₹ 10,000/-. - If duly filled **Form 121** is furnished by eligible shareholders whose dividend income is more than ₹ 10,000/- along with self-attested copy of PAN card, then **Nil** tax will be deducted. Please note that all fields are mandatory to be filled up and incomplete forms will be rejected. - Self-declaration to be provided if the shareholder is exempted from TDS provisions through any circular or notification along with self-attested copy of PAN card and documentary evidence supporting the exemption.
	10%	- Shareholder having valid PAN and having dividend income more than ₹ 10,000/- and not furnishing **Form 121**.
	20%	Shareholder not having PAN / invalid PAN / not having linked with their Aadhaar wherever applicable.

B. Tax deductible at source for other than Individual Shareholders:

Category	TDS Rate	Applicable Conditions / Documents Required
Section 393 Shareholders covered u/s 393(5) of the Act such as Government, RBI, Mutual Funds specified under Schedule VII to Section 11 of the Act, corporations established by Central Act and exempt from Income Tax.	Nil	- Copy of PAN card - Self-declaration in **Annexure 1**, along with adequate documentary evidence, substantiating applicability of Section 393(5) of the Act.
Section 393 Shareholders to whom Section 393(1) of the Act does not apply, such as LIC, GIC, Business Trust (REIT, InVIT) etc.	Nil	- Copy of PAN card - Self-declaration in **Annexure 1**, along with adequate documentary evidence (e.g., registration certificate), to the effect that no tax withholding is required as per provisions of Section 393(1) of the Act.
Section 393 Category I and II Alternative Investment Fund ("AIF") established in India.	Nil	- Copy of PAN card - Self-declaration in **Annexure 1**, that AIF's income is exempt under Schedule V to Section 11 of the Act and they are governed by SEBI regulations as applicable to Category I or Category II AIFs, along with copy of registration certificate.
Section 393 Any other entity exempt from withholding tax under the provisions of Section 393(6) of the Act.	Nil	- Copy of PAN card - Self-declaration in **Annexure 1 & 2**, along with adequate documentary evidence, substantiating the nature of the entity. - Copy of the lower tax withholding certificate obtained from Income Tax Department.
Section 395 Resident shareholders obtaining certificate under Section 395 of the Act	Rate provided in the certificate	- Copy of PAN Card - Copy of the Certificate issued under Section 395 of the Act is to be provided. The certificate should be valid for the financial year 2026-27 and should cover dividend income.

II. Non-Resident Shareholders:

Tax will be deducted on the amount of dividend payable to non-resident shareholders at the rate given below:

Category	TDS Rate	Applicable Conditions / Documents Required
Section 393 Non-residents shareholders/FII/FPI	20% (plus applicable surcharge and cess) or tax treaty rate whichever is beneficial	- Self-attested copy of PAN Card, if any, allotted by the Indian tax authorities. - Self-declaration in **Annexure 3**. - Copy of Tax Residency certificate issued by revenue authority of country of residence of shareholder for the Tax Year 2026-27 (covering the period from April 1, 2026 to March 31, 2027). - Shareholders needs to mandatorily provide digital **Form 41** covering the period from April 1, 2026 to March 31, 2027. (Note: Application of beneficial Tax Treaty Rate shall depend upon the completeness and satisfactory review by the Company of the documents submitted by the non-resident shareholders. In case the documents are found to be incomplete, the Company reserves the right to not consider the tax rate prescribed under the tax treaty)
Section 393 Alternative Investment Fund – Category III located in International Financial Services Centre	10% plus applicable surcharge and cess#	- Copy of PAN card (if available) - Self-declaration in **Annexure 4**, along with adequate documentary evidence substantiating the nature of the entity.

Category	TDS Rate	Applicable Conditions / Documents Required
Section 393/395 Other Non-resident shareholders (except those who are tax residents of Notified Jurisdictional Area)	20% (plus applicable surcharge and cess) or tax treaty rate whichever is beneficial	To avail beneficial rate of tax treaty, following tax documents would be required: - Copy of PAN card (if available) - Copy of Tax Residency certificate issued by revenue authority of country of residence of shareholder for the Tax Year 2026-27 (covering the period from April 1, 2026 to March 31, 2027). - Shareholders needs to mandatorily provide digital Form 41 covering the period from April 1, 2026 to March 31, 2027. - Self-declaration for non-existence of permanent establishment / fixed base / business connection in India, place of effective management, beneficial ownership and eligibility to avail tax treaty benefit [on shareholder's letterhead] in **Annexure 3**. - In case of shareholder being tax resident of Singapore, please furnish the letter issued by the competent authority or any other evidences demonstrating the non-applicability of Article 24 - Limitation of Relief under India-Singapore Double Taxation Avoidance Agreement (DTAA). (Note: Application of beneficial Tax Treaty Rate shall depend upon the completeness and satisfactory review by the Company of the documents submitted by the non-resident shareholders. In case the documents are found to be incomplete, the Company reserves the right to not consider the tax rate prescribed under the tax treaty)
Non-Resident Shareholders who are tax residents of Notified Jurisdictional Area as defined u/s 176(1) of the Act	30%	NA
Sovereign Wealth funds and Pension funds notified by Central Government specified under Schedule V to Section 11 of the Act	NIL	- Copy of the notification issued by CBDT substantiating the applicability of Schedule V (Table Sl. No. 7) of the Act issued by the Government of India. - Self-declaration in **Annexure 5 & 6**, that the conditions specified under Schedule V to Section 11 have been complied with.
Subsidiary of Abu Dhabi Investment Authority (ADIA) as prescribed specified under Schedule V to Section 11 of the Act		- Self-declaration in **Annexure 7**, substantiating the fulfilment of conditions specified under Schedule V to Section 11 of the Act.

#In case PAN is not updated with the Company's RTA or depository; or PAN is not available; and information sought in the declaration are not provided, higher rate of withholding tax as per Section 397(2) shall be applied.

Notes:

i. **Updation of bank account details:** In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, dividend shall be paid only in electronic form. Shareholders are requested to ensure that their bank account details in their respective demat accounts are updated, to enable the Company to make timely credit of dividend in their bank accounts. Shareholders are also requested to update their Email Id, KYC details etc. with their respective Depository Participant to ensure ease of communication and seamless remittances.

ii. The aforementioned forms/annexures can be downloaded from the link https://www.marksanspharma.com/forms.html.

iii. The aforementioned documents duly completed and signed are required to be emailed to our RTA at tds@bigshareonline.com on or before Thursday, August 20, 2026 so as to enable the Company to determine applicable amount of TDS / withholding tax. Any communication in relation to tax rate determination / deduction received post Thursday, August 20, 2026 shall not be considered.

iv. As per Section 262 of the Act, every person who has been allotted a PAN and who is eligible to obtain Aadhaar, shall be required to link the PAN with Aadhaar. In case of failure to comply to this, the PAN allotted shall be deemed to be invalid / inoperative and tax shall be deducted at the rate of 20% as per the provisions of Section 397(2) of the Act. Shareholders may visit https://www.incometax.gov.in/iec/foportal/ for FAQ issued by Government on PAN Aadhar linking.

v. Shareholders holding shares under multiple accounts under different residential status / category and single PAN, may note that, higher of the tax rate as applicable to different residential status / category will be considered for their entire shareholding under different accounts.

vi. The documents furnished by the shareholders (such as Form 121, TRC, Form 41, Self-Attested Declaration etc.) shall be subject to review and examination by the Company before granting any beneficial rate or NIL Rate. The Company reserves the right to reject the documents in case of any discrepancies, or the documents are found to be incomplete.

vii. In case withholding tax is deducted at a higher rate, an option is still available with the shareholder to file the return of income and claim an appropriate refund. No claim shall lie against the Company for any tax deducted by the Company.

viii. In the event of any income tax demand (including interest, penalty, etc.) arising from any misrepresentation, inaccuracy or omission of information provided by the shareholder, the shareholder will be responsible to indemnify the Company and also, provide the Company with all information / documents and co-operation in any tax proceedings.

ix. This Communication is not exhaustive and does not purport to be a complete analysis or listing of all potential tax consequences in the matter of dividend payment. Shareholders should consult their tax advisors for requisite action to be taken by them.

x. In case of any discrepancy in documents submitted by the shareholder, the Company will deduct tax at higher rate as applicable, without any further communication in this regard.

xi. Post payment of the said dividend, shareholders will also be able to see the credit of TDS in Form 168, which can be downloaded from their e-filing account at https://www.incometax.gov.in.

xii. A declaration must be filed with the Company where the whole or any part of the dividend income is assessable, under the provisions of the Act, in the hands of a person other than the shareholder in accordance with Rule 203 of the Income Tax Rules, 2026. The declaration must consist of Name, address, PAN of the person to whom credit is to be given and proportion of credit to be given in respect of dividend income and the said documents are required to be emailed at tds@bigshareonline.com on or before Thursday, August 20, 2026. The Company will not consider any documents received after Thursday, August 20, 2026.

Resident Individual Shareholders can alternatively submit Form 121 (Declaration for receipt of dividend without deduction of Tax) through their depository i.e. National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). NSDL and CDSL have been enabled to accept Form 121 electronically. The steps for submitting Form 121 in NSDL and CDSL are provided at https://eservices.nsdl.com/ and https://www.cdslindia.com/Form121/Form121Login.aspx respectively.

Accordingly, shareholders may submit Form 121 directly through their respective depository on or before Thursday, August 20, 2026.

Thanking you.

Yours faithfully,
For **Marksans Pharma Limited**

Sd/-
Harshavardhan Panigrahi
Company Secretary

Notes

Marksans Pharma Ltd.

11th Floor Grandeur,
Off Veera Desai Road,
Opp Gundecha Symphony,
Andheri (W), Mumbai 400 053.
Tel no: +91 (22) 4001-20-00
www.marksanspharma.com